The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing liver disease.

Description

45 parts

›REFERENCE TO A SEQUENCE LISTING

This application includes a Sequence Listing submitted electronically as a text file named 18923806201SEQ, created on Dec. 21, 2021, with a size of 2,576 kilobytes. The Sequence Listing is incorporated herein by reference.

›FIELD

The present disclosure relates generally to the treatment of subjects having a liver disease with cell death inducing DFFA like effector B (CIDEB) inhibitors, patatin-like phospholipase domain containing 3 (PNPLA3) inhibitors, or hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitors, or any combination thereof, and methods of identifying subjects having an increased risk of developing a liver disease.

›BACKGROUND

Chronic liver disease and liver cirrhosis are leading causes of morbidity and mortality in the United States, accounting for 38,170 deaths (1.5% of total deaths) in 2014 (Kochanek et al., Nat'l. Vital Stat. Rep., 2016, 65, 1-122). The most common etiologies of liver cirrhosis in the U.S. are alcoholic liver disease, chronic hepatitis C, and nonalcoholic fatty liver disease (NAFLD), together accounting for about 80% of patients awaiting liver transplant between 2004 and 2013 (Wong et al., Gastroenterology, 2015, 148, 547-555). The estimated prevalence of NAFLD in the U.S. is between 19 and 46 percent (Browning et al., Hepatology, 2004, 40, 1387-1395; Lazo et al., Am. J. Epidemiol., 2013, 178, 38-45; and Williams et al., Gastroenterology, 2011, 140, 124-131) and has been rising over time (Younossi et al., Clin. Gastroenterol. Hepatol., 2011, 9, 524-530), likely in conjunction with increased prevalence of obesity, which is one of its primary risk factors (Cohen et al., Science, 2011, 332, 1519-1523). While significant advances have been made in the treatment of hepatitis C, there are currently no evidence-based treatments for alcoholic or nonalcoholic liver disease or liver cirrhosis. Identifying naturally occurring genetic variants that protect from liver damage and liver disease outcomes can be a pathway to identify novel therapeutic targets for liver disease (Abul-Husn et al. N. Engl. J. Med., 2018, 378, 1096-106).

CIDEB is expressed in the liver and small intestine and has been shown to play roles in regulating various aspects of lipid metabolism. CIDEB may participate in lipid metabolism by regulating lipid droplet fusion and very low density lipoprotein (VLDL) lipidation by interacting with ApoB. CIDEB is also required for the biogenesis of VLDL transport vesicles and for chylomicron lipidation in the small intestine. In addition, CIDEB regulates hepatic SREBP activation (master regulators of lipid metabolism) by selectively promoting ER-to-Golgi delivery of the SREBP/SCAP complex. Sterol depletion induces SCAP to interact with CIDEB, which also binds Sec12, the GEF of Sari, thereby enriching SCAP/SREBP at ER exit sites and increasing the packaging of SREBP/SCAP into COPII-coated vesicles.

›SUMMARY · 1 of 3

The present disclosure provides methods of treating a subject having a liver disease or at risk of developing a liver disease, the methods comprising administering a CIDEB inhibitor to the subject.

The present disclosure also provides methods of treating a subject with a CIDEB inhibitor, wherein the subject has a liver disease or is at risk of developing a liver disease, the methods comprising the steps of: determining whether the subject has a CIDEB variant nucleic acid molecule by: obtaining or having obtained a biological sample from the subject; and performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the CIDEB variant nucleic acid molecule; and administering or continuing to administer the CIDEB inhibitor in a standard dosage amount to a CIDEB reference subject; and administering or continuing to administer the CIDEB inhibitor in a dosage amount that is the same as or less than a standard dosage amount to a subject that is heterozygous or homozygous for the CIDEB variant nucleic acid molecule; wherein the presence of a genotype having the CIDEB variant nucleic acid molecule indicates the subject has a decreased risk of developing the liver disease or has a decreased risk of developing a more severe form of the liver disease.

The present disclosure also provides methods of identifying a subject having an increased risk of developing a liver disease, the methods comprising: determining or having determined the presence or absence of a CIDEB variant nucleic acid molecule in a biological sample obtained from the subject; wherein: when the subject is CIDEB reference, the subject has an increased risk of developing the liver disease; and when the subject is heterozygous or homozygous for the CIDEB variant nucleic acid molecule, the subject has a decreased risk of developing the liver disease or has a decreased risk of developing a more severe form of the liver disease.

The present disclosure also provides therapeutic compositions that treat or inhibit a liver disease for use in the treatment of a liver disease in a subject having a CIDEB variant nucleic acid molecule comprising: 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G, 14:24307833:G:C, 14:24307851:T:TAC, 14:24306426:T:C, 14:24307849:G:C, 14:24307448:G:T, 14:24305671:C:T, 14:24305663:C:T, 14:24305686:C:G, 14:24307829:A:C, 14:24307818:CTGAG:C, 14:24307856:C:T, 14:24306423:T:C, 14:24306061:AC:A, 14:24307390:C:T, 14:24306382:G:T, 14:24306373:C:T, 14:24305733:T:C, 14:24307858:T:C, 14:24306387:C:T, 14:24305637:T:C, 14:24306062:C:T, 14:24307853:C:G, 14:24307450:C:G, 14:24306052:TG:T, 14:24305673:G:A, 14:24306043:C:T, 14:24307834:G:A, 14:24306417:C:T, 14:24307451:G:A, 14:24307436:A:C, 14:24305953:ACTTT:A, 14:24306489:G:T, 14:24307441:C:T, 14:24306375:C:T, 14:24305657:C:G, 14:24306427:C:T, 14:24306524:C:T, 14:24307516:C:A, 14:24307840:G:C, 14:24307501:A:G, 14:24305968:A:C, 14:24305986:C:T, 14:24307441:C:G, 14:24307459:G:T, 14:24306017:T:A, 14:24307424:G:A, 14:24306072:G:T, 14:24307423:C:T, 14:24307450:C:T, 14:24306420:G:A, 14:24307454:G:A, 14:24305653:C:T, 14:24307442:G:A, 14:24306002:C:T, 14:24306076:C:T, 14:24305664:C:T, 14:24305961:TG:T, 14:24305706:A:G, 14:24305946:C:T, 14:24306455:G:C, 14:24307468:G:A, 14:24307825:A:C, 14:24306110:G:A, 14:24305710:C:T, 14:24307483:C:T, 14:24306459:A:G, 14:24305754:C:T, 14:24305650:G:C, 14:24305691:C:T, 14:24306508:G:C, 14:24306039:G:T, 14:24306139:T:C, 14:24306391:T:C, 14:24306373:C:A, 14:24307498:C:T, 14:24307415:G:A, 14:24306138:CTG:C, 14:24307453:T:C, 14:24305692:G:A, 14:24305683:C:G, 14:24307484:G:A, 14:24307385:C:T, 14:24306519:A:T, 14:24307839:A:C, 14:24305965:C:T, 14:24305988:CAT:C, 14:24306087:C:G, 14:24307439:C:T, 14:24307477:A:C, 14:24306436:G:T, 14:24306507:A:G, 14:24307397:C:T, 14:24307495:G:A, 14:24306034:A:T, 14:24306013:G:A, 14:24307381:A:G, 14:24306383:G:C, 14:24305638:A:G, 14:24307420:G:A, 14:24306020:C:T, 14:24306470:A:C, 14:24307435:C:T, 14:24306469:C:G, 14:24306451:C:T, 14:24306403:G:A, 14:24307515:C:G, 14:24307489:A:G, 14:24307414:C:T, 14:24306483:A:G, 14:24305755:G:A, 14:24305766:C:T, 14:24306064:T:G, 14:24307516:C:G, 14:24305766:C:G, 14:24306489:G:A, 14:24306097:T:C, 14:24305763:T:G, 14:24307447:G:A, 14:24307402:G:A, 14:24305972:C:G, 14:24306423:T:G, 14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C, according to GRCh38/hg38 human genome assembly coordinates.

›SUMMARY · 2 of 3

The present disclosure also provides compositions comprising a CIDEB inhibitor, a PNPLA3 inhibitor, or an HSD17B13 inhibitor, or any combination thereof, for use in the treatment of a liver disease in a subject having a CIDEB variant nucleic acid molecule comprising: 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G, 14:24307833:G:C, 14:24307851:T:TAC, 14:24306426:T:C, 14:24307849:G:C, 14:24307448:G:T, 14:24305671:C:T, 14:24305663:C:T, 14:24305686:C:G, 14:24307829:A:C, 14:24307818:CTGAG:C, 14:24307856:C:T, 14:24306423:T:C, 14:24306061:AC:A, 14:24307390:C:T, 14:24306382:G:T, 14:24306373:C:T, 14:24305733:T:C, 14:24307858:T:C, 14:24306387:C:T, 14:24305637:T:C, 14:24306062:C:T, 14:24307853:C:G, 14:24307450:C:G, 14:24306052:TG:T, 14:24305673:G:A, 14:24306043:C:T, 14:24307834:G:A, 14:24306417:C:T, 14:24307451:G:A, 14:24307436:A:C, 14:24305953:ACTTT:A, 14:24306489:G:T, 14:24307441:C:T, 14:24306375:C:T, 14:24305657:C:G, 14:24306427:C:T, 14:24306524:C:T, 14:24307516:C:A, 14:24307840:G:C, 14:24307501:A:G, 14:24305968:A:C, 14:24305986:C:T, 14:24307441:C:G, 14:24307459:G:T, 14:24306017:T:A, 14:24307424:G:A, 14:24306072:G:T, 14:24307423:C:T, 14:24307450:C:T, 14:24306420:G:A, 14:24307454:G:A, 14:24305653:C:T, 14:24307442:G:A, 14:24306002:C:T, 14:24306076:C:T, 14:24305664:C:T, 14:24305961:TG:T, 14:24305706:A:G, 14:24305946:C:T, 14:24306455:G:C, 14:24307468:G:A, 14:24307825:A:C, 14:24306110:G:A, 14:24305710:C:T, 14:24307483:C:T, 14:24306459:A:G, 14:24305754:C:T, 14:24305650:G:C, 14:24305691:C:T, 14:24306508:G:C, 14:24306039:G:T, 14:24306139:T:C, 14:24306391:T:C, 14:24306373:C:A, 14:24307498:C:T, 14:24307415:G:A, 14:24306138:CTG:C, 14:24307453:T:C, 14:24305692:G:A, 14:24305683:C:G, 14:24307484:G:A, 14:24307385:C:T, 14:24306519:A:T, 14:24307839:A:C, 14:24305965:C:T, 14:24305988:CAT:C, 14:24306087:C:G, 14:24307439:C:T, 14:24307477:A:C, 14:24306436:G:T, 14:24306507:A:G, 14:24307397:C:T, 14:24307495:G:A, 14:24306034:A:T, 14:24306013:G:A, 14:24307381:A:G, 14:24306383:G:C, 14:24305638:A:G, 14:24307420:G:A, 14:24306020:C:T, 14:24306470:A:C, 14:24307435:C:T, 14:24306469:C:G, 14:24306451:C:T, 14:24306403:G:A, 14:24307515:C:G, 14:24307489:A:G, 14:24307414:C:T, 14:24306483:A:G, 14:24305755:G:A, 14:24305766:C:T, 14:24306064:T:G, 14:24307516:C:G, 14:24305766:C:G, 14:24306489:G:A, 14:24306097:T:C, 14:24305763:T:G, 14:24307447:G:A, 14:24307402:G:A, 14:24305972:C:G, 14:24306423:T:G, 14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C, according to GRCh38/hg38 human genome assembly coordinates.

The present disclosure also provides methods of treating a subject having a liver disease or at risk of developing a liver disease, wherein: when the subject is homozygous for a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, the subject is administered: i) a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount; ii) a combination of a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount and a PNPLA3 inhibitor; iii) a combination of a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount and an HSD17B13 inhibitor; or iv) a combination of a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount, aPNPLA3 inhibitor, and an HSD17B13 inhibitor; and when the subject is not homozygous for a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide (i.e., is a carrier for a loss-of-function HSD17B13), the subject is administered: i) a CIDEB inhibitor in an amount that is less than a standard dosage amount; ii) a combination of a CIDEB inhibitor in an amount that is less than a standard dosage amount and a PNPLA3 inhibitor; iii) a combination of a CIDEB inhibitor in an amount that is less than a standard dosage amount and an HSD17B13 inhibitor; or iv) a combination of a CIDEB inhibitor in an amount that is less than a standard dosage amount, aPNPLA3 inhibitor, and an HSD17B13 inhibitor.

›SUMMARY · 3 of 3

The present disclosure also provides methods of treating a subject with a CIDEB inhibitor, wherein the subject has a liver disease or is at risk of developing a liver disease, the methods comprising: determining whether the subject has a PNPLA3 variant nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide by: obtaining or having obtained a biological sample from the subject; and performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the PNPLA3 variant nucleic acid molecule; and administering or continuing to administer the CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount, or in combination with an HSD17B13 inhibitor and/or a PNPLA3 inhibitor to a subject that is heterozygous or homozygous for the PNPLA3 variant nucleic acid molecule; wherein the presence of a genotype having the PNPLA3 variant nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide indicates that the subject is a candidate for treatment with the CIDEB inhibitor.

The present disclosure also provides methods of treating a subject with a CIDEB inhibitor, wherein the subject has a liver disease or is at risk of developing a liver disease, the methods comprising: determining whether the subject has a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide by: obtaining or having obtained a biological sample from the subject; and performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the nucleic acid molecule encoding the reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; and administering or continuing to administer the CIDEB inhibitor, or in combination with an HSD17B13 inhibitor and/or a PNPLA3 inhibitor, to a subject that is heterozygous or homozygous for the nucleic acid molecule encoding the reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; wherein the presence of a genotype having the nucleic acid molecule encoding the reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide indicates the subject is a candidate for treatment with the CIDEB inhibitor.

The present disclosure also provides methods of treating a subject, wherein the subject is overweight, obese, has increased body mass index (BMI), has a high percentage of liver fat, or has high adiposity, the methods comprising administering to the subject a CIDEB inhibitor, or a CIDEB inhibitor in combination with a PNPLA3 inhibitor and/or an HSD17B13 inhibitor.

›BRIEF DESCRIPTION OF THE DRAWINGS · 1 of 2

The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several aspects and together with the description serve to explain the principles of the present disclosure.

FIG. 1 shows an association of rare coding variants in CIDEB with liver disease risk. The Figure shows the association with liver disease across etiology and severity spectrum for rare pLOF variants in CIDEB (top), rare coding variants in CIDEB (middle) and the HSD17B13 splice variant (gray, heterozygous variant genotype compared with reference homozygous genotype; open circles, homozygous variant genotype compared with reference homozygous genotype). Abbreviations: OR; odds ratio, CI, confidence interval.

FIG. 2 shows an association of rare coding variants in CIDEB with liver histopathology phenotypes in bariatric surgery patients. Panel a shows the breakdown of liver histopathology categories (i.e., normal liver, simple steatosis, NASH or fibrosis) among carriers and non-carriers of rare coding (i.e., pLOF and missense) variants in CIDEB. Panel b shows the distribution of nonalcoholic fatty liver disease activity score at liver histopathology among carriers and non-carriers of rare coding (i.e., pLOF plus missense) variants in CIDEB. Data are from perioperative liver biopsies of participants in the GHS bariatric surgery cohort. Abbreviations: pLOF, predicted loss of function; NASH, nonalcoholic steatohepatitis; NALD, nonalcoholic fatty liver disease.

FIG. 3 shows associations with metabolic traits of rare coding variants in CIDEB. Associations estimates in blue are for rare coding (pLOF and missense) variants, while association estimates in red are for rare pLOF variants only. Panel a shows associations with continuous traits, while Panel b shows associations with binary outcomes traits. Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMI, Body mass index; WHRadjBMI, Waist-hip ratio adjusted for BMI; DBP, Diastolic blood pressure; SBP, Systolic blood pressure; pLOF, predicted loss of function; CI, Confidence interval; kg/m 2 , kilograms per square meter; mg/DL, milligrams per deciliter; and mmHg, millimeter of mercury.

FIG. 4 shows a visualization of the interaction between the burden of rare coding variants in CIDEB and body mass index on alanine aminotransferase levels. CIDEB rare coding (pLOF and missense) variants (Panel a) and CIDEB rare pLOF variants alone (Panel b) were associated with a larger decrease in ALT when individuals have higher body mass index compared to individuals with a lower body mass index. Interaction p-values were used to determine whether this difference in association with ALT by BMI was statistically significant. Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; pLOF, predicted loss of function; AAF, alternate allele frequency; SD, standard deviation; U/L, units per liter.

FIG. 5 shows a visualization of the interaction between rare coding variants in CIDEB and body mass index. Panel a shows the interaction of CIDEB genotype (i.e., rare pLOF variants) and body mass index on alanine aminotransferase level. Panel b shows the interaction of CIDEB genotype (i.e., rare pLOF and missense variants) and body mass index on alanine aminotransferase level. Abbreviations: pLOF, predicted loss of function; SD, standard deviation; P, p-value; ALT, alanine aminotransferase; BMI, body mass index; U/L, units per liter.

FIG. 6 shows a proportion of nonalcoholic liver disease in carriers and non-carriers of CIDEB rare coding variants across body mass index categories. The percentage of non-alcoholic liver disease is shown for carriers vs non-carriers of rare coding CIDEB variants, stratified by body mass index. Panel a shows carriers of only pLOF variants, and Panel b shows carriers of pLOF and missense variants. Abbreviations: BMI, body mass index; pLOF, predicted loss of function; AAF, alternate allele frequency. Numbers above each bar represents the observed sample size within the group being represented by the bar.

FIG. 7 shows a visualization of the interaction between rare coding variants in CIDEB with PNPLA3 Ile148Met. Panel a shows the interaction of CIDEB genotype (i.e., rare pLOF variants) and Ile148Met on alanine aminotransferase level. Panel b shows the interaction of CIDEB genotype (i.e., rare pLOF and missense variants) and Ile148Met on alanine aminotransferase level. Abbreviations: pLOF, predicted loss of function; SD, standard deviation; P, p-value; ALT, alanine aminotransferase; BMI, body mass index; U/L, units per liter.

FIG. 8 shows CIDEB expression patterns across tissues (Panel a) and liver cell-types (Panel b). Panel a shows, per tissue, the normalized mRNA expression values for CIDEB in counts per million (CPM) for each individual using data from genotype tissue expression (GTEx) consortium (GTEx Portal 2021. Accessed 2021, June 1st via the world wide web at gtexportal.org/). Panel b shows normalized cell-type specific expression levels within liver, in transcripts per million protein coding genes (pTPM), obtained from the human protein atlas (HPA) (Nat. Biotechnol., 2010, 28, 1248-50). Box plots depict the median (thick black vertical bar), the interquartile range, and minimum and maximum CPM values across individuals per tissue.

FIG. 9 shows rare pLOF variants in CIDEB impart a loss-of-function via defective mRNA processing in the liver. Panel a shows the level of mRNA expression of CIDEB in liver of bariatric surgery patients from GHS (left), that of two Lys153* heterozygous carriers (middle) and that of two c.336+1G>A heterozygous carriers (right). Panel b shows allele-specific expression results for the two Lys153* heterozygous carriers in RNA sequence reads mapped to the variant site (left; dashed red lines indicate variant site and arrows indicate rare instances where the reads carry the mutant allele) and in a comparison of read counts with or without the mutant allele (right). Panel c shows allele-specific expression results for the two c.336+1G>A heterozygous carriers. The left panel shows RNA sequence reads mapped to the variant site (dashed red lines indicate variant site and arrows indicate rare instances where the reads carry the mutant allele). The middle panel shows the number of spliced and unspliced reads in the two carriers, with unspliced reads being the less frequent occurrence. The right panel shows the allele-specific expression in unspliced reads, which disproportionally carried the variant allele. Abbreviations: pLOF, predicted loss of function; CPM, counts per million; P, p-value; mRNA, mature messenger RNA.

›BRIEF DESCRIPTION OF THE DRAWINGS · 2 of 2

FIG. 10 shows siRNA-mediated knockdown of CIDEB prevents lipid droplet build-up in HepG2 cells. Panel A shows intracellular localization of endogenous CIDEB to the interface of lipid droplets via immunofluorescent staining under basal conditions (no oleic acid) or in the presence of 400 μM oleic acid. Panel B shows the CIDEB protein staining is detectable in cells treated with control siRNA (top) but not CIDEB siRNA (bottom), demonstrating specificity of the CIDEB antibody used in both basal conditions (left) and oleic acid treatment (right). Purple, antibody staining of CIDEB; green, neutral lipids stained by BODIPY; blue, nuclei stained by DAPI; scale bar, 10 μm. Panel C shows western blot analysis (left and center) of CIDEB protein expression and Taqman analysis of CIDEB mRNA expression (right) in control or CIDEB siRNA-treated HepG2 cells. Data are presented as mean±s.d of independent wells and Welch's t-test was performed to determine statistical significance where * represents p<0.05. Panel D shows representative images of oleic acid treatment and CIDEB siRNA impact on lipid droplet size and distribution. Red, neutral lipids stained by AdipoRed; blue, nuclei stained by DAPI; scale bar, 20 μm. Panels E, F, and H show quantification of imaging-derived lipid droplet characteristics, barplots show mean±s.d. of 4 independent wells, depicted as individual points, per condition. Panel E shows the average number of lipid droplets per cell; Panel F shows the average lipid droplet size (quantified from the three-dimensional volume of individual lipid droplets); Panel H shows the average cell lipid droplet staining (quantified as the total area of lipid droplet staining in each cell). Panel G shows average triglyceride concentration per cell quantified using an enzymatic assay; data are mean±s.d of nine independent wells, depicted as individual points, per condition. Panel I shows concentrated of proinflammatory cytokine IL-8 secreted into the cell media quantified by immunoassay; data are mean±s.d. Differences in E-I were assessed using a two-way ANOVA; Tukey's multiple comparisons tests with Sidak correction were used to assess pairwise comparisons of CIDEB siRNA or oleic acid treatment (ns, not significant; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). Panel i shows AdipoRed staining of neutral lipids demonstrating increasing concentrations of oleic acid result in a dose-dependent increase lipid droplet size and cell lipid droplet staining (left). CIDEB siRNA pretreatment reduces the size of lipid droplets relative to control siRNA pretreatment (right). Red, neutral lipids stained by AdipoRed; blue, nuclei stained by 4′,6-diamidino-2-phenylindole (DAPI); scale bar, 20 μm. Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; OA, oleic acid; LD, lipid droplet.

›DESCRIPTION · 1 of 30

Various terms relating to aspects of the present disclosure are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art, unless otherwise indicated. Other specifically defined terms are to be construed in a manner consistent with the definitions provided herein.

Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps are to be limited to a specific order, it is in no way intended that an order be inferred, in any respect. This holds for any possible non-expressed basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.

As used herein, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.

As used herein, the term “about” means that the recited numerical value is approximate and small variations would not significantly affect the practice of the disclosed embodiments. Where a numerical value is used, unless indicated otherwise by the context, the term “about” means the numerical value can vary by ±10% and remain within the scope of the disclosed embodiments.

As used herein, the term “comprising” may be replaced with “consisting” or “consisting essentially of” in particular embodiments as desired.

As used herein, the terms “nucleic acid”, “nucleic acid molecule”, “nucleic acid sequence”, “polynucleotide”, or “oligonucleotide” can comprise a polymeric form of nucleotides of any length, can comprise DNA and/or RNA, and can be single-stranded, double-stranded, or multiple stranded. One strand of a nucleic acid also refers to its complement.

As used herein, the term “subject” includes any animal, including mammals. Mammals include, but are not limited to, farm animals (such as, for example, horse, cow, pig), companion animals (such as, for example, dog, cat), laboratory animals (such as, for example, mouse, rat, rabbits), and non-human primates (such as, for example, apes and monkeys). In some embodiments, the subject is a human. In some embodiments, the subject is a patient under the care of a physician.

It has been observed in accordance with the present disclosure that a gene burden of particular CIDEB variations (i.e., CIDEB variant nucleic acid molecules) associate with a decreased risk of developing a liver disease. It is believed that variants in CIDEB genes or proteins have not been significantly associated with liver disease or markers of liver damage in previous exome-sequencing association studies. Therefore, it is believed that humans having a liver disease or at risk of developing a liver disease may be treated with CIDEB inhibitors. Accordingly, the present disclosure provides methods for leveraging the identification of subjects who do not have such protective CIDEB variant nucleic acid molecules who, thus, are at risk of developing a liver disease, and to stratify the risk in such subjects of developing liver disease, such that subjects at risk or subjects with active disease may be treated with CIDEB inhibitors.

In any of the embodiments described herein, the CIDEB variant nucleic acid molecules can be any CIDEB nucleic acid molecule (such as, for example, genomic nucleic acid molecule, mRNA molecule, or cDNA molecule) encoding a CIDEB polypeptide having a partial loss-of-function, a complete loss-of-function, a predicted partial loss-of-function, or a predicted complete loss-of-function, or encoding a missense polypeptide, or resulting in the absence of an encoded polypeptide, or having an impact on the CIDEB mRNA sequence or expression. For example, the CIDEB variant nucleic acid molecules can be any of the CIDEB variant nucleic acid molecules described herein. A CIDEB variant nucleic acid molecule can be a variant that is predicted to result in the premature truncation of the CIDEB polypeptide (including, but not limited to, frameshift mutations, insertions or deletions, stop-gain, stop-lost, start-lost, splice site variants or large chromosomal or sub-chromosomal re-arrangements affecting the CIDEB gene). CIDEB variant nucleic acid molecules can include, but are not limited, to in-frame insertions or deletions in the CIDEB gene or variants in the untranslated regions of the CIDEB gene. A missense variant is a variant predicted to result in the change of an amino acid sequence of the CIDEB polypeptide.

For purposes of the present disclosure, any particular subject, such as a human, can be categorized as having one of three CIDEB genotypes: i) CIDEB reference; ii) heterozygous for a CIDEB variant nucleic acid molecule, and iii) homozygous for a CIDEB variant nucleic acid molecule. A subject is CIDEB reference when the subject does not have a copy of a CIDEB variant nucleic acid molecule. A subject is heterozygous for a CIDEB variant nucleic acid molecule when the subject has a single copy of a CIDEB variant nucleic acid molecule. A CIDEB variant nucleic acid molecule is any CIDEB nucleic acid molecule (such as, a genomic nucleic acid molecule, an mRNA molecule, or a cDNA molecule) encoding a CIDEB polypeptide having a partial loss-of-function, a complete loss-of-function, a predicted partial loss-of-function, or a predicted complete loss-of-function, or encoding a missense polypeptide, or having an impact on the CIDEB mRNA sequence. A subject who has a CIDEB polypeptide having a partial loss-of-function (or predicted partial loss-of-function, or a missense) is hypomorphic for CIDEB (lower abundance or function of the gene compared to the reference sequence version). The CIDEB variant nucleic acid molecule can be any variant nucleic acid molecule described herein. A subject is homozygous for a CIDEB variant nucleic acid molecule when the subject has two copies of any of the CIDEB variant nucleic acid molecules.

›DESCRIPTION · 2 of 30

For subjects that are genotyped or determined to be heterozygous or homozygous for a CIDEB variant nucleic acid molecule, such subjects have a decreased risk of developing a liver disease compared to CIDEB reference subjects. For subjects that are genotyped or determined to be CIDEB reference, such subjects have an increased risk of developing a liver disease compared to carriers of the aforementioned CIDEB variants. For subjects that are genotyped or determined to be CIDEB reference or are heterozygous for a CIDEB variant nucleic acid molecule, such subjects can be treated with one or more CIDEB inhibitors. Such subjects can also be treated with therapeutic agents used to treat a liver disease. For subjects that are genotyped or determined to be CIDEB reference or are heterozygous for a CIDEB variant nucleic acid molecule, such subjects can also be treated with a combination of a CIDEB inhibitor and a PNPLA3 inhibitor and/or an HSD17B13 inhibitor.

For subjects that are genotyped or determined to be CIDEB reference and are carriers of a PNPLA3 variant nucleic acid molecule encoding PNPLA3 Ile148Met or Ile144Met, such subjects have an increased risk of developing a liver disease compared to subjects who are either CIDEB reference or carriers of the aforementioned CIDEB variant types, but do not carry a PNPLA3 variant nucleic acid molecule encoding PNPLA3 Ile148Met or Ile144Met (PNPLA3 reference). For subjects that are genotyped or determined to be CIDEB reference or are heterozygous for a CIDEB variant nucleic acid molecule and to be carriers of a PNPLA3 variant nucleic acid molecule encoding PNPLA3 Ile148Met or Ile144Met, such subjects can be treated with a combination of one or more CIDEB inhibitors and/or one or more PNPLA3 inhibitors. Such subjects can also be treated with therapeutic agents used to treat a liver disease. Such subjects can also be treated with an HSD17B13 inhibitor.

For subjects that are genotyped or determined to be CIDEB reference and are carriers of a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, such subjects have an increased risk of developing a liver disease compared to subjects who are either CIDEB reference or heterozygous carriers of the aforementioned CIDEB variants, but do not carry a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide. For subjects that are genotyped or determined to be CIDEB reference or are heterozygous for a CIDEB variant nucleic acid molecule and to be carriers of a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, such subjects can be treated with a combination of one or more CIDEB inhibitors and/or one or more HSD17B13 inhibitors. Such subjects can also be treated with therapeutic agents used to treat a liver disease. Such subjects can also be treated with a PNPLA3 inhibitor.

In any of the embodiments described herein, the CIDEB variant nucleic acid molecule can be any nucleic acid molecule (such as, for example, genomic nucleic acid molecule, mRNA molecule, or cDNA molecule) encoding a CIDEB polypeptide having a partial loss-of-function, a complete loss-of-function, a predicted partial loss-of-function, or a predicted complete loss-of-function, or encoding a missense polypeptide, or having an impact on the CIDEB mRNA sequence. In some embodiments, the CIDEB variant nucleic acid molecule is a variant that causes or is predicted to cause a nonsynonymous amino acid substitution in CIDEB and whose allele frequency is less than 1/100 alleles in the population from which the subject is selected. In some embodiments, the CIDEB variant nucleic acid molecule is any rare missense variant (allele frequency <1%; or 1 in 100 alleles) or any missense variant predicted or demonstrated to result in a change in CIDEB polypeptide sequence, folding, structure, abundance or function regardless of frequency, or any splice-site, stop-gain, start-loss, stop-loss, frameshift, or in-frame indel, or other frameshift CIDEB variant or any other variant predicted or demonstrated to result in a change in the amino acid sequence of the CIDEB polypeptide. In some embodiments, the subject has one or more of the following CIDEB variant nucleic acid molecules: 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G, 14:24307833:G:C, 14:24307851:T:TAC, 14:24306426:T:C, 14:24307849:G:C, 14:24307448:G:T, 14:24305671:C:T, 14:24305663:C:T, 14:24305686:C:G, 14:24307829:A:C, 14:24307818:CTGAG:C, 14:24307856:C:T, 14:24306423:T:C, 14:24306061:AC:A, 14:24307390:C:T, 14:24306382:G:T, 14:24306373:C:T, 14:24305733:T:C, 14:24307858:T:C, 14:24306387:C:T, 14:24305637:T:C, 14:24306062:C:T, 14:24307853:C:G, 14:24307450:C:G, 14:24306052:TG:T, 14:24305673:G:A, 14:24306043:C:T, 14:24307834:G:A, 14:24306417:C:T, 14:24307451:G:A, 14:24307436:A:C, 14:24305953:ACTTT:A, 14:24306489:G:T, 14:24307441:C:T, 14:24306375:C:T, 14:24305657:C:G, 14:24306427:C:T, 14:24306524:C:T, 14:24307516:C:A, 14:24307840:G:C, 14:24307501:A:G, 14:24305968:A:C, 14:24305986:C:T, 14:24307441:C:G, 14:24307459:G:T, 14:24306017:T:A, 14:24307424:G:A, 14:24306072:G:T, 14:24307423:C:T, 14:24307450:C:T, 14:24306420:G:A, 14:24307454:G:A, 14:24305653:C:T, 14:24307442:G:A, 14:24306002:C:T, 14:24306076:C:T, 14:24305664:C:T, 14:24305961:TG:T, 14:24305706:A:G, 14:24305946:C:T, 14:24306455:G:C, 14:24307468:G:A, 14:24307825:A:C, 14:24306110:G:A, 14:24305710:C:T, 14:24307483:C:T, 14:24306459:A:G, 14:24305754:C:T, 14:24305650:G:C, 14:24305691:C:T, 14:24306508:G:C, 14:24306039:G:T, 14:24306139:T:C, 14:24306391:T:C, 14:24306373:C:A, 14:24307498:C:T, 14:24307415:G:A, 14:24306138:CTG:C, 14:24307453:T:C, 14:24305692:G:A, 14:24305683:C:G, 14:24307484:G:A, 14:24307385:C:T, 14:24306519:A:T, 14:24307839:A:C, 14:24305965:C:T, 14:24305988:CAT:C, 14:24306087:C:G, 14:24307439:C:T, 14:24307477:A:C, 14:24306436:G:T, 14:24306507:A:G, 14:24307397:C:T, 14:24307495:G:A, 14:24306034:A:T, 14:24306013:G:A, 14:24307381:A:G, 14:24306383:G:C, 14:24305638:A:G, 14:24307420:G:A, 14:24306020:C:T, 14:24306470:A:C, 14:24307435:C:T, 14:24306469:C:G, 14:24306451:C:T, 14:24306403:G:A, 14:24307515:C:G, 14:24307489:A:G, 14:24307414:C:T, 14:24306483:A:G, 14:24305755:G:A, 14:24305766:C:T, 14:24306064:T:G, 14:24307516:C:G, 14:24305766:C:G, 14:24306489:G:A, 14:24306097:T:C, 14:24305763:T:G, 14:24307447:G:A, 14:24307402:G:A, 14:24305972:C:G, 14:24306423:T:G, 14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C (according to GRCh38/hg38 human genome assembly coordinates).

›DESCRIPTION · 3 of 30

In any of the embodiments described herein, the CIDEB variant nucleic acid molecules have one or more variations at the indicated positions of chromosome 14 using the nucleotide sequence of the CIDEB reference genomic nucleic acid molecule (SEQ ID NO:1; ENSG00000136305.11 in the GRCh38/hg38 human genome assembly, for which position 24,311,422 of chromosome 14 is the first nucleotide in SEQ ID NO:1).

In any of the embodiments described herein, the CIDEB variant nucleic acid molecules can be mRNA and cDNA molecules having the corresponding variant positions referring to the reference genomic sequence as a reference sequence.

The nucleotide sequences of CIDEB reference mRNA molecules produced through alternative splicing are set forth in SEQ ID NOs:2-12. The variant nucleotides at their respective variant positions for the variant genomic nucleic acid molecules described herein also have corresponding variant nucleotides at their respective variant positions for the variant mRNA molecules based upon the CIDEB reference mRNA sequences according to SEQ ID NOs:2-12. Any of these CIDEB variant mRNA molecules can be detected in any of the methods described herein.

The nucleotide sequences of CIDEB reference cDNA molecules produced through alternative splicing are set forth in SEQ ID NOs:13-23. The variant nucleotides at their respective variant positions for the variant genomic nucleic acid molecules described herein also have corresponding variant nucleotides at their respective variant positions for the variant cDNA molecules based upon the CIDEB reference cDNA sequences according to SEQ ID NOs:13-23. Any of these CIDEB variant cDNA molecules can be detected in any of the methods described herein.

The amino acid sequence of a CIDEB reference polypeptide is set forth in SEQ ID NO:24. Using the translated nucleotide sequence of either the CIDEB mRNA or cDNA molecules, the CIDEB variant polypeptides have corresponding translated variant amino acids at variant positions. Any of these CIDEB predicted loss-of-function polypeptides can be detected in any of the methods described herein.

The nucleotide and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three-letter code for amino acids. The nucleotide sequences follow the standard convention of beginning at the 5′ end of the sequence and proceeding forward (i.e., from left to right in each line) to the 3′ end. Only one strand of each nucleotide sequence is shown, but the complementary strand is understood to be included by any reference to the displayed strand. The amino acid sequence follows the standard convention of beginning at the amino terminus of the sequence and proceeding forward (i.e., from left to right in each line) to the carboxy terminus.

As used herein, the phrase “corresponding to” or grammatical variations thereof when used in the context of the numbering of a particular nucleotide or nucleotide sequence or position refers to the numbering of a specified reference sequence when the particular nucleotide or nucleotide sequence is compared to a reference sequence. In other words, the residue (such as, for example, nucleotide or amino acid) number or residue (such as, for example, nucleotide or amino acid) position of a particular polymer is designated with respect to the reference sequence rather than by the actual numerical position of the residue within the particular nucleotide or nucleotide sequence. For example, a particular nucleotide sequence can be aligned to a reference sequence by introducing gaps to optimize residue matches between the two sequences. In these cases, although the gaps are present, the numbering of the residue in the particular nucleotide or nucleotide sequence is made with respect to the reference sequence to which it has been aligned. A variety of computational algorithms exist that can be used for performing a sequence alignment to identify a nucleotide or amino acid position in one polymeric molecule that corresponds to a nucleotide or amino acid position in another polymeric molecule. For example, by using the NCBI BLAST algorithm (Altschul et al., Nucleic Acids Res., 1997, 25, 3389-3402) or CLUSTALW software (Sievers and Higgins, Methods Mol. Biol., 2014, 1079, 105-116) sequence alignments may be performed. However, sequences can also be aligned manually.

Any one or more (i.e., any combination) of the variants recited herein can be used within any of the methods described herein to determine whether a subject has an increased or decreased risk of developing a liver disease. The combinations of particular variants can form a gene-burden or “mask” used for statistical analysis of the particular correlation of CIDEB and higher or lower risk of developing a liver disease or liver damage (e.g., as quantified by liver biomarkers or imaging related variables).

In any of the embodiments described herein, the CIDEB predicted loss-of-function polypeptide can be any CIDEB polypeptide having a partial loss-of-function, a complete loss-of-function, a predicted partial loss-of-function, or a predicted complete loss-of-function, or missense polypeptide.

In any of the embodiments described herein, the liver disease is a fatty liver disease (such as, for example, alcoholic fatty liver disease (AFLD), non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH)), liver cirrhosis, liver fibrosis, an increased liver enzyme (such as, for example, alanine transaminase (ALT) or aspartate transaminase (AST)), simple steatosis, steatohepatitis, parenchymal liver disease, viral hepatitis, or hepatocellular carcinoma, or any of the complications of such conditions (including, but not limited to, heart or metabolic disease related to NASH or NAFLD, portal vein hypertension or thrombosis, esophageal or gastric varices or bleeding from those varices, and other liver-disease related co-morbidities). In some embodiments, the liver disease is a fatty liver disease. In some embodiments, the liver disease is AFLD. In some embodiments, the liver disease is NAFLD. In some embodiments, the liver disease is NASH. In some embodiments, the liver disease is liver cirrhosis. In some embodiments, the liver disease is liver fibrosis. In some embodiments, the liver disease is an increased liver enzyme. In some embodiments, the liver disease is increased ALT. In some embodiments, the liver disease is increased AST. In some embodiments, the liver disease is simple steatosis. In some embodiments, the liver disease is steatohepatitis. In some embodiments, the liver disease is parenchymal liver disease. In some embodiments, the liver disease is viral hepatitis. In some embodiments, the liver disease is hepatocellular carcinoma. In some embodiments, the liver disease is liver damage quantified by a liver biomarker (e.g., liver transaminase), a change in a liver biomarker, by liver imaging, or by liver histology.

›DESCRIPTION · 4 of 30

Symptoms of liver disease include, but are not limited to, enlarged liver, fatigue, pain in the upper right abdomen, abdominal swelling (ascites), enlarged blood vessels just beneath the skin's surface, enlarged breasts in men, enlarged spleen, red palms, and yellowing of the skin and eyes (jaundice), pruritus, dark urine color, pale stool color nausea or vomiting, loss of appetite, and tendency to bruise easily. Testing for liver diseases can involve blood tests, imaging of the liver, and biopsy of the liver. An individual is at increased risk of a liver disease if the subject has at least one known risk-factor (e.g., genetic factor such as a disease-causing mutation) placing individuals with that risk factor at a statistically significant greater risk of developing the disease than individuals without the risk factor. Risk factors for liver diseases are also well known and can include, for example, excessive alcohol use, obesity, high cholesterol, high levels of triglycerides in the blood, polycystic ovary syndrome, sleep apnea, type 2 diabetes, underactive thyroid (hypothyroidism), underactive pituitary gland (hypopituitarism), and metabolic syndromes including raised blood lipids.

The present disclosure provides methods of treating a subject having a liver disease or at risk of developing a liver disease, the methods comprising administering a CIDEB inhibitor to the subject.

The present disclosure also provides methods of treating a subject having a liver disease or at risk of developing a liver disease, wherein the subject is heterozygous or homozygous for a nucleic acid molecule encoding PNPLA3 Ile148Met or Ile144Met, the methods comprising administering: i) a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount; ii) a combination of a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount and a PNPLA3 inhibitor; iii) a combination of a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount and an HSD17B13 inhibitor; or iv) a combination of a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount, aPNPLA3 inhibitor, and an HSD17B13 inhibitor.

The present disclosure also provides methods of treating a subject having a liver disease or at risk of developing a liver disease, wherein the subject is heterozygous or homozygous for a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide and is heterozygous or homozygous for a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, the methods comprising administering a combination of a CIDEB inhibitor, a PNPLA3 inhibitor, and/or an HSD17B13 inhibitor to the subject.

In these methods, the subject can have any one or more of the liver diseases disclosed herein. In some embodiments, the liver disease is a fatty liver disease. In some embodiments, the liver disease is NAFLD or NASH. In some embodiments, the liver disease is NAFLD. In some embodiments, the liver disease is NASH. In some embodiments, the liver disease is liver cirrhosis. In some embodiments, the liver disease is fibrosis. In some embodiments, the liver disease is an increased liver enzyme. In some embodiments, the liver enzyme is ALT. In some embodiments, the liver enzyme is AST.

The present disclosure also provides methods of treating a subject having a liver disease or at risk of developing a liver disease, the methods comprising determining a nonalcoholic fatty liver disease (NAFLD) activity score (or NASH-CRN nonalcoholic fatty-liver disease activity score or NAS (NASH-CRN nonalcoholic fatty-liver disease activity score)), and when the NAFLD activity score is greater than a pre-determined score, administering to the subject a CIDEB inhibitor, a PNPLA3 inhibitor, or an HSD17B13 inhibitor, or any combination thereof, as described herein. The NAFLD activity score is defined by histological examinations from liver biopsies and scored based on the NASH Clinical Research Network system: steatosis Grade 0 (<5% parenchymal involvement), steatosis Grade 1 (5 to <34%), steatosis Grade 2 (34 to <67%), and steatosis Grade 3 (>67%); lobular inflammation Grade 0 (no foci), lobular inflammation Grade 1 (mild, <2 foci per 200× field), lobular inflammation Grade 2 (moderate, 2-4 foci per 200× field), lobular inflammation Grade 3 (severe, >4 foci per 200× field); ballooning Grade 0 (none), ballooning Grade 1 (few balloon cells), ballooning Grade 2 (many cells/prominent ballooning); fibrosis Stage 0 (none), fibrosis Stage 1 (perisinusoidal or periportal fibrosis), fibrosis Stage 2 (perisinusoidal and periportal fibrosis), fibrosis Stage 3 (bridging fibrosis), and fibrosis Stage 4 (cirrhosis). 5) Nonalcoholic fatty liver disease (NAFLD) activity score (NAS) defined as the unweighted sum of the scores for steatosis (0-3), lobular inflammation (0-3), and ballooning (0-2), thus ranging from 0-8. In some embodiments, the pre-determined NAFLD activity score is greater than 0. In some embodiments, the pre-determined NAFLD activity score is greater than 1. In some embodiments, the pre-determined NAFLD activity score is greater than 2. In some embodiments, the pre-determined NAFLD activity score is greater than 3. In some embodiments, the pre-determined NAFLD activity score is greater than 4. In some embodiments, the pre-determined NAFLD activity score is greater than 5.

›DESCRIPTION · 5 of 30

In some embodiments, the CIDEB inhibitor comprises an inhibitory nucleic acid molecule. Examples of inhibitory nucleic acid molecules include, but are not limited to, antisense nucleic acid molecules, small interfering RNAs (siRNAs), and short hairpin RNAs (shRNAs). Such inhibitory nucleic acid molecules can be designed to target any region of a CIDEB mRNA. In some embodiments, the antisense RNA, siRNA, or shRNA hybridizes to a sequence within a CIDEB genomic nucleic acid molecule or mRNA molecule and decreases expression of the CIDEB polypeptide in a cell in the subject. In some embodiments, the CIDEB inhibitor comprises an antisense RNA that hybridizes to a CIDEB genomic nucleic acid molecule or mRNA molecule and decreases expression of the CIDEB polypeptide in a cell in the subject. In some embodiments, the CIDEB inhibitor comprises an siRNA that hybridizes to a CIDEB genomic nucleic acid molecule or mRNA molecule and decreases expression of the CIDEB polypeptide in a cell in the subject. In some embodiments, the CIDEB inhibitor comprises an shRNA that hybridizes to a CIDEB genomic nucleic acid molecule or mRNA molecule and decreases expression of the CIDEB polypeptide in a cell in the subject.

The inhibitory nucleic acid molecules described herein can be targeted to various CIDEB transcripts. For example, the inhibitory nucleic acid molecules described herein can be targeted to the CIDEB transcripts (derived from chromosome 14; Ensembl Gene ID=ENSG00000136305; hgnc symbol=CIDEB; from top to bottom=Transcript A, Transcript B, Transcript C, Transcript D, Transcript E, and Transcript F) in Table 1.

Additional CIDEB transcripts include, but are not limited to those of the following Ensembl Gene IDs=ENST00000555471, ENST00000555817, ENST00000556756, ENST00000258807, ENS100000336557, and ENST00000554411.

In some embodiments, the antisense nucleic acid molecules targeted to Transcript A comprise or consist of the nucleotide sequences shown in Table 2.

In some embodiments, the antisense nucleic acid molecules targeted to Transcript B comprise or consist of the nucleotide sequences shown in Table 3.

In some embodiments, the antisense nucleic acid molecules targeted to Transcript C comprise or consist of the nucleotide sequences shown in Table 4.

In some embodiments, the antisense nucleic acid molecules targeted to Transcript D comprise or consist of the nucleotide sequences shown in Table 5.

In some embodiments, the antisense nucleic acid molecules targeted to Transcript E comprise or consist of the nucleotide sequences shown in Table 6.

In some embodiments, the antisense nucleic acid molecules targeted to Transcript F comprise or consist of the nucleotide sequences shown in Table 7.

In some embodiments, the siRNA molecules targeted to Transcript A comprise or consist of the nucleotide sequences (sense and antisense strands) shown in Table 8.

In some embodiments, the siRNA molecules targeted to Transcript B comprise or consist of the nucleotide sequences (sense and antisense strands) shown in Table 9.

In some embodiments, the siRNA molecules targeted to Transcript C comprise or consist of the nucleotide sequences (sense and antisense strands) shown in Table 10.

In some embodiments, the siRNA molecules targeted to Transcript D comprise or consist of the nucleotide sequences (sense and antisense strands) shown in Table 11.

In some embodiments, the siRNA molecules targeted to Transcript E comprise or consist of the nucleotide sequences (sense and antisense strands) shown in Table 12.

In some embodiments, the siRNA molecules targeted to Transcript F comprise or consist of the nucleotide sequences (sense and antisense strands) shown in Table 13.

In some embodiments, the PNPLA3 inhibitor comprises an inhibitory nucleic acid molecule. Examples of inhibitory nucleic acid molecules include, but are not limited to, antisense nucleic acid molecules, siRNAs, and shRNAs. Such inhibitory nucleic acid molecules can be designed to target any region of a PNPLA3 mRNA. In some embodiments, the antisense RNA, siRNA, or shRNA hybridizes to a sequence within a PNPLA3 genomic nucleic acid molecule or mRNA molecule and decreases expression of the PNPLA3 polypeptide in a cell in the subject. In some embodiments, the PNPLA3 inhibitor comprises an antisense RNA that hybridizes to a PNPLA3 genomic nucleic acid molecule or mRNA molecule and decreases expression of the PNPLA3 polypeptide in a cell in the subject. In some embodiments, the PNPLA3 inhibitor comprises an siRNA that hybridizes to a PNPLA3 genomic nucleic acid molecule or mRNA molecule and decreases expression of the PNPLA3 polypeptide in a cell in the subject. In some embodiments, the PNPLA3 inhibitor comprises an shRNA that hybridizes to a PNPLA3 genomic nucleic acid molecule or mRNA molecule and decreases expression of the PNPLA3 polypeptide in a cell in the subject.

The inhibitory nucleic acid molecules described herein can be targeted to various PNPLA3 transcripts. For example, the inhibitory nucleic acid molecules described herein can be targeted to the PNPLA3 transcripts (derived from chromosome 22; Ensembl Gene ID=ENSG00000100344.11; hgnc symbol=PNPLA3).

In some embodiments, the HSD17B13 inhibitor comprises an inhibitory nucleic acid molecule. Examples of inhibitory nucleic acid molecules include, but are not limited to, antisense nucleic acid molecules, siRNAs, and shRNAs. Such inhibitory nucleic acid molecules can be designed to target any region of a HSD17B13 mRNA. In some embodiments, the antisense RNA, siRNA, or shRNA hybridizes to a sequence within a HSD17B13 genomic nucleic acid molecule or mRNA molecule and decreases expression of the HSD17B13 polypeptide in a cell in the subject. In some embodiments, the HSD17B13 inhibitor comprises an antisense RNA that hybridizes to a HSD17B13 genomic nucleic acid molecule or mRNA molecule and decreases expression of the HSD17B13 polypeptide in a cell in the subject. In some embodiments, the HSD17B13 inhibitor comprises an siRNA that hybridizes to a HSD17B13 genomic nucleic acid molecule or mRNA molecule and decreases expression of the HSD17B13 polypeptide in a cell in the subject. In some embodiments, the HSD17B13 inhibitor comprises an shRNA that hybridizes to a HSD17B13 genomic nucleic acid molecule or mRNA molecule and decreases expression of the HSD17B13 polypeptide in a cell in the subject.

›DESCRIPTION · 6 of 30

The inhibitory nucleic acid molecules described herein can be targeted to various HSD17B13 transcripts. For example, the inhibitory nucleic acid molecules described herein can be targeted to the HSD17B13 transcripts (derived from chromosome 4; Ensembl Gene ID=ENSG00000170509.8; hgnc symbol=HSD17B13).

The inhibitory nucleic acid molecules disclosed herein can comprise RNA, DNA, or both RNA and DNA. The inhibitory nucleic acid molecules can also be linked or fused to a heterologous nucleic acid sequence, such as in a vector, or a heterologous label. For example, the inhibitory nucleic acid molecules disclosed herein can be within a vector or as an exogenous donor sequence comprising the inhibitory nucleic acid molecule and a heterologous nucleic acid sequence. The inhibitory nucleic acid molecules can also be linked or fused to a heterologous label. The label can be directly detectable (such as, for example, fluorophore) or indirectly detectable (such as, for example, hapten, enzyme, or fluorophore quencher). Such labels can be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Such labels include, for example, radiolabels, pigments, dyes, chromogens, spin labels, and fluorescent labels. The label can also be, for example, a chemiluminescent substance; a metal-containing substance; or an enzyme, where there occurs an enzyme-dependent secondary generation of signal. The term “label” can also refer to a “tag” or hapten that can bind selectively to a conjugated molecule such that the conjugated molecule, when added subsequently along with a substrate, is used to generate a detectable signal. For example, biotin can be used as a tag along with an avidin or streptavidin conjugate of horseradish peroxidate (HRP) to bind to the tag, and examined using a calorimetric substrate (such as, for example, tetramethylbenzidine (TMB)) or a fluorogenic substrate to detect the presence of HRP. Exemplary labels that can be used as tags to facilitate purification include, but are not limited to, myc, HA, FLAG or 3×FLAG, 6×His (SEQ ID NO:10045) or polyhistidine, glutathione-S-transferase (GST), maltose binding protein, an epitope tag, or the Fc portion of immunoglobulin. Numerous labels include, for example, particles, fluorophores, haptens, enzymes and their calorimetric, fluorogenic and chemiluminescent substrates and other labels.

The inhibitory nucleic acid molecules disclosed herein can comprise, for example, nucleotides or non-natural or modified nucleotides, such as nucleotide analogs or nucleotide substitutes. Such nucleotides include a nucleotide that contains a modified base, sugar, or phosphate group, or that incorporates a non-natural moiety in its structure. Examples of non-natural nucleotides include, but are not limited to, dideoxynucleotides, biotinylated, aminated, deaminated, alkylated, benzylated, and fluorophor-labeled nucleotides.

The inhibitory nucleic acid molecules disclosed herein can also comprise one or more nucleotide analogs or substitutions. A nucleotide analog is a nucleotide which contains a modification to either the base, sugar, or phosphate moieties. Modifications to the base moiety include, but are not limited to, natural and synthetic modifications of A, C, G, and T/U, as well as different purine or pyrimidine bases such as, for example, pseudouridine, uracil-5-yl, hypoxanthin-9-yl (I), and 2-aminoadenin-9-yl. Modified bases include, but are not limited to, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo (such as, for example, 5-bromo), 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine, 7-methyladenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, and 3-deazaadenine.

Nucleotide analogs can also include modifications of the sugar moiety.

Modifications to the sugar moiety include, but are not limited to, natural modifications of the ribose and deoxy ribose as well as synthetic modifications. Sugar modifications include, but are not limited to, the following modifications at the 2′ position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl, and alkynyl may be substituted or unsubstituted C 1-10 alkyl or C 2-10 alkenyl, and C 2-10 alkynyl. Exemplary 2′ sugar modifications also include, but are not limited to, —O[(CH 2 ) n O] m CH 3 , —O(CH 2 ) n OCH 3 , —O(CH 2 ) n NH 2 , —O(CH 2 ) n CH 3 , —O(CH 2 ) n —ONH 2 , and —O(CH 2 ) n ON[(CH 2 ) n CH 3 )] 2 , where n and m, independently, are from 1 to about 10. Other modifications at the 2′ position include, but are not limited to, C 1-10 alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , SO 2 CH 3 , ONO 2 , NO 2 , N 3 , NH 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. Similar modifications may also be made at other positions on the sugar, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide. Modified sugars can also include those that contain modifications at the bridging ring oxygen, such as CH 2 and S. Nucleotide sugar analogs can also have sugar mimetics, such as cyclobutyl moieties in place of the pentofuranosyl sugar.

›DESCRIPTION · 7 of 30

Nucleotide analogs can also be modified at the phosphate moiety. Modified phosphate moieties include, but are not limited to, those that can be modified so that the linkage between two nucleotides contains a phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, methyl and other alkyl phosphonates including 3′-alkylene phosphonate and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates. These phosphate or modified phosphate linkage between two nucleotides can be through a 3′-5′ linkage or a 2′-5′ linkage, and the linkage can contain inverted polarity such as 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts, and free acid forms are also included. Nucleotide substitutes also include peptide nucleic acids (PNAs).

In some embodiments, the antisense nucleic acid molecules are gapmers, whereby the first one to seven nucleotides at the 5′ and 3′ ends each have 2′-methoxyethyl (2′-MOE) modifications. In some embodiments, the first five nucleotides at the 5′ and 3′ ends each have 2′-MOE modifications. In some embodiments, the first one to seven nucleotides at the 5′ and 3′ ends are RNA nucleotides. In some embodiments, the first five nucleotides at the 5′ and 3′ ends are RNA nucleotides. In some embodiments, each of the backbone linkages between the nucleotides is a phosphorothioate linkage.

In some embodiments, the siRNA molecules have termini modifications. In some embodiments, the 5′ end of the antisense strand is phosphorylated. In some embodiments, 5′-phosphate analogs that cannot be hydrolyzed, such as 5′-(E)-vinyl-phosphonate are used.

In some embodiments, the siRNA molecules have backbone modifications. In some embodiments, the modified phosphodiester groups that link consecutive ribose nucleosides have been shown to enhance the stability and in vivo bioavailability of siRNAs The non-ester groups (—OH, ═O) of the phosphodiester linkage can be replaced with sulfur, boron, or acetate to give phosphorothioate, boranophosphate, and phosphonoacetate linkages. In addition, substituting the phosphodiester group with a phosphotriester can facilitate cellular uptake of siRNAs and retention on serum components by eliminating their negative charge. In some embodiments, the siRNA molecules have sugar modifications. In some embodiments, the sugars are deprotonated (reaction catalyzed by exo- and endonucleases) whereby the 2′-hydroxyl can act as a nucleophile and attack the adjacent phosphorous in the phosphodiester bond. Such alternatives include 2′-O-methyl, 2′-O-methoxyethyl, and 2′-fluoro modifications.

In some embodiments, the siRNA molecules have base modifications. In some embodiments, the bases can be substituted with modified bases such as pseudouridine, 5′-methylcytidine, N6-methyladenosine, inosine, and N7-methylguanosine.

In some embodiments, the siRNA molecules are conjugated to lipids. Lipids can be conjugated to the 5′ or 3′ termini of siRNA to improve their in vivo bioavailability by allowing them to associate with serum lipoproteins. Representative lipids include, but are not limited to, cholesterol and vitamin E, and fatty acids, such as palmitate and tocopherol.

In some embodiments, a representative siRNA has the following formula:

Sense: mN*mN*/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/*mN*/32FN/ Antisense: /52FN/*/i2FN/*mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN*N*N

wherein: “N” is the base; “2F” is a 2′-F modification; “m” is a 2′-O-methyl modification, “I” is an internal base; and “*” is a phosphorothioate backbone linkage.

The present disclosure also provides vectors comprising any one or more of the inhibitory nucleic acid molecules disclosed herein. In some embodiments, the vectors comprise any one or more of the inhibitory nucleic acid molecules disclosed herein and a heterologous nucleic acid. The vectors can be viral or nonviral vectors capable of transporting a nucleic acid molecule. In some embodiments, the vector is a plasmid or cosmid (such as, for example, a circular double-stranded DNA into which additional DNA segments can be ligated). In some embodiments, the vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Expression vectors include, but are not limited to, plasmids, cosmids, retroviruses, adenoviruses, adeno-associated viruses (AAV), plant viruses such as cauliflower mosaic virus and tobacco mosaic virus, yeast artificial chromosomes (YACs), Epstein-Barr (EBV)-derived episomes, and other expression vectors known in the art.

The present disclosure also provides compositions comprising any one or more of the inhibitory nucleic acid molecules disclosed herein. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the compositions comprise a carrier and/or excipient. Examples of carriers include, but are not limited to, poly(lactic acid) (PLA) microspheres, poly(D,L-lactic-coglycolic-acid) (PLGA) microspheres, liposomes, micelles, inverse micelles, lipid cochleates, and lipid microtubules. A carrier may comprise a buffered salt solution such as PBS, HBSS, etc.

In some embodiments, the CIDEB inhibitor comprises a nuclease agent that induces one or more nicks or double-strand breaks at a recognition sequence(s) or a DNA-binding protein that binds to a recognition sequence within a CIDEB genomic nucleic acid molecule. The recognition sequence can be located within a coding region of the CIDEB gene, or within regulatory regions that influence the expression of the gene. A recognition sequence of the DNA-binding protein or nuclease agent can be located in an intron, an exon, a promoter, an enhancer, a regulatory region, or any non-protein coding region. The recognition sequence can include or be proximate to the start codon of the CIDEB gene. For example, the recognition sequence can be located about 10, about 20, about 30, about 40, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon.

›DESCRIPTION · 8 of 30

In some embodiments, the PNPLA3 inhibitor comprises a nuclease agent that induces one or more nicks or double-strand breaks at a recognition sequence(s) or a DNA-binding protein that binds to a recognition sequence within a PNPLA3 genomic nucleic acid molecule. The recognition sequence can be located within a coding region of the PNPLA3 gene, or within regulatory regions that influence the expression of the gene. A recognition sequence of the DNA-binding protein or nuclease agent can be located in an intron, an exon, a promoter, an enhancer, a regulatory region, or any non-protein coding region. The recognition sequence can include or be proximate to the start codon of the PNPLA3 gene. For example, the recognition sequence can be located about 10, about 20, about 30, about 40, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon.

In some embodiments, the HSD17B13 inhibitor comprises a nuclease agent that induces one or more nicks or double-strand breaks at a recognition sequence(s) or a DNA-binding protein that binds to a recognition sequence within an HSD17B13 genomic nucleic acid molecule. The recognition sequence can be located within a coding region of the HSD17B13 gene, or within regulatory regions that influence the expression of the gene. A recognition sequence of the DNA-binding protein or nuclease agent can be located in an intron, an exon, a promoter, an enhancer, a regulatory region, or any non-protein coding region. The recognition sequence can include or be proximate to the start codon of the HSD17B13 gene. For example, the recognition sequence can be located about 10, about 20, about 30, about 40, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon.

As another example, two or more nuclease agents can be used, each targeting a nuclease recognition sequence including or proximate to the start codon. As another example, two nuclease agents can be used, one targeting a nuclease recognition sequence including or proximate to the start codon, and one targeting a nuclease recognition sequence including or proximate to the stop codon, wherein cleavage by the nuclease agents can result in deletion of the coding region between the two nuclease recognition sequences. Any nuclease agent that induces a nick or double-strand break into a desired recognition sequence can be used in the methods and compositions disclosed herein. Any DNA-binding protein that binds to a desired recognition sequence can be used in the methods and compositions disclosed herein.

Suitable nuclease agents and DNA-binding proteins for use herein include, but are not limited to, zinc finger protein or zinc finger nuclease (ZFN) pair, Transcription Activator-Like Effector (TALE) protein or Transcription Activator-Like Effector Nuclease (TALEN), or Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) systems. The length of the recognition sequence can vary, and includes, for example, recognition sequences that are about 30-36 bp for a zinc finger protein or ZFN pair, about 15-18 bp for each ZFN, about 36 bp for a TALE protein or TALEN, and about 20 bp for a CRISPR/Cas guide RNA.

In some embodiments, CRISPR/Cas systems can be used to modify a CIDEB genomic nucleic acid molecule, a PNPLA3 genomic nucleic acid molecule, or an HSD17B13 genomic nucleic acid molecule within a cell. The methods and compositions disclosed herein can employ CRISPR-Cas systems by utilizing CRISPR complexes (comprising a guide RNA (gRNA) complexed with a Cas protein) for site-directed cleavage of CIDEB nucleic acid molecules, PNPLA3 nucleic acid molecules, or HSD17B13 nucleic acid molecules.

Cas proteins generally comprise at least one RNA recognition or binding domain that can interact with gRNAs. Cas proteins can also comprise nuclease domains (such as, for example, DNase or RNase domains), DNA binding domains, helicase domains, protein-protein interaction domains, dimerization domains, and other domains. Suitable Cas proteins include, for example, a wild type Cas9 protein and a wild type Cpf1 protein (such as, for example, FnCpf1). A Cas protein can have full cleavage activity to create a double-strand break in a CIDEB genomic nucleic acid molecule, a PNPLA3 genomic nucleic acid molecule, or an HSD17B13 genomic nucleic acid molecule, or it can be a nickase that creates a single-strand break in a CIDEB genomic nucleic acid molecule, a PNPLA3 genomic nucleic acid molecule, or an HSD17B13 genomic nucleic acid molecule. Additional examples of Cas proteins include, but are not limited to, Cas1, Cas1B, Cast, Cas3, Cas4, Cas5, Cas5e (CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9 (Csn1 or Csx12), Cas10, Cas10d, Cas12a, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (CasA), Cse2 (CasB), Cse3 (CasE), Cse4 (CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966, and homologs or modified versions thereof. In some embodiments, a Cas system, such as Cas12a, can have multiple gRNAs encoded into a single crRNA. Cas proteins can also be operably linked to heterologous polypeptides as fusion proteins. For example, a Cas protein can be fused to a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Cas proteins can be provided in any form. For example, a Cas protein can be provided in the form of a protein, such as a Cas protein complexed with a gRNA. Alternately, a Cas protein can be provided in the form of a nucleic acid molecule encoding the Cas protein, such as an RNA or DNA.

In some embodiments, targeted genetic modifications of CIDEB genomic nucleic acid molecules can be generated by contacting a cell with a Cas protein and one or more gRNAs that hybridize to one or more gRNA recognition sequences within a target genomic locus in the CIDEB genomic nucleic acid molecule. For example, a gRNA recognition sequence can be located within a region of SEQ ID NO:1. For example, the gRNA recognition sequence can be located from about 1000, from about 500, from about 400, from about 300, from about 200, from about 100, from about 50, from about 45, from about 40, from about 35, from about 30, from about 25, from about 20, from about 15, from about 10, or from about 5 nucleotides of a position corresponding to any one or more of positions: 14:24305635, 14:24305641, 14:24305650, 14:24305657, 14:24305662, 14:24305667, 14:24305671, 14:24305701, 14:24305709, 14:24305718, 14:24305721, 14:24305728, 14:24305743, 14:24305948, 14:24305966, 14:24305974, 14:24305980, 14:24305988, 14:24306014, 14:24306034, 14:24306041, 14:24306044, 14:24306047, 14:24306051, 14:24306064, 14:24306074, 14:24306077, 14:24306082, 14:24306083, 14:24306095, 14:24306122, 14:24306134, 14:24306373, 14:24306379, 14:24306382, 14:24306383, 14:24306426, 14:24306437, 14:24306439, 14:24306442, 14:24306444, 14:24306457, 14:24306463, 14:24306469, 14:24306480, 14:24306486, 14:24306504, 14:24306519, 14:24307382, 14:24307405, 14:24307417, 14:24307421, 14:24307441, 14:24307444, 14:24307444, 14:24307450, 14:24307461, 14:24307469, 14:24307474, 14:24307475, 14:24307833, 14:24307851, 14:24306426, 14:24307849, 14:24307448, 14:24305671, 14:24305663, 14:24305686, 14:24307829, 14:24307818, 14:24307856, 14:24306423, 14:24306061, 14:24307390, 14:24306382, 14:24306373, 14:24305733, 14:24307858, 14:24306387, 14:24305637, 14:24306062, 14:24307853, 14:24307450, 14:24306052, 14:24305673, 14:24306043, 14:24307834, 14:24306417, 14:24307451, 14:24307436, 14:24305953, 14:24306489, 14:24307441, 14:24306375, 14:24305657, 14:24306427, 14:24306524, 14:24307516, 14:24307840, 14:24307501, 14:24305968, 14:24305986, 14:24307441, 14:24307459, 14:24306017, 14:24307424, 14:24306072, 14:24307423, 14:24307450, 14:24306420, 14:24307454, 14:24305653, 14:24307442, 14:24306002, 14:24306076, 14:24305664, 14:24305961, 14:24305706, 14:24305946, 14:24306455, 14:24307468, 14:24307825, 14:24306110, 14:24305710, 14:24307483, 14:24306459, 14:24305754, 14:24305650, 14:24305691, 14:24306508, 14:24306039, 14:24306139, 14:24306391, 14:24306373, 14:24307498, 14:24307415, 14:24306138, 14:24307453, 14:24305692, 14:24305683, 14:24307484, 14:24307385, 14:24306519, 14:24307839, 14:24305965, 14:24305988, 14:24306087, 14:24307439, 14:24307477, 14:24306436, 14:24306507, 14:24307397, 14:24307495, 14:24306034, 14:24306013, 14:24307381, 14:24306383, 14:24305638, 14:24307420, 14:24306020, 14:24306470, 14:24307435, 14:24306469, 14:24306451, 14:24306403, 14:24307515, 14:24307489, 14:24307414, 14:24306483, 14:24305755, 14:24305766, 14:24306064, 14:24307516, 14:24305766, 14:24306489, 14:24306097, 14:24305763, 14:24307447, 14:24307402, 14:24305972, 14:24306423, 14:24305974, 14:24307411, 14:24306121, 14:24307516, 14:24306424, 14:24306039, 14:24307853, 14:24306388, 14:24305990, 14:24307822, 14:24305640, 14:24307418, 14:24305758, 14:24306131, 14:24305953, 14:24305730, 14:24306418, 14:24306059, 14:24307842, 14:24307837, 14:24306095, 14:24306109, 14:24307822, 14:24306077, 14:24307824, 14:24306080, 14:24305649, 14:24306433, 14:24306420, 14:24305658, 14:24306472, 14:24307412, 14:24306062, 14:24306044, 14:24306047, 14:24306126, 14:24306449, 14:24307391, or 14:24307857 (according to GRCh38/hg38 human genome assembly coordinates). The gRNA recognition sequence can include or be proximate to the start codon of a CIDEB genomic nucleic acid molecule or the stop codon of a CIDEB genomic nucleic acid molecule. For example, the gRNA recognition sequence can be located from about 10, from about 20, from about 30, from about 40, from about 50, from about 100, from about 200, from about 300, from about 400, from about 500, or from about 1,000 nucleotides of the start codon or the stop codon.

›DESCRIPTION · 9 of 30

The gRNA recognition sequences within a target genomic locus in a CIDEB genomic nucleic acid molecule can be located near a Protospacer Adjacent Motif (PAM) sequence, which is a 2-6 base pair DNA sequence immediately following the DNA sequence targeted by the Cas9 nuclease. The canonical PAM is the sequence 5′-NGG-3′ where “N” is any nucleobase followed by two guanine (“G”) nucleobases. gRNAs can transport Cas9 to anywhere in the genome for gene editing, but no editing can occur at any site other than one at which Cas9 recognizes PAM. In addition, 5′-NGA-3′ can be a highly efficient non-canonical PAM for human cells. Generally, the PAM is about 2-6 nucleotides downstream of the DNA sequence targeted by the gRNA. The PAM can flank the gRNA recognition sequence. In some embodiments, the gRNA recognition sequence can be flanked on the 3′ end by the PAM. In some embodiments, the gRNA recognition sequence can be flanked on the 5′ end by the PAM. For example, the cleavage site of Cas proteins can be about 1 to about 10, about 2 to about 5 base pairs, or three base pairs upstream or downstream of the PAM sequence. In some embodiments (such as when Cas9 from S. pyogenes or a closely related Cas9 is used), the PAM sequence of the non-complementary strand can be 5′-NGG-3′, where N is any DNA nucleotide and is immediately 3′ of the gRNA recognition sequence of the non-complementary strand of the target DNA. As such, the PAM sequence of the complementary strand would be 5′-CCN-3′, where N is any DNA nucleotide and is immediately 5′ of the gRNA recognition sequence of the complementary strand of the target DNA.

A gRNA is an RNA molecule that binds to a Cas protein and targets the Cas protein to a specific location within a CIDEB genomic nucleic acid molecule. An exemplary gRNA is a gRNA effective to direct a Cas enzyme to bind to or cleave a CIDEB genomic nucleic acid molecule, wherein the gRNA comprises a DNA-targeting segment that hybridizes to a gRNA recognition sequence within the CIDEB genomic nucleic acid molecule that includes or is proximate to a position corresponding to positions: 14:24305635, 14:24305641, 14:24305650, 14:24305657, 14:24305662, 14:24305667, 14:24305671, 14:24305701, 14:24305709, 14:24305718, 14:24305721, 14:24305728, 14:24305743, 14:24305948, 14:24305966, 14:24305974, 14:24305980, 14:24305988, 14:24306014, 14:24306034, 14:24306041, 14:24306044, 14:24306047, 14:24306051, 14:24306064, 14:24306074, 14:24306077, 14:24306082, 14:24306083, 14:24306095, 14:24306122, 14:24306134, 14:24306373, 14:24306379, 14:24306382, 14:24306383, 14:24306426, 14:24306437, 14:24306439, 14:24306442, 14:24306444, 14:24306457, 14:24306463, 14:24306469, 14:24306480, 14:24306486, 14:24306504, 14:24306519, 14:24307382, 14:24307405, 14:24307417, 14:24307421, 14:24307441, 14:24307444, 14:24307444, 14:24307450, 14:24307461, 14:24307469, 14:24307474, 14:24307475, 14:24307833, 14:24307851, 14:24306426, 14:24307849, 14:24307448, 14:24305663, 14:24305686, 14:24307829, 14:24307818, 14:24307856, 14:24306423, 14:24306061, 14:24307390, 14:24306382, 14:24306373, 14:24305733, 14:24307858, 14:24306387, 14:24305637, 14:24306062, 14:24307853, 14:24307450, 14:24306052, 14:24305673, 14:24306043, 14:24307834, 14:24306417, 14:24307451, 14:24307436, 14:24305953, 14:24306489, 14:24307441, 14:24306375, 14:24305657, 14:24306427, 14:24306524, 14:24307516, 14:24307840, 14:24307501, 14:24305968, 14:24305986, 14:24307441, 14:24307459, 14:24306017, 14:24307424, 14:24306072, 14:24307423, 14:24307450, 14:24306420, 14:24307454, 14:24305653, 14:24307442, 14:24306002, 14:24306076, 14:24305664, 14:24305961, 14:24305706, 14:24305946, 14:24306455, 14:24307468, 14:24307825, 14:24306110, 14:24305710, 14:24307483, 14:24306459, 14:24305754, 14:24305650, 14:24305691, 14:24306508, 14:24306039, 14:24306139, 14:24306391, 14:24306373, 14:24307498, 14:24307415, 14:24306138, 14:24307453, 14:24305692, 14:24305683, 14:24307484, 14:24307385, 14:24306519, 14:24307839, 14:24305965, 14:24305988, 14:24306087, 14:24307439, 14:24307477, 14:24306436, 14:24306507, 14:24307397, 14:24307495, 14:24306034, 14:24306013, 14:24307381, 14:24306383, 14:24305638, 14:24307420, 14:24306020, 14:24306470, 14:24307435, 14:24306469, 14:24306451, 14:24306403, 14:24307515, 14:24307489, 14:24307414, 14:24306483, 14:24305755, 14:24305766, 14:24306064, 14:24307516, 14:24305766, 14:24306489, 14:24306097, 14:24305763, 14:24307447, 14:24307402, 14:24305972, 14:24306423, 14:24305974, 14:24307411, 14:24306121, 14:24307516, 14:24306424, 14:24306039, 14:24307853, 14:24306388, 14:24305990, 14:24307822, 14:24305640, 14:24307418, 14:24305758, 14:24306131, 14:24305953, 14:24305730, 14:24306418, 14:24306059, 14:24307842, 14:24307837, 14:24306095, 14:24306109, 14:24307822, 14:24306077, 14:24307824, 14:24306080, 14:24305649, 14:24306433, 14:24306420, 14:24305658, 14:24306472, 14:24307412, 14:24306062, 14:24306044, 14:24306047, 14:24306126, 14:24306449, 14:24307391, or 14:24307857 (according to GRCh38/hg38 human genome assembly coordinates). For example, a gRNA can be selected such that it hybridizes to a gRNA recognition sequence that is located from about 5, from about 10, from about 15, from about 20, from about 25, from about 30, from about 35, from about 40, from about 45, from about 50, from about 100, from about 200, from about 300, from about 400, from about 500, or from about 1,000 nucleotides of a position corresponding to: 14:24305635, 14:24305641, 14:24305650, 14:24305657, 14:24305662, 14:24305667, 14:24305671, 14:24305701, 14:24305709, 14:24305718, 14:24305721, 14:24305728, 14:24305743, 14:24305948, 14:24305966, 14:24305974, 14:24305980, 14:24305988, 14:24306014, 14:24306034, 14:24306041, 14:24306044, 14:24306047, 14:24306051, 14:24306064, 14:24306074, 14:24306077, 14:24306082, 14:24306083, 14:24306095, 14:24306122, 14:24306134, 14:24306373, 14:24306379, 14:24306382, 14:24306383, 14:24306426, 14:24306437, 14:24306439, 14:24306442, 14:24306444, 14:24306457, 14:24306463, 14:24306469, 14:24306480, 14:24306486, 14:24306504, 14:24306519, 14:24307382, 14:24307405, 14:24307417, 14:24307421, 14:24307441, 14:24307444, 14:24307444, 14:24307450, 14:24307461, 14:24307469, 14:24307474, 14:24307475, 14:24307833, 14:24307851, 14:24306426, 14:24307849, 14:24307448, 14:24305663, 14:24305686, 14:24307829, 14:24307818, 14:24307856, 14:24306423, 14:24306061, 14:24307390, 14:24306382, 14:24306373, 14:24305733, 14:24307858, 14:24306387, 14:24305637, 14:24306062, 14:24307853, 14:24307450, 14:24306052, 14:24305673, 14:24306043, 14:24307834, 14:24306417, 14:24307451, 14:24307436, 14:24305953, 14:24306489, 14:24307441, 14:24306375, 14:24305657, 14:24306427, 14:24306524, 14:24307516, 14:24307840, 14:24307501, 14:24305968, 14:24305986, 14:24307441, 14:24307459, 14:24306017, 14:24307424, 14:24306072, 14:24307423, 14:24307450, 14:24306420, 14:24307454, 14:24305653, 14:24307442, 14:24306002, 14:24306076, 14:24305664, 14:24305961, 14:24305706, 14:24305946, 14:24306455, 14:24307468, 14:24307825, 14:24306110, 14:24305710, 14:24307483, 14:24306459, 14:24305754, 14:24305650, 14:24305691, 14:24306508, 14:24306039, 14:24306139, 14:24306391, 14:24306373, 14:24307498, 14:24307415, 14:24306138, 14:24307453, 14:24305692, 14:24305683, 14:24307484, 14:24307385, 14:24306519, 14:24307839, 14:24305965, 14:24305988, 14:24306087, 14:24307439, 14:24307477, 14:24306436, 14:24306507, 14:24307397, 14:24307495, 14:24306034, 14:24306013, 14:24307381, 14:24306383, 14:24305638, 14:24307420, 14:24306020, 14:24306470, 14:24307435, 14:24306469, 14:24306451, 14:24306403, 14:24307515, 14:24307489, 14:24307414, 14:24306483, 14:24305755, 14:24305766, 14:24306064, 14:24307516, 14:24305766, 14:24306489, 14:24306097, 14:24305763, 14:24307447, 14:24307402, 14:24305972, 14:24306423, 14:24305974, 14:24307411, 14:24306121, 14:24307516, 14:24306424, 14:24306039, 14:24307853, 14:24306388, 14:24305990, 14:24307822, 14:24305640, 14:24307418, 14:24305758, 14:24306131, 14:24305953, 14:24305730, 14:24306418, 14:24306059, 14:24307842, 14:24307837, 14:24306095, 14:24306109, 14:24307822, 14:24306077, 14:24307824, 14:24306080, 14:24305649, 14:24306433, 14:24306420, 14:24305658, 14:24306472, 14:24307412, 14:24306062, 14:24306044, 14:24306047, 14:24306126, 14:24306449, 14:24307391, or 14:24307857 (according to GRCh38/hg38 human genome assembly coordinates). Other exemplary gRNAs comprise a DNA-targeting segment that hybridizes to a gRNA recognition sequence present within a CIDEB genomic nucleic acid molecule that includes or is proximate to the start codon or the stop codon. For example, a gRNA can be selected such that it hybridizes to a gRNA recognition sequence that is located from about 5, from about 10, from about 15, from about 20, from about 25, from about 30, from about 35, from about 40, from about 45, from about 50, from about 100, from about 200, from about 300, from about 400, from about 500, or from about 1,000 nucleotides of the start codon or located from about 5, from about 10, from about 15, from about 20, from about 25, from about 30, from about 35, from about 40, from about 45, from about 50, from about 100, from about 200, from about 300, from about 400, from about 500, or from about 1,000 nucleotides of the stop codon. Suitable gRNAs can comprise from about 17 to about 25 nucleotides, from about 17 to about 23 nucleotides, from about 18 to about 22 nucleotides, or from about 19 to about 21 nucleotides. In some embodiments, the gRNAs can comprise 20 nucleotides.

›DESCRIPTION · 10 of 30

Examples of suitable gRNA recognition sequences located within the human CIDEB reference gene are set forth in Table 14 as SEQ ID NOs:25-37.

The Cas protein and the gRNA form a complex, and the Cas protein cleaves the target CIDEB genomic nucleic acid molecule. The Cas protein can cleave the nucleic acid molecule at a site within or outside of the nucleic acid sequence present in the target CIDEB, genomic nucleic acid molecule to which the DNA-targeting segment of a gRNA will bind. For example, formation of a CRISPR complex (comprising a gRNA hybridized to a gRNA recognition sequence and complexed with a Cas protein) can result in cleavage of one or both strands in or near (such as, for example, within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the nucleic acid sequence present in the CIDEB genomic nucleic acid molecule to which a DNA-targeting segment of a gRNA will bind.

Such methods can result, for example, in a CIDEB genomic nucleic acid molecule in which a region of SEQ ID NO:1 is disrupted, the start codon is disrupted, the stop codon is disrupted, or the coding sequence is disrupted or deleted. Optionally, the cell can be further contacted with one or more additional gRNAs that hybridize to additional gRNA recognition sequences within the target genomic locus in the CIDEB genomic nucleic acid molecule. By contacting the cell with one or more additional gRNAs (such as, for example, a second gRNA that hybridizes to a second gRNA recognition sequence), cleavage by the Cas protein can create two or more double-strand breaks or two or more single-strand breaks.

In some embodiments, targeted genetic modifications of PNPLA3 genomic nucleic acid molecules can be generated by contacting a cell with a Cas protein and one or more gRNAs that hybridize to one or more gRNA recognition sequences within a target genomic locus in the PHPLA3 genomic nucleic acid molecule. For example, a gRNA recognition sequence can be located within a region of SEQ ID NO:43. For example, the gRNA recognition sequence can be located from about 1000, from about 500, from about 400, from about 300, from about 200, from about 100, from about 50, from about 45, from about 40, from about 35, from about 30, from about 25, from about 20, from about 15, from about 10, or from about 5 nucleotides of a position corresponding to position 5109 according to SEQ ID NO:43. Other exemplary gRNAs comprise a DNA-targeting segment that hybridizes to a gRNA recognition sequence present within a PNPLA3 genomic nucleic acid molecule that includes or is proximate to the start codon or the stop codon. For example, a gRNA can be selected such that it hybridizes to a gRNA recognition sequence that is located about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon or located about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the stop codon. Suitable gRNAs can comprise from about 17 to about 25 nucleotides, from about 17 to about 23 nucleotides, from about 18 to about 22 nucleotides, or from about 19 to about 21 nucleotides. In some embodiments, the gRNAs comprise 20 nucleotides.

Examples of suitable gRNA recognition sequences located within the PNPLA3 reference gene are set forth in Table 15 as SEQ ID NOs:75-94.

The Cas protein and the gRNA form a complex, and the Cas protein cleaves the target PNPLA3 genomic nucleic acid molecule. The Cas protein can cleave the nucleic acid molecule at a site within or outside of the nucleic acid sequence present in the target PNPLA3, genomic nucleic acid molecule to which the DNA-targeting segment of a gRNA will bind. For example, formation of a CRISPR complex (comprising a gRNA hybridized to a gRNA recognition sequence and complexed with a Cas protein) can result in cleavage of one or both strands in or near (such as, for example, within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the nucleic acid sequence present in the PNPLA3 genomic nucleic acid molecule to which a DNA-targeting segment of a gRNA will bind.

Such methods can result, for example, in a PNPLA3 genomic nucleic acid molecule in which a region of SEQ ID NO:43 is disrupted, the start codon is disrupted, the stop codon is disrupted, or the coding sequence is disrupted or deleted. Optionally, the cell can be further contacted with one or more additional gRNAs that hybridize to additional gRNA recognition sequences within the target genomic locus in the PNPLA3 genomic nucleic acid molecule. By contacting the cell with one or more additional gRNAs (such as, for example, a second gRNA that hybridizes to a second gRNA recognition sequence), cleavage by the Cas protein can create two or more double-strand breaks or two or more single-strand breaks.

In some embodiments, targeted genetic modifications of HSD17B13 genomic nucleic acid molecules can be generated by contacting a cell with a Cas protein and one or more gRNAs that hybridize to one or more gRNA recognition sequences within a target genomic locus in the PHPLA3 genomic nucleic acid molecule. For example, a gRNA recognition sequence can a DNA-targeting segment that hybridizes to a gRNA recognition sequence present within an HSD17B13 genomic nucleic acid molecule that includes or is proximate to the start codon or the stop codon. For example, a gRNA can be selected such that it hybridizes to a gRNA recognition sequence that is located about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon or located about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the stop codon. Suitable gRNAs can comprise from about 17 to about 25 nucleotides, from about 17 to about 23 nucleotides, from about 18 to about 22 nucleotides, or from about 19 to about 21 nucleotides. In some embodiments, the gRNAs comprise 20 nucleotides.

›DESCRIPTION · 11 of 30

Examples of suitable gRNA recognition sequences located within the HSD17B13 reference gene are set forth in Table 16 as SEQ ID NOs:95-114.

The Cas protein and the gRNA form a complex, and the Cas protein cleaves the target HSD17B13 genomic nucleic acid molecule. The Cas protein can cleave the nucleic acid molecule at a site within or outside of the nucleic acid sequence present in the target HSD17B13, genomic nucleic acid molecule to which the DNA-targeting segment of a gRNA will bind. For example, formation of a CRISPR complex (comprising a gRNA hybridized to a gRNA recognition sequence and complexed with a Cas protein) can result in cleavage of one or both strands in or near (such as, for example, within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the nucleic acid sequence present in the HSD17B13 genomic nucleic acid molecule to which a DNA-targeting segment of a gRNA will bind.

Such methods can also result, for example, in an HSD17B13 genomic nucleic acid molecule in which a region of SEQ ID NO:52 is disrupted, the start codon is disrupted, the stop codon is disrupted, or the coding sequence is disrupted or deleted. Optionally, the cell can be further contacted with one or more additional gRNAs that hybridize to additional gRNA recognition sequences within the target genomic locus in the HSD17B13 genomic nucleic acid molecule. By contacting the cell with one or more additional gRNAs (such as, for example, a second gRNA that hybridizes to a second gRNA recognition sequence), cleavage by the Cas protein can create two or more double-strand breaks or two or more single-strand breaks.

In some embodiments, the CIDEB inhibitor is a small molecule. In some embodiments, the CIDEB inhibitor is an antibody. In some embodiments, the CIDEB inhibitor comprises an inhibitory nucleic acid molecule, such as, for example an antisense nucleic acid molecule, an siRNA, or an shRNA.

In some embodiments, the PNPLA3 inhibitor is a small molecule. In some embodiments, the PNPLA3 inhibitor is an antibody. In some embodiments, the PNPLA3 inhibitor comprises an inhibitory nucleic acid molecule, such as, for example an antisense nucleic acid molecule, an siRNA, or an shRNA. An exemplary PNPLA3 inhibitor is AZD2693.

In some embodiments, the HSD17B13 inhibitor is a small molecule. Numerous HSD17B13 inhibitors are described in, for example, PCT Publications WO2019/183329, WO2019/183164, and WO2020/061177. In some embodiments, the HSD17B13 inhibitor is an antibody. In some embodiments, the HSD17B13 inhibitor comprises an inhibitory nucleic acid molecule, such as, for example an antisense nucleic acid molecule, an siRNA, or an shRNA. Additional examples of HSD17B13 inhibitors include, but are not limited to ARO-HSD or ALN-HSD.

In some embodiments, the dose of the CIDEB inhibitor can be reduced by about 10%, by about 20%, by about 30%, by about 40%, by about 50%, by about 60%, by about 70%, by about 80%, or by about 90% for subjects that are heterozygous for one or more CIDEB variant nucleic acid molecules compared to subjects that are CIDEB reference (who may receive a standard dosage amount). In some embodiments, the dose of the CIDEB inhibitor can be reduced by about 10%, by about 20%, by about 30%, by about 40%, or by about 50%. In addition, the dose of the CIDEB inhibitor in subjects that are heterozygous for one or more CIDEB variant nucleic acid molecules can be administered less frequently compared to subjects that are CIDEB reference. The dose can also be changed based on BMI, % liver fat, liver span, age, sex, etc.

In some embodiments, the dose of the PNPLA3 inhibitor can be increased by about 10%, by about 20%, by about 30%, by about 40%, by about 50%, by about 60%, by about 70%, by about 80%, or by about 90% for subjects that are heterozygous for one or more PNPLA3 variant nucleic acid molecules compared to subjects that are PNPLA3 reference (who may receive a standard dosage amount). In some embodiments, the dose of the PNPLA3 inhibitor can be increased by about 10%, by about 20%, by about 30%, by about 40%, or by about 50%. In addition, the dose of the PNPLA3 inhibitor in subjects that are heterozygous for one or more PNPLA3 variant nucleic acid molecules can be administered more frequently compared to subjects that are PNPLA3 reference.

In some embodiments, the dose of the HSD17B13 inhibitor can be reduced by about 10%, by about 20%, by about 30%, by about 40%, by about 50%, by about 60%, by about 70%, by about 80%, or by about 90% for subjects that are heterozygous for one or more HSD17B13 variant nucleic acid molecules compared to subjects that are HSD17B13 reference (who may receive a standard dosage amount). In some embodiments, the dose of the HSD17B13 inhibitor can be reduced by about 10%, by about 20%, by about 30%, by about 40%, or by about 50%. In addition, the dose of the HSD17B13 inhibitor in subjects that are heterozygous for one or more HSD17B13 variant nucleic acid molecules can be administered less frequently compared to subjects that are HSD17B13 reference.

In some embodiments, the methods further comprise detecting the presence or absence of a CIDEB variant nucleic acid molecule and/or a CIDEB predicted loss-of-function polypeptide in a biological sample from the subject. In some embodiments, the CIDEB variant nucleic acid molecule is a genomic nucleic acid molecule. In some embodiments, the CIDEB variant nucleic acid molecule is an mRNA molecule. In some embodiments, the CIDEB variant nucleic acid molecule is a cDNA molecule produced from an mRNA molecule. In some embodiments, the CIDEB variant nucleic acid molecule is a missense variant, a splice-site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant that encodes a truncated or mutated CIDEB polypeptide. In some embodiments, the CIDEB variant nucleic acid molecule comprises 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G, 14:24307833:G:C, 14:24307851:T:TAC, 14:24306426:T:C, 14:24307849:G:C, 14:24307448:G:T, 14:24305671:C:T, 14:24305663:C:T, 14:24305686:C:G, 14:24307829:A:C, 14:24307818:CTGAG:C, 14:24307856:C:T, 14:24306423:T:C, 14:24306061:AC:A, 14:24307390:C:T, 14:24306382:G:T, 14:24306373:C:T, 14:24305733:T:C, 14:24307858:T:C, 14:24306387:C:T, 14:24305637:T:C, 14:24306062:C:T, 14:24307853:C:G, 14:24307450:C:G, 14:24306052:TG:T, 14:24305673:G:A, 14:24306043:C:T, 14:24307834:G:A, 14:24306417:C:T, 14:24307451:G:A, 14:24307436:A:C, 14:24305953:ACTTT:A, 14:24306489:G:T, 14:24307441:C:T, 14:24306375:C:T, 14:24305657:C:G, 14:24306427:C:T, 14:24306524:C:T, 14:24307516:C:A, 14:24307840:G:C, 14:24307501:A:G, 14:24305968:A:C, 14:24305986:C:T, 14:24307441:C:G, 14:24307459:G:T, 14:24306017:T:A, 14:24307424:G:A, 14:24306072:G:T, 14:24307423:C:T, 14:24307450:C:T, 14:24306420:G:A, 14:24307454:G:A, 14:24305653:C:T, 14:24307442:G:A, 14:24306002:C:T, 14:24306076:C:T, 14:24305664:C:T, 14:24305961:TG:T, 14:24305706:A:G, 14:24305946:C:T, 14:24306455:G:C, 14:24307468:G:A, 14:24307825:A:C, 14:24306110:G:A, 14:24305710:C:T, 14:24307483:C:T, 14:24306459:A:G, 14:24305754:C:T, 14:24305650:G:C, 14:24305691:C:T, 14:24306508:G:C, 14:24306039:G:T, 14:24306139:T:C, 14:24306391:T:C, 14:24306373:C:A, 14:24307498:C:T, 14:24307415:G:A, 14:24306138:CTG:C, 14:24307453:T:C, 14:24305692:G:A, 14:24305683:C:G, 14:24307484:G:A, 14:24307385:C:T, 14:24306519:A:T, 14:24307839:A:C, 14:24305965:C:T, 14:24305988:CAT:C, 14:24306087:C:G, 14:24307439:C:T, 14:24307477:A:C, 14:24306436:G:T, 14:24306507:A:G, 14:24307397:C:T, 14:24307495:G:A, 14:24306034:A:T, 14:24306013:G:A, 14:24307381:A:G, 14:24306383:G:C, 14:24305638:A:G, 14:24307420:G:A, 14:24306020:C:T, 14:24306470:A:C, 14:24307435:C:T, 14:24306469:C:G, 14:24306451:C:T, 14:24306403:G:A, 14:24307515:C:G, 14:24307489:A:G, 14:24307414:C:T, 14:24306483:A:G, 14:24305755:G:A, 14:24305766:C:T, 14:24306064:T:G, 14:24307516:C:G, 14:24305766:C:G, 14:24306489:G:A, 14:24306097:T:C, 14:24305763:T:G, 14:24307447:G:A, 14:24307402:G:A, 14:24305972:C:G, 14:24306423:T:G, 14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C (according to GRCh38/hg38 human genome assembly coordinates).

›DESCRIPTION · 12 of 30

Detecting the presence or absence of a CIDEB variant nucleic acid molecule in a biological sample from a subject and/or determining whether a subject has a CIDEB variant nucleic acid molecule can be carried out by any of the methods described herein. In some embodiments, these methods can be carried out in vitro. In some embodiments, these methods can be carried out in situ. In some embodiments, these methods can be carried out in vivo. In any of these embodiments, the nucleic acid molecule can be present within a cell obtained from the subject.

In some embodiments, the detecting step comprises obtaining or having obtained a biological sample from the subject, and performing or having performed an assay on the biological sample to determine whether the subject has the CIDEB variant nucleic acid molecule, and/or a CIDEB predicted loss-of-function polypeptide. In some embodiments, the assay is a sequence analysis that comprises sequencing at least a portion of the nucleotide sequence of the CIDEB genomic nucleic acid molecule in the biological sample. In some embodiments, the assay is a sequence analysis that comprises sequencing at least a portion of the nucleotide sequence of the CIDEB mRNA molecule in the biological sample. In some embodiments, the assay is a sequence analysis that comprises sequencing at least a portion of the nucleotide sequence of the CIDEB cDNA molecule produced from an mRNA molecule in the biological sample.

In some embodiments, the sequence analysis comprises: a) contacting the biological sample with a primer hybridizing to a portion of the nucleotide sequence of the CIDEB nucleic acid molecule that is proximate to a CIDEB variant nucleic acid molecule position; b) extending the primer at least through the CIDEB variant nucleic acid molecule position; and c) determining whether the extension product of the primer comprises a variant nucleotide at the CIDEB variant nucleic acid molecule position. In some embodiments, the sequence analysis comprises sequencing the entire nucleic acid molecule in the biological sample.

In some embodiments, the assay is a sequence analysis that comprises: a) amplifying at least a portion of the CIDEB nucleic acid molecule in the biological sample, wherein the portion comprises a CIDEB variant nucleic acid molecule position; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising an alteration-specific probe, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to the CIDEB variant nucleic acid molecule position; and d) detecting the detectable label. In some embodiments, the CIDEB nucleic acid molecule in the biological sample is mRNA and the mRNA is reverse-transcribed into cDNA prior to the amplifying step.

In some embodiments, the assay is a sequence analysis that comprises contacting the CIDEB nucleic acid molecule in the biological sample with an alteration-specific probe comprising a detectable label, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to a CIDEB variant nucleic acid molecule position, and detecting the detectable label.

In some embodiments, the assay is an immunoassay for detecting the presence of a CIDEB predicted loss-of-function polypeptide. In some embodiments, mass spectrometry is used for detecting the presence of a CIDEB predicted loss-of-function polypeptide.

In some embodiments, the methods further comprise determining the subject's gene burden of having a CIDEB variant nucleic acid molecule and/or a CIDEB predicted loss-of-function polypeptide. When the subject has a lower gene burden, the subject is administered or continued to be administered the CIDEB inhibitor in a standard dosage amount. When the subject has a greater gene burden, the subject is administered or continued to be administered the CIDEB inhibitor in an amount that is the same as or less than the standard dosage amount. In some embodiments, the subject's gene burden represents a weighted sum of a plurality of genetic variants associated with protection against developing a liver disease. In some embodiments, the gene burden is calculated using at least about 2, at least about 3, at least about 4, at least about 5, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 100, at least about 120, at least about 150, at least about 200, at least about 250, at least about 300, at least about 400, at least about 500, or at least about 1,000 genetic variants associated with liver disease. In some embodiments, the gene burden may be divided into quintiles, e.g., top quintile, intermediate quintile, and bottom quintile, wherein the top quintile of gene burden corresponds to the lowest risk group and the bottom quintile of gene burden corresponds to the highest risk group.

The sequence analysis to determine whether a subject has a CIDEB variant nucleic acid molecule can be carried out by any of the methods described herein. In some embodiments, these methods can be carried out in vitro. In some embodiments, these methods can be carried out in situ. In some embodiments, these methods can be carried out in vivo. In any of these embodiments, the nucleic acid molecule can be present within a cell obtained from the subject.

In some embodiments, the methods further comprise detecting the presence or absence of a PNPLA3 variant nucleic acid molecule encoding PNPLA3 Ile148Met or PNPLA3 Ile144Met polypeptide and/or a PNPLA3 Ile148Met or a PNPLA3 Ile144Met polypeptide in a biological sample from the subject. In some embodiments, the PNPLA3 variant nucleic acid molecule is a genomic DNA molecule comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO:43; an mRNA molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47; a cDNA molecule produced from an mRNA molecule, wherein the cDNA molecule has a nucleotide sequence comprising: a guanine at a position corresponding to position 444 according to SEQ ID NO: 50, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51.

›DESCRIPTION · 13 of 30

Detecting the presence or absence of a PNPLA3 variant nucleic acid molecule encoding PNPLA3 Ile148Met or PNPLA3 Ile144Met polypeptide in a biological sample from a subject and/or determining whether a subject has a PNPLA3 variant nucleic acid molecule encoding PNPLA3 Ile148Met or PNPLA3 Ile144Met polypeptide can be carried out by any of the methods described herein. In some embodiments, these methods can be carried out in vitro. In some embodiments, these methods can be carried out in situ. In some embodiments, these methods can be carried out in vivo. In any of these embodiments, the nucleic acid molecule can be present within a cell obtained from the subject.

In some embodiments, the detecting step comprises obtaining or having obtained a biological sample from the subject, and performing or having performed an assay on the biological sample to determine whether the subject has: i) a PNPLA3 genomic nucleic acid molecule comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or a complement thereof; ii) a PNPLA3 mRNA molecule comprising: a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47, or a complement thereof; or iii) a PNPLA3 cDNA molecule comprising: a guanine at a position corresponding to position 444 according to SEQ ID NO: 50, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or a complement thereof.

In some embodiments, the sequence analysis comprises: a) contacting the biological sample with a primer hybridizing to: i) a portion of the nucleotide sequence of the PNPLA3 genomic nucleic acid molecule, or a complement thereof, that is proximate to a position corresponding to position 5109 according to SEQ ID NO:43; ii) a portion of the nucleotide sequence of the PNPLA3 mRNA molecule, or the complement thereof, that is proximate to a position corresponding to position 444 according to SEQ ID NO:46, or position 432 according to SEQ ID NO:47; or iii) a portion of the nucleotide sequence of the PNPLA3 cDNA molecule, or the complement thereof, that is proximate to a position corresponding to position 444 according to SEQ ID NO:50, or position 432 according to SEQ ID NO:51; b) extending the primer at least through: i) position of the nucleotide sequence of PNPLA3 genomic nucleic acid molecule, or a complement thereof corresponding to position corresponding to position 5109 according to SEQ ID NO:43; ii) position of the nucleotide sequence of PNPLA3 mRNA molecule, or a complement thereof corresponding to a position corresponding to position 444 according to SEQ ID NO:46, or position 432 according to SEQ ID NO:47; or iii) position of the nucleotide sequence of PNPLA3 cDNA molecule, or a complement thereof corresponding to a position corresponding to position 444 according to SEQ ID NO:50, or position 432 according to SEQ ID NO:51; and c) determining whether the extension product of the primer comprises: a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or a complement thereof; a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47, or a complement thereof; or a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or a complement thereof.

In some embodiments, the assay is a sequence analysis that comprises a) amplifying at least a portion of: i) a PNPLA3 genomic nucleic acid molecule comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or a complement thereof; ii) a PNPLA3 mRNA molecule comprising: a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47, or a complement thereof; or iii) a PNPLA3 cDNA molecule comprising: a guanine at a position corresponding to position 444 according to SEQ ID NO: 50, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising an alteration-specific probe, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to the nucleotide sequence of the amplified nucleic acid molecule comprising: i) a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or a complement thereof; ii) a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47, or a complement thereof; or iii) a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or a complement thereof; and d) detecting the detectable label.

In some embodiments, the assay is a sequence analysis that comprises contacting the PNPLA3 nucleic acid molecule in the biological sample with an alteration-specific probe comprising a detectable label, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to: i) a PNPLA3 genomic nucleic acid molecule comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or a complement thereof; ii) a PNPLA3 mRNA molecule comprising: a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47, or a complement thereof; or iii) a PNPLA3 cDNA molecule comprising: a guanine at a position corresponding to position 444 according to SEQ ID NO: 50, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51; and detecting the detectable label.

›DESCRIPTION · 14 of 30

The sequence analysis to determine whether a subject has a PNPLA3 variant nucleic acid molecule encoding a PNPLA3 predicted loss-of-function polypeptide can be carried out by any of the methods described herein. In some embodiments, these methods can be carried out in vitro. In some embodiments, these methods can be carried out in situ. In some embodiments, these methods can be carried out in vivo. In any of these embodiments, the nucleic acid molecule can be present within a cell obtained from the subject.

In some embodiments, the assay is an immunoassay for detecting the presence of a PNPLA3 Ile148Met or Ile144Met variant polypeptide. In some embodiments, mass spectrometry is used for detecting the presence of a PNPLA3 Ile148Met or Ile144Met variant polypeptide.

In some embodiments, the methods further comprise detecting the presence or absence of a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide and/or a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide in a biological sample from the subject. In some embodiments, the nucleic acid molecule encoding the reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide comprises: a genomic nucleic acid molecule comprising the nucleotide sequence according to SEQ ID NO:52, or a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:52 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; an mRNA molecule comprising the nucleotide sequence according to any one of SEQ ID NOs:53-62 or a nucleotide sequence having at least 90% sequence identity to SEQ ID NOs:53-62 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; or a cDNA molecule comprising the nucleotide sequence according to any one of SEQ ID NOs:63-72 or a nucleotide sequence having at least 90% sequence identity to SEQ ID NOs:63-72 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide.

Detecting the presence or absence of a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide and/or determining whether a subject has a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide can be carried out by any of the methods described herein. In some embodiments, these methods can be carried out in vitro. In some embodiments, these methods can be carried out in situ. In some embodiments, these methods can be carried out in vivo. In any of these embodiments, the nucleic acid molecule can be present within a cell obtained from the subject.

In some embodiments, the detecting step comprises obtaining or having obtained a biological sample from the subject; and performing or having performed an assay on the biological sample to determine whether the subject has: i) an HSD17B13 genomic nucleic acid molecule comprising SEQ ID NO:52, or a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:52 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; ii) an HSD17B13 mRNA molecule comprising any one of SEQ ID NOs:53-62, or a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs:53-62 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; or iii) an HSD17B13 cDNA molecule comprising any one of SEQ ID NOs:63-72, or a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs:63-72 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide.

In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of the HSD17B13 genomic nucleic acid molecule, mRNA molecule, or cDNA molecule produced from mRNA molecule in the biological sample.

In some embodiments, the assay is an immunoassay for detecting the presence of an HSD17B13 wild type or reference polypeptide. In some embodiments, mass spectrometry is used for detecting the presence of an HSD17B13 wild type or reference polypeptide.

In any of the embodiments described herein, when the subject is CIDEB reference, the subject can be administered the CIDEB inhibitor in a standard dosage amount. When the subject is heterozygous for a CIDEB variant nucleic acid molecule encoding a CIDEB predicted loss-of-function polypeptide, the subject can be administered the CIDEB inhibitor in a dosage amount that is the same as or less than a standard dosage amount. The CIDEB inhibitor can also be administered in combination with one or more PNPLA3 inhibitors and/or one or more HSD17B13 inhibitors.

In any of the embodiments described herein, when the subject is CIDEB reference or is heterozygous for a CIDEB variant nucleic acid molecule and is also a carrier for a nucleic acid molecule encoding a PNPLA3 Ile148Met or an Ile144Met polypeptide, such a subject can be treated with a combination of one or more CIDEB inhibitors, one or more PNPLA3 inhibitors and/or one or more HSD17B13 inhibitors.

In any of the embodiments described herein, when the subject is homozygous for a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, the subject is administered a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount, or is administered a combination of a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount, an HSD17B13 inhibitor, and/or a PNPLA3 inhibitor. When the subject is not homozygous for a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide (i.e., is a carrier for a loss-of-function HSD17B13), the subject is administered a CIDEB inhibitor in an amount that is less than a standard dosage amount, or is administered a combination of a CIDEB inhibitor in an amount that is less than a standard dosage amount, an HSD17B13 inhibitor, and/or a PNPLA3 inhibitor.

In some embodiments, when the subject is CIDEB reference, the subject is also administered a therapeutic agent that treats or inhibits liver disease in a standard dosage amount. In some embodiments, when the subject is heterozygous for a CIDEB variant nucleic acid molecule, the subject is also administered a therapeutic agent that treats or inhibits liver disease in a dosage amount that is the same as or less than a standard dosage amount.

›DESCRIPTION · 15 of 30

In some embodiments, the treatment methods further comprise detecting the presence or absence of a CIDEB predicted loss-of-function polypeptide in a biological sample from the subject. In some embodiments, when the subject does not have a CIDEB predicted loss-of-function or polypeptide, the subject is also administered a therapeutic agent that treats or inhibits liver disease in a standard dosage amount. In some embodiments, when the subject has a CIDEB predicted loss-of-function polypeptide, the subject is also administered a therapeutic agent that treats or inhibits liver disease in a dosage amount that is the same as or less than a standard dosage amount.

In some embodiments, the treatment methods further comprise detecting the presence or absence of a PNPLA3 Ile148Met or an Ile144Met polypeptide in a biological sample from the subject. In some embodiments, when the subject has a CIDEB predicted loss-of-function polypeptide and a PNPLA3 Ile148Met or an Ile144Met polypeptide, the subject is also administered a therapeutic agent that treats or inhibits liver disease in a dosage amount that is the same as or greater than a standard dosage amount.

In some embodiments, the treatment methods further comprise detecting the presence or absence of a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide in a biological sample from the subject. In some embodiments, when the subject is homozygous for a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, the subject is administered a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount, or is administered a combination of a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount, an HSD17B13 inhibitor, and/or a PNPLA3 inhibitor. When the subject is not homozygous for a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide (i.e., is a carrier for a loss-of-function HSD17B13), the subject is administered a CIDEB inhibitor in an amount that is less than a standard dosage amount, or is administered a combination of a CIDEB inhibitor in an amount that is less than a standard dosage amount, an HSD17B13 inhibitor, and/or a PNPLA3 inhibitor.

The present disclosure also provides methods of treating a subject with a CIDEB inhibitor, wherein the subject has a liver disease or is at risk of developing a liver disease. The methods comprise determining whether the subject has a CIDEB variant nucleic acid molecule by obtaining or having obtained a biological sample from the subject, and performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the CIDEB variant nucleic acid molecule. When the subject is CIDEB reference, the method further comprises administering or continuing to administer to the subject the CIDEB inhibitor in a standard dosage amount. When the subject is heterozygous for the CIDEB variant nucleic acid molecule, the method further comprises administering or continuing to administer to the subject the CIDEB inhibitor in a dosage amount that is the same as or less than a standard dosage amount. The presence of a genotype having the CIDEB variant nucleic acid molecule indicates the subject has a decreased risk of developing the liver disease or has a decreased risk of developing a more severe form of the liver disease. Determining whether the subject has a genotype comprising the CIDEB variant nucleic acid molecule can be carried out as described herein.

In some embodiments, the subject is CIDEB reference, and the subject is administered or continued to be administered the CIDEB inhibitor in a standard dosage amount. In some embodiments, the subject is heterozygous for the CIDEB variant nucleic acid molecule, and the subject is administered or continued to be administered the CIDEB inhibitor in a dosage amount that is the same as or less than a standard dosage amount.

In some embodiments, the subject is CIDEB reference or is heterozygous for the CIDEB variant nucleic acid molecule and the subject is a carrier of a nucleic acid molecule encoding a PNPLA3 Ile148Met or an Ile144Met polypeptide, the subject is administered or continued to be administered the CIDEB inhibitor and is also administered a PNPLA3 inhibitor and/or an HSD17B13 inhibitor.

In some embodiments, the subject is CIDEB reference or heterozygous for the CIDEB variant nucleic acid molecule and the subject is a carrier of a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, the subject is administered or continued to be administered the CIDEB inhibitor and is also administered an HSD17B13 inhibitor and/or a PNPLA3 inhibitor.

In any of the embodiments described herein, the method can further comprise administering a therapeutic agent for treating a liver disease to the subject.

In some embodiments, the subject being treated with the CIDEB inhibitor, the PNPLA3 inhibitor, or the HSD17B13 inhibitor, or any combination thereof, has excessive weight, has elevated BMI, is obese, has elevated body fat mass, has elevated percentage of liver fat, has elevated body fat percentage, has elevated body fat volume, and/or has excessive food intake. In some embodiments, the subject is obese. In some embodiments, the subject has excessive weight. In some embodiments, the subject has elevated BMI. In some embodiments, the subject has elevated body fat mass. In some embodiments, the subject has elevated body fat percentage. In some embodiments, the subject has elevated percentage of liver fat. In some embodiments, the subject has elevated body fat volume. In some embodiments, the subject has excessive food intake. In such subjects, the CIDEB inhibitor, the PNPLA3 inhibitor, or the HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent the complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, liver cirrhosis or its comorbidities. In some embodiments, the CIDEB inhibitor, the PNPLA3 inhibitor, or the HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent the complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, liver cirrhosis, or its comorbidities. In some embodiments, the CIDEB inhibitor, the PNPLA3 inhibitor, the HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent the complications of liver injury. In some embodiments, the CIDEB inhibitor, the PNPLA3 inhibitor, or the HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent the complications of liver fat accumulation. In some embodiments, the CIDEB inhibitor, the PNPLA3 inhibitor, or the HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent the complications of liver inflammation. In some embodiments, the CIDEB inhibitor, the PNPLA3 inhibitor, or the HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent the complications of fibrosis. In some embodiments, the CIDEB inhibitor, the PNPLA3 inhibitor, or the HSD17B13 inhibitor, or any combination thereof, is administered to treat or prevent the complications of liver cirrhosis or its comorbidities. In some embodiments, BMI is measured, body fat is determined, or fat distribution is determined to determine if the CIDEB inhibitor, the PNPLA3 inhibitor, or the HSD17B13 inhibitor, or any combination thereof, has to be used or used in different doses or patterns of administration. In some embodiments, BMI is measured. In some embodiments, body fat is determined. In some embodiments, fat distribution is determined. In some embodiments, the dosage of the CIDEB inhibitor, the PNPLA3 inhibitor, or the HSD17B13 inhibitor, or any combination thereof, can be increased upon an increase in any one or more of weight, BMI, obesity, body fat mass, liver fat percentage, body fat percentage, body fat volume, and/or food intake.

›DESCRIPTION · 16 of 30

In some embodiments, the subject being treated with a CIDEB inhibitor, HSD17B13 inhibitor, and/or a PNPLA3 inhibitor is heterozygous or homozygous for a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide. In some embodiments, the subject being treated and having the PNPLA3 Ile148Met or Ile144Met polypeptide is administered the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor to treat or prevent the complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, liver cirrhosis or its comorbidities. In some embodiments, the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor is administered to treat or prevent the complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, liver cirrhosis or its comorbidities. In some embodiments, the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor is administered to treat or prevent the complications of liver injury. In some embodiments, the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor is administered to treat or prevent the complications of liver fat accumulation. In some embodiments, the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor is administered to treat or prevent the complications of liver inflammation. In some embodiments, the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor is administered to treat or prevent the complications of fibrosis. In some embodiments, the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor is administered to treat or prevent the complications of liver cirrhosis or its comorbidities. In some embodiments, the methods further comprise genetic testing for the PNPLA3 Ile148Met or Ile144Met polypeptide to determine if the PNPLA3 inhibitor has to be used or used in a different dose or pattern of administration.

The present disclosure also provides methods of treating a subject having a liver disease or is at risk of developing a liver disease and who is heterozygous or homozygous for a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, the methods comprising administering a CIDEB inhibitor, an HSD17B13 inhibitor, and/or a PNPLA3 inhibitor to the subject.

The amino acid sequences for two reference PNPLA3 polypeptides are set forth in SEQ ID NO:38 and SEQ ID NO:39. The reference PNPLA3 polypeptide having SEQ ID NO:38 is 481 amino acids in length, whereas the reference PNPLA3 polypeptide having SEQ ID NO:39 is 477 amino acids in length. The reference PNPLA3 polypeptide having SEQ ID NO:38 has an isoleucine at position 148. The reference PNPLA3 polypeptide having SEQ ID NO:39 has an isoleucine at position 144.

The PNPLA3 Ile148Met polypeptide comprises an amino acid sequence set forth in SEQ ID NO:40, where the isoleucine at position 148 is replaced with a methionine. The PNPLA3 Ile144Met polypeptide comprises an amino acid sequence set forth in SEQ ID NO:41, where the isoleucine at position 144 is replaced with a methionine.

The nucleotide sequence of a PNPLA3 genomic nucleic acid molecule encoding a reference PNPLA3 polypeptide is set forth in SEQ ID NO:42. The reference PNPLA3 genomic nucleic acid molecule having SEQ ID NO:42 comprises a cytosine at position 5109. The reference PNPLA3 genomic nucleic acid molecule having SEQ ID NO:42 comprises an ATC codon at positions 5107 to 5109.

The nucleotide sequence of a PNPLA3 variant genomic nucleic acid molecule encoding the PNPLA3 Ile148Met and Ile144Met polypeptide is set forth in SEQ ID NO:43, wherein the cytosine at the position corresponding to position 5109 of the reference PNPLA3 genomic nucleic acid molecule (according to SEQ ID NO:42) is replaced with a guanine, and the ATC codon at the positions corresponding to positions 5107 to 5109 of the reference PNPLA3 genomic DNA molecule (according to SEQ ID NO:42) is replaced by an ATG codon.

The nucleotide sequence of a PNPLA3 mRNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:38 is set forth in SEQ ID NO:44. The mRNA molecule encoding the PNPLA3 reference polypeptide having SEQ ID NO:38 comprises a cytosine at position 444. The mRNA molecule encoding the PNPLA3 reference polypeptide having SEQ ID NO:38 comprises an AUC codon at the positions 442 to 444. The nucleotide sequence of a PNPLA3 mRNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:39 is set forth in SEQ ID NO:45. The mRNA molecule encoding the PNPLA3 reference polypeptide having SEQ ID NO:39 comprises a cytosine at position 432. The mRNA molecule encoding the PNPLA3 reference polypeptide having SEQ ID NO:39 comprises an AUC codon at positions 430 to 432.

The nucleotide sequence of a PNPLA3 mRNA molecule encoding a PNPLA3 Ile148Met polypeptide is set forth in SEQ ID NO:46, wherein the cytosine at the position corresponding to position 444 of the PNPLA3 reference mRNA molecule (according to SEQ ID NO:44) is replaced with a guanine, and the AUC codon at positions corresponding to positions 442 to 444 of the PNPLA3 reference mRNA molecule (according to SEQ ID NO:44) is replaced by an AUG codon. The nucleotide sequence of a PNPLA3 mRNA molecule encoding a PNPLA3 Ile144Met polypeptide is set forth in SEQ ID NO:47, wherein the cytosine at the position corresponding to position 432 of the PNPLA3 reference mRNA molecule (according to SEQ ID NO:45) is replaced with a guanine, and the AUC codon at the positions corresponding to positions 430 to 432 of the PNPLA3 reference mRNA molecule (according to SEQ ID NO:45) is replaced by an AUG codon.

The nucleotide sequence of a PNPLA3 cDNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:38 is set forth in SEQ ID NO:48. The cDNA molecule encoding the PNPLA3 reference polypeptide having SEQ ID NO:38 comprises a cytosine at position 444. The cDNA molecule encoding the PNPLA3 reference polypeptide having SEQ ID NO:38 comprises an ATC codon at positions 442 to 444. The nucleotide sequence of a PNPLA3 cDNA molecule encoding a PNPLA3 reference polypeptide having SEQ ID NO:39 is set forth in SEQ ID NO:49. The cDNA molecule encoding the PNPLA3 reference polypeptide having SEQ ID NO:39 comprises a cytosine at position 432. The cDNA molecule encoding the PNPLA3 reference polypeptide having SEQ ID NO:39 comprises an ATC codon at positions 430 to 432.

›DESCRIPTION · 17 of 30

The nucleotide sequence of a PNPLA3 cDNA molecule encoding PNPLA3 Ile148Met polypeptide is set forth in SEQ ID NO:50, wherein the cytosine at the position corresponding to position 444 of the PNPLA3 reference cDNA molecule (according to SEQ ID NO:48) is replaced with a guanine, and the ATC codon at positions corresponding to positions 442 to 444 of the PNPLA3 reference cDNA molecule (according to SEQ ID NO:48) is replaced by an ATG codon. The nucleotide sequence of a PNPLA3 cDNA molecule encoding PNPLA3 Ile144Met polypeptide is set forth in SEQ ID NO:51, wherein the cytosine at the position corresponding to position 432 of the PNPLA3 reference cDNA molecule (according to SEQ ID NO:49) is replaced with a guanine, and the ATC codon at positions corresponding to positions 430 to 432 of the PNPLA3 reference cDNA molecule (according to SEQ ID NO:49) is replaced by an ATG codon.

The present disclosure also provides methods of treating a subject with a CIDEB inhibitor and/or a PNPLA3 inhibitor and/or an HSD17B13 inhibitor, wherein the subject has a liver disease or is at risk of developing a liver disease, the methods comprising: determining whether the subject has a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide by: obtaining or having obtained a biological sample from the subject; and performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the nucleic acid molecule encoding the PNPLA3 Ile148Met or Ile144Met polypeptide; and administering or continuing to administer the CIDEB inhibitor and/or a PNPLA3 inhibitor and/or an HSD17B13 inhibitor to a subject that is heterozygous or homozygous for the nucleic acid molecule encoding the PNPLA3 Ile148Met or Ile144Met polypeptide; wherein the presence of a genotype having the PNPLA3 nucleic acid molecule encoding the Ile148Met or Ile144Met polypeptide indicates the subject is a candidate for treatment with the CIDEB inhibitor and/or the HSD17B13 inhibitor and/or the PNPLA3 inhibitor. In some embodiments, the PNPLA3 nucleic acid molecule encodes PNPLA3 Ile148Met. In some embodiments, the PNPLA3 nucleic acid molecule encodes PNPLA3 Ile144Met. In some embodiments, the subject is also administered a therapeutic agent that treats or inhibits liver disease.

In some embodiments, the PNPLA3 nucleic acid molecule encoding the Ile148Met or Ile144Met polypeptide is: a genomic nucleic acid molecule having a nucleotide sequence comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO:43; an mRNA molecule having a nucleotide sequence comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47; or a cDNA molecule produced from an mRNA molecule, wherein the cDNA molecule has a nucleotide sequence comprising a guanine at a position corresponding to position 444 according to SEQ ID NO: 50, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51.

Methods of detection of any of the PNPLA3 genomic nucleic acid molecules, mRNA molecules, cDNA molecules, or polypeptides can be carried out by gene chip assays, bead assays, sequencing, or immunoassays.

In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of the PNPLA3 genomic nucleic acid molecule in the biological sample, wherein the sequenced portion comprises a position corresponding to position 5109 according to SEQ ID NO:43, or the complement thereof. In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of the PNPLA3 mRNA molecule in the biological sample, wherein the sequenced portion comprises a position corresponding to position 444 according to SEQ ID NO:46, or the complement thereof, or position 432 according to SEQ ID NO:47, or the complement thereof. In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of the PNPLA3 cDNA molecule in the biological sample, wherein the sequenced portion comprises a position corresponding to position 444 according to SEQ ID NO:50, or the complement thereof, or position 432 according to SEQ ID NO:51, or the complement thereof.

In some embodiments, the sequence analysis comprises: a) contacting the biological sample with a primer hybridizing to a portion of the nucleotide sequence of the PNPLA3 genomic nucleic acid molecule that is proximate to a position corresponding to position 5109 according to SEQ ID NO:43; b) extending the primer at least through the position of the nucleotide sequence of the PNPLA3 genomic nucleic acid molecule corresponding to position 5109 according to SEQ ID NO:43; and c) determining whether the extension product of the primer comprises a guanine at a position corresponding to position 5109 according to SEQ ID NO:43.

In some embodiments, the sequence analysis comprises: a) contacting the biological sample with a primer hybridizing to a portion of the nucleotide sequence of the PNPLA3 mRNA molecule that is proximate to a position corresponding to position 444 according to SEQ ID NO:46, or position 432 according to SEQ ID NO:47; b) extending the primer at least through the position of the nucleotide sequence of the PNPLA3 mRNA molecule corresponding to position 444 according to SEQ ID NO:46, or position 432 according to SEQ ID NO:47; and c) determining whether the extension product of the primer comprises a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or a guanine at a position corresponding to position 432 according to SEQ ID NO:47.

In some embodiments, the sequence analysis comprises: a) contacting the biological sample with a primer hybridizing to a portion of the nucleotide sequence of the PNPLA3 cDNA molecule that is proximate to a position corresponding to position 444 according to SEQ ID NO:50, or position 432 according to SEQ ID NO:51; b) extending the primer at least through the position of the nucleotide sequence of the PNPLA3 cDNA molecule corresponding to position 444 according to SEQ ID NO:50, or position 432 according to SEQ ID NO:51; and c) determining whether the extension product of the primer comprises a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or a guanine at a position corresponding to position 432 according to SEQ ID NO:51.

›DESCRIPTION · 18 of 30

In some embodiments, the sequence analysis comprises sequencing the entire nucleic acid molecule.

In some embodiments, the sequence analysis comprises: a) amplifying at least a portion of the nucleic acid molecule that encodes the PNPLA3 polypeptide, wherein the portion comprises a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or the complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:47, or the complement thereof; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising an alteration-specific probe, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to the nucleic acid sequence of the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or the complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:47, or the complement thereof; and d) detecting the detectable label.

In some embodiments, the sequence analysis comprises: a) amplifying at least a portion of the nucleic acid molecule that encodes the PNPLA3 polypeptide, wherein the portion comprises a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or the complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or the complement thereof; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising an alteration-specific probe, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to the nucleic acid sequence of the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or the complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or the complement thereof; and d) detecting the detectable label. In some embodiments, the nucleic acid molecule in the sample is mRNA and the mRNA is reverse-transcribed into cDNA prior to the amplifying step.

In some embodiments, the sequence analysis comprises: contacting the nucleic acid molecule in the biological sample with an alteration-specific probe comprising a detectable label, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to the nucleotide sequence of the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 5109 according to SEQ ID NO:43, or the complement thereof; and detecting the detectable label. In some embodiments, the sequence analysis comprises: contacting the nucleic acid molecule in the biological sample with an alteration-specific probe comprising a detectable label, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to the nucleotide sequence of the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:46, or the complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:47, or the complement thereof; and detecting the detectable label. In some embodiments, the sequence analysis comprises: contacting the nucleic acid molecule in the biological sample with an alteration-specific probe comprising a detectable label, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to the nucleotide sequence of the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or the complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or the complement thereof; and detecting the detectable label.

In some embodiments, the subject being treated with a CIDEB inhibitor, an HSD17B13 inhibitor, and/or a PNPLA3 inhibitor is heterozygous or homozygous for a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide. In some embodiments, the subject being treated and having a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide is administered the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor to treat or prevent the complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, liver cirrhosis or its comorbidities. In some embodiments, the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor is administered to treat or prevent the complications of liver injury, liver fat accumulation, liver inflammation, fibrosis, liver cirrhosis or its comorbidities. In some embodiments, the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor is administered to treat or prevent the complications of liver injury. In some embodiments, the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor is administered to treat or prevent the complications of liver fat accumulation. In some embodiments, the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor is administered to treat or prevent the complications of liver inflammation. In some embodiments, the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor is administered to treat or prevent the complications of fibrosis. In some embodiments, the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor is administered to treat or prevent the complications of liver cirrhosis or its comorbidities. In some embodiments, the methods further comprise genetic testing for the reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide to determine if the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor has to be used or used in different doses or patterns of administration.

›DESCRIPTION · 19 of 30

The present disclosure also provides methods of treating a subject having a liver disease or at risk of developing a liver disease and who is heterozygous or homozygous for a nucleic acid encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, the methods comprising administering a CIDEB inhibitor, an HSD17B13 inhibitor, and/or a PNPLA3 inhibitor to the subject.

The amino acid sequences of two reference HSD17B13 polypeptides are set forth in SEQ ID NO:73 and SEQ ID NO:74. The reference HSD17B13 polypeptide having SEQ ID NO:73 is 264 amino acids in length, whereas the reference HSD17B13 polypeptide having SEQ ID NO:74 is 300 amino acids in length.

The nucleotide sequence of a genomic nucleic acid molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:52 (corresponding to ENSG00000170509.8 located at chr4:87,303,789-87,322,906 according to GRCh38/hg38 Human Genome Assembly).

The nucleotide sequence of an mRNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:53. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:54. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:55. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:56. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:57. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:58. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:59. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:60. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:61. The nucleotide sequence of another mRNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:62.

The nucleotide sequence of a cDNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:63. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:64. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:65. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:66. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:67. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:68. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:69. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:70. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:71. The nucleotide sequence of another cDNA molecule encoding a reference HSD17B13 polypeptide is set forth in SEQ ID NO:72.

The present disclosure also provides methods of treating a subject with a CIDEB inhibitor, an HSD17B13 inhibitor, and/or a PNPLA3 inhibitor, wherein the subject has a liver disease or is at risk of developing a liver disease, the methods comprising: determining whether the subject has a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide by: obtaining or having obtained a biological sample from the subject; and performing or having performed an assay on the biological sample to determine whether the subject has: i) an HSD17B13 genomic nucleic acid molecule comprising SEQ ID NO:52, or a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:52 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; ii) an HSD17B13 mRNA molecule comprising any one of SEQ ID NOs:53-62 or a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs:53-62 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; or iii) an HSD17B13 cDNA molecule comprising any one of SEQ ID NOs:63-72 or a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs:63-72 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, wherein the presence of a genotype having a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide indicates the subject is a candidate for treatment with the CIDEB inhibitor, the HSD17B13 inhibitor, and/or the PNPLA3 inhibitor. In some embodiments, the subject is also administered a therapeutic agent that treats or inhibits liver disease.

In some embodiments, the nucleic acid molecule encoding the reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide is: a genomic nucleic acid molecule comprising the nucleotide sequence according to SEQ ID NO:52, or a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:52 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; an mRNA comprising the nucleotide sequence according to any one of SEQ ID NOs:53-62, or a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs:53-62 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; or a cDNA comprising the nucleotide sequence according to any one of SEQ ID NOs:63-72 or a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs:63-72 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide.

Methods of detection of any of the HSD17B13 genomic nucleic acid molecules, mRNA molecules, cDNA molecules, or polypeptides can be carried out by gene chip assays, bead assays, sequencing, or immunoassays.

›DESCRIPTION · 20 of 30

In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of the HSD17B13 genomic DNA, mRNA or cDNA produced from mRNA molecule in the biological sample.

In some embodiments, the sequence analysis comprises sequencing the entire nucleic acid molecule.

In some embodiments, the nucleic acid molecule is present within a cell obtained from the subject.

In some embodiments, the CIDEB inhibitor comprises an inhibitory nucleic acid molecule. In some embodiments, the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, an siRNA, or an shRNA that hybridizes to a CIDEB nucleic acid molecule.

Examples of therapeutic agents that treat or inhibit liver disease include, but are not limited to: disulfiram, naltrexone, acamprosate, prednisone, azathioprine, penicillamine, trientine, deferoxamine, ciprofloxacin, norofloxacin, ceftriaxone, ofloxacin, amoxicillin-clavulanate, phytonadione, bumetanide, furosemide, hydrochlorothiazide, chlorothiazide, amiloride, triamterene, spironolactone, octreotide, atenolol, metoprolol, nadolol, propranolol, timolol, and carvedilol, or any combination thereof.

Additional examples of liver disease therapeutic agents (e.g., for use in chronic hepatitis C treatment) include, but are not limited to, ribavirin, paritaprevir, OLYSIO® (simeprevir), grazoprevir, ledipasvir, ombitasvir, elbasvir, DAKLINZA® (daclatasvir), dasabuvir, ritonavir, sofosbuvir, velpatasvir, voxilaprevir, glecaprevir, pibrentasvir, peginterferon alfa-2a, peginterferon alfa-2b, and interferon alfa-2b, or any combination thereof.

Additional examples of liver disease therapeutic agents (e.g., for use in nonalcoholic fatty liver disease) include, but are not limited to, weight loss inducing agents such as orlistat or sibutramine; insulin sensitizing agents such as thiazolidinediones (TZDs), metformin, and meglitinides; lipid lowering agents such as statins, fibrates, and omega-3 fatty acids; antioxidants such as, vitamin E, betaine, N-Acetyl-cysteine, lecithin, silymarin, and beta-carotene; anti TNF agents such as pentoxifylline; probiotics, such as VSL #3; and cytoprotective agents such as ursodeoxycholic acid (UDCA), or any combination thereof. Other suitable treatments include ACE inhibitors/ARBs, oligofructose, and Incretin analogs.

Additional examples of liver disease therapeutic agents (e.g., for use in NASH) include, but are not limited to, OCALIVA® (obeticholic acid), Selonsertib, Elafibranor, Cenicriviroc, GR_MD_02, MGL_3196, IMM124E, ARAMCHOL™ (arachidyl amido cholanoic acid), GS0976, Emricasan, Volixibat, NGM282, GS9674, Tropifexor, MN_001, LMB763, BI_1467335, MSDC_0602, PF_05221304, DF102, Saroglitazar, BMS986036, Lanifibranor, Semaglutide, Nitazoxanide, GRI_0621, EYP001, VK2809, Nalmefene, LIK066, MT_3995, Elobixibat, Namodenoson, Foralumab, SAR425899, Sotagliflozin, EDP_305, Isosabutate, Gemcabene, TERN_101, KBP_042, PF_06865571, DUR928, PF_06835919, NGM313, BMS_986171, Namacizumab, CER_209, ND_L02_s0201, RTU_1096, DRX_065, IONIS_DGAT2Rx, INT_767, NC_001, Seladepar, PXL770, TERN_201, NV556, AZD2693, SP_1373, VK0214, Hepastem, TGFTX4, RLBN1127, GKT_137831, RYI_018, CB4209-CB4211, and JH_0920, or any combination thereof.

Administration of the CIDEB inhibitor, PNPLA3 inhibitor, or HSD17B13 inhibitor, or any combination thereof, and/or therapeutic agents that treat or inhibit a liver disease can be repeated, for example, after one day, two days, three days, five days, one week, two weeks, three weeks, one month, five weeks, six weeks, seven weeks, eight weeks, two months, or three months. The repeated administration can be at the same dose or at a different dose. The administration can be repeated once, twice, three times, four times, five times, six times, seven times, eight times, nine times, ten times, or more. For example, according to certain dosage regimens a subject can receive therapy for a prolonged period of time such as, for example, 6 months, 1 year, or more.

Administration of the CIDEB inhibitor, PNPLA3 inhibitor, or HSD17B13 inhibitor, or any combination thereof, and/or therapeutic agents that treat or inhibit a liver disease can occur by any suitable route including, but not limited to, parenteral, intravenous, oral, subcutaneous, intra-arterial, intracranial, intrathecal, intraperitoneal, topical, intranasal, or intramuscular. Pharmaceutical compositions for administration are desirably sterile and substantially isotonic and manufactured under GMP conditions. Pharmaceutical compositions can be provided in unit dosage form (i.e., the dosage for a single administration). Pharmaceutical compositions can be formulated using one or more physiologically and pharmaceutically acceptable carriers, diluents, excipients or auxiliaries. The formulation depends on the route of administration chosen. The term “pharmaceutically acceptable” means that the carrier, diluent, excipient, or auxiliary is compatible with the other ingredients of the formulation and not substantially deleterious to the recipient thereof.

In any of the embodiments described herein, the subject can have or be at risk of developing any one or more of the liver diseases described herein. In some embodiments, the subject is CIDEB reference. In some embodiments, the subject is heterozygous for a CIDEB variant nucleic acid molecule. In some embodiments, the subject is homozygous for a CIDEB variant nucleic acid molecule.

The present disclosure also provides methods of treating a subject, wherein the subject is overweight, obese, has increased body mass index (BMI), has high liver fat percentage, or has high adiposity, the methods comprising administering to the subject a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount, or a CIDEB inhibitor in combination with a PNPLA3 inhibitor and/or an HSD17B13 inhibitor. In some embodiments, the subject is obese. In some embodiments, the subject is overweight. In some embodiments, the subject has increased BMI. In some embodiments, the subject has high adiposity.

›DESCRIPTION · 21 of 30

The terms “treat”, “treating”, and “treatment” and “prevent”, “preventing”, and “prevention” as used herein, refer to eliciting the desired biological response, such as a therapeutic and prophylactic effect, respectively. In some embodiments, a therapeutic effect comprises one or more of a decrease and/or reduction in a liver disease, a decrease and/or reduction in the severity of a liver disease, a decrease and/or reduction in symptoms and liver disease-related effects, delaying the onset of symptoms and liver disease-related effects, reducing the severity of symptoms of liver disease-related effects, reducing the number of symptoms and liver disease-related effects, reducing the latency of symptoms and liver disease-related effects, an amelioration of symptoms and liver disease-related effects, reducing secondary symptoms, reducing secondary infections, preventing relapse to a liver disease, decreasing the number or frequency of relapse episodes, increasing latency between symptomatic episodes, increasing time to sustained progression, speeding recovery, or increasing efficacy of or decreasing resistance to alternative therapeutics, and/or an increased survival time of the affected host animal, following administration of the agent or composition comprising the agent. A prophylactic effect may comprise a complete or partial avoidance and/or inhibition or a delay of liver disease development and/or progression (such as, for example, a complete or partial avoidance/inhibition or a delay), and an increased survival time of the affected host animal, following administration of a therapeutic protocol. Treatment of liver disease encompasses the treatment of subjects already diagnosed as having any form of liver disease at any clinical stage or manifestation, the delay of the onset or evolution or aggravation or deterioration of the symptoms or signs of liver disease, and/or preventing and/or reducing the severity of a liver disease.

The present disclosure also provides methods of identifying a subject having an increased risk of developing a liver disease. In some embodiments, the methods comprise determining or having determined in a biological sample obtained from the subject the presence or absence of a CIDEB variant nucleic acid molecule (such as a genomic nucleic acid molecule, mRNA molecule, and/or cDNA molecule). When the subject lacks a CIDEB variant nucleic acid molecule (i.e., the subject is genotypically categorized as a CIDEB reference), then the subject has an increased risk of developing a liver disease. When the subject has a CIDEB variant nucleic acid molecule (i.e., the subject is heterozygous or homozygous for a CIDEB variant nucleic acid molecule), then the subject has a decreased risk of developing a liver disease compared to a subject who is CIDEB reference.

Having a single copy of a CIDEB variant nucleic acid molecule is more protective of a subject from developing a liver disease than having no copies of a CIDEB variant nucleic acid molecule. Without intending to be limited to any particular theory or mechanism of action, it is believed that a single copy of a CIDEB variant nucleic acid molecule (i.e., heterozygous for a CIDEB variant nucleic acid molecule) is protective of a subject from developing a liver disease, and it is also believed that having two copies of a CIDEB variant nucleic acid molecule (i.e., homozygous for a CIDEB variant nucleic acid molecule) may be more protective of a subject from developing a liver disease, relative to a subject with a single copy. Thus, in some embodiments, a single copy of a CIDEB variant nucleic acid molecule may not be completely protective, but instead, may be partially or incompletely protective of a subject from developing a liver disease. While not desiring to be bound by any particular theory, there may be additional factors or molecules involved in the development of a liver disease that are still present in a subject having a single copy of a CIDEB variant nucleic acid molecule, thus resulting in less than complete protection from the development of a liver disease.

Determining whether a subject has a CIDEB variant nucleic acid molecule in a biological sample from a subject and/or determining whether a subject has a CIDEB variant nucleic acid molecule can be carried out by any of the methods described herein. In some embodiments, these methods can be carried out in vitro. In some embodiments, these methods can be carried out in situ. In some embodiments, these methods can be carried out in vivo. In any of these embodiments, the nucleic acid molecule can be present within a cell obtained from the subject.

The present disclosure also provides methods of identifying a subject having an increased risk of developing a liver disease, such as fatty liver disease, parenchymal liver disease, liver cirrhosis, and/or fibrosis, wherein the methods comprise determining or having determined the subject's gene burden of having one or more CIDEB variant genomic nucleic acid molecules described herein, one or more CIDEB variant mRNA molecules described herein, or one or more variant cDNA molecules described herein, and/or one or more CIDEB predicted loss-of-function polypeptides or missense polypeptides described herein. The greater the gene burden the subject has, the lower the risk of developing a liver disease. The lower the gene burden the subject has, the greater the risk of developing a liver disease.

In some embodiments, the subject's gene burden of having a plurality of (or all) CIDEB variant nucleic acid molecules represents a weighted sum of a plurality of genetic variants associated with protection against developing a liver disease. In some embodiments, the gene burden is calculated using at least about 2, at least about 3, at least about 4, at least about 5, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 100, at least about 120, at least about 150, at least about 200, at least about 250, at least about 300, at least about 400, at least about 500, or at least about 1,000 genetic variants associated with liver disease. In some embodiments, when the subject has a gene burden greater than a threshold score, the subject has a decreased risk of developing a liver disease. In some embodiments, when the subject has a gene burden below a threshold score, the subject has an increased risk of developing a liver disease.

›DESCRIPTION · 22 of 30

In some embodiments, the gene burden is determined by consideration of one or more, or each, of the following variants: 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G, 14:24307833:G:C, 14:24307851:T:TAC, 14:24306426:T:C, 14:24307849:G:C, 14:24307448:G:T, 14:24305671:C:T, 14:24305663:C:T, 14:24305686:C:G, 14:24307829:A:C, 14:24307818:CTGAG:C, 14:24307856:C:T, 14:24306423:T:C, 14:24306061:AC:A, 14:24307390:C:T, 14:24306382:G:T, 14:24306373:C:T, 14:24305733:T:C, 14:24307858:T:C, 14:24306387:C:T, 14:24305637:T:C, 14:24306062:C:T, 14:24307853:C:G, 14:24307450:C:G, 14:24306052:TG:T, 14:24305673:G:A, 14:24306043:C:T, 14:24307834:G:A, 14:24306417:C:T, 14:24307451:G:A, 14:24307436:A:C, 14:24305953:ACTTT:A, 14:24306489:G:T, 14:24307441:C:T, 14:24306375:C:T, 14:24305657:C:G, 14:24306427:C:T, 14:24306524:C:T, 14:24307516:C:A, 14:24307840:G:C, 14:24307501:A:G, 14:24305968:A:C, 14:24305986:C:T, 14:24307441:C:G, 14:24307459:G:T, 14:24306017:T:A, 14:24307424:G:A, 14:24306072:G:T, 14:24307423:C:T, 14:24307450:C:T, 14:24306420:G:A, 14:24307454:G:A, 14:24305653:C:T, 14:24307442:G:A, 14:24306002:C:T, 14:24306076:C:T, 14:24305664:C:T, 14:24305961:TG:T, 14:24305706:A:G, 14:24305946:C:T, 14:24306455:G:C, 14:24307468:G:A, 14:24307825:A:C, 14:24306110:G:A, 14:24305710:C:T, 14:24307483:C:T, 14:24306459:A:G, 14:24305754:C:T, 14:24305650:G:C, 14:24305691:C:T, 14:24306508:G:C, 14:24306039:G:T, 14:24306139:T:C, 14:24306391:T:C, 14:24306373:C:A, 14:24307498:C:T, 14:24307415:G:A, 14:24306138:CTG:C, 14:24307453:T:C, 14:24305692:G:A, 14:24305683:C:G, 14:24307484:G:A, 14:24307385:C:T, 14:24306519:A:T, 14:24307839:A:C, 14:24305965:C:T, 14:24305988:CAT:C, 14:24306087:C:G, 14:24307439:C:T, 14:24307477:A:C, 14:24306436:G:T, 14:24306507:A:G, 14:24307397:C:T, 14:24307495:G:A, 14:24306034:A:T, 14:24306013:G:A, 14:24307381:A:G, 14:24306383:G:C, 14:24305638:A:G, 14:24307420:G:A, 14:24306020:C:T, 14:24306470:A:C, 14:24307435:C:T, 14:24306469:C:G, 14:24306451:C:T, 14:24306403:G:A, 14:24307515:C:G, 14:24307489:A:G, 14:24307414:C:T, 14:24306483:A:G, 14:24305755:G:A, 14:24305766:C:T, 14:24306064:T:G, 14:24307516:C:G, 14:24305766:C:G, 14:24306489:G:A, 14:24306097:T:C, 14:24305763:T:G, 14:24307447:G:A, 14:24307402:G:A, 14:24305972:C:G, 14:24306423:T:G, 14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C (according to GRCh38/hg38 human genome assembly coordinates).

In some embodiments, the gene burden may be divided into quintiles, e.g., top quintile, intermediate quintile, and bottom quintile, wherein the top quintile of gene burden corresponds to the lowest risk group and the bottom quintile of gene burden corresponds to the highest risk group.

In some embodiments, when a subject is identified as having an increased risk of developing a liver disease, the subject is further treated with a therapeutic agent that treats or inhibits liver disease and/or a CIDEB inhibitor, as described herein. For example, when the subject is CIDEB reference, and therefore has an increased risk of developing a liver disease, the subject can be administered a CIDEB inhibitor in a standard dosage amount. In some embodiments, such a subject is also administered a therapeutic agent that treats or inhibits a liver disease. In some embodiments, when the subject is heterozygous for a CIDEB variant nucleic acid molecule, the subject is administered the CIDEB inhibitor in a dosage amount that is the same as or less than a standard dosage amount, and can also be administered a therapeutic agent that treats or inhibits a liver disease. In some embodiments, the subject is CIDEB reference. In some embodiments, the subject is heterozygous for a CIDEB variant nucleic acid molecule.

The present disclosure also provides, in any of the methods described herein, the detection or determination of the presence of a CIDEB variant genomic nucleic acid molecule, a CIDEB variant mRNA molecule, and/or a CIDEB variant cDNA molecule produced from an mRNA molecule in a biological sample from a subject. It is understood that gene sequences within a population and mRNA molecules encoded by such genes can vary due to polymorphisms such as single-nucleotide polymorphisms. The sequences provided herein for the CIDEB variant nucleic acid molecules disclosed herein are only exemplary sequences. Other sequences for the CIDEB variant nucleic acid molecules are also possible.

The present disclosure also provides, in any of the methods described herein, the detection or determination of the presence of a genomic nucleic acid molecule encoding a PNPLA3 Ile148Met polypeptide or a PNPLA3 Ile144Met polypeptide, an mRNA molecule encoding a PNPLA3 Ile148Met polypeptide or a PNPLA3 Ile144Met polypeptide, a cDNA molecule encoding a PNPLA3 Ile148Met polypeptide or a PNPLA3 Ile144Met polypeptide, and/or a PNPLA3 Ile148Met polypeptide or a PNPLA3 Ile144Met polypeptide in a biological sample from the subject. It is understood that gene sequences within a population and mRNA molecules encoded by such genes can vary due to polymorphisms such as single-nucleotide polymorphisms. The sequences provided herein for the PNPLA3 variant nucleic acid molecules disclosed herein are only exemplary sequences. Other sequences for the PNPLA3 variant nucleic acid molecules are also possible. The detection or determination of the presence of PNPLA3 variant nucleic acid molecules is described in, for example, U.S. Pat. No. 10,961,583.

›DESCRIPTION · 23 of 30

The present disclosure also provides, in any of the methods described herein, the detection or determination of the presence of a genomic nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, an mRNA molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, a cDNA molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, and/or a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide in a biological sample from the subject. It is understood that gene sequences within a population and mRNA molecules encoded by such genes can vary due to polymorphisms such as single-nucleotide polymorphisms. The sequences provided herein for the HSD17B13 variant nucleic acid molecules disclosed herein are only exemplary sequences. Other sequences for the HSD17B13 nucleic acid molecules are also possible. The detection or determination of the presence of HSD17B13 nucleic acid molecules is described in, for example, U.S. Pat. No. 10,961,583.

The biological sample can be derived from any cell, tissue, or biological fluid from the subject. The sample may comprise any clinically relevant tissue, such as a bone marrow sample, a tumor biopsy, a fine needle aspirate, or a sample of bodily fluid, such as blood, gingival crevicular fluid, plasma, serum, lymph, ascitic fluid, cystic fluid, or urine. In some cases, the sample comprises a buccal swab. The sample used in the methods disclosed herein will vary based on the assay format, nature of the detection method, and the tissues, cells, or extracts that are used as the sample. A biological sample can be processed differently depending on the assay being employed. For example, when detecting any of the nucleic acid molecules, preliminary processing designed to isolate or enrich the sample for the genomic DNA can be employed. A variety of known techniques may be used for this purpose. When detecting the presence of or level of any CIDEB, PNPLA3, and/or HSD17B13 mRNA molecule, different techniques can be used enrich the biological sample with mRNA. Various methods to detect the presence or level of a mRNA or the presence of a particular variant genomic DNA locus can be used.

In some embodiments, detecting a CIDEB variant nucleic acid molecule in a subject comprises assaying or performing a sequence analysis on a biological sample obtained from the subject to determine whether a CIDEB genomic nucleic acid molecule, a CIDEB mRNA molecule, or a CIDEB cDNA molecule produced from an mRNA molecule in the biological sample is a CIDEB variant nucleic acid molecule.

In some embodiments, the methods of detecting the presence or absence of a CIDEB variant nucleic acid molecule (such as, for example, a genomic nucleic acid molecule, an mRNA molecule, and/or a cDNA molecule) in a subject, comprise performing an assay on a biological sample obtained from the subject, which assay determines whether a nucleic acid molecule in the biological sample comprises a particular nucleotide sequence.

In some embodiments, detecting a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide in a subject comprises assaying or performing a sequence analysis on a biological sample obtained from the subject to determine whether a PNPLA3 genomic nucleic acid molecule, a PNPLA3 mRNA molecule, or a PNPLA3 cDNA molecule produced from an mRNA molecule in the biological sample encodes an Ile148Met or Ile144Met polypeptide.

In some embodiments, the methods of detecting the presence or absence of a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide (such as, for example, a genomic nucleic acid molecule, an mRNA molecule, and/or a cDNA molecule) in a subject, comprise performing an assay on a biological sample obtained from the subject, which assay determines whether a nucleic acid molecule in the biological sample comprises a particular nucleotide sequence.

In some embodiments, detecting a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide comprises assaying or performing a sequence analysis on a biological sample obtained from the subject to determine whether a HSD17B13 genomic nucleic acid molecule, a HSD17B13 mRNA molecule, or a HSD17B13 cDNA molecule produced from an mRNA molecule in the biological sample encodes a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide.

In some embodiments, the methods of detecting the presence or absence of a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide (such as, for example, a genomic nucleic acid molecule, an mRNA molecule, and/or a cDNA molecule) in a subject, comprise performing an assay on a biological sample obtained from the subject, which assay determines whether a nucleic acid molecule in the biological sample comprises a particular nucleotide sequence.

In some embodiments, the biological sample comprises a cell or cell lysate. Such methods can further comprise, for example, obtaining a biological sample from the subject comprising a CIDEB, PNPLA3, and/or HSD17B13 genomic nucleic acid molecule or mRNA molecule, and if mRNA, optionally reverse transcribing the mRNA into cDNA. Such assays can comprise, for example determining the identity of these positions of the particular, CIDEB, PNPLA3, and/or HSD17B13 nucleic acid molecule. In some embodiments, the method is an in vitro method.

In some embodiments, the determining step, detecting step, or sequence analysis comprises sequencing at least a portion of the nucleotide sequence of the CIDEB, PNPLA3, and/or HSD17B13 genomic nucleic acid molecule, the CIDEB, PNPLA3, and/or HSD17B13 mRNA molecule, or the CIDEB, PNPLA3, and/or HSD17B13 cDNA molecule produced from the mRNA molecule in the biological sample, wherein the sequenced portion comprises one or more variations that cause a loss-of-function or missense (partial or complete) or are predicted to cause a loss-of-function or missense (partial or complete), such as any one or more of the CIDEB, PNPLA3, and/or HSD17B13 nucleic acid molecules described herein.

›DESCRIPTION · 24 of 30

In any of the methods described herein, the determining step, detecting step, or sequence analysis comprises sequencing at least a portion of the nucleotide sequence of the CIDEB or PNPLA3 nucleic acid molecule in the biological sample, wherein the sequenced portion comprises a position corresponding to a variant nucleic acid molecule position, wherein when a variant nucleotide at the variant nucleic acid molecule position is detected, the CIDEB or PNPLA3 nucleic acid molecule in the biological sample is a CIDEB or PNPLA3 variant nucleic acid molecule.

In some embodiments, the determining step, detecting step, or sequence analysis comprises: a) contacting the biological sample with a primer hybridizing to a portion of the nucleotide sequence of the CIDEB nucleic acid molecule that is proximate to a variant nucleic acid molecule position; b) extending the primer at least through the variant nucleic acid molecule position; and c) determining whether the extension product of the primer comprises a variant nucleotide at the variant nucleic acid molecule position.

In some embodiments, the assay comprises sequencing the entire nucleic acid molecule. In some embodiments, only a CIDEB genomic nucleic acid molecule is analyzed. In some embodiments, only a CIDEB mRNA is analyzed. In some embodiments, only a CIDEB cDNA obtained from CIDEB mRNA is analyzed.

In some embodiments, the determining step, detecting step, or sequence analysis comprises: a) amplifying at least a portion of the CIDEB nucleic acid molecule that encodes the CIDEB polypeptide, wherein the portion comprises a variant nucleic acid molecule position; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising an alteration-specific probe, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to the variant nucleic acid molecule position; and d) detecting the detectable label.

In any of the methods described herein, the determining step, detecting step, or sequence analysis comprises sequencing at least a portion of the nucleotide sequence of the nucleotide sequence of the PNPLA3 genomic nucleic acid molecule in the biological sample, wherein the sequenced portion comprises a position corresponding to position 5109 according to SEQ ID NO:43 (i.e., the variant nucleic acid molecule position), or the complement thereof. In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of the PNPLA3 mRNA molecule in the biological sample, wherein the sequenced portion comprises a position corresponding to position 444 according to SEQ ID NO:46 (i.e., the variant nucleic acid molecule position), or the complement thereof; or position 432 according to SEQ ID NO:47 (i.e., the variant nucleic acid molecule position), or the complement thereof. In some embodiments, the sequence analysis comprises sequencing at least a portion of the nucleotide sequence of the PNPLA3 cDNA molecule in the biological sample, wherein the sequenced portion comprises a position corresponding to position 444 according to SEQ ID NO:50 (i.e., the variant nucleic acid molecule position), or the complement thereof; or position 432 according to SEQ ID NO:51 (i.e., the variant nucleic acid molecule position), or the complement thereof.

In some embodiments, the assay comprises sequencing the entire nucleic acid molecule. In some embodiments, only a PNPLA3 genomic nucleic acid molecule is analyzed. In some embodiments, only a PNPLA3 mRNA is analyzed. In some embodiments, only a PNPLA3 cDNA obtained from PNPLA3 mRNA is analyzed.

›DESCRIPTION · 25 of 30

In some embodiments, the sequence analysis comprises: a) amplifying at least a portion of the nucleic acid molecule that encodes the PNPLA3 polypeptide, wherein the portion comprises a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or the complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or the complement thereof; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising an alteration-specific probe, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to the nucleic acid sequence of the amplified nucleic acid molecule comprising a guanine at a position corresponding to position 444 according to SEQ ID NO:50, or the complement thereof; or a guanine at a position corresponding to position 432 according to SEQ ID NO:51, or the complement thereof; and d) detecting the detectable label.

In any of the methods described herein, the determining step, detecting step, or sequence analysis comprises obtaining or having obtained a biological sample from the subject; and performing or having performed an assay on the biological sample to determine whether the subject has: i) an HSD17B13 genomic DNA comprising SEQ ID NO:52; or a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:52 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; ii) an HSD17B13 mRNA comprising any one of SEQ ID NOs:53-62, or a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NOs:53-62 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; or iii) an HSD17B13 cDNA comprising any one of SEQ ID NOs:63-72, or a nucleotide sequence having at least 90% sequence identity to any one SEQ ID NOs:63-72 and encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide.

In some embodiments, the nucleic acid molecule is mRNA and the determining step further comprises reverse-transcribing the mRNA into a cDNA prior to the amplifying step.

In some embodiments, the determining step, detecting step, or sequence analysis comprises: contacting the nucleic acid molecule in the biological sample with an alteration-specific probe comprising a detectable label, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to a variant nucleic acid molecule position; and detecting the detectable label.

The alteration-specific probes or alteration-specific primers described herein comprise a nucleic acid sequence which is complementary to and/or hybridizes, or specifically hybridizes, to a CIDEB variant nucleic acid molecule, or the complement thereof. In some embodiments, the alteration-specific probes or alteration-specific primers comprise or consist of at least about 1, at least about 5, at least about 8, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, or at least about 50 nucleotides. In some embodiments, the alteration-specific probes or alteration-specific primers comprise or consist of at least 15 nucleotides. In some embodiments, the alteration-specific probes or alteration-specific primers comprise or consist of at least 15 nucleotides to at least about 35 nucleotides. In some embodiments, alteration-specific probes or alteration-specific primers hybridize to CIDEB variant genomic nucleic acid molecules, CIDEB variant mRNA molecules, and/or CIDEB variant cDNA molecules under stringent conditions.

The alteration-specific probes or alteration-specific primers described herein comprise a nucleic acid sequence which is complementary to and/or hybridizes, or specifically hybridizes, to a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, or the complement thereof. In some embodiments, the alteration-specific probes or alteration-specific primers comprise or consist of at least about 1, at least about 5, at least about 8, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, or at least about 50 nucleotides. In some embodiments, the alteration-specific probes or alteration-specific primers comprise or consist of at least 15 nucleotides. In some embodiments, the alteration-specific probes or alteration-specific primers comprise or consist of at least 15 nucleotides to at least about 35 nucleotides. In some embodiments, alteration-specific probes or alteration-specific primers hybridize to genomic nucleic acid molecules encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, mRNA molecules encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, and/or cDNA molecules encoding a PNPLA3 Ile148Met or Ile144Met polypeptide under stringent conditions.

›DESCRIPTION · 26 of 30

Alteration-specific polymerase chain reaction techniques can be used to detect mutations such as SNPs in a nucleic acid sequence. Alteration-specific primers can be used because the DNA polymerase will not extend when a mismatch with the template is present.

In some embodiments, the nucleic acid molecule in the sample is mRNA and the mRNA is reverse-transcribed into a cDNA prior to the amplifying step. In some embodiments, the nucleic acid molecule is present within a cell obtained from the subject.

In some embodiments, the assay comprises contacting the biological sample with a primer or probe, such as an alteration-specific primer or alteration-specific probe, that specifically hybridizes to a CIDEB variant genomic sequence, variant mRNA sequence, or variant cDNA sequence and not the corresponding CIDEB reference sequence under stringent conditions, and determining whether hybridization has occurred.

In some embodiments, the assay comprises contacting the biological sample with a primer or probe, such as an alteration-specific primer or alteration-specific probe, that specifically hybridizes to genomic nucleic acid molecules encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, mRNA molecules encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, and/or cDNA molecules encoding a PNPLA3 Ile148Met or Ile144Met polypeptide under stringent conditions, and determining whether hybridization has occurred.

In some embodiments, the assay comprises RNA sequencing (RNA-Seq). In some embodiments, the assays also comprise reverse transcribing mRNA into cDNA, such as by the reverse transcriptase polymerase chain reaction (RT-PCR).

In some embodiments, the methods utilize probes and primers of sufficient nucleotide length to bind to the target nucleotide sequence and specifically detect and/or identify a polynucleotide comprising a CIDEB variant genomic nucleic acid molecule, a variant mRNA molecule, or a variant cDNA molecule, and/or a nucleic acid molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, an mRNA molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, and/or a cDNA molecule encoding a PNPLA3 Ile148Met or Ile144Met polypeptide. The hybridization conditions or reaction conditions can be determined by the operator to achieve this result. The nucleotide length may be any length that is sufficient for use in a detection method of choice, including any assay described or exemplified herein. Such probes and primers can hybridize specifically to a target nucleotide sequence under high stringency hybridization conditions. Probes and primers may have complete nucleotide sequence identity of contiguous nucleotides within the target nucleotide sequence, although probes differing from the target nucleotide sequence and that retain the ability to specifically detect and/or identify a target nucleotide sequence may be designed by conventional methods. Probes and primers can have about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% sequence identity or complementarity with the nucleotide sequence of the target nucleic acid molecule.

Illustrative examples of nucleic acid sequencing techniques include, but are not limited to, chain terminator (Sanger) sequencing and dye terminator sequencing. Other methods involve nucleic acid hybridization methods other than sequencing, including using labeled primers or probes directed against purified DNA, amplified DNA, and fixed cell preparations (fluorescence in situ hybridization (FISH)). In some methods, a target nucleic acid molecule may be amplified prior to or simultaneous with detection. Illustrative examples of nucleic acid amplification techniques include, but are not limited to, polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), and nucleic acid sequence based amplification (NASBA). Other methods include, but are not limited to, ligase chain reaction, strand displacement amplification, and thermophilic SDA (tSDA).

In hybridization techniques, stringent conditions can be employed such that a probe or primer will specifically hybridize to its target. In some embodiments, a polynucleotide primer or probe under stringent conditions will hybridize to its target sequence to a detectably greater degree than to other non-target sequences, such as, at least 2-fold, at least 3-fold, at least 4-fold, or more over background, including over 10-fold over background. Stringent conditions are sequence-dependent and will be different in different circumstances.

Appropriate stringency conditions which promote DNA hybridization, for example, 6× sodium chloride/sodium citrate (SSC) at about 45° C., followed by a wash of 2×SSC at 50° C., are known or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Typically, stringent conditions for hybridization and detection will be those in which the salt concentration is less than about 1.5 M Na + ion, typically about 0.01 to 1.0 M Na + ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (such as, for example, 10 to 50 nucleotides) and at least about 60° C. for longer probes (such as, for example, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Optionally, wash buffers may comprise about 0.1% to about 1% SDS. Duration of hybridization is generally less than about 24 hours, usually about 4 to about 12 hours. The duration of the wash time will be at least a length of time sufficient to reach equilibrium.

In some embodiments, detecting the presence of a predicted loss-of-function polypeptide or missense polypeptide comprises performing an assay on a sample obtained from a subject to determine whether a CIDEB polypeptide in the subject contains one or more variations that causes the polypeptide to have a loss-of-function (partial or complete) or predicted loss-of-function (partial or complete) or missense variant. In some embodiments, the assay comprises sequencing at least a portion of the CIDEB polypeptide that comprises a variant position. In some embodiments, the detecting step comprises sequencing the entire polypeptide. Identification of a variant amino acid at the variant position of the CIDEB polypeptide indicates that the CIDEB polypeptide is a predicted loss-of-function or missense CIDEB polypeptide. In some embodiments, the assay comprises an immunoassay for detecting the presence of a polypeptide that comprises a variant. Detection of a variant amino acid at the variant position of the CIDEB polypeptide indicates that the CIDEB polypeptide is a CIDEB predicted loss-of-function or missense polypeptide.

›DESCRIPTION · 27 of 30

In some embodiments, detecting the presence of a PNPLA3 Ile148Met or Ile144Met polypeptide comprises performing an assay on a sample obtained from a subject to determine whether a PNPLA3 polypeptide in the subject contains the Ile148Met or Ile144Met variation. In some embodiments, the assay comprises sequencing at least a portion of the PNPLA3 polypeptide that comprises a variant position. In some embodiments, the detecting step comprises sequencing the entire polypeptide. In some embodiments, the assay comprises an immunoassay for detecting the presence of a polypeptide that comprises a variant.

In some embodiments, isolated nucleic acid molecules hybridize to CIDEB variant nucleic acid molecules, nucleic acid molecules encoding a PNPLA3 Ile148Met or Ile144Met polypeptide, or nucleic acid molecules encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide (such as genomic nucleic acid molecules, mRNA molecules, and/or cDNA molecules) under stringent conditions. Such nucleic acid molecules can be used, for example, as probes, primers, alteration-specific probes, or alteration-specific primers as described or exemplified herein, and include, without limitation primers, probes, antisense RNAs, shRNAs, and siRNAs, each of which is described in more detail elsewhere herein, and can be used in any of the methods described herein.

In some embodiments, the isolated nucleic acid molecules hybridize to at least about 15 contiguous nucleotides of a nucleic acid molecule that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to HSD17B13 genomic nucleic acid molecules encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, HSD17B13 mRNA molecules encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, and/or HSD17B13 cDNA molecules encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide. In some embodiments, the isolated nucleic acid molecules consist of or comprise from about 15 to about 100 nucleotides, or from about 15 to about 35 nucleotides. In some embodiments, the isolated nucleic acid molecules consist of or comprise from about 15 to about 100 nucleotides. In some embodiments, the isolated nucleic acid molecules consist of or comprise from about 15 to about 35 nucleotides.

In some embodiments, the alteration-specific probes and alteration-specific primers comprise DNA. In some embodiments, the alteration-specific probes and alteration-specific primers comprise RNA.

In some embodiments, the probes and primers described herein (including alteration-specific probes and alteration-specific primers) have a nucleotide sequence that specifically hybridizes to any of the nucleic acid molecules disclosed herein, or the complement thereof. In some embodiments, the probes and primers specifically hybridize to any of the nucleic acid molecules disclosed herein under stringent conditions.

In some embodiments, the primers, including alteration-specific primers, can be used in second generation sequencing or high throughput sequencing. In some instances, the primers, including alteration-specific primers, can be modified. In particular, the primers can comprise various modifications that are used at different steps of, for example, Massive Parallel Signature Sequencing (MPSS), Polony sequencing, and 454 Pyrosequencing. Modified primers can be used at several steps of the process, including biotinylated primers in the cloning step and fluorescently labeled primers used at the bead loading step and detection step. Polony sequencing is generally performed using a paired-end tags library wherein each molecule of DNA template is about 135 bp in length. Biotinylated primers are used at the bead loading step and emulsion PCR. Fluorescently labeled degenerate nonamer oligonucleotides are used at the detection step. An adaptor can contain a 5′-biotin tag for immobilization of the DNA library onto streptavidin-coated beads.

The probes and primers described herein can also be used to detect a nucleotide variation within any of the CIDEB variant genomic nucleic acid molecules, CIDEB variant mRNA molecules, and/or CIDEB variant cDNA molecules disclosed herein. The primers described herein can be used to amplify CIDEB variant genomic nucleic acid molecules, CIDEB variant mRNA molecules, or CIDEB variant cDNA molecules, or a fragment thereof.

In some embodiments, the probes (such as, for example, an alteration-specific probe) comprise a label. In some embodiments, the label is a fluorescent label, a radiolabel, or biotin.

The present disclosure also provides supports comprising a substrate to which any one or more of the probes disclosed herein is attached. Solid supports are solid-state substrates or supports with which molecules, such as any of the probes disclosed herein, can be associated. A form of solid support is an array. Another form of solid support is an array detector. An array detector is a solid support to which multiple different probes have been coupled in an array, grid, or other organized pattern. A form for a solid-state substrate is a microtiter dish, such as a standard 96-well type. In some embodiments, a multiwell glass slide can be employed that normally contains one array per well.

›DESCRIPTION · 28 of 30

The present disclosure also provides therapeutic compositions that treat or inhibit a liver disease for use in the treatment of a liver disease in a subject having one or more CIDEB variant nucleic acid molecules comprising: 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G, 14:24307833:G:C, 14:24307851:T:TAC, 14:24306426:T:C, 14:24307849:G:C, 14:24307448:G:T, 14:24305671:C:T, 14:24305663:C:T, 14:24305686:C:G, 14:24307829:A:C, 14:24307818:CTGAG:C, 14:24307856:C:T, 14:24306423:T:C, 14:24306061:AC:A, 14:24307390:C:T, 14:24306382:G:T, 14:24306373:C:T, 14:24305733:T:C, 14:24307858:T:C, 14:24306387:C:T, 14:24305637:T:C, 14:24306062:C:T, 14:24307853:C:G, 14:24307450:C:G, 14:24306052:TG:T, 14:24305673:G:A, 14:24306043:C:T, 14:24307834:G:A, 14:24306417:C:T, 14:24307451:G:A, 14:24307436:A:C, 14:24305953:ACTTT:A, 14:24306489:G:T, 14:24307441:C:T, 14:24306375:C:T, 14:24305657:C:G, 14:24306427:C:T, 14:24306524:C:T, 14:24307516:C:A, 14:24307840:G:C, 14:24307501:A:G, 14:24305968:A:C, 14:24305986:C:T, 14:24307441:C:G, 14:24307459:G:T, 14:24306017:T:A, 14:24307424:G:A, 14:24306072:G:T, 14:24307423:C:T, 14:24307450:C:T, 14:24306420:G:A, 14:24307454:G:A, 14:24305653:C:T, 14:24307442:G:A, 14:24306002:C:T, 14:24306076:C:T, 14:24305664:C:T, 14:24305961:TG:T, 14:24305706:A:G, 14:24305946:C:T, 14:24306455:G:C, 14:24307468:G:A, 14:24307825:A:C, 14:24306110:G:A, 14:24305710:C:T, 14:24307483:C:T, 14:24306459:A:G, 14:24305754:C:T, 14:24305650:G:C, 14:24305691:C:T, 14:24306508:G:C, 14:24306039:G:T, 14:24306139:T:C, 14:24306391:T:C, 14:24306373:C:A, 14:24307498:C:T, 14:24307415:G:A, 14:24306138:CTG:C, 14:24307453:T:C, 14:24305692:G:A, 14:24305683:C:G, 14:24307484:G:A, 14:24307385:C:T, 14:24306519:A:T, 14:24307839:A:C, 14:24305965:C:T, 14:24305988:CAT:C, 14:24306087:C:G, 14:24307439:C:T, 14:24307477:A:C, 14:24306436:G:T, 14:24306507:A:G, 14:24307397:C:T, 14:24307495:G:A, 14:24306034:A:T, 14:24306013:G:A, 14:24307381:A:G, 14:24306383:G:C, 14:24305638:A:G, 14:24307420:G:A, 14:24306020:C:T, 14:24306470:A:C, 14:24307435:C:T, 14:24306469:C:G, 14:24306451:C:T, 14:24306403:G:A, 14:24307515:C:G, 14:24307489:A:G, 14:24307414:C:T, 14:24306483:A:G, 14:24305755:G:A, 14:24305766:C:T, 14:24306064:T:G, 14:24307516:C:G, 14:24305766:C:G, 14:24306489:G:A, 14:24306097:T:C, 14:24305763:T:G, 14:24307447:G:A, 14:24307402:G:A, 14:24305972:C:G, 14:24306423:T:G, 14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C (according to GRCh38/hg38 human genome assembly coordinates).

The present disclosure also provides compositions comprising therapeutic agents that treat or inhibit a liver disease for use in the preparation of a medicament for treatment of a liver disease in a subject having one or more CIDEB variant nucleic acid molecules comprising: 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G, 14:24307833:G:C, 14:24307851:T:TAC, 14:24306426:T:C, 14:24307849:G:C, 14:24307448:G:T, 14:24305671:C:T, 14:24305663:C:T, 14:24305686:C:G, 14:24307829:A:C, 14:24307818:CTGAG:C, 14:24307856:C:T, 14:24306423:T:C, 14:24306061:AC:A, 14:24307390:C:T, 14:24306382:G:T, 14:24306373:C:T, 14:24305733:T:C, 14:24307858:T:C, 14:24306387:C:T, 14:24305637:T:C, 14:24306062:C:T, 14:24307853:C:G, 14:24307450:C:G, 14:24306052:TG:T, 14:24305673:G:A, 14:24306043:C:T, 14:24307834:G:A, 14:24306417:C:T, 14:24307451:G:A, 14:24307436:A:C, 14:24305953:ACTTT:A, 14:24306489:G:T, 14:24307441:C:T, 14:24306375:C:T, 14:24305657:C:G, 14:24306427:C:T, 14:24306524:C:T, 14:24307516:C:A, 14:24307840:G:C, 14:24307501:A:G, 14:24305968:A:C, 14:24305986:C:T, 14:24307441:C:G, 14:24307459:G:T, 14:24306017:T:A, 14:24307424:G:A, 14:24306072:G:T, 14:24307423:C:T, 14:24307450:C:T, 14:24306420:G:A, 14:24307454:G:A, 14:24305653:C:T, 14:24307442:G:A, 14:24306002:C:T, 14:24306076:C:T, 14:24305664:C:T, 14:24305961:TG:T, 14:24305706:A:G, 14:24305946:C:T, 14:24306455:G:C, 14:24307468:G:A, 14:24307825:A:C, 14:24306110:G:A, 14:24305710:C:T, 14:24307483:C:T, 14:24306459:A:G, 14:24305754:C:T, 14:24305650:G:C, 14:24305691:C:T, 14:24306508:G:C, 14:24306039:G:T, 14:24306139:T:C, 14:24306391:T:C, 14:24306373:C:A, 14:24307498:C:T, 14:24307415:G:A, 14:24306138:CTG:C, 14:24307453:T:C, 14:24305692:G:A, 14:24305683:C:G, 14:24307484:G:A, 14:24307385:C:T, 14:24306519:A:T, 14:24307839:A:C, 14:24305965:C:T, 14:24305988:CAT:C, 14:24306087:C:G, 14:24307439:C:T, 14:24307477:A:C, 14:24306436:G:T, 14:24306507:A:G, 14:24307397:C:T, 14:24307495:G:A, 14:24306034:A:T, 14:24306013:G:A, 14:24307381:A:G, 14:24306383:G:C, 14:24305638:A:G, 14:24307420:G:A, 14:24306020:C:T, 14:24306470:A:C, 14:24307435:C:T, 14:24306469:C:G, 14:24306451:C:T, 14:24306403:G:A, 14:24307515:C:G, 14:24307489:A:G, 14:24307414:C:T, 14:24306483:A:G, 14:24305755:G:A, 14:24305766:C:T, 14:24306064:T:G, 14:24307516:C:G, 14:24305766:C:G, 14:24306489:G:A, 14:24306097:T:C, 14:24305763:T:G, 14:24307447:G:A, 14:24307402:G:A, 14:24305972:C:G, 14:24306423:T:G, 14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C (according to GRCh38/hg38 human genome assembly coordinates).

›DESCRIPTION · 29 of 30

The present disclosure also provides compositions comprising one or more CIDEB inhibitors, one or more PNPLA3 inhibitors, or one or more HSD17B13 inhibitors, or any combination thereof, for use in the treatment of a liver disease in a subject having one or more CIDEB variant nucleic acid molecules comprising: 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G, 14:24307833:G:C, 14:24307851:T:TAC, 14:24306426:T:C, 14:24307849:G:C, 14:24307448:G:T, 14:24305671:C:T, 14:24305663:C:T, 14:24305686:C:G, 14:24307829:A:C, 14:24307818:CTGAG:C, 14:24307856:C:T, 14:24306423:T:C, 14:24306061:AC:A, 14:24307390:C:T, 14:24306382:G:T, 14:24306373:C:T, 14:24305733:T:C, 14:24307858:T:C, 14:24306387:C:T, 14:24305637:T:C, 14:24306062:C:T, 14:24307853:C:G, 14:24307450:C:G, 14:24306052:TG:T, 14:24305673:G:A, 14:24306043:C:T, 14:24307834:G:A, 14:24306417:C:T, 14:24307451:G:A, 14:24307436:A:C, 14:24305953:ACTTT:A, 14:24306489:G:T, 14:24307441:C:T, 14:24306375:C:T, 14:24305657:C:G, 14:24306427:C:T, 14:24306524:C:T, 14:24307516:C:A, 14:24307840:G:C, 14:24307501:A:G, 14:24305968:A:C, 14:24305986:C:T, 14:24307441:C:G, 14:24307459:G:T, 14:24306017:T:A, 14:24307424:G:A, 14:24306072:G:T, 14:24307423:C:T, 14:24307450:C:T, 14:24306420:G:A, 14:24307454:G:A, 14:24305653:C:T, 14:24307442:G:A, 14:24306002:C:T, 14:24306076:C:T, 14:24305664:C:T, 14:24305961:TG:T, 14:24305706:A:G, 14:24305946:C:T, 14:24306455:G:C, 14:24307468:G:A, 14:24307825:A:C, 14:24306110:G:A, 14:24305710:C:T, 14:24307483:C:T, 14:24306459:A:G, 14:24305754:C:T, 14:24305650:G:C, 14:24305691:C:T, 14:24306508:G:C, 14:24306039:G:T, 14:24306139:T:C, 14:24306391:T:C, 14:24306373:C:A, 14:24307498:C:T, 14:24307415:G:A, 14:24306138:CTG:C, 14:24307453:T:C, 14:24305692:G:A, 14:24305683:C:G, 14:24307484:G:A, 14:24307385:C:T, 14:24306519:A:T, 14:24307839:A:C, 14:24305965:C:T, 14:24305988:CAT:C, 14:24306087:C:G, 14:24307439:C:T, 14:24307477:A:C, 14:24306436:G:T, 14:24306507:A:G, 14:24307397:C:T, 14:24307495:G:A, 14:24306034:A:T, 14:24306013:G:A, 14:24307381:A:G, 14:24306383:G:C, 14:24305638:A:G, 14:24307420:G:A, 14:24306020:C:T, 14:24306470:A:C, 14:24307435:C:T, 14:24306469:C:G, 14:24306451:C:T, 14:24306403:G:A, 14:24307515:C:G, 14:24307489:A:G, 14:24307414:C:T, 14:24306483:A:G, 14:24305755:G:A, 14:24305766:C:T, 14:24306064:T:G, 14:24307516:C:G, 14:24305766:C:G, 14:24306489:G:A, 14:24306097:T:C, 14:24305763:T:G, 14:24307447:G:A, 14:24307402:G:A, 14:24305972:C:G, 14:24306423:T:G, 14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C (according to GRCh38/hg38 human genome assembly coordinates). The CIDEB inhibitors, PNPLA3 inhibitors, and/or HSD17B13 inhibitors can be any of the CIDEB inhibitors, PNPLA3 inhibitors, and/or HSD17B13 inhibitors described herein.

The present disclosure also provides one or more CIDEB inhibitors, one or more PNPLA3 inhibitors, and/or one or more HSD17B13 inhibitors for use in the preparation of a medicament for treatment of a liver disease in a subject having one or more CIDEB variant nucleic acid molecules comprising: 14:24305635:A:AGTAG, 14:24305641:A:C, 14:24305650:G:A, 14:24305657:C:A, 14:24305662:G:T, 14:24305667:T:C, 14:24305671:C:A, 14:24305671:C:G, 14:24305701:A:T, 14:24305709:C:T, 14:24305718:A:G, 14:24305721:T:C, 14:24305728:G:GGCCTT, 14:24305743:T:C, 14:24305948:T:C, 14:24305966:C:T, 14:24305974:T:C, 14:24305980:TCA:T, 14:24305988:C:T, 14:24306014:C:T, 14:24306034:A:C, 14:24306041:C:G, 14:24306044:G:A, 14:24306047:G:A, 14:24306051:T:G, 14:24306064:T:C, 14:24306074:A:G, 14:24306077:G:C, 14:24306082:A:G, 14:24306083:T:A, 14:24306095:G:A, 14:24306122:A:G, 14:24306134:C:G, 14:24306373:C:G, 14:24306379:T:C, 14:24306382:G:A, 14:24306383:G:T, 14:24306426:T:G, 14:24306437:C:G, 14:24306439:G:C, 14:24306442:A:G, 14:24306444:A:G, 14:24306457:C:T, 14:24306463:C:T, 14:24306469:C:T, 14:24306480:A:G, 14:24306486:A:C, 14:24306504:A:G, 14:24306519:A:G, 14:24307382:G:C, 14:24307405:A:G, 14:24307417:A:T, 14:24307421:T:A, 14:24307441:C:A, 14:24307444:A:C, 14:24307444:A:G, 14:24307450:C:CGCTG, 14:24307461:TG:T, 14:24307469:AG:A, 14:24307474:C:T, 14:24307475:A:G, 14:24307833:G:C, 14:24307851:T:TAC, 14:24306426:T:C, 14:24307849:G:C, 14:24307448:G:T, 14:24305671:C:T, 14:24305663:C:T, 14:24305686:C:G, 14:24307829:A:C, 14:24307818:CTGAG:C, 14:24307856:C:T, 14:24306423:T:C, 14:24306061:AC:A, 14:24307390:C:T, 14:24306382:G:T, 14:24306373:C:T, 14:24305733:T:C, 14:24307858:T:C, 14:24306387:C:T, 14:24305637:T:C, 14:24306062:C:T, 14:24307853:C:G, 14:24307450:C:G, 14:24306052:TG:T, 14:24305673:G:A, 14:24306043:C:T, 14:24307834:G:A, 14:24306417:C:T, 14:24307451:G:A, 14:24307436:A:C, 14:24305953:ACTTT:A, 14:24306489:G:T, 14:24307441:C:T, 14:24306375:C:T, 14:24305657:C:G, 14:24306427:C:T, 14:24306524:C:T, 14:24307516:C:A, 14:24307840:G:C, 14:24307501:A:G, 14:24305968:A:C, 14:24305986:C:T, 14:24307441:C:G, 14:24307459:G:T, 14:24306017:T:A, 14:24307424:G:A, 14:24306072:G:T, 14:24307423:C:T, 14:24307450:C:T, 14:24306420:G:A, 14:24307454:G:A, 14:24305653:C:T, 14:24307442:G:A, 14:24306002:C:T, 14:24306076:C:T, 14:24305664:C:T, 14:24305961:TG:T, 14:24305706:A:G, 14:24305946:C:T, 14:24306455:G:C, 14:24307468:G:A, 14:24307825:A:C, 14:24306110:G:A, 14:24305710:C:T, 14:24307483:C:T, 14:24306459:A:G, 14:24305754:C:T, 14:24305650:G:C, 14:24305691:C:T, 14:24306508:G:C, 14:24306039:G:T, 14:24306139:T:C, 14:24306391:T:C, 14:24306373:C:A, 14:24307498:C:T, 14:24307415:G:A, 14:24306138:CTG:C, 14:24307453:T:C, 14:24305692:G:A, 14:24305683:C:G, 14:24307484:G:A, 14:24307385:C:T, 14:24306519:A:T, 14:24307839:A:C, 14:24305965:C:T, 14:24305988:CAT:C, 14:24306087:C:G, 14:24307439:C:T, 14:24307477:A:C, 14:24306436:G:T, 14:24306507:A:G, 14:24307397:C:T, 14:24307495:G:A, 14:24306034:A:T, 14:24306013:G:A, 14:24307381:A:G, 14:24306383:G:C, 14:24305638:A:G, 14:24307420:G:A, 14:24306020:C:T, 14:24306470:A:C, 14:24307435:C:T, 14:24306469:C:G, 14:24306451:C:T, 14:24306403:G:A, 14:24307515:C:G, 14:24307489:A:G, 14:24307414:C:T, 14:24306483:A:G, 14:24305755:G:A, 14:24305766:C:T, 14:24306064:T:G, 14:24307516:C:G, 14:24305766:C:G, 14:24306489:G:A, 14:24306097:T:C, 14:24305763:T:G, 14:24307447:G:A, 14:24307402:G:A, 14:24305972:C:G, 14:24306423:T:G, 14:24305974:T:TG, 14:24307411:T:C, 14:24306121:T:C, 14:24307516:C:T, 14:24306424:C:T, 14:24306039:G:C, 14:24307853:C:A, 14:24306388:A:G, 14:24305990:T:C, 14:24307822:G:GT, 14:24305640:G:A, 14:24307418:T:C, 14:24305758:G:C, 14:24306131:C:T, 14:24305953:A:G, 14:24305730:C:A, 14:24306418:A:G, 14:24306059:AC:A, 14:24307842:G:A, 14:24307837:T:G, 14:24306095:G:T, 14:24306109:C:T, 14:24307822:G:A, 14:24306077:G:A, 14:24307824:A:T, 14:24306080:C:T, 14:24305649:C:T, 14:24306433:G:GA, 14:24306420:G:C, 14:24305658:T:G, 14:24306472:C:T, 14:24307412:TC:T, 14:24306062:C:A, 14:24306044:G:C, 14:24306047:G:T, 14:24306126:CAG:C, 14:24306449:C:G, 14:24307391:G:A, or 14:24307857:A:C (according to GRCh38/hg38 human genome assembly coordinates). The CIDEB inhibitors, PNPLA3 inhibitors, and/or HSD17B13 inhibitors can be any of the CIDEB inhibitors, PNPLA3 inhibitors, and/or HSD17B13 inhibitors described herein.

›DESCRIPTION · 30 of 30

The present disclosure also provides methods of treating a subject with a CIDEB inhibitor, wherein the subject has a liver disease or is at risk of developing a liver disease, the methods comprising: determining whether the subject has a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide by: obtaining or having obtained a biological sample from the subject; and performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the nucleic acid molecule encoding the reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide; and when the subject is homozygous for a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide, the subject is administered a CIDEB inhibitor in an amount that is the same as or greater than a standard dosage amount, or is administered a combination of a CIDEB inhibitor and an HSD17B13 inhibitor and/or a PNPLA3 inhibitor; and when the subject is not homozygous for a nucleic acid molecule encoding a reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide (i.e., is a carrier for a loss-of-function HSD17B13), the subject is administered a CIDEB inhibitor in an amount that is less than a standard dosage amount; wherein the presence of a genotype having the nucleic acid molecule encoding the reference HSD17B13 polypeptide or a functional HSD17B13 polypeptide indicates the subject is a candidate for treatment with the CIDEB inhibitor.

All patent documents, websites, other publications, accession numbers and the like cited above or below are incorporated by reference in their entirety for all purposes to the same extent as if each individual item were specifically and individually indicated to be so incorporated by reference. If different versions of a sequence are associated with an accession number at different times, the version associated with the accession number at the effective filing date of this application is meant. The effective filing date means the earlier of the actual filing date or filing date of a priority application referring to the accession number if applicable. Likewise, if different versions of a publication, website or the like are published at different times, the version most recently published at the effective filing date of the application is meant unless otherwise indicated. Any feature, step, element, embodiment, or aspect of the present disclosure can be used in combination with any other feature, step, element, embodiment, or aspect unless specifically indicated otherwise. Although the present disclosure has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

The following examples are provided to describe the embodiments in greater detail. They are intended to illustrate, not to limit, the claimed embodiments. The following examples provide those of ordinary skill in the art with a disclosure and description of how the compounds, compositions, articles, devices and/or methods described herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the scope of any claims. Efforts have been made to ensure accuracy with respect to numbers (such as, for example, amounts, temperature, etc.), but some errors and deviations may be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C. or is at ambient temperature, and pressure is at or near atmospheric.

EXAMPLES

›Examples6

›Example 1: General Methodology and Frequency of Rare Coding Variants in CIDEB Across Populations · 1 of 4

Study Participants

Discovery exome-wide association analyses were performed in the UK Biobank (UKB) cohort and in the MyCode Community Health Initiative from Geisinger Health System (GHS). The UKB is a population-based cohort including individuals 40-69 years of age recruited at 22 testing sites in the UK between 2006-2010. 411,926 European ancestry, 9,830 South Asian ancestry, 8,544 African ancestry, 2,108 East Asian ancestry, and 587 American ancestry participants with available whole-exome sequencing and transaminase data were included. MyCode is a health system-based cohort of patients from rural Pennsylvania (USA) recruited in 2007-2021. 109,909 European ancestry participants with available whole-exome sequencing and transaminase data were included. Liver disease outcome association analyses further included up to 28,948 participants from the Malmo Diet and Cancer Study (MDCS). 13,418 participants from the University of Pennsylvania PennMedicine BioBank (UPENN-PMBB) and 23,849 participants from the Mount Sinai BioMe BioBank cohort (BioMe). Liver-histopathology association analyses were also performed in 3,599 bariatric surgery patients from GHS who were not included in the primary discovery analyses.

DNA Exome Sequencing

NimbleGen VCRome probes (for part of GHS) or a modified version of the xGen design available from Integrated DNA Technologies (IDT; for the rest of GHS and for other cohorts) were used to capture exome sequences. Following capture, balanced pools were sequenced using 75 bp paired-end reads on Illumina v4 HiSeq 2500 (for part of the GHS cohort) or NovaSeq (for the rest of GHS and for other cohorts) instruments. Sequencing achieved greater than 20× coverage over 85% of targeted bases in 96% of VCRome samples and 20× coverage over 90% of targeted bases in 99% of IDT samples. Following sequencing, pooled samples were demultiplexed using Illumina software, aligned sequenced reads to the GRCh38 Human Genome reference sequence using BWA-mem, and generated cohort-level genotype files with GLnexus.

Variants were annotated using the snpEff software and Ensembl v85 gene definitions. Annotations were prioritized for protein-coding transcripts based on the most deleterious functional effect for each gene based with the following hierarchy (from most to least deleterious): frameshift, stop-gain, stop-loss, splice acceptor, splice donor, in-frame indel, missense, other annotations. Predicted LOF genetic variants included: a) insertions or deletions resulting in a frameshift, b) insertions, deletions or single nucleotide variants resulting in the introduction of a premature stop codon or in the loss of the transcription start site or stop site, and c) variants in donor or acceptor splice sites. Missense variants were classified for likely functional impact according to the number of in silico prediction algorithms that predicted deleteriousness using SIFT, Polyphen2_HDIV and Polyphen2_HVAR, LRT and MutationTaster. For each gene, the alternative allele frequency (AAF) and functional annotation of each variant determined inclusion into these 7 gene burden exposures: 1) pLOF variants with AAF <1%; 2) pLOF or missense variants predicted deleterious by 5/5 algorithms with AAF <1%; 3) pLOF or missense variants predicted deleterious by 5/5 algorithms with AAF <0.1%; 4) pLOF or missense variants predicted deleterious by at least 1/5 algorithms with AAF <1%; 5) pLOF or missense variants predicted deleterious by at least 1/5 algorithms with AAF <0.1%; 6) pLOF or any missense with AAF <1%; 7) pLOF or any missense variants with AAF <0.1%.

Phenotype Definitions

For continuous traits, data cleaning was performed by removing non-physiologic lab values, or results stemming from invalid or contaminated specimens. In Geisinger Health System (GHS), the median transaminase values for each individual were extracted from electronic health records. In the UK Biobank (UKB), transaminases were measured using a Beckman Coulter AU5800 at the baseline study visit.

Cases of binary liver disease outcomes were defined based on one or more of the following criteria: i) self-reported disease obtained from digital questionnaire or interview with a trained nurse, ii) in-patient hospitalization for the disease or clinical-problem list entries of the disease according to International Classification of Diseases, Ninth (ICD-9) or Tenth (ICD-10) Revision diagnosis code, iii) medical procedures or surgery due to the disease, iv) death due to the disease, and v) a disease diagnosis code entered for two or more outpatient visits in separate calendar days. The specific entries used to define different types of liver disease are described in detail in Table 17. Controls were defined as individuals who did not meet any of the criteria for case status. To minimize misclassification, the following were excluded from the control group: i) non-cases diagnosed with any type of liver disease (not restricted to the type of liver disease in question), ii) non-cases with only one out-patient encounter related to the type of liver disease in question, iii) non-cases diagnosed with ascites presumably related to liver failure, and iv) non-cases with elevated alanine aminotransferase (ALT) levels (>33 IU/L for men, >25 IU/L for women).

ICD10 indicates the 10th revision of the International Statistical Classification of Diseases and Related Health Problems; OPCS4 indicates Office of Population Censuses and Surveys (OPCS) Classification of Interventions and Procedures version 4; NOMESCO indicates Nordic Medico-Statistical Committee procedure codes. Participants were excluded from the control population if they were: i) diagnosed with the “any liver disease” outcome codes (as defined in the table), ii) ascites presumably related to liver failure (ICD10 R18 (Ascites), excluding individuals with other potential causes of ascites; C16 (Malignant neoplasm of stomach), C17 (Malignant neoplasm of small intestine), C18 (Malignant neoplasm of colon), C20 (Malignant neoplasm of rectum), I42 (Cardiomyopathy), I50 (Heart failure)) or iii) if they had elevated ALT >33 U/L for men and >25 U/L for women.

›Example 1: General Methodology and Frequency of Rare Coding Variants in CIDEB Across Populations · 2 of 4

Liver Histopathologic Phenotype Definitions in the GHS Bariatric Surgery Cohort

The GHS bariatric cohort consists of 3,599 individuals of European descent who underwent bariatric surgery and were enrolled in GHS's MyCode and GHS-Regeneron Genetics Center (RGC) DiscovEHR collaboration. Surgeons took wedge biopsies of the liver 10 cm to the left of falciform ligament prior to any liver retraction or surgery on the stomach, following a standardized protocol. The biopsy was divided into sections, with the primary section delivered to the clinical pathologists for liver histology (fixed in 10% neutral buffered formalin and stained with hematoxylin and eosin for routine histology and Masson's trichrome for assessment of fibrosis) and remaining sections stored within a research biobank (stabilized with the RNAlater tissue collection system (ThermoFisher Scientific) or frozen in liquid nitrogen). An experienced pathologist conducted histological examinations, which were subsequently re-reviewed by a second pathologist, and scored based on the NASH Clinical Research Network system: steatosis Grade 0 (<5% parenchymal involvement), Grade 1 (5 to <34%), Grade 2 (34 to <67%), and Grade 3 (>67%); lobular inflammation Grade 0 (no foci), Grade 1 (mild, <2 foci per 200× field), Grade 2 (moderate, 2-4 foci per 200× field), Grade 3 (severe, >4 foci per 200× field); ballooning Grade 0 (none), Grade 1 (few balloon cells), Grade 2 (many cells/prominent ballooning); fibrosis Stage 0 (none), Stage 1 (perisinusoidal or periportal fibrosis), Stage 2 (perisinusoidal and periportal fibrosis), Stage 3 (bridging fibrosis), and Stage 4 (liver cirrhosis). These histologic diagnoses were used to define the following phenotypes: 1) Normal liver: no evidence of steatosis, nonalcoholic steatohepatitis (NASH), or fibrosis; 2) Simple steatosis: Steatosis (regardless of grade) with no evidence of NASH or fibrosis; 3) NASH: Any presence of lobular inflammation or hepatocyte ballooning (regardless of grade), or any presence of fibrosis (regardless of stage); 4) Fibrosis: Any presence of fibrosis (regardless of stage); 5) Nonalcoholic fatty liver disease (NAFLD) activity score (NAS) defined as the unweighted sum of the scores for steatosis (0-3), lobular inflammation (0-3) and ballooning (0-2), thus ranging from 0-8.

Statistical Analysis

Associations between genotypes and phenotypes were estimated by fitting linear (for quantitative traits) or Firth bias-corrected logistic (for binary traits) regression models using REGENIE v2+(10.1038/s41588-021-00870-7) or the logistf function in R. Analyses were stratified by cohort and ancestry and adjusted for age, age 2 , sex, age-by-sex and age 2 -by-sex interaction terms, experimental batch-related covariates, the first 10 common variant-derived genetic principal components (PCs), the first 20 rare variant-derived PCs, and a polygenic score generated by REGENIE that accounts for relatedness, population structure, and polygenicity (10.1038/ng.257). To ensure independence between rare and common variants signals, discovery exome-wide analyses for common variant signals identified by fine-mapping were additionally adjusted as previously described. Results across studies were combined by fixed-effect inverse variance-weighted meta-analysis.

Frequency of CIDEB Coding Variants Identified by Exome Sequencing Across Ancestries

Using exome sequencing across ancestry groups as described above, the frequency of homozygous reference genotype (reference-reference, RR), heterozygous alternative allele carrier genotype (reference-alternative, RA) and homozygous alternative allele carrier genotype (alternative-alternative, AA) were determined in sequenced individuals across ancestry groups. In each ancestry group, the RR genotype, which in the genetic analyses were associated with higher liver fat, injury and liver disease risk was the most common genotype (Table 18).

Abbreviations: RR, reference-reference genotype; RA, reference-alternative genotype; AA, alternative-alternative genotype for predicted loss-of-function or missense variants in CIDEB. The sum of percentages may differ from 100% due to rounding.

GTEx RNA-Seq

TMM normalized gene expression matrices per tissue were obtained using GTEx v8 raw expression matrices download from the GTEx portal. Within each tissue, we subset to samples included in the GTEx v8 analysis freeze and filter to genes using the same quality control filters described below.

Liver RNA-Seq in Bariatric Cohort Samples

Liver RNA-seq was performed in 2,304 patients from GHS who underwent a perioperative wedge biopsy of the liver as part of bariatric surgery.

RNA concentration was determined by UV absorbance and 500 ng of total RNA was used for processing. Samples were processed with the NEBNext Poly(A) mRNA Magnetic Isolation Module and NEB NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New England Biolabs), according to the manufacturer recommendations. Samples were amplified with 10 cycles of PCR with Kapa HiFi polymerase (Roche) and custom barcoded primers (IDT). Samples were sequenced on the Illumina NovaSeq 6000 platform on S2 flow cells with paired-end 75 bp reads. The mean number of reads per sample was 72 million and the median was 68 million; 93% of the samples had at least 50 million reads and 99% of the samples had more than 45 million reads, reflecting high coverage sequencing. The gene expression values for all samples were then normalized across samples using the trimmed mean of m-values approach (TMM) as implemented in edgeR.

RNA-seq data were processed broadly following the GTEx v8 analysis protocol (world wide web at gtexportal.org/home/documentationPage#staticTextAnalysisMethods). Briefly, sequenced samples were aligned to the human reference genome GRCh38/hg38 with STAR v2.5.3a. Duplicate marking was applied to optical duplicates only with Picard using the pixel distance setting OPTICAL_DUPLICATE_PIXEL_DISTANCE=15000.

The quantification of mRNA was based on the GENCODE Release 32 annotation (world wide web at gencodegenes.org/human/release_32.html), collapsed to a single transcript model for each gene. Gene-level expression quantification was performed using RNA-SeQC. Gene-level read counts and TPM values were produced using the following read-level filters: 1) reads were uniquely mapped; 2) reads were aligned in proper pairs; 3) the read alignment distance was 6; 4) reads were fully contained within exon boundaries.

›Example 1: General Methodology and Frequency of Rare Coding Variants in CIDEB Across Populations · 3 of 4

Gene expression values for all samples were normalized: 1) read counts were normalized between samples using TMM; 2) genes were selected based on expression thresholds of 1:11 TPM in 20% of samples and reads (unnormalized) in 20% of samples.

Allele Specific Read Counts and Analyses

Read counts per allele generated by counting the number of reads overlapping the variant's position and carrying the allele of interest (reference or alternative). P-values for the observed degree of imbalance in read counts per allele were based on an exact binomial test as implemented in binom.test function in R version 4.0.5 assuming a 50% probability of success under the null.

CIDEB Knockdown in HepG2 Cells

HepG2 (ATCC) cells were cultured in MEM with Earle's salt supplemented with 10% FBS, 1% Penicillin-Streptomycin, and 1% L-glutamine. For siRNA knockdown, cells were transfected with CIDEB siRNA (Smartpool, Dharmacon L-004410-00-0050) or control siRNA (Non-targeting pool, Dharmacon D-001810-10-50) for 48 hours. For OA treatment, cells were treated with 400 μM OA for 24 hours, beginning 24 hours after transfection.

For localization of CIDEB with lipid droplets, cells were fixed in 3% PFA for 20 minutes then permeabilized in 0.1% saponin, blocked in 1% BSA and incubated overnight with primary antibody against CIDEB (1:1000, Abnova H00027141-M01). Alexa Fluor 594 goat anti-mouse IgG (Thermo) was used during the secondary antibody incubation. BODIPY493/503 was incubated for 1 hour during the secondary antibody incubation step followed by a 10-minute incubation with DAPI to stain nuclei. After washing, PBS was replaced with mounting medium for fluorescence microscopy (Ibidi 50001) then imaged using a Zeiss LSM 880 confocal microscope.

For western blotting, cells were lysed in RIPA lysis buffer plus protease and phosphatase inhibitors. Lysate was cleared, quantified, electrophoresed, and transferred to PVDF membranes. Membranes were blocked in Superblock T20 TBS buffer (Thermo 37536) then incubated in primary antibodies (CIDEB: Abnova H00027141-M01 1:1000; GAPDH: HRP-conjugated Sigma G9295). For CIDEB, bound antibody was detected via incubation with anti-mouse IgG, HRP secondary antibody (Cell Signaling 7076, 1:10000 dilution. Supersignal West Pico Plus Chemiluminescent Substrate (Thermo 4579) and Supersignal West Femto Maximum Sensitivity Substrate (Thermo 34094) were used for the development of chemiluminescent signal. Relative protein expression was determined by quantification of CIDEB and GAPDH bands on ImageJ. Data was normalized using GAPDH and control cells.

RNA isolation was performed using the RNeasy mini kit (QIAGEN 74104) with DNase I digestion (QIAGEN 79254) as per manufacturer's instructions. Total of 1 μg of RNA was used for cDNA synthesis using the SuperScript IV VILO cDNA synthesis kit (Thermo 11754050). Gene expression levels were determined using Taqman gene expression assays (Applied Biosystems assay IDs: CIDEB (Hs00205339_m1), GAPDH (Hs02786624_g1)) using the Taqman Fast Advanced Master Mix (Thermo 4444963) with the QuantStudio 6 instrument. The data was normalized using GAPDH and the control cells.

For lipid droplet visualization, cells were incubated with AdipoRed (Lonza PT-7009) for 10 minutes then fixed for 10 minutes in 4% paraformaldehyde (PFA). Cells were washed then incubated with 4′,6-diamidino-2-phenylindole (DAPI) for 10 minutes to stain nuclei. After washing, PBS was replaced with mounting medium for fluorescence microscopy (Ibidi 50001) then imaged using a Zeiss LSM 880 confocal microscope.

For quantification of lipid droplets, lipid droplets were detected in the red channel (excitation at 485 nm and emission at 572 nm) using Laplacian-of-Gaussian blob detection, as implemented in the Scikit-Image Python package. To tune the detection threshold parameter of the blob detection algorithm, lipid droplets were manually marked for six random small regions (250×250 pixels) from three images per experimental group. The number of cells in each field was estimated from the DAPI channel. For each experimental group, the following quantitative endpoints were derived: average lipid droplet size (quantified as lipid droplet volumes), average number of lipid droplets per nucleus, and average cell lipid droplet staining (quantified as total lipid droplet areas per nucleus).

Levels of intracellular triglyceride content was measured using the Triglyceride Assay Kit (Abcam ab65336) according to manufacturer's instructions. Triglyceride content was normalized to total protein content as determined by the DC Protein assay (BioRad 5000111). IL8 protein concentrations in cell media were measured using a Meso Scale Diagnostics Proinflammatory Panel and were normalized to total protein content.

Two-way analysis of variation (ANOVA) was used to determine if an interaction between the effects of oleic acid and CIDEB siRNA was present, with Tukey's multiple comparisons tests with Sidak correction used to determine the pairwise effects of 1) 0 μM vs 400 μM oleic acid in the presence of control siRNA; 2) 0 μM vs 400 μM oleic acid in the presence of CIDEB siRNA; 3) control vs CIDEB siRNA in the presence of 0 μM oleic acid; 4) control vs CIDEB siRNA in the presence of 400 μM oleic acid. Welch's t-test was used to compare effects of control siRNA vs CIDEB siRNA on CIDEB expression via western blot and Taqman analysis since no oleic acid treatment was present. Statistical testing was performed using Prism 9.

Example 2: Loss-of-Function in CIDEB is Associated with Lower Liver Transaminases and Protection Against Liver Disease

To identify genetic factors contributing to predisposition for or protection against chronic liver disease, an exome-sequencing analysis of alanine aminotransferase (ALT), a widely used biomarker of liver damage, was performed in over 500,000 people from the UK Biobank (UKB) cohort and the MyCode Community Health Initiative from Geisinger Health System (GHS). The UKB is a population-based cohort including individuals 40-69 years of age recruited at 22 testing sites in the UK between 2006-2010 (PLoS Med 2015; 12:e1001779). 411,926 European ancestry, 9,830 South Asian ancestry, 8,544 African ancestry, 2,108 East Asian ancestry and 587 American ancestry participants with available whole-exome sequencing and transaminase data were included (Table 19). MyCode is a health system-based cohort of patients from rural Pennsylvania (USA) recruited in 2007-2021 (Genet Med 2016; 18:906-13). 109,909 European ancestry participants with available whole-exome sequencing and transaminase data were included (Table 19).

›Example 1: General Methodology and Frequency of Rare Coding Variants in CIDEB Across Populations · 4 of 4

For each gene in the genome, associations with ALT were estimated for the burden of rare predicted loss-of-function (pLOF) and missense variants identified by exome sequencing (see Methods in Example 1). Statistically significant findings for a novel association in the CIDEB gene were subsequently evaluated for their association with: 1) aspartate aminotransferase (AST), another transaminase often associated with liver damage, 2) liver disease clinical outcomes, and 3) liver histopathology (see Methods in Example 1).

In the exome-wide analysis, the burden of rare (alternative allele frequency (AAF)<1%) predicted loss-of-function (pLOF) or missense genetic variants in the CIDEB gene was strongly associated with lower ALT at the exome-wide level of statistical significance (p<3.6×10 −7 , a Bonferroni correction for 20,000 genes and seven variant selection models, Table 20), a novel association. Rare pLOF or missense variants in CIDEB were also associated with lower AST levels (Table 20).

An association for rare CIDEB pLOF variants alone (excluding missense variants) with lower transaminases was also observed (Table 21), indicating that the association for rare pLOF plus missense variants reflects a loss-of-function in CIDEB.

The associations of CIDEB rare coding variants with risk of liver disease outcomes across etiologies and severity spectrum we estimated. Rare coding variants in CIDEB were associated with: 1) lower risk of any-cause, alcoholic and nonalcoholic liver disease, 2) lower risk of any-cause, alcoholic and nonalcoholic cirrhosis, and 3) lower risk of viral hepatitis. Heterozygous carriers of rare coding variants had 29-53% lower odds of these outcomes compared with non-carriers ( FIG. 1 ). On the log-linear scale and in the same set of individuals, the protective associations for rare coding variants in CIDEB were 3- to 7-fold larger than the rs72613567 splice LOF variant in the HSD17B13 gene previously reported to be associated with protection against liver disease (N. Engl. J. Med., 2018, 378, 1096-106) ( FIG. 1 ).

Associations with liver histopathology phenotypes in 3,599 bariatric surgery patients who underwent a perioperative liver biopsy (see Methods in Example 1) were estimated. Individuals carrying rare pLOF or missense variants in CIDEB had lower odds of biopsy-defined hepatic steatosis, NASH or fibrosis compared to non-carriers (per-allele odds ratio (OR), 0.34; 95% confidence interval, 0.14 to 0.79; p=0.012; FIG. 2 , panel a). This association was driven by both a lower proportion of bariatric patients with simple steatosis and a lower proportion of patients with NASH or fibrosis among carriers (Table 22). Rare pLOF or missense variants in CIDEB were also associated with a lower NASH-CRN nonalcoholic fatty-liver disease activity score (NAS) at biopsy (per-allele beta in standard deviation units of the score, −0.56, 95% CI −0.88 to −0.24; per-allele beta in untransformed score units, −0.98; 95% CI −1.54 to −0.41; p=7×10 −4 , FIG. 2 , panel b and Table 22).

Associations with lipid, glycemic, and anthropometric traits for rare coding variants in CIDEB in over 500,000 people ( FIG. 3 ) were estimated. Statistically significant associations for CIDEB pLOF or missense variants were not found with these traits, except for a nominally significant association with lower risk of type 2 diabetes (per-allele odds ratio, 0.87; 95% CI, 0.79 to 0.97; p=0.011).

Furthermore, whether rare pLOF or missense variants in CIDEB were associated with any of 6,040 clinical phenotypes was explored in a phenome-wide wide analysis in the GHS, UKB, or a meta-analysis of these two cohorts. In this analysis, no statistically significant associations were observed with clinical phenotypes other than the associations with lower liver enzymes and outcomes described above, after correction for the number of statistical tests performed (p<8.3×10 −6 ).

The associations between CIDEB and liver phenotypes were driven by multiple rare pLOF or missense variants in the CIDEB gene (Table 23).

C:P:R:A indicates the genomic coordinates of the genetic variant including chromosome (C), physical genomic position in base pairs (P), reference allele (R) and alternative allele (A) relative to build 38 of the Human Genome sequence by the Human Genome Reference Consortium. Coding DNA and protein changes follow the Human Genome Variation Society nomenclature and refer to three CIDEB transcripts annotated in the in the Ensembl database (URL: https://useast.ensembl.org/index.html). Annotations on these three transcripts are reported in the Table 23 in the following order: ENST00000258807, ENST00000554411, ENST00000336557. AAF indicates the alternative allele frequency. pLOF indicates predicted loss of function variant.

›Example 3: Interaction of CIDEB Rare Coding Variants with Body Mass Index · 1 of 2

It was hypothesized that rare coding variants in CIDEB may protect from liver disease by preventing excessive build-up of liver fat into enlarged and inflammation-prone lipid droplets. If that were the case, the protective association of CIDEB rare pLOF and missense variants might be stronger in individuals with higher adiposity who are exposed to a higher risk of liver steatosis and injury. Thus, interactions for rare coding variants in CIDEB with body mass index (BMI), the principal epidemiological risk factor for liver steatosis, were estimated. The association of CIDEB rare coding variants with lower ALT was amplified in individuals with higher BMI when BMI was modelled as a continuous variable (p interaction =4.5×10 −7 rare pLOF plus missense variants in CIDEB and P interaction =0.0046 for pLOF variants in CIDEB, as shown in FIG. 4 ).

An interaction on ALT between rare coding variants in CIDEB and clinical categories of BMI was identified. Specifically, CIDEB rare coding variants were not associated with ALT levels in non-overweight individuals (per-allele beta in U/L, 0.1; 95% CI, −0.7 to 0.8; p=0.85), but were associated with −2.8 U/L lower ALT in obese individuals (95% CI, −3.6 to −2.1; p=1.7×10 −13 ; p interaction with BMI category=2.9×10 −8 ; FIG. 5 , panel a and Table 24). This interaction was also observed for CIDEB pLOF variants ( FIG. 5 , panel b and Table 24). Therefore, the protective association against liver damage observed in carriers of rare pLOF variants in CIDEB is greater in individuals with higher body mass index or who are categorically classified as overweight or obese.

BMI indicates body mass index. BMI categories were defined according to the World Health Organization as follows: “non-overweight” (BMI <25 kg/m 2 ), “overweight” (BMI 25 and <30 kg/m 2 ), “obesity” (BMI 30). RR indicates the number of individuals carrying no rare missense or pLOF variants in CIDEB (homozygous non-carriers); RA indicates the number of individuals carrying rare missense or pLOF variants in a single CIDEB allele (heterozygous carriers); AA indicates the number of individuals carrying rare missense or pLOF variants in both CIDEB alleles (homozygous carriers); SD indicates standard deviation units; AAF indicates the alternative allele frequency; pLOF indicates predicted loss of function; CI indicates confidence interval; kg/m 2 kilograms per square meter.

Table 24 shows the association with ALT levels of rare pLOF or missense variants in CIDEB within BMI categories in a meta-analysis of the GHS and UKB cohorts and the estimates from the linear interaction analysis.

Given the significant interactions for CIDEB with BMI (this example) and PNPLA3 (Example 4) on ALT and potential for CIDEB to affect liver fat through experimental evidence (Example 5), it was hypothesized that rare coding variants in CIDEB are associated with liver fat and that the association is more pronounced in overweight individuals. Rare coding variants in CIDEB were significantly associated with MRI-measured liver fat (Table 25): rare pLOF variants were associated with lower liver fat in overweight or obese individuals (per-allele beta in % units of liver fat fraction, −1.5%; 95% CI, −3.0% to −0.1%; p=0.04). In addition, a significant interaction was found between rare pLOF or missense variants in CIDEB and BMI on MRI-measured liver fat (p-interaction=0.02).

A linear regression was performed between PDFF and CIDEB rare coding variants within not-overweight and overweight or obese individuals separately. Interaction estimates were calculated in the full model, in each ancestry separately and meta-analyzed-same as the discovery analysis. Abbreviations: pLOF, predicted loss of function; SD, standard deviation; P, p-value; AAF, alternate allele frequency.

The proportion of liver disease by CIDEB genotypes and BMI categories were also estimated and it was found that the difference in proportion of liver disease in CIDEB rare coding variant carriers versus non-carriers was highest in the obesity category ( FIG. 6 ).

Example 4: Rare Coding Variants in CIDEB Interact with PNPLA3 Genotypes and Show Additive Associations with HSD17B13 Genotypes

A common missense variant in the Patatin Like Phospholipase Domain Containing 3 (PNPLA3) gene, encoding a p.Ile148Met (dbSNP rslD, r5738409; C>G substitution) missense change in the PNPLA3 protein is one of the most common and strongest genetic risk factors for liver damage (measured by ALT levels), alcoholic and non-alcoholic liver disease and cirrhosis (Nat. Genet., 2008, 40, 1461-5; and Nat. Genet., 2010, 42, 21-3). In the exome-sequencing dataset, the 148Met risk allele was strongly associated with higher ALT levels (per allele beta in SD units of ALT, 0.11; 95% confidence interval, 0.10, 0.11; p<1.0×10 −300 ) consistent with previous literature.

A statistically significant interaction was observed between rare coding variants in CIDEB and the common PNPLA3 148Met risk allele on ALT (Table 26 and FIG. 7 ).

RR indicates the number of individuals carrying no rare missense or pLOF variants in CIDEB (homozygous non-carriers); RA indicates the number of individuals carrying rare missense or pLOF variants in a single CIDEB allele (heterozygous carriers); AA indicates the number of individuals carrying rare missense or pLOF variants in both CIDEB alleles (homozygous carriers); SD indicates standard deviation units; AAF indicates the alternative allele frequency; pLOF indicates predicted loss of function; CI indicates confidence interval.

The first section of Table 26 describes the burden of pLOF or missense variants in CIDEB with AAF<1% as the genetic exposure; second section describes the burden of only pLOF variants in CIDEB with AAF<1% as the genetic exposure. Table 26 shows the association with ALT levels of CIDEB genotype within PNPLA3 rs738409 Ile148Met genotype categories in a meta-analysis of the GHS and UKB cohorts and the estimates from the linear interaction analysis.

The association with lower ALT levels for rare pLOF variants in CIDEB was strongest in homozygous carriers of the 148Met risk allele (G/G group), with an estimated effect size that was 5 times larger in a protective direction than what was observed in homozygous carriers of the PNPLA3 148Ile allele (C/C group; Table 26). Therefore, the protective association against liver damage observed in carriers of rare pLOF or missense variants in CIDEB is greater in individuals carrying the common PNPLA3 148Met risk allele.

›Example 3: Interaction of CIDEB Rare Coding Variants with Body Mass Index · 2 of 2

No significant interactions were found between rare coding variants in CIDEB and the splice variant rs72613567 which causes loss of function in HSDB17B13 and has been shown to protect against liver disease (N. Engl. J. Med., 2018, 378, 1096-106) (Table 27). These results indicate that rare coding variants in CIDEB have additive protective associations to those of rs72613567-TA in HSD17B13.

Example 5: CIDEB is Expressed in Hepatocytes at the Surface of Lipid Droplets, Predicted-Loss-of-Function Variants in CIDEB are Associated with Lower Gene Expression in Liver, and Inhibition of CIDEB Expression Via siRNA Decreases Lipid Droplet Size and Reduces Lipid Accumulation in HepG2 Cells

The mRNA expression of CIDEB was examined across tissues in humans from the Genotype Tissue Expression consortium (GTEx) and it was found that CIDEB is most highly expressed in liver among the GTEx tissues ( FIG. 8 ). The mRNA expression of CIDEB was also examined among cell types in data from the Human Protein Atlas (HPA) and found that CIDEB is most highly expressed in hepatocytes ( FIG. 8 ).

Given that CIDEB is expressed in liver, the impact of predicted loss-of-function (pLOF) variants in the gene was investigated using liver RNASeq data from bariatric surgery patients from GHS. Using liver RNASeq, the impact of two pLOF variants (c.336+1G>A, and Lys153*) was evaluated. These were the only two pLOF variants present in the 2,304 bariatric surgery patients in GHS who underwent RNASeq. Two heterozygous carriers for each of the two variant sites were found and expression levels for CIDEB below the 25th percentile in each of the four carriers were observed ( FIG. 9 ). Both carriers of the Lys153* variant expressed reads containing the stop-gained mutation much less frequently than those carrying the reference allele (expected proportion under the assumption of no impact, 50%; Carrier 1 proportion, 9.9%; p binomial for the observed imbalance=1.8×10 −89 ; Carrier 2 proportion, 11.9%; p binomial =5.2×10 −51 ; FIG. 9 ), indicating that the variant is subject to nonsense mediated decay and results in loss of a copy of CIDEB. In carriers of the c.336+1G>A variant, none of the RNASeq reads with spliced sequences that overlap the variant position carried the splice-donor allele. However, RNAseq reads whose unspliced sequences overlapped the position of the splice site were enriched for the splice-donor variant compared to the reference allele (expected proportion under the assumption of no impact, 50%; Carrier 3 proportion, 78.0%; p binomial =4.1×10 −06 ; Carrier 4 proportion, 76.5%; p binomial =2.0×10 −04 ; FIG. 9 ), indicating that the variant results in intron retention.

Given that the protective loss-of-function variants in CIDEB were associated with lower liver expression of this gene, the effects of siRNA-mediated knockdown of CIDEB were studied in human hepatocellular carcinoma HepG2 cells with and without treatment with oleic acid, a monosaturated omega-9 fatty acid that is routinely used to mimic steatosis conditions in vitro. In particular, HepG2 human hepatoma cells were treated with control siRNA or siRNA targeting CIDEB. 24 hours after siRNA transfection, cells were treated with 0 μM or 400 μM oleic acid for 24 hours. Endogenous CIDEB protein localized to punctae on the surfaces of lipid droplets and at the interfaces of adjacent lipid droplets in both conditions in cells treated with a non-targeting pool of control siRNA ( FIG. 10 , Panel A); no CIDEB staining was observed in cells treated with CIDEB siRNA to inhibit CIDEB expression ( FIG. 10 , Panel B), demonstrating the specificity of the CIDEB antibody used. For each treatment, the left-side image shows the merge of all three stains and the right-side image shows staining of CIDEB only. Further quantification showed that the CIDEB siRNA inhibited CIDEB mRNA expression by 71% and inhibited CIDEB protein expression by 89% ( FIG. 10 , Panel C). GAPDH was used as loading and normalization control.

Silencing of CIDEB did not affect lipid droplet number or average lipid droplet size, cell triglyceride content or cell lipid droplet staining in the basal condition ( FIG. 10 , Panels D, E, F, G, and H). CIDEB siRNA-treated cells secreted less IL-8 ( FIG. 10 , Panel I), a proinflammatory cytokine linked to NAFLD progression, consistent with the genetic associations showing decreased risk of inflammatory liver diseases such as NASH and cirrhosis. Cells were next treated with oleic acid to induce fat accumulation. Oleic acid resulted in the appearance of larger lipid droplets in cells treated with control siRNA in a manner proportional to the amount of oleic acid administered ( FIG. 10 , Panel J), with increased average lipid droplet size, cell triglyceride content and cell lipid droplet staining ( FIG. 10 , Panels E, F, G, and H). Numerical, non statistically-significant reductions in average cell triglyceride content or cell lipid droplet staining were observed in CIDEB siRNA-treated cells ( FIG. 10 , Panels G and H), in line with the genetic association results for liver fat fraction. However, inhibition of CIDEB expression prior to oleic acid treatment resulted in an increased number of smaller lipid droplets compared to cells treated with control siRNA, with significantly reduced average lipid droplet size (p<0.0001) and increased number of lipid droplets per cell (p<0.01) ( FIG. 10 , Panels D, E, and F).

Various modifications of the described subject matter, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference (including, but not limited to, journal articles, U.S. and non-U.S. patents, patent application publications, international patent application publications, gene bank accession numbers, and the like) cited in the present application is incorporated herein by reference in its entirety.

›Tables in the description — 20

TABLE 2 — SEQ ID

Sequence	NO:
ACCACGCAGUCAACCUUCUG	115
UACCACGCAGUCAACCUUCU	116
CUACCACGCAGUCAACCUUC	117
CCUACCACGCAGUCAACCUU	118
CCCUACCACGCAGUCAACCU	119
UUGCCUUCGGCUUGCUCUGG	120
CUUGCCUUCGGCUUGCUCUG	121
GCUUGCCUUCGGCUUGCUCU	122
UGCUUGCCUUCGGCUUGCUC	123
GUGCUUGCCUUCGGCUUGCU	124
UCGUGCUUGCCUUCGGCUUG	125
AUCGUGCUUGCCUUCGGCUU	126
CAUCGUGCUUGCCUUCGGCU	127
AGCGCCAUCGUGCUUGCCUU	128
UGGUGAGCGCCAUCGUGCUU	129
CUGAUGCUCGGCUGCUACAG	130
GCUGAUGCUCGGCUGCUACA	131
UUUCGGGCUGAUGCUCGGCU	132
UCCUUUCGGGCUGAUGCUCG	133
UUCCUUUCGGGCUGAUGCUC	134
CUUCCUUUCGGGCUGAUGCU	135
GCUUCCUUUCGGGCUGAUGC	136
UGCUUCCUUUCGGGCUGAUG	137
GUGCUUCCUUUCGGGCUGAU	138
CGUGCUUCCUUUCGGGCUGA	139
UCGUGCUUCCUUUCGGGCUG	140
UUCGUGCUUCCUUUCGGGCU	141
UUUCGUGCUUCCUUUCGGGC	142
CUUUCGUGCUUCCUUUCGGG	143
GCUUUCGUGCUUCCUUUCGG	144
AUGUACGCCAGCGUGCUGCU	145
UCAGCAUGUACGCCAGCGUG	146
AGGCGGUGUACUACGUGUGC	147
AAGGCGGUGUACUACGUGUG	148
CAAGGCGGUGUACUACGUGU	149
GCAAGGCGGUGUACUACGUG	150
UGCAAGGCGGUGUACUACGU	151
CUGCAAGGCGGUGUACUACG	152
GCUGCAAGGCGGUGUACUAC	153
GGCUGCAAGGCGGUGUACUA	154
GCUCUUUGUGGCCUUCCUGA	155
CGCUCUUUGUGGCCUUCCUG	156
CUUCGUGGUGUGGAGCUUGG	157
GGCUUCGUGGUGUGGAGCUU	158
CAACGGCUUCGUGGUGUGGA	159
UGGCAACGGCUUCGUGGUGU	160
UGAGCUGGAAGACUUCGCGG	161
CUGAGCUGGAAGACUUCGCG	162
GCUGAGCUGGAAGACUUCGC	163
ACACUGCUGAGCUGGAAGAC	164
CGAGACACUGCUGAGCUGGA	165
ACGAGACACUGCUGAGCUGG	166
AACGAGACACUGCUGAGCUG	167
GAACGAGACACUGCUGAGCU	168
GGAACGAGACACUGCUGAGC	169
GGGAACGAGACACUGCUGAG	170
AGGGAACGAGACACUGCUGA	171
CAGGGAACGAGACACUGCUG	172
CCAGGGAACGAGACACUGCU	173
AAGGAUGUCGGUCUGCUACC	174
GAAGGAUGUCGGUCUGCUAC	175
AGAAGGAUGUCGGUCUGCUA	176
UAGGCCCAGAAGGAUGUCGG	177
GUAGGCCCAGAAGGAUGUCG	178
UGUAGGCCCAGAAGGAUGUC	179
CUGUAGGCCCAGAAGGAUGU	180
CCUGUAGGCCCAGAAGGAUG	181
ACCUGUAGGCCCAGAAGGAU	182
CUUCUCAUCGGGCAUCACAG	183
CCUUCUCAUCGGGCAUCACA	184
ACCUUCUCAUCGGGCAUCAC	185
CACCUUCUCAUCGGGCAUCA	186
GCACCUUCUCAUCGGGCAUC	187
GGCACCUUCUCAUCGGGCAU	188
UGGCACCUUCUCAUCGGGCA	189
AUGGCACCUUCUCAUCGGGC	190
CAUGGCACCUUCUCAUCGGG	191
GCAUGGCACCUUCUCAUCGG	192
GGCAUGGCACCUUCUCAUCG	193
GAGGCAUGGCACCUUCUCAU	194
GGAGGCAUGGCACCUUCUCA	195
GACUCCCAGGCAGAAAAGAG	196
GGACUCCCAGGCAGAAAAGA	197
AGGACUCCCAGGCAGAAAAG	198
UCAGGACUCCCAGGCAGAAA	199
GAAGUCAGGACUCCCAGGCA	200
GUGGAAGUCAGGACUCCCAG	201
UCGUGGAAGUCAGGACUCCC	202
CUCGUGGAAGUCAGGACUCC	203
CCUCGUGGAAGUCAGGACUC	204
UGGGUCCUCGUGGAAGUCAG	205
CUGGGUCCUCGUGGAAGUCA	206
UCUGGGUCCUCGUGGAAGUC	207
GUCUGGGUCCUCGUGGAAGU	208
AAGAAGGAGUUGUGUUUGAG	209
CCAAGAAGGAGUUGUGUUUG	210
GUUCCAAGAAGGAGUUGUGU	211
GGUUCCAAGAAGGAGUUGUG	212
CAGGUCAACUGACUGGGAGC	213
UGCCUGUUUACCACUGAGCU	214
AUGCCUGUUUACCACUGAGC	215
UAUGCCUGUUUACCACUGAG	216
UUAUGCCUGUUUACCACUGA	217
UUUAUGCCUGUUUACCACUG	218
CUUUAUGCCUGUUUACCACU	219
ACUUUAUGCCUGUUUACCAC	220
UAGAGAUAGUGACAGCCUGG	221
GUAGAGAUAGUGACAGCCUG	222
UGGUGGUAGAGAUAGUGACA	223
GUGGUGGUAGAGAUAGUGAC	224
UAGAGGAGUGGUGGUAGAGA	225
ACUAGAGGAGUGGUGGUAGA	226
AGACUAGAGGAGUGGUGGUA	227
CAGACUAGAGGAGUGGUGGU	228
CCAGACUAGAGGAGUGGUGG	229
GCCAGACUAGAGGAGUGGUG	230
GGCCAGACUAGAGGAGUGGU	231
GCCCAGAUGUGCUAGAAUGG	232
UGCCCAGAUGUGCUAGAAUG	233
UUGCCCAGAUGUGCUAGAAU	234
UUUGCCCAGAUGUGCUAGAA	235
UUUUGCCCAGAUGUGCUAGA	236
CCAGUUUUGCCCAGAUGUGC	237
AUCCAGUUUUGCCCAGAUGU	238
CCAUCCAGUUUUGCCCAGAU	239
CACCAUCCAGUUUUGCCCAG	240
CCACCAUCCAGUUUUGCCCA	241
CCCACCAUCCAGUUUUGCCC	242
UUGCUCCCAGCUUGGUAAGU	243
GCUUGCUCCCAGCUUGGUAA	244
AUCCUGCUUGCUCCCAGCUU	245
AAUCCUGCUUGCUCCCAGCU	246
CAAUCCUGCUUGCUCCCAGC	247
CCAAUCCUGCUUGCUCCCAG	248
AACCUUUCAGCUUCUCCAGG	249
UAACCUUUCAGCUUCUCCAG	250
UUAACCUUUCAGCUUCUCCA	251
ACUGCUGCUUAACCUUUCAG	252
UACUGCUGCUUAACCUUUCA	253
CUACUGCUGCUUAACCUUUC	254
CCUACUGCUGCUUAACCUUU	255
GCCUACUGCUGCUUAACCUU	256
CAGGACAGGAGUAGGCACCU	257
ACAGGACAGGAGUAGGCACC	258
GCACAGGACAGGAGUAGGCA	259
AUAGGCACAGGACAGGAGUA	260
GAUAGGCACAGGACAGGAGU	261
UGAUAGGCACAGGACAGGAG	262
ACCCUCUGCAAAUGUGAUAG	263
CUUACCCUCUGCAAAUGUGA	264
GUCUUACCCUCUGCAAAUGU	265
UGUCUUACCCUCUGCAAAUG	266
UUGUCUUACCCUCUGCAAAU	267
CUUGUCUUACCCUCUGCAAA	268
UCUUGUCUUACCCUCUGCAA	269
CAUUCUUGUCUUACCCUCUG	270
CCCAUUCUUGUCUUACCCUC	271
GAGCCUCAUCUUGUCCCUCC	272
UGAGCCUCAUCUUGUCCCUC	273
UGCGUUGGUGAUGGGAAGGA	274
GUGCGUUGGUGAUGGGAAGG	275
GGUGCGUUGGUGAUGGGAAG	276
GGGUGCGUUGGUGAUGGGAA	277
UGGGUGCGUUGGUGAUGGGA	278
UCUCACAUGCCUGGACGCCU	279
CAAGGCAGGCUCUCACAUGC	280
UGCUGUUUCCUGGCAAGGCA	281
UUGUGCUGUUUCCUGGCAAG	282
CUUGUGCUGUUUCCUGGCAA	283
ACCACCAGGGAAUCUUACUG	284
UCCACCACCAGGGAAUCUUA	285
AUUUCCUUCCACCACCAGGG	286
UAUUUCCUUCCACCACCAGG	287
CCUAUUUCCUUCCACCACCA	288
AGUCCUCCUAUUUCCUUCCA	289
AGAGUCCUCCUAUUUCCUUC	290
AGCAGAGUCCUCCUAUUUCC	291
CAGCAGAGUCCUCCUAUUUC	292
AUUCAGCAGAGUCCUCCUAU	293
ACCAGGAUUCAGCAGAGUCC	294
GACCAGGAUUCAGCAGAGUC	295
GGACCAGGAUUCAGCAGAGU	296
CAGGACCAGGAUUCAGCAGA	297
CAGAAGCAGGACCAGGAUUC	298
ACAGAAGCAGGACCAGGAUU	299
AACAGAAGCAGGACCAGGAU	300
AGAACAGAAGCAGGACCAGG	301
GGGAGGGAUGAGAACAGAAG	302
CAGGCAACAUACACACUGCA	303
CCAGGCAACAUACACACUGC	304
ACCAGGCAACAUACACACUG	305
AGACCAGGCAACAUACACAC	306
GAGAGACCAGGCAACAUACA	307
CCAGAGAGACCAGGCAACAU	308
UUGUUUGGGUCACCUCUGCA	309
GUUGUUUGGGUCACCUCUGC	310
AGUUGUUUGGGUCACCUCUG	311
UGAGUUGUUUGGGUCACCUC	312
CUGAGUUGUUUGGGUCACCU	313
GACUGAGUUGUUUGGGUCAC	314
AAACAGGCAAGGAUAAGGCA	315
ACAUGGAAAAGCUGUCAUUG	316
CCUUACAUGGAAAAGCUGUC	317
GCCUUACAUGGAAAAGCUGU	318
CUCCUGGAACCUAGCACCAU	319
CCUCCUGGAACCUAGCACCA	320
UCCUCCUGGAACCUAGCACC	321
AACCAUUAUGCCUCCAUGCA	322
UAACCAUUAUGCCUCCAUGC	323
CUAACCAUUAUGCCUCCAUG	324
CCUAACCAUUAUGCCUCCAU	325
CCCUAACCAUUAUGCCUCCA	326
ACUCCCUAACCAUUAUGCCU	327
GACUCCCUAACCAUUAUGCC	328
UGACUCCCUAACCAUUAUGC	329
AUGACUCCCUAACCAUUAUG	330
CAUGACUCCCUAACCAUUAU	331
GGGCCUCUUCAUGGUUGUGU	332
UGGUGCAGCCUGGUAAUGGG	333
CUGGUGCAGCCUGGUAAUGG	334
CCUGGUGCAGCCUGGUAAUG	335
AUCCUGGUGCAGCCUGGUAA	336
UAUCCUGGUGCAGCCUGGUA	337
GUAUCCUGGUGCAGCCUGGU	338
UGUAUCCUGGUGCAGCCUGG	339
UCUUGUAUCCUGGUGCAGCC	340
GUCUUGUAUCCUGGUGCAGC	341
UGUCUUGUAUCCUGGUGCAG	342
UUGUCUUGUAUCCUGGUGCA	343
CUUGUCUUGUAUCCUGGUGC	344
UCUUGUCUUGUAUCCUGGUG	345
UUCUUGUCUUGUAUCCUGGU	346
UUUCUUGUCUUGUAUCCUGG	347
CCUUUCUUGUCUUGUAUCCU	348
ACUCAUCCUUUCCUUUCUUG	349
CCUACUCAUCCUUUCCUUUC	350
CCCUACUCAUCCUUUCCUUU	351
UCCCUACUCAUCCUUUCCUU	352
GCUUCUUAGUAUGUCCCUAC	353
GCUGCUUCUUAGUAUGUCCC	354
GGCUGCUUCUUAGUAUGUCC	355
GGGCUGCUUCUUAGUAUGUC	356
AGGGCUGCUUCUUAGUAUGU	357
GAGAGGGCUGCUUCUUAGUA	358
UCCAAGAGGAGAGGGCUGCU	359
UUGACUUUUCCAAGAGGAGA	360
AGCUCUAUCCAUCUGCCAGG	361
GCUGUUACUUGAGCAGAGGC	362
GGCUGUUACUUGAGCAGAGG	363
UGGCUGUUACUUGAGCAGAG	364
CUGGCUGUUACUUGAGCAGA	365
UCUGGCUGUUACUUGAGCAG	366
CCUCAAGUUCUGGCUGUUAC	367
ACCUCAAGUUCUGGCUGUUA	368
CAACCUCAAGUUCUGGCUGU	369
GCAACCUCAAGUUCUGGCUG	370
AGCAACCUCAAGUUCUGGCU	371
CAAGCAACCUCAAGUUCUGG	372
CCAAGCAACCUCAAGUUCUG	373
CCCAAGCAACCUCAAGUUCU	374
ACUAAGACAGUGCUCCUGGU	375
CAAACUAAGACAGUGCUCCU	376
AGCUCUGCUUUGGAAGAACC	377
CCCUUAGCUCAAGCUCUGCU	378
GCCCUUAGCUCAAGCUCUGC	379
AAGCCCUUAGCUCAAGCUCU	380
CAAGCCCUUAGCUCAAGCUC	381
CCAAGCCCUUAGCUCAAGCU	382
CCCAAGCCCUUAGCUCAAGC	383
GUACCCAAGCCCUUAGCUCA	384
UGUACCCAAGCCCUUAGCUC	385
CUGUACCCAAGCCCUUAGCU	386
CCUGUACCCAAGCCCUUAGC	387
ACCUGUACCCAAGCCCUUAG	388
UCACCUGUACCCAAGCCCUU	389
AUCACCUGUACCCAAGCCCU	390
GGAUCACCUGUACCCAAGCC	391
CUCAAGAAUACAGGAUCACC	392
CUUAGCUCAAGAAUACAGGA	393
CCUUAGCUCAAGAAUACAGG	394
GCCCUUAGCUCAAGAAUACA	395
AGCCCUUAGCUCAAGAAUAC	396
AAGCCCUUAGCUCAAGAAUA	397
CAAGCCCUUAGCUCAAGAAU	398
CCAAGCCCUUAGCUCAAGAA	399
CCCAAGCCCUUAGCUCAAGA	400
GUACCCAAGCCCUUAGCUCA	401
UGUACCCAAGCCCUUAGCUC	402
CUGUACCCAAGCCCUUAGCU	403
CCUGUACCCAAGCCCUUAGC	404
ACCUGUACCCAAGCCCUUAG	405
UCACCUGUACCCAAGCCCUU	406
AUCACCUGUACCCAAGCCCU	407
GGAUCACCUGUACCCAAGCC	408
UAACCUCCCAAAUACAGGAU	409
UACCUUAUGCCCUCACUUCC	410
UUACCUUAUGCCCUCACUUC	411
UUUACCUUAUGCCCUCACUU	412
UUUUACCUUAUGCCCUCACU	413
UUGUUUUACCUUAUGCCCUC	414
CUUGUUUUACCUUAUGCCCU	415
UUAAUGGCUUUCCUCUCUCU	416
ACUCUUAAUGGCUUUCCUCU	417
UACUCUUAAUGGCUUUCCUC	418
CAUACUCUUAAUGGCUUUCC	419
GAAGGGACUUAACAUACUCU	420
UGAAGGGACUUAACAUACUC	421
ACUGAAGGGACUUAACAUAC	422
CUACUGAAGGGACUUAACAU	423
GCCUACUGAAGGGACUUAAC	424
GGCCUACUGAAGGGACUUAA	425
UUCUCAGAGGUUCCCAAGGC	426
UUUUCUCAGAGGUUCCCAAG	427
ACUUUUCUCAGAGGUUCCCA	428
UACUUUUCUCAGAGGUUCCC	429
GGGCAAUCUAUACUUUUCUC	430
UGUCUUGGGCAAUCUAUACU	431
CCAGUCUUUUGUCUUGGGCA	432
GCCAGUCUUUUGUCUUGGGC	433
UGCCAGUCUUUUGUCUUGGG	434
CUGCCAGUCUUUUGUCUUGG	435
UCACCCUGCCAGUCUUUUGU	436
AUCACCCUGCCAGUCUUUUG	437
GCCCACUCAUUAAGUACAUU	438
CUGUAGCCCACUCAUUAAGU	439
CGCUGUAGCCCACUCAUUAA	440
ACGCUGUAGCCCACUCAUUA	441
UACGCUGUAGCCCACUCAUU	442
AUACGCUGUAGCCCACUCAU	443
GAUACGCUGUAGCCCACUCA	444
GGAUACGCUGUAGCCCACUC	445
AGGAUACGCUGUAGCCCACU	446
GAGGAUACGCUGUAGCCCAC	447
UGAGGAUACGCUGUAGCCCA	448
GUGAGGAUACGCUGUAGCCC	449
UGUGAGGAUACGCUGUAGCC	450
CUGUUGUGAGGAUACGCUGU	451
UCUGUUGUGAGGAUACGCUG	452
GUCUGUUGUGAGGAUACGCU	453
UGUCUGUUGUGAGGAUACGC	454
ACUGUCUGUUGUGAGGAUAC	455
CACUGUCUGUUGUGAGGAUA	456
CAACUCUCUCUCACUGUCUG	457
AACAACUCUCUCUCACUGUC	458
AGAACAACUCUCUCUCACUG	459
GUAGAACAACUCUCUCUCAC	460
GGUAGAACAACUCUCUCUCA	461
CAGGUAGAACAACUCUCUCU	462
CCAGGUAGAACAACUCUCUC	463
ACCCAGGUAGAACAACUCUC	464
UAUACCCAGGUAGAACAACU	465
AUAUACCCAGGUAGAACAAC	466
GGAUAUACCCAGGUAGAACA	467
GUUUUGGAUAUACCCAGGUA	468
CCUUGUUUUGGAUAUACCCA	469
CCCUUGUUUUGGAUAUACCC	470
CCUCGUAAACUCCAUACCCU	471
CCCUCGUAAACUCCAUACCC	472
ACCCUCGUAAACUCCAUACC	473
AACCCUCGUAAACUCCAUAC	474
GAACCCUCGUAAACUCCAUA	475
UGAACCCUCGUAAACUCCAU	476
UUGAACCCUCGUAAACUCCA	477
CUUGAACCCUCGUAAACUCC	478
CCUUGAACCCUCGUAAACUC	479
ACCUUGAACCCUCGUAAACU	480
UACCUUGAACCCUCGUAAAC	481
AUACCUUGAACCCUCGUAAA	482
AAUACCUUGAACCCUCGUAA	483
AAAUACCUUGAACCCUCGUA	484
CAAAUACCUUGAACCCUCGU	485
CCAAAUACCUUGAACCCUCG	486
ACCAAAUACCUUGAACCCUC	487
AACCAAAUACCUUGAACCCU	488
GAACCAAAUACCUUGAACCC	489
UGAACCAAAUACCUUGAACC	490
CCCUGAACCAAAUACCUUGA	491
GGCCCUGAACCAAAUACCUU	492
UGGCCCUGAACCAAAUACCU	493
UAUUCAGGUUGUUGCCCAAA	494
GGUAUUCAGGUUGUUGCCCA	495
AGGUAUUCAGGUUGUUGCCC	496
AAGGUAUUCAGGUUGUUGCC	497
AAAGGUAUUCAGGUUGUUGC	498
UAACUUGAUUGCCCUGUGAC	499
GUAACUUGAUUGCCCUGUGA	500
AGUAACUUGAUUGCCCUGUG	501
CAGAGUAACUUGAUUGCCCU	502
ACAGAGUAACUUGAUUGCCC	503
CACAGAGUAACUUGAUUGCC	504
UGUCCUGACAAAGAAACACA	505
CAAUCCCUGCUUUCCUGCCA	506
ACAAUCCCUGCUUUCCUGCC	507
AACACAAUCCCUGCUUUCCU	508
GAACACAAUCCCUGCUUUCC	509
AAUGAACACAAUCCCUGCUU	510
AAAUGAACACAAUCCCUGCU	511
GUGAAACCCUCAAAUGAACA	512
AGUGAAACCCUCAAAUGAAC	513
CAGUGAAACCCUCAAAUGAA	514
ACAGUGAAACCCUCAAAUGA	515
GCAUGGAAGCUGAGACUCUC	516
UUGCAUGGAAGCUGAGACUC	517
CAGUUGCAUGGAAGCUGAGA	518
ACAGUUGCAUGGAAGCUGAG	519
GACAGUUGCAUGGAAGCUGA	520
AUGGACAGUUGCAUGGAAGC	521
GUGAUGGACAGUUGCAUGGA	522
CGUGAUGGACAGUUGCAUGG	523
CCGUGAUGGACAGUUGCAUG	524
GCCGUGAUGGACAGUUGCAU	525
AGCCGUGAUGGACAGUUGCA	526
CAGCCGUGAUGGACAGUUGC	527
GCAGCCGUGAUGGACAGUUG	528
UGCAGCCGUGAUGGACAGUU	529
UUGCAGCCGUGAUGGACAGU	530
GUUGCAGCCGUGAUGGACAG	531
CAGUUGCAGCCGUGAUGGAC	532
UCAGUUGCAGCCGUGAUGGA	533
UUCAGUUGCAGCCGUGAUGG	534
UUUCAGUUGCAGCCGUGAUG	535
AUUUCAGUUGCAGCCGUGAU	536
GAUUUCAGUUGCAGCCGUGA	537
UGAUUUCAGUUGCAGCCGUG	538
CUCUGAUUUCAGUUGCAGCC	539
UUAGCUUCUGGUGCGCUGUG	540
UUUAGCUUCUGGUGCGCUGU	541
CUUUAGCUUCUGGUGCGCUG	542
GACUUUAGCUUCUGGUGCGC	543
AGACUUUAGCUUCUGGUGCG	544
AAGACUUUAGCUUCUGGUGC	545
UCAAGACUUUAGCUUCUGGU	546
AUCAAGACUUUAGCUUCUGG	547
GCAUCAAGACUUUAGCUUCU	548
AUGGCAUCAAGACUUUAGCU	549
GAUGGCAUCAAGACUUUAGC	550
AGGGAUGUCCUUUGAUGGCA	551
GCAGGGAUGUCCUUUGAUGG	552
GGCAGGGAUGUCCUUUGAUG	553
CGUGACAGAGAUGUGAAUGG	554
GGACGUGACAGAGAUGUGAA	555
UGGACGUGACAGAGAUGUGA	556
GUGGACGUGACAGAGAUGUG	557
AGUGGACGUGACAGAGAUGU	558
UAGUGGACGUGACAGAGAUG	559
UUAGUGGACGUGACAGAGAU	560
AUUAGUGGACGUGACAGAGA	561
GAUUAGUGGACGUGACAGAG	562
CGAUUAGUGGACGUGACAGA	563
CCGAUUAGUGGACGUGACAG	564
UGCCGAUUAGUGGACGUGAC	565
UUGCCGAUUAGUGGACGUGA	566
UUUGCCGAUUAGUGGACGUG	567
UUUUGCCGAUUAGUGGACGU	568
CUUUUGCCGAUUAGUGGACG	569
CCUUUUGCCGAUUAGUGGAC	570
UCCUUUUGCCGAUUAGUGGA	571
CUCCUUUUGCCGAUUAGUGG	572
UCUCCUUUUGCCGAUUAGUG	573
UUCUCCUUUUGCCGAUUAGU	574
UUUCUCCUUUUGCCGAUUAG	575
AGGUCAUCUUCUCUCACUUU	576
UUAGGUCAUCUUCUCUCACU	577
CUUAGGUCAUCUUCUCUCAC	578
ACACUUAGGUCAUCUUCUCU	579
CACACUUAGGUCAUCUUCUC	580
UCACACUUAGGUCAUCUUCU	581
GUCACACUUAGGUCAUCUUC	582
AGUCACACUUAGGUCAUCUU	583
CAGUCACACUUAGGUCAUCU	584
GCAGUCACACUUAGGUCAUC	585
UGCAGUCACACUUAGGUCAU	586
AUUUUCCAGAGCUGCCUGCU	587
CUCACUGCUCUGGCUUCAUU	588
GCUCACUGCUCUGGCUUCAU	589
UUACCUGCUCUUUCCUUCCU	590
UGCUUACCUGCUCUUUCCUU	591
UUCCUGCUUACCUGCUCUUU	592
CUUCCUGCUUACCUGCUCUU	593
ACUGGCCUUCCUGCUUACCU	594
GACACUGGCCUUCCUGCUUA	595
CAUUAGGGUCCUGUCUGGGA	596
UCAUUAGGGUCCUGUCUGGG	597
AUCAUUAGGGUCCUGUCUGG	598
GAUCAUUAGGGUCCUGUCUG	599
GGAUCAUUAGGGUCCUGUCU	600
AUUCAGGAUCAUUAGGGUCC	601
GAUUCAGGAUCAUUAGGGUC	602
GGAUUCAGGAUCAUUAGGGU	603
AUGGAUUCAGGAUCAUUAGG	604
GAUACAUGGAUUCAGGAUCA	605
UGAUACAUGGAUUCAGGAUC	606
AUGGCAGGGCUUUGGAAAAU	607
CAUGGCAGGGCUUUGGAAAA	608
GCAUGGCAGGGCUUUGGAAA	609
CAGCAUGGCAGGGCUUUGGA	610
GAAGUGGGAUGGCAGCAUGG	611
GGAAGUGGGAUGGCAGCAUG	612
GGGAAGUGGGAUGGCAGCAU	613
UGGAGAAGCCAUAAGCUGCA	614
CUGGAGAAGCCAUAAGCUGC	615
ACUGGAGAAGCCAUAAGCUG	616
UACUGGAGAAGCCAUAAGCU	617
CUACUGGAGAAGCCAUAAGC	618
CCUACUGGAGAAGCCAUAAG	619
ACCUACUGGAGAAGCCAUAA	620
CACCUACUGGAGAAGCCAUA	621
CCACCUACUGGAGAAGCCAU	622
GCCACCUACUGGAGAAGCCA	623
CUGCCACCUACUGGAGAAGC	624
GCUGCCACCUACUGGAGAAG	625
UGUGUGUGCUGCCACCUACU	626
CUGUGUGUGCUGCCACCUAC	627
UUAUGAGUGGCUCUGUGUGU	628
UUUAUGAGUGGCUCUGUGUG	629
AGUUUAUGAGUGGCUCUGUG	630
CAGUUUAUGAGUGGCUCUGU	631
GUUUCUGGCUCUCAGGCUCU	632
GGUUUCUGGCUCUCAGGCUC	633
CGGUUUCUGGCUCUCAGGCU	634
GGACGGUUUCUGGCUCUCAG	635
GGGACGGUUUCUGGCUCUCA	636
UGAAAUGUGACUUCUGGUGU	637
GGGAACCAUGUAAAAGGAUG	638
GUGAGGGUAGAUGGGAACCA	639
UUGUGAGGGUAGAUGGGAAC	640
GUUGUGAGGGUAGAUGGGAA	641
UGUUGUGAGGGUAGAUGGGA	642
AUGUGUGUCUUUGGUGAUGA	643
GGAGCUUGUAUGUGUGUCUU	644
UUGGAGCUUGUAUGUGUGUC	645
AUUGGAGCUUGUAUGUGUGU	646
CAUUGGAGCUUGUAUGUGUG	647
CCAUUGGAGCUUGUAUGUGU	648
GCCAUUGGAGCUUGUAUGUG	649
AGCCAUUGGAGCUUGUAUGU	650
CUGGAGGAAGAAUUGCCUGG	651
GUCCUGGAGGAAGAAUUGCC	652
GCCAGUAAGAAGGGCAAAGU	653
GGCCAGUAAGAAGGGCAAAG	654
GGAAUGAGUCAAGCCUGGAC	655
GGGAAUGAGUCAAGCCUGGA	656
GUGGGAAUGAGUCAAGCCUG	657
AAGGUGGGAAUGAGUCAAGC	658
UCUCAGCCCAGGACAAGGUG	659
AUCUCAGCCCAGGACAAGGU	660
GCUGGGUGGUUCUCUCCUGU	661
UUCUGGGCUGGGUGGUUCUC	662
GAACUUCUGGGCUGGGUGGU	663
CGGAGAGUUCCUUCCCUGGA	664
ACCGGAGAGUUCCUUCCCUG	665
GACCGGAGAGUUCCUUCCCU	666
UGGACCGGAGAGUUCCUUCC	667
GUGGACCGGAGAGUUCCUUC	668
GGUGGACCGGAGAGUUCCUU	669
UGGUGGACCGGAGAGUUCCU	670
AUGGUGGACCGGAGAGUUCC	671
CAUGGUGGACCGGAGAGUUC	672
GAGCUGAGAGGUACUCCAUG	673
AGAGCUGAGAGGUACUCCAU	674
CAGAGCUGAGAGGUACUCCA	675
UUCAGAGCUGAGAGGUACUC	676
GGUUCAGAGCUGAGAGGUAC	677
GGGUUCAGAGCUGAGAGGUA	678
CACCUGAGUAAGUCACUGGG	679
UCACCUGAGUAAGUCACUGG	680
GUCACCUGAGUAAGUCACUG	681
AGUCACCUGAGUAAGUCACU	682
CAGUCACCUGAGUAAGUCAC	683
GCAGUCACCUGAGUAAGUCA	684
UUAGCAGUCACCUGAGUAAG	685
GUUAGCAGUCACCUGAGUAA	686
GGUUAGCAGUCACCUGAGUA	687
GGGUUAGCAGUCACCUGAGU	688
AGGGUUAGCAGUCACCUGAG	689
GAGGGUUAGCAGUCACCUGA	690
GGAGGGUUAGCAGUCACCUG	691
CGGAGGGUUAGCAGUCACCU	692
AGCGGAGGGUUAGCAGUCAC	693
GAGCGGAGGGUUAGCAGUCA	694
AGAGCGGAGGGUUAGCAGUC	695
UAGAGCGGAGGGUUAGCAGU	696
GUAGAGCGGAGGGUUAGCAG	697
GGUAGAGCGGAGGGUUAGCA	698
AGGGUAGAGCGGAGGGUUAG	699
GAGGGUAGAGCGGAGGGUUA	700
AUUGUUGCCCUGCCUAUAUC	701
AGUAUUGUUGCCCUGCCUAU	702
GAGUAUUGUUGCCCUGCCUA	703
GGAGUAUUGUUGCCCUGCCU	704
UGGAGUAUUGUUGCCCUGCC	705
GUGGAGUAUUGUUGCCCUGC	706
AGUGGAGUAUUGUUGCCCUG	707
GAGUGGAGUAUUGUUGCCCU	708
UGAGUGGAGUAUUGUUGCCC	709
CUGAGUGGAGUAUUGUUGCC	710
GCUGAGUGGAGUAUUGUUGC	711
GGCUGAGUGGAGUAUUGUUG	712
GGGCUGAGUGGAGUAUUGUU	713
GGUACUGGUUAGUCUCCUAG	714
GGGUACUGGUUAGUCUCCUA	715
UUGACAAGCCCACUGUGGAG	716
UGGCUCAGGAGCUUGACAAG	717
GGUGGCUCAGGAGCUUGACA	718
UAGGGAUGAGGGAGAGACCA	719
UCGAUUAGGGAUGAGGGAGA	720
UAGAGGGCUAGGGAGGGAGA	721
GUAGAGUGGCUAGAGGGCUA	722
GGUAGAGUGGCUAGAGGGCU	723
UGAGGGUAGAGUGGCUAGAG	724
GAUGAGGGUAGAGUGGCUAG	725
CAUGAUGAGGGUAGAGUGGC	726
GCAUGAUGAGGGUAGAGUGG	727
GGGCAUGAUGAGGGUAGAGU	728
GGUAGUUGAGAAGAAAAGUC	729
CCAAACUCCGAGCUUAUAUU	730
UCCAAACUCCGAGCUUAUAU	731
GUCCAAACUCCGAGCUUAUA	732
CGUCCAAACUCCGAGCUUAU	733
CCGUCCAAACUCCGAGCUUA	734
UCCGUCCAAACUCCGAGCUU	735
CUCCGUCCAAACUCCGAGCU	736
ACCCUCCGUCCAAACUCCGA	737
AGACCCUCCGUCCAAACUCC	738
CAGACCCUCCGUCCAAACUC	739
UCCAGACCCUCCGUCCAAAC	740
GUCCAGACCCUCCGUCCAAA	741
AGACACGGAAAGGUCGCUGG	742
CAGACACGGAAAGGUCGCUG	743
ACAGACACGGAAAGGUCGCU	744
CACAGACACGGAAAGGUCGC	745
UCACAGACACGGAAAGGUCG	746
AUCACAGACACGGAAAGGUC	747
GAUCACAGACACGGAAAGGU	748
UUGGCCUACUUACUUUGGCU	749
CUUGGCCUACUUACUUUGGC	750
ACUUGGCCUACUUACUUUGG	751
GAGGAACUUGGCCUACUUAC	752
CGAGGAACUUGGCCUACUUA	753
CCGAGGAACUUGGCCUACUU	754
ACCGAGGAACUUGGCCUACU	755
AACCGAGGAACUUGGCCUAC	756
GAACCGAGGAACUUGGCCUA	757
GGAACCGAGGAACUUGGCCU	758
AGGAACCGAGGAACUUGGCC	759
UAGGAACCGAGGAACUUGGC	760
AUAGGAACCGAGGAACUUGG	761
UAUAGGAACCGAGGAACUUG	762
AUCACAAGUUGCCACUGUUG	763
CAUCACAAGUUGCCACUGUU	764
AUCAUCACAAGUUGCCACUG	765
CAUCAUCACAAGUUGCCACU	766
CUGCUCCAUCAUCACAAGUU	767
UCUGCUCCAUCAUCACAAGU	768
CCCUCUGCUCCAUCAUCACA	769
UCAGCCCUCUGCUCCAUCAU	770
UGACUUCAGCCCUCUGCUCC	771
GUGACUUCAGCCCUCUGCUC	772
UGUGACUUCAGCCCUCUGCU	773
GUGUGACUUCAGCCCUCUGC	774
UGUGUGACUUCAGCCCUCUG	775
GCCCACUCCGCUGCUUUUAG	776
GGCCCACUCCGCUGCUUUUA	777
AGGCCCACUCCGCUGCUUUU	778
UAGGCCCACUCCGCUGCUUU	779
UUAGGCCCACUCCGCUGCUU	780
AUUAGGCCCACUCCGCUGCU	781
UCAUUAGGCCCACUCCGCUG	782
CUCAUUAGGCCCACUCCGCU	783
AGCUCAUUAGGCCCACUCCG	784
CUCCCAUAGAAAAGCUCACU	785
GCUCCCAUAGAAAAGCUCAC	786
UGCUCCCAUAGAAAAGCUCA	787
CUGCUCCCAUAGAAAAGCUC	788
CCUGCUCCCAUAGAAAAGCU	789
UCCCUAUCUCCUGCUAACCC	790
CCUCGAACUCUCCCUAUCUC	791
CCCUCGAACUCUCCCUAUCU	792
UCCCUCGAACUCUCCCUAUC	793
GUCCCUCGAACUCUCCCUAU	794
CUUUCCAUACUAGCUUCUGA	795
CCUUUCCAUACUAGCUUCUG	796
ACCUUUCCAUACUAGCUUCU	797
CACACAAAUCACCUUUCCAU	798
GUCACACAAAUCACCUUUCC	799
UGUCACACAAAUCACCUUUC	800
UUUGACAGGCAGGAAGUGGC	801
GGUUUGACAGGCAGGAAGUG	802
AGGUUUGACAGGCAGGAAGU	803
AAGGUUUGACAGGCAGGAAG	804
AACUUCCCAAGGUUUGACAG	805
CAACUUCCCAAGGUUUGACA	806
GAACAACUUCCCAAGGUUUG	807
UGAACAACUUCCCAAGGUUU	808
GUAGGUUGAACAACUUCCCA	809
GGUAGGUUGAACAACUUCCC	810
UGGUAGGUUGAACAACUUCC	811
GGUUUUGGUAGGUUGAACAA	812
UGAGGUUUUGGUAGGUUGAA	813
CUGAGGUUUUGGUAGGUUGA	814
CCUACAUUAUCCUCUUACUC	815
GGACUUUACCUACAUUAUCC	816
GUAUGAGGACUUUACCUACA	817
GCCAGGUAUGAGGACUUUAC	818
UGCCAGGUAUGAGGACUUUA	819
GUGCCAGGUAUGAGGACUUU	820
CUGUGCCAGGUAUGAGGACU	821
UCUGUGCCAGGUAUGAGGAC	822
CCUCAAGAGUUCUCCAGAAG	823
CCCUCAAGAGUUCUCCAGAA	824
ACCCUCAAGAGUUCUCCAGA	825
ACACCCUCAAGAGUUCUCCA	826
CACACCCUCAAGAGUUCUCC	827
CCACACCCUCAAGAGUUCUC	828
CCCACACCCUCAAGAGUUCU	829
UUCCCACACCCUCAAGAGUU	830
CAAUGCUGCACCUCACUUCC	831
UACAAUGCUGCACCUCACUU	832
CUACAAUGCUGCACCUCACU	833
UCUACAAUGCUGCACCUCAC	834
AUCUACAAUGCUGCACCUCA	835
UAUCUACAAUGCUGCACCUC	836
CUUAUCUACAAUGCUGCACC	837
GUCUUAUCUACAAUGCUGCA	838
UGUCUUAUCUACAAUGCUGC	839
CUGUCUUAUCUACAAUGCUG	840
CACCCUUCUGUCUUAUCUAC	841
UCCACCCUUCUGUCUUAUCU	842
GUCCACCCUUCUGUCUUAUC	843
AGUCCACCCUUCUGUCUUAU	844
AAGUCCACCCUUCUGUCUUA	845
GAAAGCAAGCCAGGUUCUCA	846
GGAAAGCAAGCCAGGUUCUC	847
GGAAUUGGAAAGCAAGCCAG	848
ACCAUGUCAUUGGCAUCUCC	849
UACCAUGUCAUUGGCAUCUC	850
CCUACCAUGUCAUUGGCAUC	851
UCCUACCAUGUCAUUGGCAU	852
CUCCUACCAUGUCAUUGGCA	853
GCUCCUACCAUGUCAUUGGC	854
UGCUCCUACCAUGUCAUUGG	855
UCUUUGCUCCUACCAUGUCA	856
CCUCUUUGCUCCUACCAUGU	857
UUCCUCUUUGCUCCUACCAU	858
UCUCCGUGUUCUUCAGUUUU	859
CUCUCCGUGUUCUUCAGUUU	860
AGCUCUCCGUGUUCUUCAGU	861
UGCAGCUCUCCGUGUUCUUC	862
GGUUGCAGCUCUCCGUGUUC	863
AGGUUGCAGCUCUCCGUGUU	864
AAAGGUUGCAGCUCUCCGUG	865
UAAAGGUUGCAGCUCUCCGU	866
CUAAAGGUUGCAGCUCUCCG	867
CCUAAAGGUUGCAGCUCUCC	868
UCCUAAAGGUUGCAGCUCUC	869
CUCCUAAAGGUUGCAGCUCU	870
CCUCCUAAAGGUUGCAGCUC	871
GCACUUUGAUACCUCCUAAA	872
GGCACUUUGAUACCUCCUAA	873
GAUGUCCCACUUUGACUUUC	874
UCGAUGUCCCACUUUGACUU	875
GUCGAUGUCCCACUUUGACU	876
GGUCGAUGUCCCACUUUGAC	877
UGGUCGAUGUCCCACUUUGA	878
UUGGUCGAUGUCCCACUUUG	879
AUUGGUCGAUGUCCCACUUU	880
CAUUGGUCGAUGUCCCACUU	881
AACAUCCAUCAGUUGGCUCU	882
CUGCCCAACAUCCAUCAGUU	883
AGCUGCCCAACAUCCAUCAG	884
UAGCUGCCCAACAUCCAUCA	885
UUAGCUGCCCAACAUCCAUC	886
UUUAGCUGCCCAACAUCCAU	887
CUUUAGCUGCCCAACAUCCA	888
CCUCUUUAGCUGCCCAACAU	889
CCCUCUUUAGCUGCCCAACA	890
UCCCUCUUUAGCUGCCCAAC	891
UUCCCUCUUUAGCUGCCCAA	892
CCUUCCCUCUUUAGCUGCCC	893
CCCUUCCCUCUUUAGCUGCC	894
GCAGGUCUUAUCCCAUGCCC	895
GGGCAGGUCUUAUCCCAUGC	896
AGGGCAGGUCUUAUCCCAUG	897
AAGGGCAGGUCUUAUCCCAU	898
GAAGGGCAGGUCUUAUCCCA	899
AGAAGGGCAGGUCUUAUCCC	900
CCAAUGGCAAGAAGCAAGAA	901
CCCAAUGGCAAGAAGCAAGA	902
GCCCAAUGGCAAGAAGCAAG	903
UCCAAUGCCUGCCCAAUGGC	904
CUCCAAUGCCUGCCCAAUGG	905
UCUCCAAUGCCUGCCCAAUG	906
GGUCUCCAAUGCCUGCCCAA	907
UAGGGUCUCCAAUGCCUGCC	908
GUAGGGUCUCCAAUGCCUGC	909
AGUAGGGUCUCCAAUGCCUG	910
CAGUAGGGUCUCCAAUGCCU	911
GCAGUAGGGUCUCCAAUGCC	912
AGCAGUAGGGUCUCCAAUGC	913
CAGCAGUAGGGUCUCCAAUG	914
UCAGCAGUAGGGUCUCCAAU	915
AUUCAGCAGUAGGGUCUCCA	916
CAUUCAGCAGUAGGGUCUCC	917
CCAUUCAGCAGUAGGGUCUC	918
UCCAUUCAGCAGUAGGGUCU	919
ACUCCAUUCAGCAGUAGGGU	920
CACUCCAUUCAGCAGUAGGG	921
GCACUCCAUUCAGCAGUAGG	922
AGCACUCCAUUCAGCAGUAG	923
UAGCACUCCAUUCAGCAGUA	924
GUUAGCACUCCAUUCAGCAG	925
GGUUAGCACUCCAUUCAGCA	926
GGGUUAGCACUCCAUUCAGC	927
CAGGGUUAGCACUCCAUUCA	928
CCAGGGUUAGCACUCCAUUC	929
ACCAGGGUUAGCACUCCAUU	930
CACCAGGGUUAGCACUCCAU	931
GCACCAGGGUUAGCACUCCA	932
AGCACCAGGGUUAGCACUCC	933
UAGCACCAGGGUUAGCACUC	934
CUAGCACCAGGGUUAGCACU	935
UCUAGCACCAGGGUUAGCAC	936
CUCUAGCACCAGGGUUAGCA	937
CCUCUAGCACCAGGGUUAGC	938
UCCUCUAGCACCAGGGUUAG	939
CUCCUCUAGCACCAGGGUUA	940
CCUCCUCUAGCACCAGGGUU	941
UCCUCCUCUAGCACCAGGGU	942
GUUCCAUCCUCCUCUAGCAC	943
AAGUCCUCACUGUCCACUGC	944
GAAGUCCUCACUGUCCACUG	945
AGAAGUCCUCACUGUCCACU	946
AAGAAGUCCUCACUGUCCAC	947
GAAGAAGUCCUCACUGUCCA	948
GGAAGAAGUCCUCACUGUCC	949
UGGAAGAAGUCCUCACUGUC	950
CUGGAAGAAGUCCUCACUGU	951
AGCUGGAAGAAGUCCUCACU	952
ACUGCAACACCAUCAGGCAC	953
GACUGCAACACCAUCAGGCA	954
AGACUGCAACACCAUCAGGC	955
CAGACUGCAACACCAUCAGG	956
CCAGACUGCAACACCAUCAG	957
GACCAGACUGCAACACCAUC	958
CUCUGACCAGACUGCAACAC	959
AGCUCUGACCAGACUGCAAC	960
CCAGCUCUGACCAGACUGCA	961
UGUAGGGCUCCAGCUCUGAC	962
CUUGUAGGGCUCCAGCUCUG	963
CCUUGUAGGGCUCCAGCUCU	964
ACAGGCAUUGGAAGCAGCCC	965
GACAGGCAUUGGAAGCAGCC	966
AAGGACAGGCAUUGGAAGCA	967
AAAGGACAGGCAUUGGAAGC	968
UAAAGGACAGGCAUUGGAAG	969
CUAAAGGACAGGCAUUGGAA	970
GCUCUAAAGGACAGGCAUUG	971
AGCUCUAAAGGACAGGCAUU	972
AAGCUCUAAAGGACAGGCAU	973
AAAGCUCUAAAGGACAGGCA	974
GAAAGCUCUAAAGGACAGGC	975
CGGGAAAGCUCUAAAGGACA	976
CCGGGAAAGCUCUAAAGGAC	977
AGGGUUAAGCUAGAGAGGAA	978
UCAGGGUUAAGCUAGAGAGG	979
GAUCAGGGUUAAGCUAGAGA	980
GGAUCAGGGUUAAGCUAGAG	981
AGGAUCAGGGUUAAGCUAGA	982
CCCAGGAUCAGGGUUAAGCU	983
CAACUCCUCCUGCACCUGGU	984
ACAACUCCUCCUGCACCUGG	985
GACAAUUCCACAACUCCUCC	986
UGACAAUUCCACAACUCCUC	987
UUGACAAUUCCACAACUCCU	988
CUUGACAAUUCCACAACUCC	989
UCCUUGACAAUUCCACAACU	990
AUCCUUGACAAUUCCACAAC	991
CAUCCUUGACAAUUCCACAA	992
ACAUCCUUGACAAUUCCACA	993
GACAUCCUUGACAAUUCCAC	994
UGACAUCCUUGACAAUUCCA	995
UGUGUGACAUCCUUGACAAU	996
ACUGUGUGACAUCCUUGACA	997
ACUUUCUGUCCACUGUGUGA	998
CCUCGCUUGGACUUUCUGUC	999
CCCUCGCUUGGACUUUCUGU	1000
UCCCUCGCUUGGACUUUCUG	1001
CUCCCUCGCUUGGACUUUCU	1002
CCUCCCUCGCUUGGACUUUC	1003
CCCUCCCUCGCUUGGACUUU	1004
UCCAUCAGCACUGGGUCAGA	1005
ACCACUAAUCUCCAUCAGCA	1006
CACCACUAAUCUCCAUCAGC	1007
CCACCACUAAUCUCCAUCAG	1008
CCCACCACUAAUCUCCAUCA	1009
ACCAGACACCCACCACUAAU	1010
UACCAGACACCCACCACUAA	1011
CUCAUACCAGACACCCACCA	1012
CCUCAUACCAGACACCCACC	1013
UCCUCAUACCAGACACCCAC	1014
AUCCUCAUACCAGACACCCA	1015
GAUCCUCAUACCAGACACCC	1016
AGAUCCUCAUACCAGACACC	1017
UAGAUCCUCAUACCAGACAC	1018
GUAGAUCCUCAUACCAGACA	1019
AGUAGAUCCUCAUACCAGAC	1020
CAGUAGAUCCUCAUACCAGA	1021
UGCAGUAGAUCCUCAUACCA	1022
GUGCAGUAGAUCCUCAUACC	1023
AGUGCAGUAGAUCCUCAUAC	1024
ACUCUGUAGGACACCCUUGU	1025
CACUCUGUAGGACACCCUUG	1026
CCACUCUGUAGGACACCCUU	1027
UCCACUCUGUAGGACACCCU	1028
CUCCACUCUGUAGGACACCC	1029
ACUCCACUCUGUAGGACACC	1030
CACUCCACUCUGUAGGACAC	1031
AGCACUCCACUCUGUAGGAC	1032
UAUGACAGCACUCCACUCUG	1033
AUAUGACAGCACUCCACUCU	1034
UUGCUGUGCUUGGGCCUCUC	1035
ACGUCAAAGGUGAAUCGGGC	1036
CACGUCAAAGGUGAAUCGGG	1037
ACACGUCAAAGGUGAAUCGG	1038
UACACGUCAAAGGUGAAUCG	1039
GUACACGUCAAAGGUGAAUC	1040
GGCUGCCAAAGAGGUCUCGA	1041
UCAGGCUGCCAAAGAGGUCU	1042
CAUUCAGGCUGCCAAAGAGG	1043
GACAUUCAGGCUGCCAAAGA	1044
UGACAUUCAGGCUGCCAAAG	1045
CUUUGACAUUCAGGCUGCCA	1046
GCUUUGACAUUCAGGCUGCC	1047
CCGUAGAAUGUGGCUUUGAC	1048
GCCCGUAGAAUGUGGCUUUG	1049
UAGAGCCCGUAGAAUGUGGC	1050
GUAGAGCCCGUAGAAUGUGG	1051
AGUAGAGCCCGUAGAAUGUG	1052
AGAGUAGAGCCCGUAGAAUG	1053
UAGAGUAGAGCCCGUAGAAU	1054
AUAGAGUAGAGCCCGUAGAA	1055
CAUAGAGUAGAGCCCGUAGA	1056
UCAUAGAGUAGAGCCCGUAG	1057
CUCAUAGAGUAGAGCCCGUA	1058
GAAAGUCACAACUCAUAGAG	1059
CCUUGAAAGUCACAACUCAU	1060
AAGUCCUUGAAAGUCACAAC	1061
CCAAGUCCUUGAAAGUCACA	1062
UUCUUUGGGCCAAGUCCUUG	1063
UUUCUUUGGGCCAAGUCCUU	1064
UUGAUUUCUGACCUGAGUAC	1065
GUUGAUUUCUGACCUGAGUA	1066
GGGACUAUCCAACUGUAGGG	1067
GCAAGAGGACGAAUUAUGGG	1068
UGCAAGAGGACGAAUUAUGG	1069
GUGCAAGAGGACGAAUUAUG	1070
GGUGCAAGAGGACGAAUUAU	1071
GGGUGCAAGAGGACGAAUUA	1072
UGGGUGCAAGAGGACGAAUU	1073
GUGGGUGCAAGAGGACGAAU	1074
GGUGGGUGCAAGAGGACGAA	1075
UAGGUGGGUGCAAGAGGACG	1076
GUAGGUGGGUGCAAGAGGAC	1077
GGUAGGUGGGUGCAAGAGGA	1078
CCACAAGCAAGAGCUAACUA	1079
ACUUUCCACAAGCAAGAGCU	1080
GACUUUCCACAAGCAAGAGC	1081
GGACUUUCCACAAGCAAGAG	1082
AGGACUUUCCACAAGCAAGA	1083
GAGGACUUUCCACAAGCAAG	1084
UGAGGACUUUCCACAAGCAA	1085
AUGAGGACUUUCCACAAGCA	1086
GAUGAGGACUUUCCACAAGC	1087
AGAUGAGGACUUUCCACAAG	1088
GAGAUGAGGACUUUCCACAA	1089
GGAGAUGAGGACUUUCCACA	1090
UGGGAGAUGAGGACUUUCCA	1091
GCUGGGAGAUGAGGACUUUC	1092
UCAAGCUGGGAGAUGAGGAC	1093
AAGCCAUCAAGCUGGGAGAU	1094
GAAGCCAUCAAGCUGGGAGA	1095
GGAGGAAGCCAUCAAGCUGG	1096
GGGAGGAAGCCAUCAAGCUG	1097
AACUUGGGAGGAAGCCAUCA	1098
AAACUUGGGAGGAAGCCAUC	1099
CAGCAGUGUGGAGGUCCAAC	1100
GCAGCAGUGUGGAGGUCCAA	1101
UGCAGCAGUGUGGAGGUCCA	1102
UUGCAGCAGUGUGGAGGUCC	1103
GGUGGAGGAAAUUCCCAGCA	1104
ACGAAGGGUGGAGGAAAUUC	1105
GACGAAGGGUGGAGGAAAUU	1106
AUGACGAAGGGUGGAGGAAA	1107
CAUGACGAAGGGUGGAGGAA	1108
GCAUGACGAAGGGUGGAGGA	1109
UGCAUGACGAAGGGUGGAGG	1110
CUGCAUGACGAAGGGUGGAG	1111
ACUGCAUGACGAAGGGUGGA	1112
CACUGCAUGACGAAGGGUGG	1113
CCACUGCAUGACGAAGGGUG	1114
UCCACUGCAUGACGAAGGGU	1115
CUCCACUGCAUGACGAAGGG	1116
CCUCCACUGCAUGACGAAGG	1117
CCCUCCACUGCAUGACGAAG	1118
CUUAGUAGGAAUGGAGGCGG	1119
CCUUAGUAGGAAUGGAGGCG	1120
CCCUUAGUAGGAAUGGAGGC	1121
UCGGUUGGAAUGAUUCUGGG	1122
GUCGGUUGGAAUGAUUCUGG	1123
GGUCGGUUGGAAUGAUUCUG	1124
GGGUCGGUUGGAAUGAUUCU	1125
UGGGUCGGUUGGAAUGAUUC	1126
GUGGGUCGGUUGGAAUGAUU	1127
AGUGGGUCGGUUGGAAUGAU	1128
CAGUGGGUCGGUUGGAAUGA	1129
GCAGUGGGUCGGUUGGAAUG	1130
UGCAGUGGGUCGGUUGGAAU	1131
UUGCAGUGGGUCGGUUGGAA	1132
UUUGCAGUGGGUCGGUUGGA	1133
CUUUGCAGUGGGUCGGUUGG	1134
UCUUUGCAGUGGGUCGGUUG	1135
UAGUCUUUGCAGUGGGUCGG	1136
AUAGUCUUUGCAGUGGGUCG	1137
CUGUCAUAGUCUUUGCAGUG	1138
UGCUGUCAUAGUCUUUGCAG	1139
UCUAGCCUGUACUGUCUGCA	1140
AUCUAGCCUGUACUGUCUGC	1141
UAUCUAGCCUGUACUGUCUG	1142
UUAUCUAGCCUGUACUGUCU	1143
GUUAUCUAGCCUGUACUGUC	1144
GGUUAUCUAGCCUGUACUGU	1145
GGGUUAUCUAGCCUGUACUG	1146
UGGGUUAUCUAGCCUGUACU	1147
GUGGGUUAUCUAGCCUGUAC	1148
GGUGGGUUAUCUAGCCUGUA	1149
GGGUGGGUUAUCUAGCCUGU	1150
UGGGUGGGUUAUCUAGCCUG	1151
UUGGGUGGGUUAUCUAGCCU	1152
AUUGGGUGGGUUAUCUAGCC	1153
AAUUGGGUGGGUUAUCUAGC	1154
AAAUUGGGUGGGUUAUCUAG	1155
GGAAAUUGGGUGGGUUAUCU	1156
GGGAAAUUGGGUGGGUUAUC	1157
GAAAGGUUCUGUCACGAGGG	1158
GCUGAAAGGUUCUGUCACGA	1159
UGCUGAAAGGUUCUGUCACG	1160
GGCGUUAUGCUGAAAGGUUC	1161
AGGCGUUAUGCUGAAAGGUU	1162
GAGGCGUUAUGCUGAAAGGU	1163
UGAGGCGUUAUGCUGAAAGG	1164
GUGAGGCGUUAUGCUGAAAG	1165
AUGUGAGGCGUUAUGCUGAA	1166
GAUGUGAGGCGUUAUGCUGA	1167
GGAUGUGAGGCGUUAUGCUG	1168
GGGAUGUGAGGCGUUAUGCU	1169
CUUGGGAUGUGAGGCGUUAU	1170
AGACUUGGGAUGUGAGGCGU	1171
UAGACUUGGGAUGUGAGGCG	1172
AUAGACUUGGGAUGUGAGGC	1173
UAUAGACUUGGGAUGUGAGG	1174
GGGUAUAGACUUGGGAUGUG	1175
AGGGUAUAGACUUGGGAUGU	1176
AAGGUGGCUAGGAAAGAACA	1177
AAAGGUGGCUAGGAAAGAAC	1178
GAAAGGUGGCUAGGAAAGAA	1179
ACAUCUUGAUCUUGGCCUUU	1180
GGCUGGGAUCAAGAUGCCUG	1181
GUCAGGCUGGGAUCAAGAUG	1182
AGUCAGGCUGGGAUCAAGAU	1183
CAGUCAGGCUGGGAUCAAGA	1184
AGCAGUCAGGCUGGGAUCAA	1185
GAUGUAGCAGCAGUCAGGCU	1186
GGAUUAGAUGUAGCAGCAGU	1187
GGGAUUAGAUGUAGCAGCAG	1188
GACAGGAGGCAUUGGUAGGG	1189
UUAGGGACAGGAGGCAUUGG	1190
UUUAGGGACAGGAGGCAUUG	1191
GAGUUUAGGGACAGGAGGCA	1192
GGAGUUUAGGGACAGGAGGC	1193
GCUGUCAUCAGUAUGCUGGG	1194
GGCUGUCAUCAGUAUGCUGG	1195
GGGCUGUCAUCAGUAUGCUG	1196
AGGGCUGUCAUCAGUAUGCU	1197
AGAGAGGGCUGUCAUCAGUA	1198
CAGAGAGGGCUGUCAUCAGU	1199
UCAGAGAGGGCUGUCAUCAG	1200
GUCAGAGAGGGCUGUCAUCA	1201
GGUAAAGUCAGAGAGGGCUG	1202
GGGAAGGGUAUGAAGACAGA	1203

TABLE 3 — SEQ ID

Sequence	NO:
UUGCCUUCGGCUUGCUCUGG	1204
CUUGCCUUCGGCUUGCUCUG	1205
GCUUGCCUUCGGCUUGCUCU	1206
UGCUUGCCUUCGGCUUGCUC	1207
GUGCUUGCCUUCGGCUUGCU	1208
UCGUGCUUGCCUUCGGCUUG	1209
AUCGUGCUUGCCUUCGGCUU	1210
CAUCGUGCUUGCCUUCGGCU	1211
AGCGCCAUCGUGCUUGCCUU	1212
UGGUGAGCGCCAUCGUGCUU	1213
CUGAUGCUCGGCUGCUACAG	1214
GCUGAUGCUCGGCUGCUACA	1215
UUUCGGGCUGAUGCUCGGCU	1216
UCCUUUCGGGCUGAUGCUCG	1217
UUCCUUUCGGGCUGAUGCUC	1218
CUUCCUUUCGGGCUGAUGCU	1219
GCUUCCUUUCGGGCUGAUGC	1220
UGCUUCCUUUCGGGCUGAUG	1221
GUGCUUCCUUUCGGGCUGAU	1222
CGUGCUUCCUUUCGGGCUGA	1223
UCGUGCUUCCUUUCGGGCUG	1224
UUCGUGCUUCCUUUCGGGCU	1225
UUUCGUGCUUCCUUUCGGGC	1226
CUUUCGUGCUUCCUUUCGGG	1227
GCUUUCGUGCUUCCUUUCGG	1228
AUGUACGCCAGCGUGCUGCU	1229
UCAGCAUGUACGCCAGCGUG	1230
AGGCGGUGUACUACGUGUGC	1231
AAGGCGGUGUACUACGUGUG	1232
CAAGGCGGUGUACUACGUGU	1233
GCAAGGCGGUGUACUACGUG	1234
UGCAAGGCGGUGUACUACGU	1235
CUGCAAGGCGGUGUACUACG	1236
GCUGCAAGGCGGUGUACUAC	1237
GGCUGCAAGGCGGUGUACUA	1238
GCUCUUUGUGGCCUUCCUGA	1239
CGCUCUUUGUGGCCUUCCUG	1240
CUUCGUGGUGUGGAGCUUGG	1241
GGCUUCGUGGUGUGGAGCUU	1242
CAACGGCUUCGUGGUGUGGA	1243
UGGCAACGGCUUCGUGGUGU	1244
UGAGCUGGAAGACUUCGCGG	1245
CUGAGCUGGAAGACUUCGCG	1246
GCUGAGCUGGAAGACUUCGC	1247
ACACUGCUGAGCUGGAAGAC	1248
CGAGACACUGCUGAGCUGGA	1249
ACGAGACACUGCUGAGCUGG	1250
AACGAGACACUGCUGAGCUG	1251
GAACGAGACACUGCUGAGCU	1252
GGAACGAGACACUGCUGAGC	1253
GGGAACGAGACACUGCUGAG	1254
AGGGAACGAGACACUGCUGA	1255
CAGGGAACGAGACACUGCUG	1256
CCAGGGAACGAGACACUGCU	1257
AAGGAUGUCGGUCUGCUACC	1258
GAAGGAUGUCGGUCUGCUAC	1259
AGAAGGAUGUCGGUCUGCUA	1260
UAGGCCCAGAAGGAUGUCGG	1261
GUAGGCCCAGAAGGAUGUCG	1262
UGUAGGCCCAGAAGGAUGUC	1263
CUGUAGGCCCAGAAGGAUGU	1264
CCUGUAGGCCCAGAAGGAUG	1265
ACCUGUAGGCCCAGAAGGAU	1266
CUUCUCAUCGGGCAUCACAG	1267
CCUUCUCAUCGGGCAUCACA	1268
ACCUUCUCAUCGGGCAUCAC	1269
CACCUUCUCAUCGGGCAUCA	1270
GCACCUUCUCAUCGGGCAUC	1271
GGCACCUUCUCAUCGGGCAU	1272
UGGCACCUUCUCAUCGGGCA	1273
AUGGCACCUUCUCAUCGGGC	1274
CAUGGCACCUUCUCAUCGGG	1275
GCAUGGCACCUUCUCAUCGG	1276
GGCAUGGCACCUUCUCAUCG	1277
GAGGCAUGGCACCUUCUCAU	1278
GGAGGCAUGGCACCUUCUCA	1279
GACUCCCAGGCAGAAAAGAG	1280
GGACUCCCAGGCAGAAAAGA	1281
AGGACUCCCAGGCAGAAAAG	1282
UCAGGACUCCCAGGCAGAAA	1283
GAAGUCAGGACUCCCAGGCA	1284
GUGGAAGUCAGGACUCCCAG	1285
UCGUGGAAGUCAGGACUCCC	1286
CUCGUGGAAGUCAGGACUCC	1287
CCUCGUGGAAGUCAGGACUC	1288
UGGGUCCUCGUGGAAGUCAG	1289
CUGGGUCCUCGUGGAAGUCA	1290
UCUGGGUCCUCGUGGAAGUC	1291
GUCUGGGUCCUCGUGGAAGU	1292
AAGAAGGAGUUGUGUUUGAG	1293
CCAAGAAGGAGUUGUGUUUG	1294
GUUCCAAGAAGGAGUUGUGU	1295
GGUUCCAAGAAGGAGUUGUG	1296
CAGGUCAACUGACUGGGAGC	1297
UGCCUGUUUACCACUGAGCU	1298
AUGCCUGUUUACCACUGAGC	1299
UAUGCCUGUUUACCACUGAG	1300
UUAUGCCUGUUUACCACUGA	1301
UUUAUGCCUGUUUACCACUG	1302
CUUUAUGCCUGUUUACCACU	1303
ACUUUAUGCCUGUUUACCAC	1304
UAGAGAUAGUGACAGCCUGG	1305
GUAGAGAUAGUGACAGCCUG	1306
UGGUGGUAGAGAUAGUGACA	1307
GUGGUGGUAGAGAUAGUGAC	1308
UAGAGGAGUGGUGGUAGAGA	1309
ACUAGAGGAGUGGUGGUAGA	1310
AGACUAGAGGAGUGGUGGUA	1311
CAGACUAGAGGAGUGGUGGU	1312
CCAGACUAGAGGAGUGGUGG	1313
GCCAGACUAGAGGAGUGGUG	1314
GGCCAGACUAGAGGAGUGGU	1315
GCCCAGAUGUGCUAGAAUGG	1316
UGCCCAGAUGUGCUAGAAUG	1317
UUGCCCAGAUGUGCUAGAAU	1318
UUUGCCCAGAUGUGCUAGAA	1319
UUUUGCCCAGAUGUGCUAGA	1320
CCAGUUUUGCCCAGAUGUGC	1321
AUCCAGUUUUGCCCAGAUGU	1322
CCAUCCAGUUUUGCCCAGAU	1323
CACCAUCCAGUUUUGCCCAG	1324
CCACCAUCCAGUUUUGCCCA	1325
CCCACCAUCCAGUUUUGCCC	1326
UUGCUCCCAGCUUGGUAAGU	1327
GCUUGCUCCCAGCUUGGUAA	1328
AUCCUGCUUGCUCCCAGCUU	1329
AAUCCUGCUUGCUCCCAGCU	1330
CAAUCCUGCUUGCUCCCAGC	1331
CCAAUCCUGCUUGCUCCCAG	1332
AACCUUUCAGCUUCUCCAGG	1333
UAACCUUUCAGCUUCUCCAG	1334
UUAACCUUUCAGCUUCUCCA	1335
ACUGCUGCUUAACCUUUCAG	1336
UACUGCUGCUUAACCUUUCA	1337
CUACUGCUGCUUAACCUUUC	1338
CCUACUGCUGCUUAACCUUU	1339
GCCUACUGCUGCUUAACCUU	1340
CAGGACAGGAGUAGGCACCU	1341
ACAGGACAGGAGUAGGCACC	1342
GCACAGGACAGGAGUAGGCA	1343
AUAGGCACAGGACAGGAGUA	1344
GAUAGGCACAGGACAGGAGU	1345
UGAUAGGCACAGGACAGGAG	1346
ACCCUCUGCAAAUGUGAUAG	1347
CUUACCCUCUGCAAAUGUGA	1348
GUCUUACCCUCUGCAAAUGU	1349
UGUCUUACCCUCUGCAAAUG	1350
UUGUCUUACCCUCUGCAAAU	1351
CUUGUCUUACCCUCUGCAAA	1352
UCUUGUCUUACCCUCUGCAA	1353
CAUUCUUGUCUUACCCUCUG	1354
CCCAUUCUUGUCUUACCCUC	1355
GAGCCUCAUCUUGUCCCUCC	1356
UGAGCCUCAUCUUGUCCCUC	1357
UGCGUUGGUGAUGGGAAGGA	1358
GUGCGUUGGUGAUGGGAAGG	1359
GGUGCGUUGGUGAUGGGAAG	1360
GGGUGCGUUGGUGAUGGGAA	1361
UGGGUGCGUUGGUGAUGGGA	1362
UCUCACAUGCCUGGACGCCU	1363
CAAGGCAGGCUCUCACAUGC	1364
UGCUGUUUCCUGGCAAGGCA	1365
UUGUGCUGUUUCCUGGCAAG	1366
CUUGUGCUGUUUCCUGGCAA	1367
ACCACCAGGGAAUCUUACUG	1368
UCCACCACCAGGGAAUCUUA	1369
AUUUCCUUCCACCACCAGGG	1370
UAUUUCCUUCCACCACCAGG	1371
CCUAUUUCCUUCCACCACCA	1372
AGUCCUCCUAUUUCCUUCCA	1373
AGAGUCCUCCUAUUUCCUUC	1374
AGCAGAGUCCUCCUAUUUCC	1375
CAGCAGAGUCCUCCUAUUUC	1376
AUUCAGCAGAGUCCUCCUAU	1377
ACCAGGAUUCAGCAGAGUCC	1378
GACCAGGAUUCAGCAGAGUC	1379
GGACCAGGAUUCAGCAGAGU	1380
CAGGACCAGGAUUCAGCAGA	1381
CAGAAGCAGGACCAGGAUUC	1382
ACAGAAGCAGGACCAGGAUU	1383
AACAGAAGCAGGACCAGGAU	1384
AGAACAGAAGCAGGACCAGG	1385
GGGAGGGAUGAGAACAGAAG	1386
CAGGCAACAUACACACUGCA	1387
CCAGGCAACAUACACACUGC	1388
ACCAGGCAACAUACACACUG	1389
AGACCAGGCAACAUACACAC	1390
GAGAGACCAGGCAACAUACA	1391
CCAGAGAGACCAGGCAACAU	1392
UUGUUUGGGUCACCUCUGCA	1393
GUUGUUUGGGUCACCUCUGC	1394
AGUUGUUUGGGUCACCUCUG	1395
UGAGUUGUUUGGGUCACCUC	1396
CUGAGUUGUUUGGGUCACCU	1397
GACUGAGUUGUUUGGGUCAC	1398
AAACAGGCAAGGAUAAGGCA	1399
ACAUGGAAAAGCUGUCAUUG	1400
CCUUACAUGGAAAAGCUGUC	1401
GCCUUACAUGGAAAAGCUGU	1402
CUCCUGGAACCUAGCACCAU	1403
CCUCCUGGAACCUAGCACCA	1404
UCCUCCUGGAACCUAGCACC	1405
AACCAUUAUGCCUCCAUGCA	1406
UAACCAUUAUGCCUCCAUGC	1407
CUAACCAUUAUGCCUCCAUG	1408
CCUAACCAUUAUGCCUCCAU	1409
CCCUAACCAUUAUGCCUCCA	1410
ACUCCCUAACCAUUAUGCCU	1411
GACUCCCUAACCAUUAUGCC	1412
UGACUCCCUAACCAUUAUGC	1413
AUGACUCCCUAACCAUUAUG	1414
CAUGACUCCCUAACCAUUAU	1415
GGGCCUCUUCAUGGUUGUGU	1416
UGGUGCAGCCUGGUAAUGGG	1417
CUGGUGCAGCCUGGUAAUGG	1418
CCUGGUGCAGCCUGGUAAUG	1419
AUCCUGGUGCAGCCUGGUAA	1420
UAUCCUGGUGCAGCCUGGUA	1421
GUAUCCUGGUGCAGCCUGGU	1422
UGUAUCCUGGUGCAGCCUGG	1423
UCUUGUAUCCUGGUGCAGCC	1424
GUCUUGUAUCCUGGUGCAGC	1425
UGUCUUGUAUCCUGGUGCAG	1426
UUGUCUUGUAUCCUGGUGCA	1427
CUUGUCUUGUAUCCUGGUGC	1428
UCUUGUCUUGUAUCCUGGUG	1429
UUCUUGUCUUGUAUCCUGGU	1430
UUUCUUGUCUUGUAUCCUGG	1431
CCUUUCUUGUCUUGUAUCCU	1432
ACUCAUCCUUUCCUUUCUUG	1433
CCUACUCAUCCUUUCCUUUC	1434
CCCUACUCAUCCUUUCCUUU	1435
UCCCUACUCAUCCUUUCCUU	1436
GCUUCUUAGUAUGUCCCUAC	1437
GCUGCUUCUUAGUAUGUCCC	1438
GGCUGCUUCUUAGUAUGUCC	1439
GGGCUGCUUCUUAGUAUGUC	1440
AGGGCUGCUUCUUAGUAUGU	1441
GAGAGGGCUGCUUCUUAGUA	1442
UCCAAGAGGAGAGGGCUGCU	1443
UUGACUUUUCCAAGAGGAGA	1444
AGCUCUAUCCAUCUGCCAGG	1445
GCUGUUACUUGAGCAGAGGC	1446
GGCUGUUACUUGAGCAGAGG	1447
UGGCUGUUACUUGAGCAGAG	1448
CUGGCUGUUACUUGAGCAGA	1449
UCUGGCUGUUACUUGAGCAG	1450
CCUCAAGUUCUGGCUGUUAC	1451
ACCUCAAGUUCUGGCUGUUA	1452
CAACCUCAAGUUCUGGCUGU	1453
GCAACCUCAAGUUCUGGCUG	1454
AGCAACCUCAAGUUCUGGCU	1455
CAAGCAACCUCAAGUUCUGG	1456
CCAAGCAACCUCAAGUUCUG	1457
CCCAAGCAACCUCAAGUUCU	1458
ACUAAGACAGUGCUCCUGGU	1459
CAAACUAAGACAGUGCUCCU	1460
AGCUCUGCUUUGGAAGAACC	1461
CCCUUAGCUCAAGCUCUGCU	1462
GCCCUUAGCUCAAGCUCUGC	1463
AAGCCCUUAGCUCAAGCUCU	1464
CAAGCCCUUAGCUCAAGCUC	1465
CCAAGCCCUUAGCUCAAGCU	1466
CCCAAGCCCUUAGCUCAAGC	1467
GUACCCAAGCCCUUAGCUCA	1468
UGUACCCAAGCCCUUAGCUC	1469
CUGUACCCAAGCCCUUAGCU	1470
CCUGUACCCAAGCCCUUAGC	1471
ACCUGUACCCAAGCCCUUAG	1472
UCACCUGUACCCAAGCCCUU	1473
AUCACCUGUACCCAAGCCCU	1474
GGAUCACCUGUACCCAAGCC	1475
CUCAAGAAUACAGGAUCACC	1476
CUUAGCUCAAGAAUACAGGA	1477
CCUUAGCUCAAGAAUACAGG	1478
GCCCUUAGCUCAAGAAUACA	1479
AGCCCUUAGCUCAAGAAUAC	1480
AAGCCCUUAGCUCAAGAAUA	1481
CAAGCCCUUAGCUCAAGAAU	1482
CCAAGCCCUUAGCUCAAGAA	1483
CCCAAGCCCUUAGCUCAAGA	1484
GUACCCAAGCCCUUAGCUCA	1485
UGUACCCAAGCCCUUAGCUC	1486
CUGUACCCAAGCCCUUAGCU	1487
CCUGUACCCAAGCCCUUAGC	1488
ACCUGUACCCAAGCCCUUAG	1489
UCACCUGUACCCAAGCCCUU	1490
AUCACCUGUACCCAAGCCCU	1491
GGAUCACCUGUACCCAAGCC	1492
UAACCUCCCAAAUACAGGAU	1493
UACCUUAUGCCCUCACUUCC	1494
UUACCUUAUGCCCUCACUUC	1495
UUUACCUUAUGCCCUCACUU	1496
UUUUACCUUAUGCCCUCACU	1497
UUGUUUUACCUUAUGCCCUC	1498
CUUGUUUUACCUUAUGCCCU	1499
UUAAUGGCUUUCCUCUCUCU	1500
ACUCUUAAUGGCUUUCCUCU	1501
UACUCUUAAUGGCUUUCCUC	1502
CAUACUCUUAAUGGCUUUCC	1503
GAAGGGACUUAACAUACUCU	1504
UGAAGGGACUUAACAUACUC	1505
ACUGAAGGGACUUAACAUAC	1506
CUACUGAAGGGACUUAACAU	1507
GCCUACUGAAGGGACUUAAC	1508
GGCCUACUGAAGGGACUUAA	1509
UUCUCAGAGGUUCCCAAGGC	1510
UUUUCUCAGAGGUUCCCAAG	1511
ACUUUUCUCAGAGGUUCCCA	1512
UACUUUUCUCAGAGGUUCCC	1513
GGGCAAUCUAUACUUUUCUC	1514
UGUCUUGGGCAAUCUAUACU	1515
CCAGUCUUUUGUCUUGGGCA	1516
GCCAGUCUUUUGUCUUGGGC	1517
UGCCAGUCUUUUGUCUUGGG	1518
CUGCCAGUCUUUUGUCUUGG	1519
UCACCCUGCCAGUCUUUUGU	1520
AUCACCCUGCCAGUCUUUUG	1521
GCCCACUCAUUAAGUACAUU	1522
CUGUAGCCCACUCAUUAAGU	1523
CGCUGUAGCCCACUCAUUAA	1524
ACGCUGUAGCCCACUCAUUA	1525
UACGCUGUAGCCCACUCAUU	1526
AUACGCUGUAGCCCACUCAU	1527
GAUACGCUGUAGCCCACUCA	1528
GGAUACGCUGUAGCCCACUC	1529
AGGAUACGCUGUAGCCCACU	1530
GAGGAUACGCUGUAGCCCAC	1531
UGAGGAUACGCUGUAGCCCA	1532
GUGAGGAUACGCUGUAGCCC	1533
UGUGAGGAUACGCUGUAGCC	1534
CUGUUGUGAGGAUACGCUGU	1535
UCUGUUGUGAGGAUACGCUG	1536
GUCUGUUGUGAGGAUACGCU	1537
UGUCUGUUGUGAGGAUACGC	1538
ACUGUCUGUUGUGAGGAUAC	1539
CACUGUCUGUUGUGAGGAUA	1540
CAACUCUCUCUCACUGUCUG	1541
AACAACUCUCUCUCACUGUC	1542
AGAACAACUCUCUCUCACUG	1543
GUAGAACAACUCUCUCUCAC	1544
GGUAGAACAACUCUCUCUCA	1545
CAGGUAGAACAACUCUCUCU	1546
CCAGGUAGAACAACUCUCUC	1547
ACCCAGGUAGAACAACUCUC	1548
UAUACCCAGGUAGAACAACU	1549
AUAUACCCAGGUAGAACAAC	1550
GGAUAUACCCAGGUAGAACA	1551
GUUUUGGAUAUACCCAGGUA	1552
CCUUGUUUUGGAUAUACCCA	1553
CCCUUGUUUUGGAUAUACCC	1554
CCUCGUAAACUCCAUACCCU	1555
CCCUCGUAAACUCCAUACCC	1556
ACCCUCGUAAACUCCAUACC	1557
AACCCUCGUAAACUCCAUAC	1558
GAACCCUCGUAAACUCCAUA	1559
UGAACCCUCGUAAACUCCAU	1560
UUGAACCCUCGUAAACUCCA	1561
CUUGAACCCUCGUAAACUCC	1562
CCUUGAACCCUCGUAAACUC	1563
ACCUUGAACCCUCGUAAACU	1564
UACCUUGAACCCUCGUAAAC	1565
AUACCUUGAACCCUCGUAAA	1566
AAUACCUUGAACCCUCGUAA	1567
AAAUACCUUGAACCCUCGUA	1568
CAAAUACCUUGAACCCUCGU	1569
CCAAAUACCUUGAACCCUCG	1570
ACCAAAUACCUUGAACCCUC	1571
AACCAAAUACCUUGAACCCU	1572
GAACCAAAUACCUUGAACCC	1573
UGAACCAAAUACCUUGAACC	1574
CCCUGAACCAAAUACCUUGA	1575
GGCCCUGAACCAAAUACCUU	1576
UGGCCCUGAACCAAAUACCU	1577
UAUUCAGGUUGUUGCCCAAA	1578
GGUAUUCAGGUUGUUGCCCA	1579
AGGUAUUCAGGUUGUUGCCC	1580
AAGGUAUUCAGGUUGUUGCC	1581
AAAGGUAUUCAGGUUGUUGC	1582
UAACUUGAUUGCCCUGUGAC	1583
GUAACUUGAUUGCCCUGUGA	1584
AGUAACUUGAUUGCCCUGUG	1585
CAGAGUAACUUGAUUGCCCU	1586
ACAGAGUAACUUGAUUGCCC	1587
CACAGAGUAACUUGAUUGCC	1588
UGUCCUGACAAAGAAACACA	1589
CAAUCCCUGCUUUCCUGCCA	1590
ACAAUCCCUGCUUUCCUGCC	1591
AACACAAUCCCUGCUUUCCU	1592
GAACACAAUCCCUGCUUUCC	1593
AAUGAACACAAUCCCUGCUU	1594
AAAUGAACACAAUCCCUGCU	1595
GUGAAACCCUCAAAUGAACA	1596
AGUGAAACCCUCAAAUGAAC	1597
CAGUGAAACCCUCAAAUGAA	1598
ACAGUGAAACCCUCAAAUGA	1599
GCAUGGAAGCUGAGACUCUC	1600
UUGCAUGGAAGCUGAGACUC	1601
CAGUUGCAUGGAAGCUGAGA	1602
ACAGUUGCAUGGAAGCUGAG	1603
GACAGUUGCAUGGAAGCUGA	1604
AUGGACAGUUGCAUGGAAGC	1605
GUGAUGGACAGUUGCAUGGA	1606
CGUGAUGGACAGUUGCAUGG	1607
CCGUGAUGGACAGUUGCAUG	1608
GCCGUGAUGGACAGUUGCAU	1609
AGCCGUGAUGGACAGUUGCA	1610
CAGCCGUGAUGGACAGUUGC	1611
GCAGCCGUGAUGGACAGUUG	1612
UGCAGCCGUGAUGGACAGUU	1613
UUGCAGCCGUGAUGGACAGU	1614
GUUGCAGCCGUGAUGGACAG	1615
CAGUUGCAGCCGUGAUGGAC	1616
UCAGUUGCAGCCGUGAUGGA	1617
UUCAGUUGCAGCCGUGAUGG	1618
UUUCAGUUGCAGCCGUGAUG	1619
AUUUCAGUUGCAGCCGUGAU	1620
GAUUUCAGUUGCAGCCGUGA	1621
UGAUUUCAGUUGCAGCCGUG	1622
CUCUGAUUUCAGUUGCAGCC	1623
UUAGCUUCUGGUGCGCUGUG	1624
UUUAGCUUCUGGUGCGCUGU	1625
CUUUAGCUUCUGGUGCGCUG	1626
GACUUUAGCUUCUGGUGCGC	1627
AGACUUUAGCUUCUGGUGCG	1628
AAGACUUUAGCUUCUGGUGC	1629
UCAAGACUUUAGCUUCUGGU	1630
AUCAAGACUUUAGCUUCUGG	1631
GCAUCAAGACUUUAGCUUCU	1632
AUGGCAUCAAGACUUUAGCU	1633
GAUGGCAUCAAGACUUUAGC	1634
AGGGAUGUCCUUUGAUGGCA	1635
GCAGGGAUGUCCUUUGAUGG	1636
GGCAGGGAUGUCCUUUGAUG	1637
CGUGACAGAGAUGUGAAUGG	1638
GGACGUGACAGAGAUGUGAA	1639
UGGACGUGACAGAGAUGUGA	1640
GUGGACGUGACAGAGAUGUG	1641
AGUGGACGUGACAGAGAUGU	1642
UAGUGGACGUGACAGAGAUG	1643
UUAGUGGACGUGACAGAGAU	1644
AUUAGUGGACGUGACAGAGA	1645
GAUUAGUGGACGUGACAGAG	1646
CGAUUAGUGGACGUGACAGA	1647
CCGAUUAGUGGACGUGACAG	1648
UGCCGAUUAGUGGACGUGAC	1649
UUGCCGAUUAGUGGACGUGA	1650
UUUGCCGAUUAGUGGACGUG	1651
UUUUGCCGAUUAGUGGACGU	1652
CUUUUGCCGAUUAGUGGACG	1653
CCUUUUGCCGAUUAGUGGAC	1654
UCCUUUUGCCGAUUAGUGGA	1655
CUCCUUUUGCCGAUUAGUGG	1656
UCUCCUUUUGCCGAUUAGUG	1657
UUCUCCUUUUGCCGAUUAGU	1658
UUUCUCCUUUUGCCGAUUAG	1659
AGGUCAUCUUCUCUCACUUU	1660
UUAGGUCAUCUUCUCUCACU	1661
CUUAGGUCAUCUUCUCUCAC	1662
ACACUUAGGUCAUCUUCUCU	1663
CACACUUAGGUCAUCUUCUC	1664
UCACACUUAGGUCAUCUUCU	1665
GUCACACUUAGGUCAUCUUC	1666
AGUCACACUUAGGUCAUCUU	1667
CAGUCACACUUAGGUCAUCU	1668
GCAGUCACACUUAGGUCAUC	1669
UGCAGUCACACUUAGGUCAU	1670
AUUUUCCAGAGCUGCCUGCU	1671
CUCACUGCUCUGGCUUCAUU	1672
GCUCACUGCUCUGGCUUCAU	1673
UUACCUGCUCUUUCCUUCCU	1674
UGCUUACCUGCUCUUUCCUU	1675
UUCCUGCUUACCUGCUCUUU	1676
CUUCCUGCUUACCUGCUCUU	1677
ACUGGCCUUCCUGCUUACCU	1678
GACACUGGCCUUCCUGCUUA	1679
CAUUAGGGUCCUGUCUGGGA	1680
UCAUUAGGGUCCUGUCUGGG	1681
AUCAUUAGGGUCCUGUCUGG	1682
GAUCAUUAGGGUCCUGUCUG	1683
GGAUCAUUAGGGUCCUGUCU	1684
AUUCAGGAUCAUUAGGGUCC	1685
GAUUCAGGAUCAUUAGGGUC	1686
GGAUUCAGGAUCAUUAGGGU	1687
AUGGAUUCAGGAUCAUUAGG	1688
GAUACAUGGAUUCAGGAUCA	1689
UGAUACAUGGAUUCAGGAUC	1690
AUGGCAGGGCUUUGGAAAAU	1691
CAUGGCAGGGCUUUGGAAAA	1692
GCAUGGCAGGGCUUUGGAAA	1693
CAGCAUGGCAGGGCUUUGGA	1694
GAAGUGGGAUGGCAGCAUGG	1695
GGAAGUGGGAUGGCAGCAUG	1696
GGGAAGUGGGAUGGCAGCAU	1697
UGGAGAAGCCAUAAGCUGCA	1698
CUGGAGAAGCCAUAAGCUGC	1699
ACUGGAGAAGCCAUAAGCUG	1700
UACUGGAGAAGCCAUAAGCU	1701
CUACUGGAGAAGCCAUAAGC	1702
CCUACUGGAGAAGCCAUAAG	1703
ACCUACUGGAGAAGCCAUAA	1704
CACCUACUGGAGAAGCCAUA	1705
CCACCUACUGGAGAAGCCAU	1706
GCCACCUACUGGAGAAGCCA	1707
CUGCCACCUACUGGAGAAGC	1708
GCUGCCACCUACUGGAGAAG	1709
UGUGUGUGCUGCCACCUACU	1710
CUGUGUGUGCUGCCACCUAC	1711
UUAUGAGUGGCUCUGUGUGU	1712
UUUAUGAGUGGCUCUGUGUG	1713
AGUUUAUGAGUGGCUCUGUG	1714
CAGUUUAUGAGUGGCUCUGU	1715
GUUUCUGGCUCUCAGGCUCU	1716
GGUUUCUGGCUCUCAGGCUC	1717
CGGUUUCUGGCUCUCAGGCU	1718
GGACGGUUUCUGGCUCUCAG	1719
GGGACGGUUUCUGGCUCUCA	1720
UGAAAUGUGACUUCUGGUGU	1721
GGGAACCAUGUAAAAGGAUG	1722
GUGAGGGUAGAUGGGAACCA	1723
UUGUGAGGGUAGAUGGGAAC	1724
GUUGUGAGGGUAGAUGGGAA	1725
UGUUGUGAGGGUAGAUGGGA	1726
AUGUGUGUCUUUGGUGAUGA	1727
GGAGCUUGUAUGUGUGUCUU	1728
UUGGAGCUUGUAUGUGUGUC	1729
AUUGGAGCUUGUAUGUGUGU	1730
CAUUGGAGCUUGUAUGUGUG	1731
CCAUUGGAGCUUGUAUGUGU	1732
GCCAUUGGAGCUUGUAUGUG	1733
AGCCAUUGGAGCUUGUAUGU	1734
CUGGAGGAAGAAUUGCCUGG	1735
GUCCUGGAGGAAGAAUUGCC	1736
GCCAGUAAGAAGGGCAAAGU	1737
GGCCAGUAAGAAGGGCAAAG	1738
GGAAUGAGUCAAGCCUGGAC	1739
GGGAAUGAGUCAAGCCUGGA	1740
GUGGGAAUGAGUCAAGCCUG	1741
AAGGUGGGAAUGAGUCAAGC	1742
UCUCAGCCCAGGACAAGGUG	1743
AUCUCAGCCCAGGACAAGGU	1744
GCUGGGUGGUUCUCUCCUGU	1745
UUCUGGGCUGGGUGGUUCUC	1746
GAACUUCUGGGCUGGGUGGU	1747
CGGAGAGUUCCUUCCCUGGA	1748
ACCGGAGAGUUCCUUCCCUG	1749
GACCGGAGAGUUCCUUCCCU	1750
UGGACCGGAGAGUUCCUUCC	1751
GUGGACCGGAGAGUUCCUUC	1752
GGUGGACCGGAGAGUUCCUU	1753
UGGUGGACCGGAGAGUUCCU	1754
AUGGUGGACCGGAGAGUUCC	1755
CAUGGUGGACCGGAGAGUUC	1756
GAGCUGAGAGGUACUCCAUG	1757
AGAGCUGAGAGGUACUCCAU	1758
CAGAGCUGAGAGGUACUCCA	1759
UUCAGAGCUGAGAGGUACUC	1760
GGUUCAGAGCUGAGAGGUAC	1761
GGGUUCAGAGCUGAGAGGUA	1762
CACCUGAGUAAGUCACUGGG	1763
UCACCUGAGUAAGUCACUGG	1764
GUCACCUGAGUAAGUCACUG	1765
AGUCACCUGAGUAAGUCACU	1766
CAGUCACCUGAGUAAGUCAC	1767
GCAGUCACCUGAGUAAGUCA	1768
UUAGCAGUCACCUGAGUAAG	1769
GUUAGCAGUCACCUGAGUAA	1770
GGUUAGCAGUCACCUGAGUA	1771
GGGUUAGCAGUCACCUGAGU	1772
AGGGUUAGCAGUCACCUGAG	1773
GAGGGUUAGCAGUCACCUGA	1774
GGAGGGUUAGCAGUCACCUG	1775
CGGAGGGUUAGCAGUCACCU	1776
AGCGGAGGGUUAGCAGUCAC	1777
GAGCGGAGGGUUAGCAGUCA	1778
AGAGCGGAGGGUUAGCAGUC	1779
UAGAGCGGAGGGUUAGCAGU	1780
GUAGAGCGGAGGGUUAGCAG	1781
GGUAGAGCGGAGGGUUAGCA	1782
AGGGUAGAGCGGAGGGUUAG	1783
GAGGGUAGAGCGGAGGGUUA	1784
AUUGUUGCCCUGCCUAUAUC	1785
AGUAUUGUUGCCCUGCCUAU	1786
GAGUAUUGUUGCCCUGCCUA	1787
GGAGUAUUGUUGCCCUGCCU	1788
UGGAGUAUUGUUGCCCUGCC	1789
GUGGAGUAUUGUUGCCCUGC	1790
AGUGGAGUAUUGUUGCCCUG	1791
GAGUGGAGUAUUGUUGCCCU	1792
UGAGUGGAGUAUUGUUGCCC	1793
CUGAGUGGAGUAUUGUUGCC	1794
GCUGAGUGGAGUAUUGUUGC	1795
GGCUGAGUGGAGUAUUGUUG	1796
GGGCUGAGUGGAGUAUUGUU	1797
GGUACUGGUUAGUCUCCUAG	1798
GGGUACUGGUUAGUCUCCUA	1799
UUGACAAGCCCACUGUGGAG	1800
UGGCUCAGGAGCUUGACAAG	1801
GGUGGCUCAGGAGCUUGACA	1802
UAGGGAUGAGGGAGAGACCA	1803
UCGAUUAGGGAUGAGGGAGA	1804
UAGAGGGCUAGGGAGGGAGA	1805
GUAGAGUGGCUAGAGGGCUA	1806
GGUAGAGUGGCUAGAGGGCU	1807
UGAGGGUAGAGUGGCUAGAG	1808
GAUGAGGGUAGAGUGGCUAG	1809
CAUGAUGAGGGUAGAGUGGC	1810
GCAUGAUGAGGGUAGAGUGG	1811
GGGCAUGAUGAGGGUAGAGU	1812
GGUAGUUGAGAAGAAAAGUC	1813
CCAAACUCCGAGCUUAUAUU	1814
UCCAAACUCCGAGCUUAUAU	1815
GUCCAAACUCCGAGCUUAUA	1816
CGUCCAAACUCCGAGCUUAU	1817
CCGUCCAAACUCCGAGCUUA	1818
UCCGUCCAAACUCCGAGCUU	1819
CUCCGUCCAAACUCCGAGCU	1820
ACCCUCCGUCCAAACUCCGA	1821
AGACCCUCCGUCCAAACUCC	1822
CAGACCCUCCGUCCAAACUC	1823
UCCAGACCCUCCGUCCAAAC	1824
GUCCAGACCCUCCGUCCAAA	1825
AGACACGGAAAGGUCGCUGG	1826
CAGACACGGAAAGGUCGCUG	1827
ACAGACACGGAAAGGUCGCU	1828
CACAGACACGGAAAGGUCGC	1829
UCACAGACACGGAAAGGUCG	1830
AUCACAGACACGGAAAGGUC	1831
GAUCACAGACACGGAAAGGU	1832
UUGGCCUACUUACUUUGGCU	1833
CUUGGCCUACUUACUUUGGC	1834
ACUUGGCCUACUUACUUUGG	1835
GAGGAACUUGGCCUACUUAC	1836
CGAGGAACUUGGCCUACUUA	1837
CCGAGGAACUUGGCCUACUU	1838
ACCGAGGAACUUGGCCUACU	1839
AACCGAGGAACUUGGCCUAC	1840
GAACCGAGGAACUUGGCCUA	1841
GGAACCGAGGAACUUGGCCU	1842
AGGAACCGAGGAACUUGGCC	1843
UAGGAACCGAGGAACUUGGC	1844
AUAGGAACCGAGGAACUUGG	1845
UAUAGGAACCGAGGAACUUG	1846
AUCACAAGUUGCCACUGUUG	1847
CAUCACAAGUUGCCACUGUU	1848
AUCAUCACAAGUUGCCACUG	1849
CAUCAUCACAAGUUGCCACU	1850
CUGCUCCAUCAUCACAAGUU	1851
UCUGCUCCAUCAUCACAAGU	1852
CCCUCUGCUCCAUCAUCACA	1853
UCAGCCCUCUGCUCCAUCAU	1854
UGACUUCAGCCCUCUGCUCC	1855
GUGACUUCAGCCCUCUGCUC	1856
UGUGACUUCAGCCCUCUGCU	1857
GUGUGACUUCAGCCCUCUGC	1858
UGUGUGACUUCAGCCCUCUG	1859
GCCCACUCCGCUGCUUUUAG	1860
GGCCCACUCCGCUGCUUUUA	1861
AGGCCCACUCCGCUGCUUUU	1862
UAGGCCCACUCCGCUGCUUU	1863
UUAGGCCCACUCCGCUGCUU	1864
AUUAGGCCCACUCCGCUGCU	1865
UCAUUAGGCCCACUCCGCUG	1866
CUCAUUAGGCCCACUCCGCU	1867
AGCUCAUUAGGCCCACUCCG	1868
CUCCCAUAGAAAAGCUCACU	1869
GCUCCCAUAGAAAAGCUCAC	1870
UGCUCCCAUAGAAAAGCUCA	1871
CUGCUCCCAUAGAAAAGCUC	1872
CCUGCUCCCAUAGAAAAGCU	1873
UCCCUAUCUCCUGCUAACCC	1874
CCUCGAACUCUCCCUAUCUC	1875
CCCUCGAACUCUCCCUAUCU	1876
UCCCUCGAACUCUCCCUAUC	1877
GUCCCUCGAACUCUCCCUAU	1878
CUUUCCAUACUAGCUUCUGA	1879
CCUUUCCAUACUAGCUUCUG	1880
ACCUUUCCAUACUAGCUUCU	1881
CACACAAAUCACCUUUCCAU	1882
GUCACACAAAUCACCUUUCC	1883
UGUCACACAAAUCACCUUUC	1884
UUUGACAGGCAGGAAGUGGC	1885
GGUUUGACAGGCAGGAAGUG	1886
AGGUUUGACAGGCAGGAAGU	1887
AAGGUUUGACAGGCAGGAAG	1888
AACUUCCCAAGGUUUGACAG	1889
CAACUUCCCAAGGUUUGACA	1890
GAACAACUUCCCAAGGUUUG	1891
UGAACAACUUCCCAAGGUUU	1892
GUAGGUUGAACAACUUCCCA	1893
GGUAGGUUGAACAACUUCCC	1894
UGGUAGGUUGAACAACUUCC	1895
GGUUUUGGUAGGUUGAACAA	1896
UGAGGUUUUGGUAGGUUGAA	1897
CUGAGGUUUUGGUAGGUUGA	1898
CCUACAUUAUCCUCUUACUC	1899
GGACUUUACCUACAUUAUCC	1900
GUAUGAGGACUUUACCUACA	1901
GCCAGGUAUGAGGACUUUAC	1902
UGCCAGGUAUGAGGACUUUA	1903
GUGCCAGGUAUGAGGACUUU	1904
CUGUGCCAGGUAUGAGGACU	1905
UCUGUGCCAGGUAUGAGGAC	1906
CCUCAAGAGUUCUCCAGAAG	1907
CCCUCAAGAGUUCUCCAGAA	1908
ACCCUCAAGAGUUCUCCAGA	1909
ACACCCUCAAGAGUUCUCCA	1910
CACACCCUCAAGAGUUCUCC	1911
CCACACCCUCAAGAGUUCUC	1912
CCCACACCCUCAAGAGUUCU	1913
UUCCCACACCCUCAAGAGUU	1914
CAAUGCUGCACCUCACUUCC	1915
UACAAUGCUGCACCUCACUU	1916
CUACAAUGCUGCACCUCACU	1917
UCUACAAUGCUGCACCUCAC	1918
AUCUACAAUGCUGCACCUCA	1919
UAUCUACAAUGCUGCACCUC	1920
CUUAUCUACAAUGCUGCACC	1921
GUCUUAUCUACAAUGCUGCA	1922
UGUCUUAUCUACAAUGCUGC	1923
CUGUCUUAUCUACAAUGCUG	1924
CACCCUUCUGUCUUAUCUAC	1925
UCCACCCUUCUGUCUUAUCU	1926
GUCCACCCUUCUGUCUUAUC	1927
AGUCCACCCUUCUGUCUUAU	1928
AAGUCCACCCUUCUGUCUUA	1929
GAAAGCAAGCCAGGUUCUCA	1930
GGAAAGCAAGCCAGGUUCUC	1931
GGAAUUGGAAAGCAAGCCAG	1932
ACCAUGUCAUUGGCAUCUCC	1933
UACCAUGUCAUUGGCAUCUC	1934
CCUACCAUGUCAUUGGCAUC	1935
UCCUACCAUGUCAUUGGCAU	1936
CUCCUACCAUGUCAUUGGCA	1937
GCUCCUACCAUGUCAUUGGC	1938
UGCUCCUACCAUGUCAUUGG	1939
UCUUUGCUCCUACCAUGUCA	1940
CCUCUUUGCUCCUACCAUGU	1941
UUCCUCUUUGCUCCUACCAU	1942
UCUCCGUGUUCUUCAGUUUU	1943
CUCUCCGUGUUCUUCAGUUU	1944
AGCUCUCCGUGUUCUUCAGU	1945
UGCAGCUCUCCGUGUUCUUC	1946
GGUUGCAGCUCUCCGUGUUC	1947
AGGUUGCAGCUCUCCGUGUU	1948
AAAGGUUGCAGCUCUCCGUG	1949
UAAAGGUUGCAGCUCUCCGU	1950
CUAAAGGUUGCAGCUCUCCG	1951
CCUAAAGGUUGCAGCUCUCC	1952
UCCUAAAGGUUGCAGCUCUC	1953
CUCCUAAAGGUUGCAGCUCU	1954
CCUCCUAAAGGUUGCAGCUC	1955
GCACUUUGAUACCUCCUAAA	1956
GGCACUUUGAUACCUCCUAA	1957
GAUGUCCCACUUUGACUUUC	1958
UCGAUGUCCCACUUUGACUU	1959
GUCGAUGUCCCACUUUGACU	1960
GGUCGAUGUCCCACUUUGAC	1961
UGGUCGAUGUCCCACUUUGA	1962
UUGGUCGAUGUCCCACUUUG	1963
AUUGGUCGAUGUCCCACUUU	1964
CAUUGGUCGAUGUCCCACUU	1965
AACAUCCAUCAGUUGGCUCU	1966
CUGCCCAACAUCCAUCAGUU	1967
AGCUGCCCAACAUCCAUCAG	1968
UAGCUGCCCAACAUCCAUCA	1969
UUAGCUGCCCAACAUCCAUC	1970
UUUAGCUGCCCAACAUCCAU	1971
CUUUAGCUGCCCAACAUCCA	1972
CCUCUUUAGCUGCCCAACAU	1973
CCCUCUUUAGCUGCCCAACA	1974
UCCCUCUUUAGCUGCCCAAC	1975
UUCCCUCUUUAGCUGCCCAA	1976
CCUUCCCUCUUUAGCUGCCC	1977
CCCUUCCCUCUUUAGCUGCC	1978
GCAGGUCUUAUCCCAUGCCC	1979
GGGCAGGUCUUAUCCCAUGC	1980
AGGGCAGGUCUUAUCCCAUG	1981
AAGGGCAGGUCUUAUCCCAU	1982
GAAGGGCAGGUCUUAUCCCA	1983
AGAAGGGCAGGUCUUAUCCC	1984
CCAAUGGCAAGAAGCAAGAA	1985
CCCAAUGGCAAGAAGCAAGA	1986
GCCCAAUGGCAAGAAGCAAG	1987
UCCAAUGCCUGCCCAAUGGC	1988
CUCCAAUGCCUGCCCAAUGG	1989
UCUCCAAUGCCUGCCCAAUG	1990
GGUCUCCAAUGCCUGCCCAA	1991
UAGGGUCUCCAAUGCCUGCC	1992
GUAGGGUCUCCAAUGCCUGC	1993
AGUAGGGUCUCCAAUGCCUG	1994
CAGUAGGGUCUCCAAUGCCU	1995
GCAGUAGGGUCUCCAAUGCC	1996
AGCAGUAGGGUCUCCAAUGC	1997
CAGCAGUAGGGUCUCCAAUG	1998
UCAGCAGUAGGGUCUCCAAU	1999
AUUCAGCAGUAGGGUCUCCA	2000
CAUUCAGCAGUAGGGUCUCC	2001
CCAUUCAGCAGUAGGGUCUC	2002
UCCAUUCAGCAGUAGGGUCU	2003
ACUCCAUUCAGCAGUAGGGU	2004
CACUCCAUUCAGCAGUAGGG	2005
GCACUCCAUUCAGCAGUAGG	2006
AGCACUCCAUUCAGCAGUAG	2007
UAGCACUCCAUUCAGCAGUA	2008
GUUAGCACUCCAUUCAGCAG	2009
GGUUAGCACUCCAUUCAGCA	2010
GGGUUAGCACUCCAUUCAGC	2011
CAGGGUUAGCACUCCAUUCA	2012
CCAGGGUUAGCACUCCAUUC	2013
ACCAGGGUUAGCACUCCAUU	2014
CACCAGGGUUAGCACUCCAU	2015
GCACCAGGGUUAGCACUCCA	2016
AGCACCAGGGUUAGCACUCC	2017
UAGCACCAGGGUUAGCACUC	2018
CUAGCACCAGGGUUAGCACU	2019
UCUAGCACCAGGGUUAGCAC	2020
CUCUAGCACCAGGGUUAGCA	2021
CCUCUAGCACCAGGGUUAGC	2022
UCCUCUAGCACCAGGGUUAG	2023
CUCCUCUAGCACCAGGGUUA	2024
CCUCCUCUAGCACCAGGGUU	2025
UCCUCCUCUAGCACCAGGGU	2026
GUUCCAUCCUCCUCUAGCAC	2027
AAGUCCUCACUGUCCACUGC	2028
GAAGUCCUCACUGUCCACUG	2029
AGAAGUCCUCACUGUCCACU	2030
AAGAAGUCCUCACUGUCCAC	2031
GAAGAAGUCCUCACUGUCCA	2032
GGAAGAAGUCCUCACUGUCC	2033
UGGAAGAAGUCCUCACUGUC	2034
CUGGAAGAAGUCCUCACUGU	2035
AGCUGGAAGAAGUCCUCACU	2036
ACUGCAACACCAUCAGGCAC	2037
GACUGCAACACCAUCAGGCA	2038
AGACUGCAACACCAUCAGGC	2039
CAGACUGCAACACCAUCAGG	2040
CCAGACUGCAACACCAUCAG	2041
GACCAGACUGCAACACCAUC	2042
CUCUGACCAGACUGCAACAC	2043
AGCUCUGACCAGACUGCAAC	2044
CCAGCUCUGACCAGACUGCA	2045
UGUAGGGCUCCAGCUCUGAC	2046
CUUGUAGGGCUCCAGCUCUG	2047
CCUUGUAGGGCUCCAGCUCU	2048
ACAGGCAUUGGAAGCAGCCC	2049
GACAGGCAUUGGAAGCAGCC	2050
AAGGACAGGCAUUGGAAGCA	2051
AAAGGACAGGCAUUGGAAGC	2052
UAAAGGACAGGCAUUGGAAG	2053
CUAAAGGACAGGCAUUGGAA	2054
GCUCUAAAGGACAGGCAUUG	2055
AGCUCUAAAGGACAGGCAUU	2056
AAGCUCUAAAGGACAGGCAU	2057
AAAGCUCUAAAGGACAGGCA	2058
GAAAGCUCUAAAGGACAGGC	2059
CGGGAAAGCUCUAAAGGACA	2060
CCGGGAAAGCUCUAAAGGAC	2061
AGGGUUAAGCUAGAGAGGAA	2062
UCAGGGUUAAGCUAGAGAGG	2063
GAUCAGGGUUAAGCUAGAGA	2064
GGAUCAGGGUUAAGCUAGAG	2065
AGGAUCAGGGUUAAGCUAGA	2066
CCCAGGAUCAGGGUUAAGCU	2067
CAACUCCUCCUGCACCUGGU	2068
ACAACUCCUCCUGCACCUGG	2069
GACAAUUCCACAACUCCUCC	2070
UGACAAUUCCACAACUCCUC	2071
UUGACAAUUCCACAACUCCU	2072
CUUGACAAUUCCACAACUCC	2073
UCCUUGACAAUUCCACAACU	2074
AUCCUUGACAAUUCCACAAC	2075
CAUCCUUGACAAUUCCACAA	2076
ACAUCCUUGACAAUUCCACA	2077
GACAUCCUUGACAAUUCCAC	2078
UGACAUCCUUGACAAUUCCA	2079
UGUGUGACAUCCUUGACAAU	2080
ACUGUGUGACAUCCUUGACA	2081
ACUUUCUGUCCACUGUGUGA	2082
CCUCGCUUGGACUUUCUGUC	2083
CCCUCGCUUGGACUUUCUGU	2084
UCCCUCGCUUGGACUUUCUG	2085
CUCCCUCGCUUGGACUUUCU	2086
CCUCCCUCGCUUGGACUUUC	2087
CCCUCCCUCGCUUGGACUUU	2088
UCCAUCAGCACUGGGUCAGA	2089
ACCACUAAUCUCCAUCAGCA	2090
CACCACUAAUCUCCAUCAGC	2091
CCACCACUAAUCUCCAUCAG	2092
CCCACCACUAAUCUCCAUCA	2093
ACCAGACACCCACCACUAAU	2094
UACCAGACACCCACCACUAA	2095
CUCAUACCAGACACCCACCA	2096
CCUCAUACCAGACACCCACC	2097
UCCUCAUACCAGACACCCAC	2098
AUCCUCAUACCAGACACCCA	2099
GAUCCUCAUACCAGACACCC	2100
AGAUCCUCAUACCAGACACC	2101
UAGAUCCUCAUACCAGACAC	2102
GUAGAUCCUCAUACCAGACA	2103
AGUAGAUCCUCAUACCAGAC	2104
CAGUAGAUCCUCAUACCAGA	2105
UGCAGUAGAUCCUCAUACCA	2106
GUGCAGUAGAUCCUCAUACC	2107
AGUGCAGUAGAUCCUCAUAC	2108
ACUCUGUAGGACACCCUUGU	2109
CACUCUGUAGGACACCCUUG	2110
CCACUCUGUAGGACACCCUU	2111
UCCACUCUGUAGGACACCCU	2112
CUCCACUCUGUAGGACACCC	2113
ACUCCACUCUGUAGGACACC	2114
CACUCCACUCUGUAGGACAC	2115
AGCACUCCACUCUGUAGGAC	2116
UAUGACAGCACUCCACUCUG	2117
AUAUGACAGCACUCCACUCU	2118
UUGCUGUGCUUGGGCCUCUC	2119
ACGUCAAAGGUGAAUCGGGC	2120
CACGUCAAAGGUGAAUCGGG	2121
ACACGUCAAAGGUGAAUCGG	2122
UACACGUCAAAGGUGAAUCG	2123
GUACACGUCAAAGGUGAAUC	2124
GGCUGCCAAAGAGGUCUCGA	2125
UCAGGCUGCCAAAGAGGUCU	2126
CAUUCAGGCUGCCAAAGAGG	2127
GACAUUCAGGCUGCCAAAGA	2128
UGACAUUCAGGCUGCCAAAG	2129
CUUUGACAUUCAGGCUGCCA	2130
GCUUUGACAUUCAGGCUGCC	2131
CCGUAGAAUGUGGCUUUGAC	2132
GCCCGUAGAAUGUGGCUUUG	2133
UAGAGCCCGUAGAAUGUGGC	2134
GUAGAGCCCGUAGAAUGUGG	2135
AGUAGAGCCCGUAGAAUGUG	2136
AGAGUAGAGCCCGUAGAAUG	2137
UAGAGUAGAGCCCGUAGAAU	2138
AUAGAGUAGAGCCCGUAGAA	2139
CAUAGAGUAGAGCCCGUAGA	2140
UCAUAGAGUAGAGCCCGUAG	2141
CUCAUAGAGUAGAGCCCGUA	2142
GAAAGUCACAACUCAUAGAG	2143
CCUUGAAAGUCACAACUCAU	2144
AAGUCCUUGAAAGUCACAAC	2145
CCAAGUCCUUGAAAGUCACA	2146
UUCUUUGGGCCAAGUCCUUG	2147
UUUCUUUGGGCCAAGUCCUU	2148
UUGAUUUCUGACCUGAGUAC	2149
GUUGAUUUCUGACCUGAGUA	2150
GGGACUAUCCAACUGUAGGG	2151
GCAAGAGGACGAAUUAUGGG	2152
UGCAAGAGGACGAAUUAUGG	2153
GUGCAAGAGGACGAAUUAUG	2154
GGUGCAAGAGGACGAAUUAU	2155
GGGUGCAAGAGGACGAAUUA	2156
UGGGUGCAAGAGGACGAAUU	2157
GUGGGUGCAAGAGGACGAAU	2158
GGUGGGUGCAAGAGGACGAA	2159
UAGGUGGGUGCAAGAGGACG	2160
GUAGGUGGGUGCAAGAGGAC	2161
GGUAGGUGGGUGCAAGAGGA	2162
CCACAAGCAAGAGCUAACUA	2163
ACUUUCCACAAGCAAGAGCU	2164
GACUUUCCACAAGCAAGAGC	2165
GGACUUUCCACAAGCAAGAG	2166
AGGACUUUCCACAAGCAAGA	2167
GAGGACUUUCCACAAGCAAG	2168
UGAGGACUUUCCACAAGCAA	2169
AUGAGGACUUUCCACAAGCA	2170
GAUGAGGACUUUCCACAAGC	2171
AGAUGAGGACUUUCCACAAG	2172
GAGAUGAGGACUUUCCACAA	2173
GGAGAUGAGGACUUUCCACA	2174
UGGGAGAUGAGGACUUUCCA	2175
GCUGGGAGAUGAGGACUUUC	2176
UCAAGCUGGGAGAUGAGGAC	2177
AAGCCAUCAAGCUGGGAGAU	2178
GAAGCCAUCAAGCUGGGAGA	2179
GGAGGAAGCCAUCAAGCUGG	2180
GGGAGGAAGCCAUCAAGCUG	2181
AACUUGGGAGGAAGCCAUCA	2182
AAACUUGGGAGGAAGCCAUC	2183
CAGCAGUGUGGAGGUCCAAC	2184
GCAGCAGUGUGGAGGUCCAA	2185
UGCAGCAGUGUGGAGGUCCA	2186
UUGCAGCAGUGUGGAGGUCC	2187
GGUGGAGGAAAUUCCCAGCA	2188
ACGAAGGGUGGAGGAAAUUC	2189
GACGAAGGGUGGAGGAAAUU	2190
AUGACGAAGGGUGGAGGAAA	2191
CAUGACGAAGGGUGGAGGAA	2192
GCAUGACGAAGGGUGGAGGA	2193
UGCAUGACGAAGGGUGGAGG	2194
CUGCAUGACGAAGGGUGGAG	2195
ACUGCAUGACGAAGGGUGGA	2196
CACUGCAUGACGAAGGGUGG	2197
CCACUGCAUGACGAAGGGUG	2198
UCCACUGCAUGACGAAGGGU	2199
CUCCACUGCAUGACGAAGGG	2200
CCUCCACUGCAUGACGAAGG	2201
CCCUCCACUGCAUGACGAAG	2202
CUUAGUAGGAAUGGAGGCGG	2203
CCUUAGUAGGAAUGGAGGCG	2204
CCCUUAGUAGGAAUGGAGGC	2205
UCGGUUGGAAUGAUUCUGGG	2206
GUCGGUUGGAAUGAUUCUGG	2207
GGUCGGUUGGAAUGAUUCUG	2208
GGGUCGGUUGGAAUGAUUCU	2209
UGGGUCGGUUGGAAUGAUUC	2210
GUGGGUCGGUUGGAAUGAUU	2211
AGUGGGUCGGUUGGAAUGAU	2212
CAGUGGGUCGGUUGGAAUGA	2213
GCAGUGGGUCGGUUGGAAUG	2214
UGCAGUGGGUCGGUUGGAAU	2215
UUGCAGUGGGUCGGUUGGAA	2216
UUUGCAGUGGGUCGGUUGGA	2217
CUUUGCAGUGGGUCGGUUGG	2218
UCUUUGCAGUGGGUCGGUUG	2219
UAGUCUUUGCAGUGGGUCGG	2220
AUAGUCUUUGCAGUGGGUCG	2221
CUGUCAUAGUCUUUGCAGUG	2222
UGCUGUCAUAGUCUUUGCAG	2223
UCUAGCCUGUACUGUCUGCA	2224
AUCUAGCCUGUACUGUCUGC	2225
UAUCUAGCCUGUACUGUCUG	2226
UUAUCUAGCCUGUACUGUCU	2227
GUUAUCUAGCCUGUACUGUC	2228
GGUUAUCUAGCCUGUACUGU	2229
GGGUUAUCUAGCCUGUACUG	2230
UGGGUUAUCUAGCCUGUACU	2231
GUGGGUUAUCUAGCCUGUAC	2232
GGUGGGUUAUCUAGCCUGUA	2233
GGGUGGGUUAUCUAGCCUGU	2234
UGGGUGGGUUAUCUAGCCUG	2235
UUGGGUGGGUUAUCUAGCCU	2236
AUUGGGUGGGUUAUCUAGCC	2237
AAUUGGGUGGGUUAUCUAGC	2238
AAAUUGGGUGGGUUAUCUAG	2239
GGAAAUUGGGUGGGUUAUCU	2240
GGGAAAUUGGGUGGGUUAUC	2241
GAAAGGUUCUGUCACGAGGG	2242
GCUGAAAGGUUCUGUCACGA	2243
UGCUGAAAGGUUCUGUCACG	2244
GGCGUUAUGCUGAAAGGUUC	2245
AGGCGUUAUGCUGAAAGGUU	2246
GAGGCGUUAUGCUGAAAGGU	2247
UGAGGCGUUAUGCUGAAAGG	2248
GUGAGGCGUUAUGCUGAAAG	2249
AUGUGAGGCGUUAUGCUGAA	2250
GAUGUGAGGCGUUAUGCUGA	2251
GGAUGUGAGGCGUUAUGCUG	2252
GGGAUGUGAGGCGUUAUGCU	2253
CUUGGGAUGUGAGGCGUUAU	2254
AGACUUGGGAUGUGAGGCGU	2255
UAGACUUGGGAUGUGAGGCG	2256
AUAGACUUGGGAUGUGAGGC	2257
UAUAGACUUGGGAUGUGAGG	2258
GGGUAUAGACUUGGGAUGUG	2259
AGGGUAUAGACUUGGGAUGU	2260
AAGGUGGCUAGGAAAGAACA	2261
AAAGGUGGCUAGGAAAGAAC	2262
GAAAGGUGGCUAGGAAAGAA	2263
ACAUCUUGAUCUUGGCCUUU	2264
GGCUGGGAUCAAGAUGCCUG	2265
GUCAGGCUGGGAUCAAGAUG	2266
AGUCAGGCUGGGAUCAAGAU	2267
CAGUCAGGCUGGGAUCAAGA	2268
AGCAGUCAGGCUGGGAUCAA	2269
GAUGUAGCAGCAGUCAGGCU	2270
GGAUUAGAUGUAGCAGCAGU	2271
GGGAUUAGAUGUAGCAGCAG	2272
GACAGGAGGCAUUGGUAGGG	2273
UUAGGGACAGGAGGCAUUGG	2274
UUUAGGGACAGGAGGCAUUG	2275
GAGUUUAGGGACAGGAGGCA	2276
GGAGUUUAGGGACAGGAGGC	2277
GCUGUCAUCAGUAUGCUGGG	2278
GGCUGUCAUCAGUAUGCUGG	2279
GGGCUGUCAUCAGUAUGCUG	2280
AGGGCUGUCAUCAGUAUGCU	2281
AGAGAGGGCUGUCAUCAGUA	2282
CAGAGAGGGCUGUCAUCAGU	2283
UCAGAGAGGGCUGUCAUCAG	2284
GUCAGAGAGGGCUGUCAUCA	2285
GGUAAAGUCAGAGAGGGCUG	2286
GGGAAGGGUAUGAAGACAGA	2287

TABLE 4 — SEQ ID

Sequence	NO:
GUUUCUGGCUCUCAGGCUCU	2288
GGUUUCUGGCUCUCAGGCUC	2289
CGGUUUCUGGCUCUCAGGCU	2290
GGACGGUUUCUGGCUCUCAG	2291
GGGACGGUUUCUGGCUCUCA	2292
UGAAAUGUGACUUCUGGUGU	2293
GGGAACCAUGUAAAAGGAUG	2294
GUGAGGGUAGAUGGGAACCA	2295
UUGUGAGGGUAGAUGGGAAC	2296
GUUGUGAGGGUAGAUGGGAA	2297
UGUUGUGAGGGUAGAUGGGA	2298
AUGUGUGUCUUUGGUGAUGA	2299
GGAGCUUGUAUGUGUGUCUU	2300
UUGGAGCUUGUAUGUGUGUC	2301
AUUGGAGCUUGUAUGUGUGU	2302
CAUUGGAGCUUGUAUGUGUG	2303
CCAUUGGAGCUUGUAUGUGU	2304
GCCAUUGGAGCUUGUAUGUG	2305
AGCCAUUGGAGCUUGUAUGU	2306
CUGGAGGAAGAAUUGCCUGG	2307
GUCCUGGAGGAAGAAUUGCC	2308
GCCAGUAAGAAGGGCAAAGU	2309
GGCCAGUAAGAAGGGCAAAG	2310
GGAAUGAGUCAAGCCUGGAC	2311
GGGAAUGAGUCAAGCCUGGA	2312
GUGGGAAUGAGUCAAGCCUG	2313
AAGGUGGGAAUGAGUCAAGC	2314
UCUCAGCCCAGGACAAGGUG	2315
AUCUCAGCCCAGGACAAGGU	2316
GCUGGGUGGUUCUCUCCUGU	2317
UUCUGGGCUGGGUGGUUCUC	2318
GAACUUCUGGGCUGGGUGGU	2319
CGGAGAGUUCCUUCCCUGGA	2320
ACCGGAGAGUUCCUUCCCUG	2321
GACCGGAGAGUUCCUUCCCU	2322
UGGACCGGAGAGUUCCUUCC	2323
GUGGACCGGAGAGUUCCUUC	2324
GGUGGACCGGAGAGUUCCUU	2325
UGGUGGACCGGAGAGUUCCU	2326
AUGGUGGACCGGAGAGUUCC	2327
CAUGGUGGACCGGAGAGUUC	2328
GAGCUGAGAGGUACUCCAUG	2329
AGAGCUGAGAGGUACUCCAU	2330
CAGAGCUGAGAGGUACUCCA	2331
UUCAGAGCUGAGAGGUACUC	2332
GGUUCAGAGCUGAGAGGUAC	2333
GGGUUCAGAGCUGAGAGGUA	2334
CACCUGAGUAAGUCACUGGG	2335
UCACCUGAGUAAGUCACUGG	2336
GUCACCUGAGUAAGUCACUG	2337
AGUCACCUGAGUAAGUCACU	2338
CAGUCACCUGAGUAAGUCAC	2339
GCAGUCACCUGAGUAAGUCA	2340
UUAGCAGUCACCUGAGUAAG	2341
GUUAGCAGUCACCUGAGUAA	2342
GGUUAGCAGUCACCUGAGUA	2343
GGGUUAGCAGUCACCUGAGU	2344
AGGGUUAGCAGUCACCUGAG	2345
GAGGGUUAGCAGUCACCUGA	2346
GGAGGGUUAGCAGUCACCUG	2347
CGGAGGGUUAGCAGUCACCU	2348
AGCGGAGGGUUAGCAGUCAC	2349
GAGCGGAGGGUUAGCAGUCA	2350
AGAGCGGAGGGUUAGCAGUC	2351
UAGAGCGGAGGGUUAGCAGU	2352
GUAGAGCGGAGGGUUAGCAG	2353
GGUAGAGCGGAGGGUUAGCA	2354
AGGGUAGAGCGGAGGGUUAG	2355
GAGGGUAGAGCGGAGGGUUA	2356
AUUGUUGCCCUGCCUAUAUC	2357
AGUAUUGUUGCCCUGCCUAU	2358
GAGUAUUGUUGCCCUGCCUA	2359
GGAGUAUUGUUGCCCUGCCU	2360
UGGAGUAUUGUUGCCCUGCC	2361
GUGGAGUAUUGUUGCCCUGC	2362
AGUGGAGUAUUGUUGCCCUG	2363
GAGUGGAGUAUUGUUGCCCU	2364
UGAGUGGAGUAUUGUUGCCC	2365
CUGAGUGGAGUAUUGUUGCC	2366
GCUGAGUGGAGUAUUGUUGC	2367
GGCUGAGUGGAGUAUUGUUG	2368
GGGCUGAGUGGAGUAUUGUU	2369
GGUACUGGUUAGUCUCCUAG	2370
GGGUACUGGUUAGUCUCCUA	2371
UUGACAAGCCCACUGUGGAG	2372
UGGCUCAGGAGCUUGACAAG	2373
GGUGGCUCAGGAGCUUGACA	2374
UAGGGAUGAGGGAGAGACCA	2375
UCGAUUAGGGAUGAGGGAGA	2376
UAGAGGGCUAGGGAGGGAGA	2377
GUAGAGUGGCUAGAGGGCUA	2378
GGUAGAGUGGCUAGAGGGCU	2379
UGAGGGUAGAGUGGCUAGAG	2380
GAUGAGGGUAGAGUGGCUAG	2381
CAUGAUGAGGGUAGAGUGGC	2382
GCAUGAUGAGGGUAGAGUGG	2383
GGGCAUGAUGAGGGUAGAGU	2384
GGUAGUUGAGAAGAAAAGUC	2385
CCAAACUCCGAGCUUAUAUU	2386
UCCAAACUCCGAGCUUAUAU	2387
GUCCAAACUCCGAGCUUAUA	2388
CGUCCAAACUCCGAGCUUAU	2389
CCGUCCAAACUCCGAGCUUA	2390
UCCGUCCAAACUCCGAGCUU	2391
CUCCGUCCAAACUCCGAGCU	2392
ACCCUCCGUCCAAACUCCGA	2393
AGACCCUCCGUCCAAACUCC	2394
CAGACCCUCCGUCCAAACUC	2395
UCCAGACCCUCCGUCCAAAC	2396
GUCCAGACCCUCCGUCCAAA	2397
AGACACGGAAAGGUCGCUGG	2398
CAGACACGGAAAGGUCGCUG	2399
ACAGACACGGAAAGGUCGCU	2400
CACAGACACGGAAAGGUCGC	2401
UCACAGACACGGAAAGGUCG	2402
AUCACAGACACGGAAAGGUC	2403
GAUCACAGACACGGAAAGGU	2404
UUGGCCUACUUACUUUGGCU	2405
CUUGGCCUACUUACUUUGGC	2406
ACUUGGCCUACUUACUUUGG	2407
GAGGAACUUGGCCUACUUAC	2408
CGAGGAACUUGGCCUACUUA	2409
CCGAGGAACUUGGCCUACUU	2410
ACCGAGGAACUUGGCCUACU	2411
AACCGAGGAACUUGGCCUAC	2412
GAACCGAGGAACUUGGCCUA	2413
GGAACCGAGGAACUUGGCCU	2414
AGGAACCGAGGAACUUGGCC	2415
UAGGAACCGAGGAACUUGGC	2416
AUAGGAACCGAGGAACUUGG	2417
UAUAGGAACCGAGGAACUUG	2418
AUCACAAGUUGCCACUGUUG	2419
CAUCACAAGUUGCCACUGUU	2420
AUCAUCACAAGUUGCCACUG	2421
CAUCAUCACAAGUUGCCACU	2422
CUGCUCCAUCAUCACAAGUU	2423
UCUGCUCCAUCAUCACAAGU	2424
CCCUCUGCUCCAUCAUCACA	2425
UCAGCCCUCUGCUCCAUCAU	2426
UGACUUCAGCCCUCUGCUCC	2427
GUGACUUCAGCCCUCUGCUC	2428
UGUGACUUCAGCCCUCUGCU	2429
GUGUGACUUCAGCCCUCUGC	2430
UGUGUGACUUCAGCCCUCUG	2431
GCCCACUCCGCUGCUUUUAG	2432
GGCCCACUCCGCUGCUUUUA	2433
AGGCCCACUCCGCUGCUUUU	2434
UAGGCCCACUCCGCUGCUUU	2435
UUAGGCCCACUCCGCUGCUU	2436
AUUAGGCCCACUCCGCUGCU	2437
UCAUUAGGCCCACUCCGCUG	2438
CUCAUUAGGCCCACUCCGCU	2439
AGCUCAUUAGGCCCACUCCG	2440
CUCCCAUAGAAAAGCUCACU	2441
GCUCCCAUAGAAAAGCUCAC	2442
UGCUCCCAUAGAAAAGCUCA	2443
CUGCUCCCAUAGAAAAGCUC	2444
CCUGCUCCCAUAGAAAAGCU	2445
UCCCUAUCUCCUGCUAACCC	2446
CCUCGAACUCUCCCUAUCUC	2447
CCCUCGAACUCUCCCUAUCU	2448
UCCCUCGAACUCUCCCUAUC	2449
GUCCCUCGAACUCUCCCUAU	2450
CUUUCCAUACUAGCUUCUGA	2451
CCUUUCCAUACUAGCUUCUG	2452
ACCUUUCCAUACUAGCUUCU	2453
CACACAAAUCACCUUUCCAU	2454
GUCACACAAAUCACCUUUCC	2455
UGUCACACAAAUCACCUUUC	2456
UUUGACAGGCAGGAAGUGGC	2457
GGUUUGACAGGCAGGAAGUG	2458
AGGUUUGACAGGCAGGAAGU	2459
AAGGUUUGACAGGCAGGAAG	2460
AACUUCCCAAGGUUUGACAG	2461
CAACUUCCCAAGGUUUGACA	2462
GAACAACUUCCCAAGGUUUG	2463
UGAACAACUUCCCAAGGUUU	2464
GUAGGUUGAACAACUUCCCA	2465
GGUAGGUUGAACAACUUCCC	2466
UGGUAGGUUGAACAACUUCC	2467
GGUUUUGGUAGGUUGAACAA	2468
UGAGGUUUUGGUAGGUUGAA	2469
CUGAGGUUUUGGUAGGUUGA	2470
CCUACAUUAUCCUCUUACUC	2471
GGACUUUACCUACAUUAUCC	2472
GUAUGAGGACUUUACCUACA	2473
GCCAGGUAUGAGGACUUUAC	2474
UGCCAGGUAUGAGGACUUUA	2475
GUGCCAGGUAUGAGGACUUU	2476
CUGUGCCAGGUAUGAGGACU	2477
UCUGUGCCAGGUAUGAGGAC	2478
CCUCAAGAGUUCUCCAGAAG	2479
CCCUCAAGAGUUCUCCAGAA	2480
ACCCUCAAGAGUUCUCCAGA	2481
ACACCCUCAAGAGUUCUCCA	2482
CACACCCUCAAGAGUUCUCC	2483
CCACACCCUCAAGAGUUCUC	2484
CCCACACCCUCAAGAGUUCU	2485
UUCCCACACCCUCAAGAGUU	2486
CAAUGCUGCACCUCACUUCC	2487
UACAAUGCUGCACCUCACUU	2488
CUACAAUGCUGCACCUCACU	2489
UCUACAAUGCUGCACCUCAC	2490
AUCUACAAUGCUGCACCUCA	2491
UAUCUACAAUGCUGCACCUC	2492
CUUAUCUACAAUGCUGCACC	2493
GUCUUAUCUACAAUGCUGCA	2494
UGUCUUAUCUACAAUGCUGC	2495
CUGUCUUAUCUACAAUGCUG	2496
CACCCUUCUGUCUUAUCUAC	2497
UCCACCCUUCUGUCUUAUCU	2498
GUCCACCCUUCUGUCUUAUC	2499
AGUCCACCCUUCUGUCUUAU	2500
AAGUCCACCCUUCUGUCUUA	2501
GAAAGCAAGCCAGGUUCUCA	2502
GGAAAGCAAGCCAGGUUCUC	2503
GGAAUUGGAAAGCAAGCCAG	2504
ACCAUGUCAUUGGCAUCUCC	2505
UACCAUGUCAUUGGCAUCUC	2506
CCUACCAUGUCAUUGGCAUC	2507
UCCUACCAUGUCAUUGGCAU	2508
CUCCUACCAUGUCAUUGGCA	2509
GCUCCUACCAUGUCAUUGGC	2510
UGCUCCUACCAUGUCAUUGG	2511
UCUUUGCUCCUACCAUGUCA	2512
CCUCUUUGCUCCUACCAUGU	2513
UUCCUCUUUGCUCCUACCAU	2514
UCUCCGUGUUCUUCAGUUUU	2515
CUCUCCGUGUUCUUCAGUUU	2516
AGCUCUCCGUGUUCUUCAGU	2517
UGCAGCUCUCCGUGUUCUUC	2518
GGUUGCAGCUCUCCGUGUUC	2519
AGGUUGCAGCUCUCCGUGUU	2520
AAAGGUUGCAGCUCUCCGUG	2521
UAAAGGUUGCAGCUCUCCGU	2522
CUAAAGGUUGCAGCUCUCCG	2523
CCUAAAGGUUGCAGCUCUCC	2524
UCCUAAAGGUUGCAGCUCUC	2525
CUCCUAAAGGUUGCAGCUCU	2526
CCUCCUAAAGGUUGCAGCUC	2527
GCACUUUGAUACCUCCUAAA	2528
GGCACUUUGAUACCUCCUAA	2529
GAUGUCCCACUUUGACUUUC	2530
UCGAUGUCCCACUUUGACUU	2531
GUCGAUGUCCCACUUUGACU	2532
GGUCGAUGUCCCACUUUGAC	2533
UGGUCGAUGUCCCACUUUGA	2534
UUGGUCGAUGUCCCACUUUG	2535
AUUGGUCGAUGUCCCACUUU	2536
CAUUGGUCGAUGUCCCACUU	2537
AACAUCCAUCAGUUGGCUCU	2538
CUGCCCAACAUCCAUCAGUU	2539
AGCUGCCCAACAUCCAUCAG	2540
UAGCUGCCCAACAUCCAUCA	2541
UUAGCUGCCCAACAUCCAUC	2542
UUUAGCUGCCCAACAUCCAU	2543
CUUUAGCUGCCCAACAUCCA	2544
CCUCUUUAGCUGCCCAACAU	2545
CCCUCUUUAGCUGCCCAACA	2546
UCCCUCUUUAGCUGCCCAAC	2547
UUCCCUCUUUAGCUGCCCAA	2548
CCUUCCCUCUUUAGCUGCCC	2549
CCCUUCCCUCUUUAGCUGCC	2550
GCAGGUCUUAUCCCAUGCCC	2551
GGGCAGGUCUUAUCCCAUGC	2552
AGGGCAGGUCUUAUCCCAUG	2553
AAGGGCAGGUCUUAUCCCAU	2554
GAAGGGCAGGUCUUAUCCCA	2555
AGAAGGGCAGGUCUUAUCCC	2556
CCAAUGGCAAGAAGCAAGAA	2557
CCCAAUGGCAAGAAGCAAGA	2558
GCCCAAUGGCAAGAAGCAAG	2559
UCCAAUGCCUGCCCAAUGGC	2560
CUCCAAUGCCUGCCCAAUGG	2561
UCUCCAAUGCCUGCCCAAUG	2562
GGUCUCCAAUGCCUGCCCAA	2563
UAGGGUCUCCAAUGCCUGCC	2564
GUAGGGUCUCCAAUGCCUGC	2565
AGUAGGGUCUCCAAUGCCUG	2566
CAGUAGGGUCUCCAAUGCCU	2567
GCAGUAGGGUCUCCAAUGCC	2568
AGCAGUAGGGUCUCCAAUGC	2569
CAGCAGUAGGGUCUCCAAUG	2570
UCAGCAGUAGGGUCUCCAAU	2571
AUUCAGCAGUAGGGUCUCCA	2572
CAUUCAGCAGUAGGGUCUCC	2573
CCAUUCAGCAGUAGGGUCUC	2574
UCCAUUCAGCAGUAGGGUCU	2575
ACUCCAUUCAGCAGUAGGGU	2576
CACUCCAUUCAGCAGUAGGG	2577
GCACUCCAUUCAGCAGUAGG	2578
AGCACUCCAUUCAGCAGUAG	2579
UAGCACUCCAUUCAGCAGUA	2580
GUUAGCACUCCAUUCAGCAG	2581
GGUUAGCACUCCAUUCAGCA	2582
GGGUUAGCACUCCAUUCAGC	2583
CAGGGUUAGCACUCCAUUCA	2584
CCAGGGUUAGCACUCCAUUC	2585
ACCAGGGUUAGCACUCCAUU	2586
CACCAGGGUUAGCACUCCAU	2587
GCACCAGGGUUAGCACUCCA	2588
AGCACCAGGGUUAGCACUCC	2589
UAGCACCAGGGUUAGCACUC	2590
CUAGCACCAGGGUUAGCACU	2591
UCUAGCACCAGGGUUAGCAC	2592
CUCUAGCACCAGGGUUAGCA	2593
CCUCUAGCACCAGGGUUAGC	2594
UCCUCUAGCACCAGGGUUAG	2595
CUCCUCUAGCACCAGGGUUA	2596
CCUCCUCUAGCACCAGGGUU	2597
UCCUCCUCUAGCACCAGGGU	2598
GUUCCAUCCUCCUCUAGCAC	2599
AAGUCCUCACUGUCCACUGC	2600
GAAGUCCUCACUGUCCACUG	2601
AGAAGUCCUCACUGUCCACU	2602
AAGAAGUCCUCACUGUCCAC	2603
GAAGAAGUCCUCACUGUCCA	2604
GGAAGAAGUCCUCACUGUCC	2605
UGGAAGAAGUCCUCACUGUC	2606
CUGGAAGAAGUCCUCACUGU	2607
AGCUGGAAGAAGUCCUCACU	2608
ACUGCAACACCAUCAGGCAC	2609
GACUGCAACACCAUCAGGCA	2610
AGACUGCAACACCAUCAGGC	2611
CAGACUGCAACACCAUCAGG	2612
CCAGACUGCAACACCAUCAG	2613
GACCAGACUGCAACACCAUC	2614
CUCUGACCAGACUGCAACAC	2615
AGCUCUGACCAGACUGCAAC	2616
CCAGCUCUGACCAGACUGCA	2617
UGUAGGGCUCCAGCUCUGAC	2618
CUUGUAGGGCUCCAGCUCUG	2619
CCUUGUAGGGCUCCAGCUCU	2620
ACAGGCAUUGGAAGCAGCCC	2621
GACAGGCAUUGGAAGCAGCC	2622
AAGGACAGGCAUUGGAAGCA	2623
AAAGGACAGGCAUUGGAAGC	2624
UAAAGGACAGGCAUUGGAAG	2625
CUAAAGGACAGGCAUUGGAA	2626
GCUCUAAAGGACAGGCAUUG	2627
AGCUCUAAAGGACAGGCAUU	2628
AAGCUCUAAAGGACAGGCAU	2629
AAAGCUCUAAAGGACAGGCA	2630
GAAAGCUCUAAAGGACAGGC	2631
CGGGAAAGCUCUAAAGGACA	2632
CCGGGAAAGCUCUAAAGGAC	2633
AGGGUUAAGCUAGAGAGGAA	2634
UCAGGGUUAAGCUAGAGAGG	2635
GAUCAGGGUUAAGCUAGAGA	2636
GGAUCAGGGUUAAGCUAGAG	2637
AGGAUCAGGGUUAAGCUAGA	2638
CCCAGGAUCAGGGUUAAGCU	2639
CAACUCCUCCUGCACCUGGU	2640
ACAACUCCUCCUGCACCUGG	2641
GACAAUUCCACAACUCCUCC	2642
UGACAAUUCCACAACUCCUC	2643
UUGACAAUUCCACAACUCCU	2644
CUUGACAAUUCCACAACUCC	2645
UCCUUGACAAUUCCACAACU	2646
AUCCUUGACAAUUCCACAAC	2647
CAUCCUUGACAAUUCCACAA	2648
ACAUCCUUGACAAUUCCACA	2649
GACAUCCUUGACAAUUCCAC	2650
UGACAUCCUUGACAAUUCCA	2651
UGUGUGACAUCCUUGACAAU	2652
ACUGUGUGACAUCCUUGACA	2653
ACUUUCUGUCCACUGUGUGA	2654
CCUCGCUUGGACUUUCUGUC	2655
CCCUCGCUUGGACUUUCUGU	2656
UCCCUCGCUUGGACUUUCUG	2657
CUCCCUCGCUUGGACUUUCU	2658
CCUCCCUCGCUUGGACUUUC	2659
CCCUCCCUCGCUUGGACUUU	2660
UCCAUCAGCACUGGGUCAGA	2661
ACCACUAAUCUCCAUCAGCA	2662
CACCACUAAUCUCCAUCAGC	2663
CCACCACUAAUCUCCAUCAG	2664
CCCACCACUAAUCUCCAUCA	2665
ACCAGACACCCACCACUAAU	2666
UACCAGACACCCACCACUAA	2667
CUCAUACCAGACACCCACCA	2668
CCUCAUACCAGACACCCACC	2669
UCCUCAUACCAGACACCCAC	2670
AUCCUCAUACCAGACACCCA	2671
GAUCCUCAUACCAGACACCC	2672
AGAUCCUCAUACCAGACACC	2673
UAGAUCCUCAUACCAGACAC	2674
GUAGAUCCUCAUACCAGACA	2675
AGUAGAUCCUCAUACCAGAC	2676
CAGUAGAUCCUCAUACCAGA	2677
UGCAGUAGAUCCUCAUACCA	2678
GUGCAGUAGAUCCUCAUACC	2679
AGUGCAGUAGAUCCUCAUAC	2680
ACUCUGUAGGACACCCUUGU	2681
CACUCUGUAGGACACCCUUG	2682
CCACUCUGUAGGACACCCUU	2683
UCCACUCUGUAGGACACCCU	2684
CUCCACUCUGUAGGACACCC	2685
ACUCCACUCUGUAGGACACC	2686
CACUCCACUCUGUAGGACAC	2687
AGCACUCCACUCUGUAGGAC	2688
UAUGACAGCACUCCACUCUG	2689
AUAUGACAGCACUCCACUCU	2690
UUGCUGUGCUUGGGCCUCUC	2691
ACGUCAAAGGUGAAUCGGGC	2692
CACGUCAAAGGUGAAUCGGG	2693
ACACGUCAAAGGUGAAUCGG	2694
UACACGUCAAAGGUGAAUCG	2695
GUACACGUCAAAGGUGAAUC	2696
GGCUGCCAAAGAGGUCUCGA	2697
UCAGGCUGCCAAAGAGGUCU	2698
CAUUCAGGCUGCCAAAGAGG	2699
GACAUUCAGGCUGCCAAAGA	2700
UGACAUUCAGGCUGCCAAAG	2701
CUUUGACAUUCAGGCUGCCA	2702
GCUUUGACAUUCAGGCUGCC	2703
CCGUAGAAUGUGGCUUUGAC	2704
GCCCGUAGAAUGUGGCUUUG	2705
UAGAGCCCGUAGAAUGUGGC	2706
GUAGAGCCCGUAGAAUGUGG	2707
AGUAGAGCCCGUAGAAUGUG	2708
AGAGUAGAGCCCGUAGAAUG	2709
UAGAGUAGAGCCCGUAGAAU	2710
AUAGAGUAGAGCCCGUAGAA	2711
CAUAGAGUAGAGCCCGUAGA	2712
UCAUAGAGUAGAGCCCGUAG	2713
CUCAUAGAGUAGAGCCCGUA	2714
GAAAGUCACAACUCAUAGAG	2715
CCUUGAAAGUCACAACUCAU	2716
AAGUCCUUGAAAGUCACAAC	2717
CCAAGUCCUUGAAAGUCACA	2718
UUCUUUGGGCCAAGUCCUUG	2719
UUUCUUUGGGCCAAGUCCUU	2720
UUGAUUUCUGACCUGAGUAC	2721
GUUGAUUUCUGACCUGAGUA	2722
GGGACUAUCCAACUGUAGGG	2723
GCAAGAGGACGAAUUAUGGG	2724
UGCAAGAGGACGAAUUAUGG	2725
GUGCAAGAGGACGAAUUAUG	2726
GGUGCAAGAGGACGAAUUAU	2727
GGGUGCAAGAGGACGAAUUA	2728
UGGGUGCAAGAGGACGAAUU	2729
GUGGGUGCAAGAGGACGAAU	2730
GGUGGGUGCAAGAGGACGAA	2731
UAGGUGGGUGCAAGAGGACG	2732
GUAGGUGGGUGCAAGAGGAC	2733
GGUAGGUGGGUGCAAGAGGA	2734
CCACAAGCAAGAGCUAACUA	2735
ACUUUCCACAAGCAAGAGCU	2736
GACUUUCCACAAGCAAGAGC	2737
GGACUUUCCACAAGCAAGAG	2738
AGGACUUUCCACAAGCAAGA	2739
GAGGACUUUCCACAAGCAAG	2740
UGAGGACUUUCCACAAGCAA	2741
AUGAGGACUUUCCACAAGCA	2742
GAUGAGGACUUUCCACAAGC	2743
AGAUGAGGACUUUCCACAAG	2744
GAGAUGAGGACUUUCCACAA	2745
GGAGAUGAGGACUUUCCACA	2746
UGGGAGAUGAGGACUUUCCA	2747
GCUGGGAGAUGAGGACUUUC	2748
UCAAGCUGGGAGAUGAGGAC	2749
AAGCCAUCAAGCUGGGAGAU	2750
GAAGCCAUCAAGCUGGGAGA	2751
GGAGGAAGCCAUCAAGCUGG	2752
GGGAGGAAGCCAUCAAGCUG	2753
AACUUGGGAGGAAGCCAUCA	2754
AAACUUGGGAGGAAGCCAUC	2755
CAGCAGUGUGGAGGUCCAAC	2756
GCAGCAGUGUGGAGGUCCAA	2757
UGCAGCAGUGUGGAGGUCCA	2758
UUGCAGCAGUGUGGAGGUCC	2759
GGUGGAGGAAAUUCCCAGCA	2760
ACGAAGGGUGGAGGAAAUUC	2761
GACGAAGGGUGGAGGAAAUU	2762
AUGACGAAGGGUGGAGGAAA	2763
CAUGACGAAGGGUGGAGGAA	2764
GCAUGACGAAGGGUGGAGGA	2765
UGCAUGACGAAGGGUGGAGG	2766
CUGCAUGACGAAGGGUGGAG	2767
ACUGCAUGACGAAGGGUGGA	2768
CACUGCAUGACGAAGGGUGG	2769
CCACUGCAUGACGAAGGGUG	2770
UCCACUGCAUGACGAAGGGU	2771
CUCCACUGCAUGACGAAGGG	2772
CCUCCACUGCAUGACGAAGG	2773
CCCUCCACUGCAUGACGAAG	2774
CUUAGUAGGAAUGGAGGCGG	2775
CCUUAGUAGGAAUGGAGGCG	2776
CCCUUAGUAGGAAUGGAGGC	2777
UCGGUUGGAAUGAUUCUGGG	2778
GUCGGUUGGAAUGAUUCUGG	2779
GGUCGGUUGGAAUGAUUCUG	2780
GGGUCGGUUGGAAUGAUUCU	2781
UGGGUCGGUUGGAAUGAUUC	2782
GUGGGUCGGUUGGAAUGAUU	2783
AGUGGGUCGGUUGGAAUGAU	2784
CAGUGGGUCGGUUGGAAUGA	2785
GCAGUGGGUCGGUUGGAAUG	2786
UGCAGUGGGUCGGUUGGAAU	2787
UUGCAGUGGGUCGGUUGGAA	2788
UUUGCAGUGGGUCGGUUGGA	2789
CUUUGCAGUGGGUCGGUUGG	2790
UCUUUGCAGUGGGUCGGUUG	2791
UAGUCUUUGCAGUGGGUCGG	2792
AUAGUCUUUGCAGUGGGUCG	2793
CUGUCAUAGUCUUUGCAGUG	2794
UGCUGUCAUAGUCUUUGCAG	2795
UCUAGCCUGUACUGUCUGCA	2796
AUCUAGCCUGUACUGUCUGC	2797
UAUCUAGCCUGUACUGUCUG	2798
UUAUCUAGCCUGUACUGUCU	2799
GUUAUCUAGCCUGUACUGUC	2800
GGUUAUCUAGCCUGUACUGU	2801
GGGUUAUCUAGCCUGUACUG	2802
UGGGUUAUCUAGCCUGUACU	2803
GUGGGUUAUCUAGCCUGUAC	2804
GGUGGGUUAUCUAGCCUGUA	2805
GGGUGGGUUAUCUAGCCUGU	2806
UGGGUGGGUUAUCUAGCCUG	2807
UUGGGUGGGUUAUCUAGCCU	2808
AUUGGGUGGGUUAUCUAGCC	2809
AAUUGGGUGGGUUAUCUAGC	2810
AAAUUGGGUGGGUUAUCUAG	2811
GGAAAUUGGGUGGGUUAUCU	2812
GGGAAAUUGGGUGGGUUAUC	2813
GAAAGGUUCUGUCACGAGGG	2814
GCUGAAAGGUUCUGUCACGA	2815
UGCUGAAAGGUUCUGUCACG	2816
GGCGUUAUGCUGAAAGGUUC	2817
AGGCGUUAUGCUGAAAGGUU	2818
GAGGCGUUAUGCUGAAAGGU	2819
UGAGGCGUUAUGCUGAAAGG	2820
GUGAGGCGUUAUGCUGAAAG	2821
AUGUGAGGCGUUAUGCUGAA	2822
GAUGUGAGGCGUUAUGCUGA	2823
GGAUGUGAGGCGUUAUGCUG	2824
GGGAUGUGAGGCGUUAUGCU	2825
CUUGGGAUGUGAGGCGUUAU	2826
AGACUUGGGAUGUGAGGCGU	2827
UAGACUUGGGAUGUGAGGCG	2828
AUAGACUUGGGAUGUGAGGC	2829
UAUAGACUUGGGAUGUGAGG	2830
GGGUAUAGACUUGGGAUGUG	2831
AGGGUAUAGACUUGGGAUGU	2832
AAGGUGGCUAGGAAAGAACA	2833
AAAGGUGGCUAGGAAAGAAC	2834
GAAAGGUGGCUAGGAAAGAA	2835
ACAUCUUGAUCUUGGCCUUU	2836
GGCUGGGAUCAAGAUGCCUG	2837
GUCAGGCUGGGAUCAAGAUG	2838
AGUCAGGCUGGGAUCAAGAU	2839
CAGUCAGGCUGGGAUCAAGA	2840
AGCAGUCAGGCUGGGAUCAA	2841
GAUGUAGCAGCAGUCAGGCU	2842
GGAUUAGAUGUAGCAGCAGU	2843
GGGAUUAGAUGUAGCAGCAG	2844
GACAGGAGGCAUUGGUAGGG	2845
UUAGGGACAGGAGGCAUUGG	2846
UUUAGGGACAGGAGGCAUUG	2847
GAGUUUAGGGACAGGAGGCA	2848
GGAGUUUAGGGACAGGAGGC	2849
GCUGUCAUCAGUAUGCUGGG	2850
GGCUGUCAUCAGUAUGCUGG	2851
GGGCUGUCAUCAGUAUGCUG	2852
AGGGCUGUCAUCAGUAUGCU	2853
AGAGAGGGCUGUCAUCAGUA	2854
CAGAGAGGGCUGUCAUCAGU	2855
UCAGAGAGGGCUGUCAUCAG	2856
GUCAGAGAGGGCUGUCAUCA	2857
GGUAAAGUCAGAGAGGGCUG	2858
GGGAAGGGUAUGAAGACAGA	2859
GUCAGAAGUCUUAGUGGUAA	2860
AGUCAGAAGUCUUAGUGGUA	2861
GAGUCAGAAGUCUUAGUGGU	2862
CUGGGACUGGGUGUUGAUGG	2863
AUCUGGGACUGGGUGUUGAU	2864
GAUCUGGGACUGGGUGUUGA	2865
UGGAUCUGGGACUGGGUGUU	2866
UUUGGAUCUGGGACUGGGUG	2867
GCUUUGGAUCUGGGACUGGG	2868

TABLE 5 — SEQ ID

Sequence	NO:
ACACUGCUGAGCUGGAAGAC	2869
CGAGACACUGCUGAGCUGGA	2870
ACGAGACACUGCUGAGCUGG	2871
AACGAGACACUGCUGAGCUG	2872
GAACGAGACACUGCUGAGCU	2873
GGAACGAGACACUGCUGAGC	2874
GGGAACGAGACACUGCUGAG	2875
AGGGAACGAGACACUGCUGA	2876
CAGGGAACGAGACACUGCUG	2877
CCAGGGAACGAGACACUGCU	2878
AAGGAUGUCGGUCUGCUACC	2879
GAAGGAUGUCGGUCUGCUAC	2880
AGAAGGAUGUCGGUCUGCUA	2881
UAGGCCCAGAAGGAUGUCGG	2882
GUAGGCCCAGAAGGAUGUCG	2883
UGUAGGCCCAGAAGGAUGUC	2884
CUGUAGGCCCAGAAGGAUGU	2885
CCUGUAGGCCCAGAAGGAUG	2886
ACCUGUAGGCCCAGAAGGAU	2887
CUUCUCAUCGGGCAUCACAG	2888
CCUUCUCAUCGGGCAUCACA	2889
ACCUUCUCAUCGGGCAUCAC	2890
CACCUUCUCAUCGGGCAUCA	2891
GCACCUUCUCAUCGGGCAUC	2892
GGCACCUUCUCAUCGGGCAU	2893
UGGCACCUUCUCAUCGGGCA	2894
AUGGCACCUUCUCAUCGGGC	2895
CAUGGCACCUUCUCAUCGGG	2896
GCAUGGCACCUUCUCAUCGG	2897
GGCAUGGCACCUUCUCAUCG	2898
GAGGCAUGGCACCUUCUCAU	2899
GGAGGCAUGGCACCUUCUCA	2900
GACUCCCAGGCAGAAAAGAG	2901
GGACUCCCAGGCAGAAAAGA	2902
AGGACUCCCAGGCAGAAAAG	2903
UCAGGACUCCCAGGCAGAAA	2904
GAAGUCAGGACUCCCAGGCA	2905
GUGGAAGUCAGGACUCCCAG	2906
UCGUGGAAGUCAGGACUCCC	2907
CUCGUGGAAGUCAGGACUCC	2908
CCUCGUGGAAGUCAGGACUC	2909
UGGGUCCUCGUGGAAGUCAG	2910
CUGGGUCCUCGUGGAAGUCA	2911
UCUGGGUCCUCGUGGAAGUC	2912
GUCUGGGUCCUCGUGGAAGU	2913
AAGAAGGAGUUGUGUUUGAG	2914
CCAAGAAGGAGUUGUGUUUG	2915
GUUCCAAGAAGGAGUUGUGU	2916
GGUUCCAAGAAGGAGUUGUG	2917
CAGGUCAACUGACUGGGAGC	2918
UGCCUGUUUACCACUGAGCU	2919
AUGCCUGUUUACCACUGAGC	2920
UAUGCCUGUUUACCACUGAG	2921
UUAUGCCUGUUUACCACUGA	2922
UUUAUGCCUGUUUACCACUG	2923
CUUUAUGCCUGUUUACCACU	2924
ACUUUAUGCCUGUUUACCAC	2925
UAGAGAUAGUGACAGCCUGG	2926
GUAGAGAUAGUGACAGCCUG	2927
UGGUGGUAGAGAUAGUGACA	2928
GUGGUGGUAGAGAUAGUGAC	2929
UAGAGGAGUGGUGGUAGAGA	2930
ACUAGAGGAGUGGUGGUAGA	2931
AGACUAGAGGAGUGGUGGUA	2932
CAGACUAGAGGAGUGGUGGU	2933
CCAGACUAGAGGAGUGGUGG	2934
GCCAGACUAGAGGAGUGGUG	2935
GGCCAGACUAGAGGAGUGGU	2936
GCCCAGAUGUGCUAGAAUGG	2937
UGCCCAGAUGUGCUAGAAUG	2938
UUGCCCAGAUGUGCUAGAAU	2939
UUUGCCCAGAUGUGCUAGAA	2940
UUUUGCCCAGAUGUGCUAGA	2941
CCAGUUUUGCCCAGAUGUGC	2942
AUCCAGUUUUGCCCAGAUGU	2943
CCAUCCAGUUUUGCCCAGAU	2944
CACCAUCCAGUUUUGCCCAG	2945
CCACCAUCCAGUUUUGCCCA	2946
CCCACCAUCCAGUUUUGCCC	2947
UUGCUCCCAGCUUGGUAAGU	2948
GCUUGCUCCCAGCUUGGUAA	2949
AUCCUGCUUGCUCCCAGCUU	2950
AAUCCUGCUUGCUCCCAGCU	2951
CAAUCCUGCUUGCUCCCAGC	2952
CCAAUCCUGCUUGCUCCCAG	2953
AACCUUUCAGCUUCUCCAGG	2954
UAACCUUUCAGCUUCUCCAG	2955
UUAACCUUUCAGCUUCUCCA	2956
ACUGCUGCUUAACCUUUCAG	2957
UACUGCUGCUUAACCUUUCA	2958
CUACUGCUGCUUAACCUUUC	2959
CCUACUGCUGCUUAACCUUU	2960
GCCUACUGCUGCUUAACCUU	2961
CAGGACAGGAGUAGGCACCU	2962
ACAGGACAGGAGUAGGCACC	2963
GCACAGGACAGGAGUAGGCA	2964
AUAGGCACAGGACAGGAGUA	2965
GAUAGGCACAGGACAGGAGU	2966
UGAUAGGCACAGGACAGGAG	2967
ACCCUCUGCAAAUGUGAUAG	2968
CUUACCCUCUGCAAAUGUGA	2969
GUCUUACCCUCUGCAAAUGU	2970
UGUCUUACCCUCUGCAAAUG	2971
UUGUCUUACCCUCUGCAAAU	2972
CUUGUCUUACCCUCUGCAAA	2973
UCUUGUCUUACCCUCUGCAA	2974
CAUUCUUGUCUUACCCUCUG	2975
CCCAUUCUUGUCUUACCCUC	2976
GAGCCUCAUCUUGUCCCUCC	2977
UGAGCCUCAUCUUGUCCCUC	2978

TABLE 6 — SEQ ID

Sequence	NO:
ACCACGCAGUCAACCUUCUG	2979
UACCACGCAGUCAACCUUCU	2980
CUACCACGCAGUCAACCUUC	2981
CCUACCACGCAGUCAACCUU	2982
CCCUACCACGCAGUCAACCU	2983
UUGCCUUCGGCUUGCUCUGG	2984
CUUGCCUUCGGCUUGCUCUG	2985
GCUUGCCUUCGGCUUGCUCU	2986
UGCUUGCCUUCGGCUUGCUC	2987
GUGCUUGCCUUCGGCUUGCU	2988
UCGUGCUUGCCUUCGGCUUG	2989
AUCGUGCUUGCCUUCGGCUU	2990
CAUCGUGCUUGCCUUCGGCU	2991
AGCGCCAUCGUGCUUGCCUU	2992
UGGUGAGCGCCAUCGUGCUU	2993
CUGAUGCUCGGCUGCUACAG	2994
GCUGAUGCUCGGCUGCUACA	2995
UUUCGGGCUGAUGCUCGGCU	2996
GCUGCAAGGCGGUGUACUAC	3017
GGCUGCAAGGCGGUGUACUA	3018
UCCUUUCGGGCUGAUGCUCG	2997
UUCCUUUCGGGCUGAUGCUC	2998
CUUCCUUUCGGGCUGAUGCU	2999
GCUUCCUUUCGGGCUGAUGC	3000
UGCUUCCUUUCGGGCUGAUG	3001
GUGCUUCCUUUCGGGCUGAU	3002
CGUGCUUCCUUUCGGGCUGA	3003
UCGUGCUUCCUUUCGGGCUG	3004
UUCGUGCUUCCUUUCGGGCU	3005
UUUCGUGCUUCCUUUCGGGC	3006
CUUUCGUGCUUCCUUUCGGG	3007
GCUUUCGUGCUUCCUUUCGG	3008
AUGUACGCCAGCGUGCUGCU	3009
UCAGCAUGUACGCCAGCGUG	3010
AGGCGGUGUACUACGUGUGC	3011
AAGGCGGUGUACUACGUGUG	3012
CAAGGCGGUGUACUACGUGU	3013
GCAAGGCGGUGUACUACGUG	3014
UGCAAGGCGGUGUACUACGU	3015
CUGCAAGGCGGUGUACUACG	3016
GCUCUUUGUGGCCUUCCUGA	3019
CGCUCUUUGUGGCCUUCCUG	3020

SEQ ID

Sequence	NO:
AGAAGUCCUCACUGUCCACU	3021
AAGAAGUCCUCACUGUCCAC	3022
GAAGAAGUCCUCACUGUCCA	3023
GGAAGAAGUCCUCACUGUCC	3024
UGGAAGAAGUCCUCACUGUC	3025
CUGGAAGAAGUCCUCACUGU	3026
AGCUGGAAGAAGUCCUCACU	3027
ACUGCAACACCAUCAGGCAC	3028
GACUGCAACACCAUCAGGCA	3029
AGACUGCAACACCAUCAGGC	3030
CAGACUGCAACACCAUCAGG	3031
CCAGACUGCAACACCAUCAG	3032
GACCAGACUGCAACACCAUC	3033
CUCUGACCAGACUGCAACAC	3034
AGCUCUGACCAGACUGCAAC	3035
CCAGCUCUGACCAGACUGCA	3036
UGUAGGGCUCCAGCUCUGAC	3037
CUUGUAGGGCUCCAGCUCUG	3038
CCUUGUAGGGCUCCAGCUCU	3039
ACAGGCAUUGGAAGCAGCCC	3040
GACAGGCAUUGGAAGCAGCC	3041
AAGGACAGGCAUUGGAAGCA	3042
AAAGGACAGGCAUUGGAAGC	3043
UAAAGGACAGGCAUUGGAAG	3044
CUAAAGGACAGGCAUUGGAA	3045
GCUCUAAAGGACAGGCAUUG	3046
AGCUCUAAAGGACAGGCAUU	3047
AAGCUCUAAAGGACAGGCAU	3048
AAAGCUCUAAAGGACAGGCA	3049
GAAAGCUCUAAAGGACAGGC	3050
CGGGAAAGCUCUAAAGGACA	3051
CCGGGAAAGCUCUAAAGGAC	3052
AGGGUUAAGCUAGAGAGGAA	3053
UCAGGGUUAAGCUAGAGAGG	3054
GAUCAGGGUUAAGCUAGAGA	3055
GGAUCAGGGUUAAGCUAGAG	3056
AGGAUCAGGGUUAAGCUAGA	3057
CCCAGGAUCAGGGUUAAGCU	3058
CAACUCCUCCUGCACCUGGU	3059
ACAACUCCUCCUGCACCUGG	3060
GACAAUUCCACAACUCCUCC	3061
UGACAAUUCCACAACUCCUC	3062
UUGACAAUUCCACAACUCCU	3063
CUUGACAAUUCCACAACUCC	3064
UCCUUGACAAUUCCACAACU	3065
AUCCUUGACAAUUCCACAAC	3066
CAUCCUUGACAAUUCCACAA	3067
ACAUCCUUGACAAUUCCACA	3068
GACAUCCUUGACAAUUCCAC	3069
UGACAUCCUUGACAAUUCCA	3070
UGUGUGACAUCCUUGACAAU	3071
ACUGUGUGACAUCCUUGACA	3072
ACUUUCUGUCCACUGUGUGA	3073
CCUCGCUUGGACUUUCUGUC	3074
CCCUCGCUUGGACUUUCUGU	3075
UCCCUCGCUUGGACUUUCUG	3076
CUCCCUCGCUUGGACUUUCU	3077
CCUCCCUCGCUUGGACUUUC	3078
CCCUCCCUCGCUUGGACUUU	3079
UCCAUCAGCACUGGGUCAGA	3080
ACCACUAAUCUCCAUCAGCA	3081
CACCACUAAUCUCCAUCAGC	3082
CCACCACUAAUCUCCAUCAG	3083
CCCACCACUAAUCUCCAUCA	3084
ACCAGACACCCACCACUAAU	3085
UACCAGACACCCACCACUAA	3086
CUCAUACCAGACACCCACCA	3087
CCUCAUACCAGACACCCACC	3088
UCCUCAUACCAGACACCCAC	3089
AUCCUCAUACCAGACACCCA	3090
GAUCCUCAUACCAGACACCC	3091
AGAUCCUCAUACCAGACACC	3092
UAGAUCCUCAUACCAGACAC	3093
GUAGAUCCUCAUACCAGACA	3094
AGUAGAUCCUCAUACCAGAC	3095
CAGUAGAUCCUCAUACCAGA	3096
UGCAGUAGAUCCUCAUACCA	3097
GUGCAGUAGAUCCUCAUACC	3098
AGUGCAGUAGAUCCUCAUAC	3099
ACUCUGUAGGACACCCUUGU	3100
CACUCUGUAGGACACCCUUG	3101
CCACUCUGUAGGACACCCUU	3102
UCCACUCUGUAGGACACCCU	3103
CUCCACUCUGUAGGACACCC	3104
ACUCCACUCUGUAGGACACC	3105
CACUCCACUCUGUAGGACAC	3106
AGCACUCCACUCUGUAGGAC	3107
UAUGACAGCACUCCACUCUG	3108
AUAUGACAGCACUCCACUCU	3109
UUGCUGUGCUUGGGCCUCUC	3110
ACGUCAAAGGUGAAUCGGGC	3111
CACGUCAAAGGUGAAUCGGG	3112
ACACGUCAAAGGUGAAUCGG	3113
UACACGUCAAAGGUGAAUCG	3114
GUACACGUCAAAGGUGAAUC	3115
GGCUGCCAAAGAGGUCUCGA	3116
UCAGGCUGCCAAAGAGGUCU	3117
CAUUCAGGCUGCCAAAGAGG	3118
GACAUUCAGGCUGCCAAAGA	3119
UGACAUUCAGGCUGCCAAAG	3120
CUUUGACAUUCAGGCUGCCA	3121
GCUUUGACAUUCAGGCUGCC	3122
CCGUAGAAUGUGGCUUUGAC	3123
GCCCGUAGAAUGUGGCUUUG	3124
UAGAGCCCGUAGAAUGUGGC	3125
GUAGAGCCCGUAGAAUGUGG	3126
AGUAGAGCCCGUAGAAUGUG	3127
AGAGUAGAGCCCGUAGAAUG	3128
UAGAGUAGAGCCCGUAGAAU	3129
AUAGAGUAGAGCCCGUAGAA	3130
CAUAGAGUAGAGCCCGUAGA	3131
UCAUAGAGUAGAGCCCGUAG	3132
CUCAUAGAGUAGAGCCCGUA	3133
GAAAGUCACAACUCAUAGAG	3134
CCUUGAAAGUCACAACUCAU	3135
AAGUCCUUGAAAGUCACAAC	3136
CCAAGUCCUUGAAAGUCACA	3137
UUCUUUGGGCCAAGUCCUUG	3138
UUUCUUUGGGCCAAGUCCUU	3139
UUGAUUUCUGACCUGAGUAC	3140
GUUGAUUUCUGACCUGAGUA	3141
GGGACUAUCCAACUGUAGGG	3142
GCAAGAGGACGAAUUAUGGG	3143
UGCAAGAGGACGAAUUAUGG	3144
GUGCAAGAGGACGAAUUAUG	3145
GGUGCAAGAGGACGAAUUAU	3146
GGGUGCAAGAGGACGAAUUA	3147
UGGGUGCAAGAGGACGAAUU	3148
GUGGGUGCAAGAGGACGAAU	3149
GGUGGGUGCAAGAGGACGAA	3150
UAGGUGGGUGCAAGAGGACG	3151
GUAGGUGGGUGCAAGAGGAC	3152
GGUAGGUGGGUGCAAGAGGA	3153
CCACAAGCAAGAGCUAACUA	3154
ACUUUCCACAAGCAAGAGCU	3155
GACUUUCCACAAGCAAGAGC	3156
GGACUUUCCACAAGCAAGAG	3157
AGGACUUUCCACAAGCAAGA	3158
GAGGACUUUCCACAAGCAAG	3159
UGAGGACUUUCCACAAGCAA	3160
AUGAGGACUUUCCACAAGCA	3161
GAUGAGGACUUUCCACAAGC	3162
AGAUGAGGACUUUCCACAAG	3163
GAGAUGAGGACUUUCCACAA	3164
GGAGAUGAGGACUUUCCACA	3165
UGGGAGAUGAGGACUUUCCA	3166
GCUGGGAGAUGAGGACUUUC	3167
UCAAGCUGGGAGAUGAGGAC	3168
AAGCCAUCAAGCUGGGAGAU	3169
GAAGCCAUCAAGCUGGGAGA	3170
GGAGGAAGCCAUCAAGCUGG	3171
GGGAGGAAGCCAUCAAGCUG	3172
AACUUGGGAGGAAGCCAUCA	3173
AAACUUGGGAGGAAGCCAUC	3174
CAGCAGUGUGGAGGUCCAAC	3175
GCAGCAGUGUGGAGGUCCAA	3176
UGCAGCAGUGUGGAGGUCCA	3177
UUGCAGCAGUGUGGAGGUCC	3178
GGUGGAGGAAAUUCCCAGCA	3179
ACGAAGGGUGGAGGAAAUUC	3180
GACGAAGGGUGGAGGAAAUU	3181
AUGACGAAGGGUGGAGGAAA	3182
CAUGACGAAGGGUGGAGGAA	3183
GCAUGACGAAGGGUGGAGGA	3184
UGCAUGACGAAGGGUGGAGG	3185
CUGCAUGACGAAGGGUGGAG	3186
ACUGCAUGACGAAGGGUGGA	3187
CACUGCAUGACGAAGGGUGG	3188
CCACUGCAUGACGAAGGGUG	3189
UCCACUGCAUGACGAAGGGU	3190
CUCCACUGCAUGACGAAGGG	3191
CCUCCACUGCAUGACGAAGG	3192
CCCUCCACUGCAUGACGAAG	3193
CUUAGUAGGAAUGGAGGCGG	3194
CCUUAGUAGGAAUGGAGGCG	3195
CCCUUAGUAGGAAUGGAGGC	3196

TABLE 8

	SEQ ID		SEQ ID
Sense Sequence	NO:	Antisense Sequence	NO:
GACCGCCUGCAGAAGGUUG	3197	CAACCUUCUGCAGGCGGUC	3198
ACCGCCUGCAGAAGGUUGA	3199	UCAACCUUCUGCAGGCGGU	3200
CCGCCUGCAGAAGGUUGAC	3201	GUCAACCUUCUGCAGGCGG	3202
CGCCUGCAGAAGGUUGACU	3203	AGUCAACCUUCUGCAGGCG	3204
GCCUGCAGAAGGUUGACUG	3205	CAGUCAACCUUCUGCAGGC	3206
CAGAAGGUUGACUGCGUGG	3207	CCACGCAGUCAACCUUCUG	3208
AGAAGGUUGACUGCGUGGU	3209	ACCACGCAGUCAACCUUCU	3210
GAAGGUUGACUGCGUGGUA	3211	UACCACGCAGUCAACCUUC	3212
AAGGUUGACUGCGUGGUAG	3213	CUACCACGCAGUCAACCUU	3214
AGGUUGACUGCGUGGUAGG	3215	CCUACCACGCAGUCAACCU	3216
GGUUGACUGCGUGGUAGGG	3217	CCCUACCACGCAGUCAACC	3218
CCAGAGCAAGCCGAAGGCA	3219	UGCCUUCGGCUUGCUCUGG	3220
CAGAGCAAGCCGAAGGCAA	3221	UUGCCUUCGGCUUGCUCUG	3222
AGAGCAAGCCGAAGGCAAG	3223	CUUGCCUUCGGCUUGCUCU	3224
GAGCAAGCCGAAGGCAAGC	3225	GCUUGCCUUCGGCUUGCUC	3226
AGCAAGCCGAAGGCAAGCA	3227	UGCUUGCCUUCGGCUUGCU	3228
GCAAGCCGAAGGCAAGCAC	3229	GUGCUUGCCUUCGGCUUGC	3230
CAAGCCGAAGGCAAGCACG	3231	CGUGCUUGCCUUCGGCUUG	3232
AAGCCGAAGGCAAGCACGA	3233	UCGUGCUUGCCUUCGGCUU	3234
AGCCGAAGGCAAGCACGAU	3235	AUCGUGCUUGCCUUCGGCU	3236
GCCGAAGGCAAGCACGAUG	3237	CAUCGUGCUUGCCUUCGGC	3238
AAGGCAAGCACGAUGGCGC	3239	GCGCCAUCGUGCUUGCCUU	3240
AGGCAAGCACGAUGGCGCU	3241	AGCGCCAUCGUGCUUGCCU	3242
AAGCACGAUGGCGCUCACC	3243	GGUGAGCGCCAUCGUGCUU	3244
AGCACGAUGGCGCUCACCA	3245	UGGUGAGCGCCAUCGUGCU	3246
CUGUAGCAGCCGAGCAUCA	3247	UGAUGCUCGGCUGCUACAG	3248
AGCCGAGCAUCAGCCCGAA	3249	UUCGGGCUGAUGCUCGGCU	3250
GUCAGAGUCUCCAGGCUCA	3251	UGAGCCUGGAGACUCUGAC	3252
UCAGAGUCUCCAGGCUCAG	3253	CUGAGCCUGGAGACUCUGA	3254
CAGAGUCUCCAGGCUCAGG	3255	CCUGAGCCUGGAGACUCUG	3256
AGAGUCUCCAGGCUCAGGU	3257	ACCUGAGCCUGGAGACUCU	3258
GAGUCUCCAGGCUCAGGUG	3259	CACCUGAGCCUGGAGACUC	3260
AGUCUCCAGGCUCAGGUGG	3261	CCACCUGAGCCUGGAGACU	3262
GGGUGGCACAGCUGGCAUA	3263	UAUGCCAGCUGUGCCACCC	3264
GUGGCACAGCUGGCAUACG	3265	CGUAUGCCAGCUGUGCCAC	3266
UGGCACAGCUGGCAUACGC	3267	GCGUAUGCCAGCUGUGCCA	3268
CUCCACAGGUGGCGGUAGA	3269	UCUACCGCCACCUGUGGAG	3270
UCCACAGGUGGCGGUAGAC	3271	GUCUACCGCCACCUGUGGA	3272
UGAGCAGCACGCUGGCGUA	3273	UACGCCAGCGUGCUGCUCA	3274
AGCAGCACGCUGGCGUACA	3275	UGUACGCCAGCGUGCUGCU	3276
GCAGCACGCUGGCGUACAU	3277	AUGUACGCCAGCGUGCUGC	3278
CAGCACGCUGGCGUACAUG	3279	CAUGUACGCCAGCGUGCUG	3280
AGCACGCUGGCGUACAUGC	3281	GCAUGUACGCCAGCGUGCU	3282
GCACGCUGGCGUACAUGCU	3283	AGCAUGUACGCCAGCGUGC	3284
CACGCUGGCGUACAUGCUG	3285	CAGCAUGUACGCCAGCGUG	3286
ACGCUGGCGUACAUGCUGA	3287	UCAGCAUGUACGCCAGCGU	3288
CUGGCGUACAUGCUGAGCG	3289	CGCUCAGCAUGUACGCCAG	3290
UGGCGUACAUGCUGAGCGC	3291	GCGCUCAGCAUGUACGCCA	3292
CGCGCACACGUAGUACACC	3293	GGUGUACUACGUGUGCGCG	3294
GCGCACACGUAGUACACCG	3295	CGGUGUACUACGUGUGCGC	3296
CGCACACGUAGUACACCGC	3297	GCGGUGUACUACGUGUGCG	3298
GCACACGUAGUACACCGCC	3299	GGCGGUGUACUACGUGUGC	3300
CACACGUAGUACACCGCCU	3301	AGGCGGUGUACUACGUGUG	3302
ACACGUAGUACACCGCCUU	3303	AAGGCGGUGUACUACGUGU	3304
CACGUAGUACACCGCCUUG	3305	CAAGGCGGUGUACUACGUG	3306
UAGUACACCGCCUUGCAGC	3307	GCUGCAAGGCGGUGUACUA	3308
CCAAGCUCCACACCACGAA	3309	UUCGUGGUGUGGAGCUUGG	3310
CAAGCUCCACACCACGAAG	3311	CUUCGUGGUGUGGAGCUUG	3312
AAGCUCCACACCACGAAGC	3313	GCUUCGUGGUGUGGAGCUU	3314
AGCUCCACACCACGAAGCC	3315	GGCUUCGUGGUGUGGAGCU	3316
CUCCACACCACGAAGCCGU	3317	ACGGCUUCGUGGUGUGGAG	3318
UCCACACCACGAAGCCGUU	3319	AACGGCUUCGUGGUGUGGA	3320
CCACACCACGAAGCCGUUG	3321	CAACGGCUUCGUGGUGUGG	3322
CACACCACGAAGCCGUUGC	3323	GCAACGGCUUCGUGGUGUG	3324
ACACCACGAAGCCGUUGCC	3325	GGCAACGGCUUCGUGGUGU	3326
CACCACGAAGCCGUUGCCA	3327	UGGCAACGGCUUCGUGGUG	3328
ACCACGAAGCCGUUGCCAG	3329	CUGGCAACGGCUUCGUGGU	3330
AGUCCUGACUUCCACGAGG	3417	CCUCGUGGAAGUCAGGACU	3418
CCUGACUUCCACGAGGACC	3419	GGUCCUCGUGGAAGUCAGG	3420
CUGACUUCCACGAGGACCC	3421	GGGUCCUCGUGGAAGUCAG	3422
UGACUUCCACGAGGACCCA	3423	UGGGUCCUCGUGGAAGUCA	3424
GACUUCCACGAGGACCCAG	3425	CUGGGUCCUCGUGGAAGUC	3426
ACUUCCACGAGGACCCAGA	3427	UCUGGGUCCUCGUGGAAGU	3428
CUUCCACGAGGACCCAGAC	3429	GUCUGGGUCCUCGUGGAAG	3430
UUCCACGAGGACCCAGACC	3431	GGUCUGGGUCCUCGUGGAA	3432
CCCUGCUCCCAGUCAGUUG	3433	CAACUGACUGGGAGCAGGG	3434
CCUGCUCCCAGUCAGUUGA	3435	UCAACUGACUGGGAGCAGG	3436
CUGCUCCCAGUCAGUUGAC	3437	GUCAACUGACUGGGAGCAG	3438
UGCUCCCAGUCAGUUGACC	3439	GGUCAACUGACUGGGAGCA	3440
CCCAGUCAGUUGACCUGCC	3441	GGCAGGUCAACUGACUGGG	3442
CCAGUCAGUUGACCUGCCC	3443	GGGCAGGUCAACUGACUGG	3444
GCCUCCUUCCCAGAGCUCA	3445	UGAGCUCUGGGAAGGAGGC	3446
CCUCCUUCCCAGAGCUCAG	3447	CUGAGCUCUGGGAAGGAGG	3448
CUCCUUCCCAGAGCUCAGU	3449	ACUGAGCUCUGGGAAGGAG	3450
UCCUUCCCAGAGCUCAGUG	3451	CACUGAGCUCUGGGAAGGA	3452
CCUUCCCAGAGCUCAGUGG	3453	CCACUGAGCUCUGGGAAGG	3454
UUCCCAGAGCUCAGUGGUA	3455	UACCACUGAGCUCUGGGAA	3456
UCCCAGAGCUCAGUGGUAA	3457	UUACCACUGAGCUCUGGGA	3458
CAGGCUGUCACUAUCUCUA	3459	UAGAGAUAGUGACAGCCUG	3460
AGGCUGUCACUAUCUCUAC	3461	GUAGAGAUAGUGACAGCCU	3462
UCUCUACCACCACUCCUCU	3463	AGAGGAGUGGUGGUAGAGA	3464
CCACCACUCCUCUAGUCUG	3465	CAGACUAGAGGAGUGGUGG	3466
CACCACUCCUCUAGUCUGG	3467	CCAGACUAGAGGAGUGGUG	3468
ACCACUCCUCUAGUCUGGC	3469	GCCAGACUAGAGGAGUGGU	3470
CCACUCCUCUAGUCUGGCC	3471	GGCCAGACUAGAGGAGUGG	3472
CACUCCUCUAGUCUGGCCC	3473	GGGCCAGACUAGAGGAGUG	3474
AUUCUAGCACAUCUGGGCA	3475	UGCCCAGAUGUGCUAGAAU	3476
UUCUAGCACAUCUGGGCAA	3477	UUGCCCAGAUGUGCUAGAA	3478
UCUAGCACAUCUGGGCAAA	3479	UUUGCCCAGAUGUGCUAGA	3480
CUAGCACAUCUGGGCAAAA	3481	UUUUGCCCAGAUGUGCUAG	3482
GGGUGUAAAGGGACGUGCA	3483	UGCACGUCCCUUUACACCC	3484
GGUGUAAAGGGACGUGCAC	3485	GUGCACGUCCCUUUACACC	3486
GUGUAAAGGGACGUGCACA	3487	UGUGCACGUCCCUUUACAC	3488
UGUAAAGGGACGUGCACAG	3489	CUGUGCACGUCCCUUUACA	3490
GUAAAGGGACGUGCACAGA	3491	UCUGUGCACGUCCCUUUAC	3492
UAAAGGGACGUGCACAGAU	3493	AUCUGUGCACGUCCCUUUA	3494
AAAGGGACGUGCACAGAUC	3495	GAUCUGUGCACGUCCCUUU	3496
AAGGGACGUGCACAGAUCU	3497	AGAUCUGUGCACGUCCCUU	3498
AGGGACGUGCACAGAUCUA	3499	UAGAUCUGUGCACGUCCCU	3500
CGUGCACAGAUCUACUUAC	3501	GUAAGUAGAUCUGUGCACG	3502
GUGCACAGAUCUACUUACC	3503	GGUAAGUAGAUCUGUGCAC	3504
UGCACAGAUCUACUUACCA	3505	UGGUAAGUAGAUCUGUGCA	3506
GCACAGAUCUACUUACCAA	3507	UUGGUAAGUAGAUCUGUGC	3508
CACAGAUCUACUUACCAAG	3509	CUUGGUAAGUAGAUCUGUG	3510
ACAGAUCUACUUACCAAGC	3511	GCUUGGUAAGUAGAUCUGU	3512
CAGAUCUACUUACCAAGCU	3513	AGCUUGGUAAGUAGAUCUG	3514
AGAUCUACUUACCAAGCUG	3515	CAGCUUGGUAAGUAGAUCU	3516
AUCUACUUACCAAGCUGGG	3517	CCCAGCUUGGUAAGUAGAU	3518
UCUACUUACCAAGCUGGGA	3519	UCCCAGCUUGGUAAGUAGA	3520
CUUACCAAGCUGGGAGCAA	3521	UUGCUCCCAGCUUGGUAAG	3522
UUACCAAGCUGGGAGCAAG	3523	CUUGCUCCCAGCUUGGUAA	3524
UACCAAGCUGGGAGCAAGC	3525	GCUUGCUCCCAGCUUGGUA	3526
ACCAAGCUGGGAGCAAGCA	3527	UGCUUGCUCCCAGCUUGGU	3528
GCUGGGAGCAAGCAGGAUU	3529	AAUCCUGCUUGCUCCCAGC	3530
CUGGGAGCAAGCAGGAUUG	3531	CAAUCCUGCUUGCUCCCAG	3532
UGGGAGCAAGCAGGAUUGG	3533	CCAAUCCUGCUUGCUCCCA	3534
GGGAGCAAGCAGGAUUGGG	3535	CCCAAUCCUGCUUGCUCCC	3536
AAAGGUUAAGCAGCAGUAG	3537	CUACUGCUGCUUAACCUUU	3538
AAGGUUAAGCAGCAGUAGG	3539	CCUACUGCUGCUUAACCUU	3540
AGGUUAAGCAGCAGUAGGC	3541	GCCUACUGCUGCUUAACCU	3542
GGUGCCUACUCCUGUCCUG	3543	CAGGACAGGAGUAGGCACC	3544
GUGCCUACUCCUGUCCUGU	3545	ACAGGACAGGAGUAGGCAC	3546
UGCCUACUCCUGUCCUGUG	3547	CACAGGACAGGAGUAGGCA	3548
GCCUACUCCUGUCCUGUGC	3549	GCACAGGACAGGAGUAGGC	3550
CCUACUCCUGUCCUGUGCC	3551	GGCACAGGACAGGAGUAGG	3552
CUACUCCUGUCCUGUGCCU	3553	AGGCACAGGACAGGAGUAG	3554
UACUCCUGUCCUGUGCCUA	3555	UAGGCACAGGACAGGAGUA	3556
ACUCCUGUCCUGUGCCUAU	3557	AUAGGCACAGGACAGGAGU	3558
CUCCUGUCCUGUGCCUAUC	3559	GAUAGGCACAGGACAGGAG	3560
UCCUGUCCUGUGCCUAUCA	3561	UGAUAGGCACAGGACAGGA	3562
GUGCCUAUCACAUUUGCAG	3563	CUGCAAAUGUGAUAGGCAC	3564
CUAUCACAUUUGCAGAGGG	3565	CCCUCUGCAAAUGUGAUAG	3566
UAUCACAUUUGCAGAGGGU	3567	ACCCUCUGCAAAUGUGAUA	3568
AUCACAUUUGCAGAGGGUA	3569	UACCCUCUGCAAAUGUGAU	3570
UCACAUUUGCAGAGGGUAA	3571	UUACCCUCUGCAAAUGUGA	3572
CACAUUUGCAGAGGGUAAG	3573	CUUACCCUCUGCAAAUGUG	3574
ACAUUUGCAGAGGGUAAGA	3575	UCUUACCCUCUGCAAAUGU	3576
CUCACCCUGCUCCUUCCCA	3577	UGGGAAGGAGCAGGGUGAG	3578
CACCCUGCUCCUUCCCAUC	3579	GAUGGGAAGGAGCAGGGUG	3580
CCUGCUCCUUCCCAUCACC	3581	GGUGAUGGGAAGGAGCAGG	3582
UGCUCCUUCCCAUCACCAA	3583	UUGGUGAUGGGAAGGAGCA	3584
CAGUAAGAUUCCCUGGUGG	3585	CCACCAGGGAAUCUUACUG	3586
AGUAAGAUUCCCUGGUGGU	3587	ACCACCAGGGAAUCUUACU	3588
GUAAGAUUCCCUGGUGGUG	3589	CACCACCAGGGAAUCUUAC	3590
UAAGAUUCCCUGGUGGUGG	3591	CCACCACCAGGGAAUCUUA	3592
AAGAUUCCCUGGUGGUGGA	3593	UCCACCACCAGGGAAUCUU	3594
UCCCUGGUGGUGGAAGGAA	3595	UUCCUUCCACCACCAGGGA	3596
UCUGCUGAAUCCUGGUCCU	3597	AGGACCAGGAUUCAGCAGA	3598
CUGCUGAAUCCUGGUCCUG	3599	CAGGACCAGGAUUCAGCAG	3600
UGCUGAAUCCUGGUCCUGC	3601	GCAGGACCAGGAUUCAGCA	3602
UGAAUCCUGGUCCUGCUUC	3603	GAAGCAGGACCAGGAUUCA	3604
GAAUCCUGGUCCUGCUUCU	3605	AGAAGCAGGACCAGGAUUC	3606
AAUCCUGGUCCUGCUUCUG	3607	CAGAAGCAGGACCAGGAUU	3608
AUCCUGGUCCUGCUUCUGU	3609	ACAGAAGCAGGACCAGGAU	3610
UCCUGGUCCUGCUUCUGUU	3611	AACAGAAGCAGGACCAGGA	3612
CCUGGUCCUGCUUCUGUUC	3613	GAACAGAAGCAGGACCAGG	3614
CUGGUCCUGCUUCUGUUCU	3615	AGAACAGAAGCAGGACCAG	3616
UUCUGUUCUCAUCCCUCCC	3617	GGGAGGGAUGAGAACAGAA	3618
CUUCUGCAGUGUGUAUGUU	3619	AACAUACACACUGCAGAAG	3620
UUCUGCAGUGUGUAUGUUG	3621	CAACAUACACACUGCAGAA	3622
UCUGCAGUGUGUAUGUUGC	3623	GCAACAUACACACUGCAGA	3624
CUGCAGUGUGUAUGUUGCC	3625	GGCAACAUACACACUGCAG	3626
UGCAGUGUGUAUGUUGCCU	3627	AGGCAACAUACACACUGCA	3628
GCAGUGUGUAUGUUGCCUG	3629	CAGGCAACAUACACACUGC	3630
CAGUGUGUAUGUUGCCUGG	3631	CCAGGCAACAUACACACUG	3632
AGUGUGUAUGUUGCCUGGU	3633	ACCAGGCAACAUACACACU	3634
GUGUGUAUGUUGCCUGGUC	3635	GACCAGGCAACAUACACAC	3636
UGUGUAUGUUGCCUGGUCU	3637	AGACCAGGCAACAUACACA	3638
GUGUAUGUUGCCUGGUCUC	3639	GAGACCAGGCAACAUACAC	3640
UGUAUGUUGCCUGGUCUCU	3641	AGAGACCAGGCAACAUACA	3642
GUAUGUUGCCUGGUCUCUC	3643	GAGAGACCAGGCAACAUAC	3644
UAUGUUGCCUGGUCUCUCU	3645	AGAGAGACCAGGCAACAUA	3646
AUGUUGCCUGGUCUCUCUG	3647	CAGAGAGACCAGGCAACAU	3648
UGUUGCCUGGUCUCUCUGG	3649	CCAGAGAGACCAGGCAACA	3650
GUUGCCUGGUCUCUCUGGC	3651	GCCAGAGAGACCAGGCAAC	3652
UUGCCUGGUCUCUCUGGCC	3653	GGCCAGAGAGACCAGGCAA	3654
CUGGUCUCUCUGGCCUGCA	3655	UGCAGGCCAGAGAGACCAG	3656
CCUGCAGAGGUGACCCAAA	3657	UUUGGGUCACCUCUGCAGG	3658
CUGCCUUAUCCUUGCCUGU	3659	ACAGGCAAGGAUAAGGCAG	3660
UGCCUUAUCCUUGCCUGUU	3661	AACAGGCAAGGAUAAGGCA	3662
GCCUUAUCCUUGCCUGUUU	3663	AAACAGGCAAGGAUAAGGC	3664
AGUCUCCUGGUCCGGCUGA	3665	UCAGCCGGACCAGGAGACU	3666
GUCAAUGACAGCUUUUCCA	3667	UGGAAAAGCUGUCAUUGAC	3668
UGACAGCUUUUCCAUGUAA	3669	UUACAUGGAAAAGCUGUCA	3670
GACAGCUUUUCCAUGUAAG	3671	CUUACAUGGAAAAGCUGUC	3672
ACAGCUUUUCCAUGUAAGG	3673	CCUUACAUGGAAAAGCUGU	3674
CAGCUUUUCCAUGUAAGGC	3675	GCCUUACAUGGAAAAGCUG	3676
AGCUUUUCCAUGUAAGGCA	3677	UGCCUUACAUGGAAAAGCU	3678
UGUAAGGCAUGGUGCUAGG	3679	CCUAGCACCAUGCCUUACA	3680
GUAAGGCAUGGUGCUAGGU	3681	ACCUAGCACCAUGCCUUAC	3682
UAAGGCAUGGUGCUAGGUU	3683	AACCUAGCACCAUGCCUUA	3684
GCAUGGUGCUAGGUUCCAG	3685	CUGGAACCUAGCACCAUGC	3686
CAUGGUGCUAGGUUCCAGG	3687	CCUGGAACCUAGCACCAUG	3688
AUGGUGCUAGGUUCCAGGA	3689	UCCUGGAACCUAGCACCAU	3690
UGGUGCUAGGUUCCAGGAG	3691	CUCCUGGAACCUAGCACCA	3692
GGUGCUAGGUUCCAGGAGG	3693	CCUCCUGGAACCUAGCACC	3694
GUGCUAGGUUCCAGGAGGA	3695	UCCUCCUGGAACCUAGCAC	3696
UGCAUGGAGGCAUAAUGGU	3697	ACCAUUAUGCCUCCAUGCA	3698
GCAUGGAGGCAUAAUGGUU	3699	AACCAUUAUGCCUCCAUGC	3700
CAUGGAGGCAUAAUGGUUA	3701	UAACCAUUAUGCCUCCAUG	3702
AUGGAGGCAUAAUGGUUAG	3703	CUAACCAUUAUGCCUCCAU	3704
UGGAGGCAUAAUGGUUAGG	3705	CCUAACCAUUAUGCCUCCA	3706
GGAGGCAUAAUGGUUAGGG	3707	CCCUAACCAUUAUGCCUCC	3708
GAGGCAUAAUGGUUAGGGA	3709	UCCCUAACCAUUAUGCCUC	3710
CAUAAUGGUUAGGGAGUCA	3711	UGACUCCCUAACCAUUAUG	3712
AUAAUGGUUAGGGAGUCAU	3713	AUGACUCCCUAACCAUUAU	3714
UAAUGGUUAGGGAGUCAUG	3715	CAUGACUCCCUAACCAUUA	3716
GGUUAGGGAGUCAUGACAC	3717	GUGUCAUGACUCCCUAACC	3718
CAUUACCAGGCUGCACCAG	3719	CUGGUGCAGCCUGGUAAUG	3720
AUUACCAGGCUGCACCAGG	3721	CCUGGUGCAGCCUGGUAAU	3722
UACCAGGCUGCACCAGGAU	3723	AUCCUGGUGCAGCCUGGUA	3724
ACCAGGCUGCACCAGGAUA	3725	UAUCCUGGUGCAGCCUGGU	3726
CCAGGCUGCACCAGGAUAC	3727	GUAUCCUGGUGCAGCCUGG	3728
AAAGGAUGAGUAGGGACAU	3729	AUGUCCCUACUCAUCCUUU	3730
AAGGAUGAGUAGGGACAUA	3731	UAUGUCCCUACUCAUCCUU	3732
AGGAUGAGUAGGGACAUAC	3733	GUAUGUCCCUACUCAUCCU	3734
GUAGGGACAUACUAAGAAG	3735	CUUCUUAGUAUGUCCCUAC	3736
GGACAUACUAAGAAGCAGC	3737	GCUGCUUCUUAGUAUGUCC	3738
AUACUAAGAAGCAGCCCUC	3739	GAGGGCUGCUUCUUAGUAU	3740
UACUAAGAAGCAGCCCUCU	3741	AGAGGGCUGCUUCUUAGUA	3742
ACUAAGAAGCAGCCCUCUC	3743	GAGAGGGCUGCUUCUUAGU	3744
AGAAGCAGCCCUCUCCUCU	3745	AGAGGAGAGGGCUGCUUCU	3746
GAAGCAGCCCUCUCCUCUU	3747	AAGAGGAGAGGGCUGCUUC	3748
CAGCCCUCUCCUCUUGGAA	3749	UUCCAAGAGGAGAGGGCUG	3750
GCCUGGCAGAUGGAUAGAG	3751	CUCUAUCCAUCUGCCAGGC	3752
CCUGGCAGAUGGAUAGAGC	3753	GCUCUAUCCAUCUGCCAGG	3754
CUGGCAGAUGGAUAGAGCU	3755	AGCUCUAUCCAUCUGCCAG	3756
UGGCAGAUGGAUAGAGCUG	3757	CAGCUCUAUCCAUCUGCCA	3758
GGCAGAUGGAUAGAGCUGG	3759	CCAGCUCUAUCCAUCUGCC	3760
GCAGAUGGAUAGAGCUGGG	3761	CCCAGCUCUAUCCAUCUGC	3762
AAAGGCCUCUGCUCAAGUA	3763	UACUUGAGCAGAGGCCUUU	3764
AAGGCCUCUGCUCAAGUAA	3765	UUACUUGAGCAGAGGCCUU	3766
AGGCCUCUGCUCAAGUAAC	3767	GUUACUUGAGCAGAGGCCU	3768
CAGGAGCACUGUCUUAGUU	3769	AACUAAGACAGUGCUCCUG	3770
AGGAGCACUGUCUUAGUUU	3771	AAACUAAGACAGUGCUCCU	3772
GGAGCACUGUCUUAGUUUG	3773	CAAACUAAGACAGUGCUCC	3774
GAGCACUGUCUUAGUUUGG	3775	CCAAACUAAGACAGUGCUC	3776
AGCACUGUCUUAGUUUGGG	3777	CCCAAACUAAGACAGUGCU	3778
GUUCUUCCAAAGCAGAGCU	3779	AGCUCUGCUUUGGAAGAAC	3780
AGCAGAGCUUGAGCUAAGG	3781	CCUUAGCUCAAGCUCUGCU	3782
GCAGAGCUUGAGCUAAGGG	3783	CCCUUAGCUCAAGCUCUGC	3784
CAGAGCUUGAGCUAAGGGC	3785	GCCCUUAGCUCAAGCUCUG	3786
GCUUGAGCUAAGGGCUUGG	3787	CCAAGCCCUUAGCUCAAGC	3788
UUGAGCUAAGGGCUUGGGU	3789	ACCCAAGCCCUUAGCUCAA	3790
UGAGCUAAGGGCUUGGGUA	3791	UACCCAAGCCCUUAGCUCA	3792
GAGCUAAGGGCUUGGGUAC	3793	GUACCCAAGCCCUUAGCUC	3794
AGCUAAGGGCUUGGGUACA	3795	UGUACCCAAGCCCUUAGCU	3796
GCUAAGGGCUUGGGUACAG	3797	CUGUACCCAAGCCCUUAGC	3798
AGGGCUUGGGUACAGGUGA	3799	UCACCUGUACCCAAGCCCU	3800
GGGCUUGGGUACAGGUGAU	3801	AUCACCUGUACCCAAGCCC	3802
GGCUUGGGUACAGGUGAUC	3803	GAUCACCUGUACCCAAGCC	3804
GCUUGGGUACAGGUGAUCC	3805	GGAUCACCUGUACCCAAGC	3806
AGGUGAUCCUGUAUUCUUG	3807	CAAGAAUACAGGAUCACCU	3808
GGUGAUCCUGUAUUCUUGA	3809	UCAAGAAUACAGGAUCACC	3810
GUGAUCCUGUAUUCUUGAG	3811	CUCAAGAAUACAGGAUCAC	3812
UGAUCCUGUAUUCUUGAGC	3813	GCUCAAGAAUACAGGAUCA	3814
UCCUGUAUUCUUGAGCUAA	3815	UUAGCUCAAGAAUACAGGA	3816
CCUGUAUUCUUGAGCUAAG	3817	CUUAGCUCAAGAAUACAGG	3818
UGUAUUCUUGAGCUAAGGG	3819	CCCUUAGCUCAAGAAUACA	3820
GUAUUCUUGAGCUAAGGGC	3821	GCCCUUAGCUCAAGAAUAC	3822
UCUUGAGCUAAGGGCUUGG	3823	CCAAGCCCUUAGCUCAAGA	3824
UUGAGCUAAGGGCUUGGGU	3825	ACCCAAGCCCUUAGCUCAA	3826
UGAGCUAAGGGCUUGGGUA	3827	UACCCAAGCCCUUAGCUCA	3828
GAGCUAAGGGCUUGGGUAC	3829	GUACCCAAGCCCUUAGCUC	3830
AGCUAAGGGCUUGGGUACA	3831	UGUACCCAAGCCCUUAGCU	3832
GCUAAGGGCUUGGGUACAG	3833	CUGUACCCAAGCCCUUAGC	3834
AGGGCUUGGGUACAGGUGA	3835	UCACCUGUACCCAAGCCCU	3836
GGGCUUGGGUACAGGUGAU	3837	AUCACCUGUACCCAAGCCC	3838
GGCUUGGGUACAGGUGAUC	3839	GAUCACCUGUACCCAAGCC	3840
GCUUGGGUACAGGUGAUCC	3841	GGAUCACCUGUACCCAAGC	3842
AGGUGAUCCUGUAUUUGGG	3843	CCCAAAUACAGGAUCACCU	3844
GGUGAUCCUGUAUUUGGGA	3845	UCCCAAAUACAGGAUCACC	3846
AUCCUGUAUUUGGGAGGUU	3847	AACCUCCCAAAUACAGGAU	3848
UCCUGUAUUUGGGAGGUUA	3849	UAACCUCCCAAAUACAGGA	3850
CCUGUAUUUGGGAGGUUAA	3851	UUAACCUCCCAAAUACAGG	3852
CUGUAUUUGGGAGGUUAAC	3853	GUUAACCUCCCAAAUACAG	3854
UGUAUUUGGGAGGUUAACU	3855	AGUUAACCUCCCAAAUACA	3856
GUAUUUGGGAGGUUAACUC	3857	GAGUUAACCUCCCAAAUAC	3858
UAUUUGGGAGGUUAACUCA	3859	UGAGUUAACCUCCCAAAUA	3860
GGAGGUUAACUCAGGAAGU	3861	ACUUCCUGAGUUAACCUCC	3862
GAGGUUAACUCAGGAAGUG	3863	CACUUCCUGAGUUAACCUC	3864
AGGUUAACUCAGGAAGUGA	3865	UCACUUCCUGAGUUAACCU	3866
UCAGGAAGUGAGGGCAUAA	3867	UUAUGCCCUCACUUCCUGA	3868
CAGGAAGUGAGGGCAUAAG	3869	CUUAUGCCCUCACUUCCUG	3870
AGGAAGUGAGGGCAUAAGG	3871	CCUUAUGCCCUCACUUCCU	3872
GGAAGUGAGGGCAUAAGGU	3873	ACCUUAUGCCCUCACUUCC	3874
GAAGUGAGGGCAUAAGGUA	3875	UACCUUAUGCCCUCACUUC	3876
AAGUGAGGGCAUAAGGUAA	3877	UUACCUUAUGCCCUCACUU	3878
AGUGAGGGCAUAAGGUAAA	3879	UUUACCUUAUGCCCUCACU	3880
AAAGCCAUUAAGAGUAUGU	3881	ACAUACUCUUAAUGGCUUU	3882
AAGCCAUUAAGAGUAUGUU	3883	AACAUACUCUUAAUGGCUU	3884
AGCCAUUAAGAGUAUGUUA	3885	UAACAUACUCUUAAUGGCU	3886
UAAGAGUAUGUUAAGUCCC	3887	GGGACUUAACAUACUCUUA	3888
AAGAGUAUGUUAAGUCCCU	3889	AGGGACUUAACAUACUCUU	3890
AGAGUAUGUUAAGUCCCUU	3891	AAGGGACUUAACAUACUCU	3892
GAGUAUGUUAAGUCCCUUC	3893	GAAGGGACUUAACAUACUC	3894
AGUAUGUUAAGUCCCUUCA	3895	UGAAGGGACUUAACAUACU	3896
GUAUGUUAAGUCCCUUCAG	3897	CUGAAGGGACUUAACAUAC	3898
UAUGUUAAGUCCCUUCAGU	3899	ACUGAAGGGACUUAACAUA	3900
AUGUUAAGUCCCUUCAGUA	3901	UACUGAAGGGACUUAACAU	3902
UGUUAAGUCCCUUCAGUAG	3903	CUACUGAAGGGACUUAACA	3904
GUUAAGUCCCUUCAGUAGG	3905	CCUACUGAAGGGACUUAAC	3906
UUAAGUCCCUUCAGUAGGC	3907	GCCUACUGAAGGGACUUAA	3908
UAAGUCCCUUCAGUAGGCC	3909	GGCCUACUGAAGGGACUUA	3910
AAGUCCCUUCAGUAGGCCU	3911	AGGCCUACUGAAGGGACUU	3912
AGUCCCUUCAGUAGGCCUU	3913	AAGGCCUACUGAAGGGACU	3914
GUCCCUUCAGUAGGCCUUG	3915	CAAGGCCUACUGAAGGGAC	3916
UCCCUUCAGUAGGCCUUGG	3917	CCAAGGCCUACUGAAGGGA	3918
CCCUUCAGUAGGCCUUGGG	3919	CCCAAGGCCUACUGAAGGG	3920
CCUUCAGUAGGCCUUGGGA	3921	UCCCAAGGCCUACUGAAGG	3922
CUUCAGUAGGCCUUGGGAA	3923	UUCCCAAGGCCUACUGAAG	3924
AAAAGUAUAGAUUGCCCAA	3925	UUGGGCAAUCUAUACUUUU	3926
AAAGUAUAGAUUGCCCAAG	3927	CUUGGGCAAUCUAUACUUU	3928
AAGUAUAGAUUGCCCAAGA	3929	UCUUGGGCAAUCUAUACUU	3930
AAAGACUGGCAGGGUGAUC	3931	GAUCACCCUGCCAGUCUUU	3932
AAGACUGGCAGGGUGAUCA	3933	UGAUCACCCUGCCAGUCUU	3934
CUGGCAGGGUGAUCAGUCC	3935	GGACUGAUCACCCUGCCAG	3936
GAAUGUACUUAAUGAGUGG	3937	CCACUCAUUAAGUACAUUC	3938
AAUGUACUUAAUGAGUGGG	3939	CCCACUCAUUAAGUACAUU	3940
UGUACUUAAUGAGUGGGCU	3941	AGCCCACUCAUUAAGUACA	3942
GUACUUAAUGAGUGGGCUA	3943	UAGCCCACUCAUUAAGUAC	3944
UACUUAAUGAGUGGGCUAC	3945	GUAGCCCACUCAUUAAGUA	3946
CUUAAUGAGUGGGCUACAG	3947	CUGUAGCCCACUCAUUAAG	3948
UAAUGAGUGGGCUACAGCG	3949	CGCUGUAGCCCACUCAUUA	3950
AAUGAGUGGGCUACAGCGU	3951	ACGCUGUAGCCCACUCAUU	3952
AUGAGUGGGCUACAGCGUA	3953	UACGCUGUAGCCCACUCAU	3954
UGAGUGGGCUACAGCGUAU	3955	AUACGCUGUAGCCCACUCA	3956
GAGUGGGCUACAGCGUAUC	3957	GAUACGCUGUAGCCCACUC	3958
AGUGGGCUACAGCGUAUCC	3959	GGAUACGCUGUAGCCCACU	3960
GUGGGCUACAGCGUAUCCU	3961	AGGAUACGCUGUAGCCCAC	3962
UGGGCUACAGCGUAUCCUC	3963	GAGGAUACGCUGUAGCCCA	3964
AGAGUUGUUCUACCUGGGU	3965	ACCCAGGUAGAACAACUCU	3966
GAGUUGUUCUACCUGGGUA	3967	UACCCAGGUAGAACAACUC	3968
AGUUGUUCUACCUGGGUAU	3969	AUACCCAGGUAGAACAACU	3970
GUUGUUCUACCUGGGUAUA	3971	UAUACCCAGGUAGAACAAC	3972
UUGUUCUACCUGGGUAUAU	3973	AUAUACCCAGGUAGAACAA	3974
UGUUCUACCUGGGUAUAUC	3975	GAUAUACCCAGGUAGAACA	3976
GUUCUACCUGGGUAUAUCC	3977	GGAUAUACCCAGGUAGAAC	3978
UACCUGGGUAUAUCCAAAA	3979	UUUUGGAUAUACCCAGGUA	3980
AGGGUAUGGAGUUUACGAG	3981	CUCGUAAACUCCAUACCCU	3982
GGGUAUGGAGUUUACGAGG	3983	CCUCGUAAACUCCAUACCC	3984
GGUAUGGAGUUUACGAGGG	3985	CCCUCGUAAACUCCAUACC	3986
GUAUGGAGUUUACGAGGGU	3987	ACCCUCGUAAACUCCAUAC	3988
UAUGGAGUUUACGAGGGUU	3989	AACCCUCGUAAACUCCAUA	3990
AUGGAGUUUACGAGGGUUC	3991	GAACCCUCGUAAACUCCAU	3992
UGGAGUUUACGAGGGUUCA	3993	UGAACCCUCGUAAACUCCA	3994
GGAGUUUACGAGGGUUCAA	3995	UUGAACCCUCGUAAACUCC	3996
GAGUUUACGAGGGUUCAAG	3997	CUUGAACCCUCGUAAACUC	3998
AGUUUACGAGGGUUCAAGG	3999	CCUUGAACCCUCGUAAACU	4000
GUUUACGAGGGUUCAAGGU	4001	ACCUUGAACCCUCGUAAAC	4002
UUUACGAGGGUUCAAGGUA	4003	UACCUUGAACCCUCGUAAA	4004
CGAGGGUUCAAGGUAUUUG	4005	CAAAUACCUUGAACCCUCG	4006
GAGGGUUCAAGGUAUUUGG	4007	CCAAAUACCUUGAACCCUC	4008
AGGGUUCAAGGUAUUUGGU	4009	ACCAAAUACCUUGAACCCU	4010
GGGUUCAAGGUAUUUGGUU	4011	AACCAAAUACCUUGAACCC	4012
GGUUCAAGGUAUUUGGUUC	4013	GAACCAAAUACCUUGAACC	4014
GUUCAAGGUAUUUGGUUCA	4015	UGAACCAAAUACCUUGAAC	4016
UUCAAGGUAUUUGGUUCAG	4017	CUGAACCAAAUACCUUGAA	4018
UCAAGGUAUUUGGUUCAGG	4019	CCUGAACCAAAUACCUUGA	4020
CAACUGGCCAGGUCACAGG	4021	CCUGUGACCUGGCCAGUUG	4022
GCCAGGUCACAGGGCAAUC	4023	GAUUGCCCUGUGACCUGGC	4024
CCAGGUCACAGGGCAAUCA	4025	UGAUUGCCCUGUGACCUGG	4026
AGGUCACAGGGCAAUCAAG	4027	CUUGAUUGCCCUGUGACCU	4028
GGUCACAGGGCAAUCAAGU	4029	ACUUGAUUGCCCUGUGACC	4030
GUCACAGGGCAAUCAAGUU	4031	AACUUGAUUGCCCUGUGAC	4032
UCACAGGGCAAUCAAGUUA	4033	UAACUUGAUUGCCCUGUGA	4034
CACAGGGCAAUCAAGUUAC	4035	GUAACUUGAUUGCCCUGUG	4036
ACAGGGCAAUCAAGUUACU	4037	AGUAACUUGAUUGCCCUGU	4038
CAGGGCAAUCAAGUUACUC	4039	GAGUAACUUGAUUGCCCUG	4040
AGGGCAAUCAAGUUACUCU	4041	AGAGUAACUUGAUUGCCCU	4042
CAAUCAAGUUACUCUGUGU	4043	ACACAGAGUAACUUGAUUG	4044
AAUCAAGUUACUCUGUGUU	4045	AACACAGAGUAACUUGAUU	4046
AUCAAGUUACUCUGUGUUU	4047	AAACACAGAGUAACUUGAU	4048
ACUCUGUGUUUCUUUGUCA	4049	UGACAAAGAAACACAGAGU	4050
UCUGUGUUUCUUUGUCAGG	4051	CCUGACAAAGAAACACAGA	4052
UGUUUCUUUGUCAGGACAC	4053	GUGUCCUGACAAAGAAACA	4054
AAAGCAGGGAUUGUGUUCA	4055	UGAACACAAUCCCUGCUUU	4056
AAGCAGGGAUUGUGUUCAU	4057	AUGAACACAAUCCCUGCUU	4058
AGCAGGGAUUGUGUUCAUU	4059	AAUGAACACAAUCCCUGCU	4060
GCAGGGAUUGUGUUCAUUU	4061	AAAUGAACACAAUCCCUGC	4062
CAGGGAUUGUGUUCAUUUG	4063	CAAAUGAACACAAUCCCUG	4064
AGGGAUUGUGUUCAUUUGA	4065	UCAAAUGAACACAAUCCCU	4066
GUGUUCAUUUGAGGGUUUC	4067	GAAACCCUCAAAUGAACAC	4068
UGUUCAUUUGAGGGUUUCA	4069	UGAAACCCUCAAAUGAACA	4070
GUUCAUUUGAGGGUUUCAC	4071	GUGAAACCCUCAAAUGAAC	4072
UUCAUUUGAGGGUUUCACU	4073	AGUGAAACCCUCAAAUGAA	4074
UCAUUUGAGGGUUUCACUG	4075	CAGUGAAACCCUCAAAUGA	4076
CAUUUGAGGGUUUCACUGU	4077	ACAGUGAAACCCUCAAAUG	4078
AGUCUCAGCUUCCAUGCAA	4079	UUGCAUGGAAGCUGAGACU	4080
UCUCAGCUUCCAUGCAACU	4081	AGUUGCAUGGAAGCUGAGA	4082
CUCAGCUUCCAUGCAACUG	4083	CAGUUGCAUGGAAGCUGAG	4084
UCAGCUUCCAUGCAACUGU	4085	ACAGUUGCAUGGAAGCUGA	4086
CAGCUUCCAUGCAACUGUC	4087	GACAGUUGCAUGGAAGCUG	4088
AGCUUCCAUGCAACUGUCC	4089	GGACAGUUGCAUGGAAGCU	4090
GCUUCCAUGCAACUGUCCA	4091	UGGACAGUUGCAUGGAAGC	4092
CUUCCAUGCAACUGUCCAU	4093	AUGGACAGUUGCAUGGAAG	4094
UUCCAUGCAACUGUCCAUC	4095	GAUGGACAGUUGCAUGGAA	4096
CCAUGCAACUGUCCAUCAC	4097	GUGAUGGACAGUUGCAUGG	4098
CAUGCAACUGUCCAUCACG	4099	CGUGAUGGACAGUUGCAUG	4100
AUGCAACUGUCCAUCACGG	4101	CCGUGAUGGACAGUUGCAU	4102
UGCAACUGUCCAUCACGGC	4103	GCCGUGAUGGACAGUUGCA	4104
GCAACUGUCCAUCACGGCU	4105	AGCCGUGAUGGACAGUUGC	4106
CAACUGUCCAUCACGGCUG	4107	CAGCCGUGAUGGACAGUUG	4108
AACUGUCCAUCACGGCUGC	4109	GCAGCCGUGAUGGACAGUU	4110
ACUGUCCAUCACGGCUGCA	4111	UGCAGCCGUGAUGGACAGU	4112
CUGUCCAUCACGGCUGCAA	4113	UUGCAGCCGUGAUGGACAG	4114
UGUCCAUCACGGCUGCAAC	4115	GUUGCAGCCGUGAUGGACA	4116
GUCCAUCACGGCUGCAACU	4117	AGUUGCAGCCGUGAUGGAC	4118
UCCAUCACGGCUGCAACUG	4119	CAGUUGCAGCCGUGAUGGA	4120
CCAUCACGGCUGCAACUGA	4121	UCAGUUGCAGCCGUGAUGG	4122
CAUCACGGCUGCAACUGAA	4123	UUCAGUUGCAGCCGUGAUG	4124
ACAGCGCACCAGAAGCUAA	4125	UUAGCUUCUGGUGCGCUGU	4126
CAGCGCACCAGAAGCUAAA	4127	UUUAGCUUCUGGUGCGCUG	4128
AGCGCACCAGAAGCUAAAG	4129	CUUUAGCUUCUGGUGCGCU	4130
GCGCACCAGAAGCUAAAGU	4131	ACUUUAGCUUCUGGUGCGC	4132
CGCACCAGAAGCUAAAGUC	4133	GACUUUAGCUUCUGGUGCG	4134
GCACCAGAAGCUAAAGUCU	4135	AGACUUUAGCUUCUGGUGC	4136
CACCAGAAGCUAAAGUCUU	4137	AAGACUUUAGCUUCUGGUG	4138
ACCAGAAGCUAAAGUCUUG	4139	CAAGACUUUAGCUUCUGGU	4140
CCAGAAGCUAAAGUCUUGA	4141	UCAAGACUUUAGCUUCUGG	4142
CAGAAGCUAAAGUCUUGAU	4143	AUCAAGACUUUAGCUUCUG	4144
AGAAGCUAAAGUCUUGAUG	4145	CAUCAAGACUUUAGCUUCU	4146
GAAGCUAAAGUCUUGAUGC	4147	GCAUCAAGACUUUAGCUUC	4148
AAGCUAAAGUCUUGAUGCC	4149	GGCAUCAAGACUUUAGCUU	4150
AGCUAAAGUCUUGAUGCCA	4151	UGGCAUCAAGACUUUAGCU	4152
CCCAUUCACAUCUCUGUCA	4153	UGACAGAGAUGUGAAUGGG	4154
UUCACAUCUCUGUCACGUC	4155	GACGUGACAGAGAUGUGAA	4156
UCACAUCUCUGUCACGUCC	4157	GGACGUGACAGAGAUGUGA	4158
CACAUCUCUGUCACGUCCA	4159	UGGACGUGACAGAGAUGUG	4160
UCUCUGUCACGUCCACUAA	4161	UUAGUGGACGUGACAGAGA	4162
CUCUGUCACGUCCACUAAU	4163	AUUAGUGGACGUGACAGAG	4164
UCUGUCACGUCCACUAAUC	4165	GAUUAGUGGACGUGACAGA	4166
CUGUCACGUCCACUAAUCG	4167	CGAUUAGUGGACGUGACAG	4168
UGUCACGUCCACUAAUCGG	4169	CCGAUUAGUGGACGUGACA	4170
GUCACGUCCACUAAUCGGC	4171	GCCGAUUAGUGGACGUGAC	4172
UCACGUCCACUAAUCGGCA	4173	UGCCGAUUAGUGGACGUGA	4174
CACGUCCACUAAUCGGCAA	4175	UUGCCGAUUAGUGGACGUG	4176
ACGUCCACUAAUCGGCAAA	4177	UUUGCCGAUUAGUGGACGU	4178
CGUCCACUAAUCGGCAAAA	4179	UUUUGCCGAUUAGUGGACG	4180
GUCCACUAAUCGGCAAAAG	4181	CUUUUGCCGAUUAGUGGAC	4182
UCCACUAAUCGGCAAAAGG	4183	CCUUUUGCCGAUUAGUGGA	4184
CCACUAAUCGGCAAAAGGA	4185	UCCUUUUGCCGAUUAGUGG	4186
CACUAAUCGGCAAAAGGAG	4187	CUCCUUUUGCCGAUUAGUG	4188
AGAAGAUGACCUAAGUGUG	4189	CACACUUAGGUCAUCUUCU	4190
GAAGAUGACCUAAGUGUGA	4191	UCACACUUAGGUCAUCUUC	4192
AAGAUGACCUAAGUGUGAC	4193	GUCACACUUAGGUCAUCUU	4194
AGAUGACCUAAGUGUGACU	4195	AGUCACACUUAGGUCAUCU	4196
GAUGACCUAAGUGUGACUG	4197	CAGUCACACUUAGGUCAUC	4198
AUGACCUAAGUGUGACUGC	4199	GCAGUCACACUUAGGUCAU	4200
UGACCUAAGUGUGACUGCA	4201	UGCAGUCACACUUAGGUCA	4202
AAAAUGAAGCCAGAGCAGU	4203	ACUGCUCUGGCUUCAUUUU	4204
UCCGACCAAGGAGGAAGGA	4205	UCCUUCCUCCUUGGUCGGA	4206
CCGACCAAGGAGGAAGGAA	4207	UUCCUUCCUCCUUGGUCGG	4208
AGAGCAGGUAAGCAGGAAG	4209	CUUCCUGCUUACCUGCUCU	4210
GAGCAGGUAAGCAGGAAGG	4211	CCUUCCUGCUUACCUGCUC	4212
AGGUAAGCAGGAAGGCCAG	4213	CUGGCCUUCCUGCUUACCU	4214
AGCAGGAAGGCCAGUGUCC	4215	GGACACUGGCCUUCCUGCU	4216
CAGGAAGGCCAGUGUCCCA	4217	UGGGACACUGGCCUUCCUG	4218
UCCCAGACAGGACCCUAAU	4219	AUUAGGGUCCUGUCUGGGA	4220
CCCAGACAGGACCCUAAUG	4221	CAUUAGGGUCCUGUCUGGG	4222
CCAGACAGGACCCUAAUGA	4223	UCAUUAGGGUCCUGUCUGG	4224
CAGACAGGACCCUAAUGAU	4225	AUCAUUAGGGUCCUGUCUG	4226
AGACAGGACCCUAAUGAUC	4227	GAUCAUUAGGGUCCUGUCU	4228
GACAGGACCCUAAUGAUCC	4229	GGAUCAUUAGGGUCCUGUC	4230
GGACCCUAAUGAUCCUGAA	4231	UUCAGGAUCAUUAGGGUCC	4232
CCUAAUGAUCCUGAAUCCA	4233	UGGAUUCAGGAUCAUUAGG	4234
CUAAUGAUCCUGAAUCCAU	4235	AUGGAUUCAGGAUCAUUAG	4236
UGAUCCUGAAUCCAUGUAU	4237	AUACAUGGAUUCAGGAUCA	4238
GAUCCUGAAUCCAUGUAUC	4239	GAUACAUGGAUUCAGGAUC	4240
AUCCUGAAUCCAUGUAUCA	4241	UGAUACAUGGAUUCAGGAU	4242
UCCAUGUAUCAGGAUCCAU	4243	AUGGAUCCUGAUACAUGGA	4244
CCAUGUAUCAGGAUCCAUC	4245	GAUGGAUCCUGAUACAUGG	4246
CAUGUAUCAGGAUCCAUCC	4247	GGAUGGAUCCUGAUACAUG	4248
UCACCUCUCAUUUUCCAAA	4249	UUUGGAAAAUGAGAGGUGA	4250
UCCAAAGCCCUGCCAUGCU	4251	AGCAUGGCAGGGCUUUGGA	4252
CCAAAGCCCUGCCAUGCUG	4253	CAGCAUGGCAGGGCUUUGG	4254
CAUGCUGCCAUCCCACUUC	4255	GAAGUGGGAUGGCAGCAUG	4256
AUGCUGCCAUCCCACUUCC	4257	GGAAGUGGGAUGGCAGCAU	4258
UGCUGCCAUCCCACUUCCC	4259	GGGAAGUGGGAUGGCAGCA	4260
CGGGUUCCCUUUUCCUAAA	4261	UUUAGGAAAAGGGAACCCG	4262
AGCUGCAGCUUAUGGCUUC	4263	GAAGCCAUAAGCUGCAGCU	4264
GCUGCAGCUUAUGGCUUCU	4265	AGAAGCCAUAAGCUGCAGC	4266
CUGCAGCUUAUGGCUUCUC	4267	GAGAAGCCAUAAGCUGCAG	4268
UGCAGCUUAUGGCUUCUCC	4269	GGAGAAGCCAUAAGCUGCA	4270
GCAGCUUAUGGCUUCUCCA	4271	UGGAGAAGCCAUAAGCUGC	4272
CAGCUUAUGGCUUCUCCAG	4273	CUGGAGAAGCCAUAAGCUG	4274
AGCUUAUGGCUUCUCCAGU	4275	ACUGGAGAAGCCAUAAGCU	4276
GCUUAUGGCUUCUCCAGUA	4277	UACUGGAGAAGCCAUAAGC	4278
CUUAUGGCUUCUCCAGUAG	4279	CUACUGGAGAAGCCAUAAG	4280
UUAUGGCUUCUCCAGUAGG	4281	CCUACUGGAGAAGCCAUAA	4282
UAUGGCUUCUCCAGUAGGU	4283	ACCUACUGGAGAAGCCAUA	4284
AUGGCUUCUCCAGUAGGUG	4285	CACCUACUGGAGAAGCCAU	4286
UGGCUUCUCCAGUAGGUGG	4287	CCACCUACUGGAGAAGCCA	4288
GGCUUCUCCAGUAGGUGGC	4289	GCCACCUACUGGAGAAGCC	4290
GCUUCUCCAGUAGGUGGCA	4291	UGCCACCUACUGGAGAAGC	4292
CUUCUCCAGUAGGUGGCAG	4293	CUGCCACCUACUGGAGAAG	4294
UUCUCCAGUAGGUGGCAGC	4295	GCUGCCACCUACUGGAGAA	4296
UCUCCAGUAGGUGGCAGCA	4297	UGCUGCCACCUACUGGAGA	4298
CUCCAGUAGGUGGCAGCAC	4299	GUGCUGCCACCUACUGGAG	4300
ACACCAGAAGUCACAUUUC	4301	GAAAUGUGACUUCUGGUGU	4302
GAAGUCACAUUUCAUCCUU	4303	AAGGAUGAAAUGUGACUUC	4304
AAGUCACAUUUCAUCCUUU	4305	AAAGGAUGAAAUGUGACUU	4306
AGUCACAUUUCAUCCUUUU	4307	AAAAGGAUGAAAUGUGACU	4308
UUUCAUCCUUUUACAUGGU	4309	ACCAUGUAAAAGGAUGAAA	4310
UUCAUCCUUUUACAUGGUU	4311	AACCAUGUAAAAGGAUGAA	4312
UCAUCCUUUUACAUGGUUC	4313	GAACCAUGUAAAAGGAUGA	4314
CAUCCUUUUACAUGGUUCC	4315	GGAACCAUGUAAAAGGAUG	4316
UGGUUCCCAUCUACCCUCA	4317	UGAGGGUAGAUGGGAACCA	4318
GGUUCCCAUCUACCCUCAC	4319	GUGAGGGUAGAUGGGAACC	4320
GUUCCCAUCUACCCUCACA	4321	UGUGAGGGUAGAUGGGAAC	4322
GGCAAUUCUUCCUCCAGGA	4323	UCCUGGAGGAAGAAUUGCC	4324
GCAAUUCUUCCUCCAGGAC	4325	GUCCUGGAGGAAGAAUUGC	4326
CAAUUCUUCCUCCAGGACC	4327	GGUCCUGGAGGAAGAAUUG	4328
AAUUCUUCCUCCAGGACCC	4329	GGGUCCUGGAGGAAGAAUU	4330
CCCUUGGACUUUGCCCUUC	4331	GAAGGGCAAAGUCCAAGGG	4332
CCUUGGACUUUGCCCUUCU	4333	AGAAGGGCAAAGUCCAAGG	4334
CUUGGACUUUGCCCUUCUU	4335	AAGAAGGGCAAAGUCCAAG	4336
UUGGACUUUGCCCUUCUUA	4337	UAAGAAGGGCAAAGUCCAA	4338
UGGACUUUGCCCUUCUUAC	4339	GUAAGAAGGGCAAAGUCCA	4340
GGACUUUGCCCUUCUUACU	4341	AGUAAGAAGGGCAAAGUCC	4342
UUUGCCCUUCUUACUGGCC	4343	GGCCAGUAAGAAGGGCAAA	4344
UUGCCCUUCUUACUGGCCA	4345	UGGCCAGUAAGAAGGGCAA	4346
UGCCCUUCUUACUGGCCAG	4347	CUGGCCAGUAAGAAGGGCA	4348
UCUUACUGGCCAGGCAGGG	4349	CCCUGCCUGGCCAGUAAGA	4350
GGCCAGAGUCCAGGCUUGA	4351	UCAAGCCUGGACUCUGGCC	4352
GCCAGAGUCCAGGCUUGAC	4353	GUCAAGCCUGGACUCUGGC	4354
GUCCAGGCUUGACUCAUUC	4355	GAAUGAGUCAAGCCUGGAC	4356
AGGCUUGACUCAUUCCCAC	4357	GUGGGAAUGAGUCAAGCCU	4358
GACUCAUUCCCACCUUGUC	4359	GACAAGGUGGGAAUGAGUC	4360
ACUCAUUCCCACCUUGUCC	4361	GGACAAGGUGGGAAUGAGU	4362
UCAUUCCCACCUUGUCCUG	4363	CAGGACAAGGUGGGAAUGA	4364
CACCUUGUCCUGGGCUGAG	4365	CUCAGCCCAGGACAAGGUG	4366
ACCACCCAGCCCAGAAGUU	4367	AACUUCUGGGCUGGGUGGU	4368
CCACCCAGCCCAGAAGUUC	4369	GAACUUCUGGGCUGGGUGG	4370
CACCCAGCCCAGAAGUUCC	4371	GGAACUUCUGGGCUGGGUG	4372
ACCCAGCCCAGAAGUUCCA	4373	UGGAACUUCUGGGCUGGGU	4374
CCAGAAGUUCCAGGGAAGG	4375	CCUUCCCUGGAACUUCUGG	4376
CAGAAGUUCCAGGGAAGGA	4377	UCCUUCCCUGGAACUUCUG	4378
AACUCUCCGGUCCACCAUG	4379	CAUGGUGGACCGGAGAGUU	4380
ACUCUCCGGUCCACCAUGG	4381	CCAUGGUGGACCGGAGAGU	4382
CACCAUGGAGUACCUCUCA	4383	UGAGAGGUACUCCAUGGUG	4384
ACCAUGGAGUACCUCUCAG	4385	CUGAGAGGUACUCCAUGGU	4386
UGGAGUACCUCUCAGCUCU	4387	AGAGCUGAGAGGUACUCCA	4388
GGAGUACCUCUCAGCUCUG	4389	CAGAGCUGAGAGGUACUCC	4390
GAGUACCUCUCAGCUCUGA	4391	UCAGAGCUGAGAGGUACUC	4392
AGUACCUCUCAGCUCUGAA	4393	UUCAGAGCUGAGAGGUACU	4394
CCAGUGACUUACUCAGGUG	4395	CACCUGAGUAAGUCACUGG	4396
CAGUGACUUACUCAGGUGA	4397	UCACCUGAGUAAGUCACUG	4398
AGUGACUUACUCAGGUGAC	4399	GUCACCUGAGUAAGUCACU	4400
GUGACUUACUCAGGUGACU	4401	AGUCACCUGAGUAAGUCAC	4402
UGACUUACUCAGGUGACUG	4403	CAGUCACCUGAGUAAGUCA	4404
GACUUACUCAGGUGACUGC	4405	GCAGUCACCUGAGUAAGUC	4406
ACUUACUCAGGUGACUGCU	4407	AGCAGUCACCUGAGUAAGU	4408
CUUACUCAGGUGACUGCUA	4409	UAGCAGUCACCUGAGUAAG	4410
UUACUCAGGUGACUGCUAA	4411	UUAGCAGUCACCUGAGUAA	4412
UACUCAGGUGACUGCUAAC	4413	GUUAGCAGUCACCUGAGUA	4414
ACUCAGGUGACUGCUAACC	4415	GGUUAGCAGUCACCUGAGU	4416
CUCAGGUGACUGCUAACCC	4417	GGGUUAGCAGUCACCUGAG	4418
GGUGACUGCUAACCCUCCG	4419	CGGAGGGUUAGCAGUCACC	4420
GUGACUGCUAACCCUCCGC	4421	GCGGAGGGUUAGCAGUCAC	4422
UGACUGCUAACCCUCCGCU	4423	AGCGGAGGGUUAGCAGUCA	4424
GACUGCUAACCCUCCGCUC	4425	GAGCGGAGGGUUAGCAGUC	4426
ACUGCUAACCCUCCGCUCU	4427	AGAGCGGAGGGUUAGCAGU	4428
CUGCUAACCCUCCGCUCUA	4429	UAGAGCGGAGGGUUAGCAG	4430
UGCUAACCCUCCGCUCUAC	4431	GUAGAGCGGAGGGUUAGCA	4432
AACCCUCCGCUCUACCCUC	4433	GAGGGUAGAGCGGAGGGUU	4434
ACUCCACAGUGGGCUUGUC	4435	GACAAGCCCACUGUGGAGU	4436
CUCCACAGUGGGCUUGUCA	4437	UGACAAGCCCACUGUGGAG	4438
UCCACAGUGGGCUUGUCAA	4439	UUGACAAGCCCACUGUGGA	4440
CCACAGUGGGCUUGUCAAG	4441	CUUGACAAGCCCACUGUGG	4442
GUCAAGCUCCUGAGCCACC	4443	GGUGGCUCAGGAGCUUGAC	4444
CCAUGGUCUCUCCCUCAUC	4445	GAUGAGGGAGAGACCAUGG	4446
CAUGGUCUCUCCCUCAUCC	4447	GGAUGAGGGAGAGACCAUG	4448
AUGGUCUCUCCCUCAUCCC	4449	GGGAUGAGGGAGAGACCAU	4450
UCUCUCCCUCAUCCCUAAU	4451	AUUAGGGAUGAGGGAGAGA	4452
CUCUCCCUCAUCCCUAAUC	4453	GAUUAGGGAUGAGGGAGAG	4454
UCUCCCUCAUCCCUAAUCG	4455	CGAUUAGGGAUGAGGGAGA	4456
CUCCCUCAUCCCUAAUCGA	4457	UCGAUUAGGGAUGAGGGAG	4458
UCCCUCAUCCCUAAUCGAU	4459	AUCGAUUAGGGAUGAGGGA	4460
CCCUCAUCCCUAAUCGAUA	4461	UAUCGAUUAGGGAUGAGGG	4462
CCUCAUCCCUAAUCGAUAA	4463	UUAUCGAUUAGGGAUGAGG	4464
CUCAUCCCUAAUCGAUAAA	4465	UUUAUCGAUUAGGGAUGAG	4466
AACCUAGAUCUCUCCCUCC	4467	GGAGGGAGAGAUCUAGGUU	4468
ACCUAGAUCUCUCCCUCCC	4469	GGGAGGGAGAGAUCUAGGU	4470
CUAGAUCUCUCCCUCCCUA	4471	UAGGGAGGGAGAGAUCUAG	4472
UAGAUCUCUCCCUCCCUAG	4473	CUAGGGAGGGAGAGAUCUA	4474
AGAUCUCUCCCUCCCUAGC	4475	GCUAGGGAGGGAGAGAUCU	4476
GAUCUCUCCCUCCCUAGCC	4477	GGCUAGGGAGGGAGAGAUC	4478
AUCUCUCCCUCCCUAGCCC	4479	GGGCUAGGGAGGGAGAGAU	4480
UAGCCCUCUAGCCACUCUA	4481	UAGAGUGGCUAGAGGGCUA	4482
AGCCCUCUAGCCACUCUAC	4483	GUAGAGUGGCUAGAGGGCU	4484
CUCUAGCCACUCUACCCUC	4485	GAGGGUAGAGUGGCUAGAG	4486
UCUAGCCACUCUACCCUCA	4487	UGAGGGUAGAGUGGCUAGA	4488
CUAGCCACUCUACCCUCAU	4489	AUGAGGGUAGAGUGGCUAG	4490
UAGCCACUCUACCCUCAUC	4491	GAUGAGGGUAGAGUGGCUA	4492
AGCCACUCUACCCUCAUCA	4493	UGAUGAGGGUAGAGUGGCU	4494
GCCACUCUACCCUCAUCAU	4495	AUGAUGAGGGUAGAGUGGC	4496
CCACUCUACCCUCAUCAUG	4497	CAUGAUGAGGGUAGAGUGG	4498
CACUCUACCCUCAUCAUGC	4499	GCAUGAUGAGGGUAGAGUG	4500
ACUCUACCCUCAUCAUGCC	4501	GGCAUGAUGAGGGUAGAGU	4502
CUCUACCCUCAUCAUGCCC	4503	GGGCAUGAUGAGGGUAGAG	4504
UCUACCCUCAUCAUGCCCU	4505	AGGGCAUGAUGAGGGUAGA	4506
CUACCCUCAUCAUGCCCUU	4507	AAGGGCAUGAUGAGGGUAG	4508
UACCCUCAUCAUGCCCUUU	4509	AAAGGGCAUGAUGAGGGUA	4510
ACCCUCAUCAUGCCCUUUA	4511	UAAAGGGCAUGAUGAGGGU	4512
CCCUCAUCAUGCCCUUUAC	4513	GUAAAGGGCAUGAUGAGGG	4514
CUCAUCAUGCCCUUUACAC	4515	GUGUAAAGGGCAUGAUGAG	4516
UCAUCAUGCCCUUUACACU	4517	AGUGUAAAGGGCAUGAUGA	4518
CCCUUCUUGACUUUUCUUC	4519	GAAGAAAAGUCAAGAAGGG	4520
CUUCUUGACUUUUCUUCUC	4521	GAGAAGAAAAGUCAAGAAG	4522
GACUUUUCUUCUCAACUAC	4523	GUAGUUGAGAAGAAAAGUC	4524
ACUUUUCUUCUCAACUACC	4525	GGUAGUUGAGAAGAAAAGU	4526
CUUUUCUUCUCAACUACCA	4527	UGGUAGUUGAGAAGAAAAG	4528
UUUUCUUCUCAACUACCAG	4529	CUGGUAGUUGAGAAGAAAA	4530
UAUCUAAUAUAAGCUCGGA	4531	UCCGAGCUUAUAUUAGAUA	4532
AUCUAAUAUAAGCUCGGAG	4533	CUCCGAGCUUAUAUUAGAU	4534
UCUAAUAUAAGCUCGGAGU	4535	ACUCCGAGCUUAUAUUAGA	4536
CUAAUAUAAGCUCGGAGUU	4537	AACUCCGAGCUUAUAUUAG	4538
UAAUAUAAGCUCGGAGUUU	4539	AAACUCCGAGCUUAUAUUA	4540
AAUAUAAGCUCGGAGUUUG	4541	CAAACUCCGAGCUUAUAUU	4542
AUAUAAGCUCGGAGUUUGG	4543	CCAAACUCCGAGCUUAUAU	4544
UAUAAGCUCGGAGUUUGGA	4545	UCCAAACUCCGAGCUUAUA	4546
AUAAGCUCGGAGUUUGGAC	4547	GUCCAAACUCCGAGCUUAU	4548
UAAGCUCGGAGUUUGGACG	4549	CGUCCAAACUCCGAGCUUA	4550
AAGCUCGGAGUUUGGACGG	4551	CCGUCCAAACUCCGAGCUU	4552
AGCUCGGAGUUUGGACGGA	4553	UCCGUCCAAACUCCGAGCU	4554
GCUCGGAGUUUGGACGGAG	4555	CUCCGUCCAAACUCCGAGC	4556
CUCGGAGUUUGGACGGAGG	4557	CCUCCGUCCAAACUCCGAG	4558
UCGGAGUUUGGACGGAGGG	4559	CCCUCCGUCCAAACUCCGA	4560
CGGAGUUUGGACGGAGGGU	4561	ACCCUCCGUCCAAACUCCG	4562
UUUGGACGGAGGGUCUGGA	4563	UCCAGACCCUCCGUCCAAA	4564
CCCAGCGACCUUUCCGUGU	4565	ACACGGAAAGGUCGCUGGG	4566
CCAGCGACCUUUCCGUGUC	4567	GACACGGAAAGGUCGCUGG	4568
CAGCGACCUUUCCGUGUCU	4569	AGACACGGAAAGGUCGCUG	4570
AGCGACCUUUCCGUGUCUG	4571	CAGACACGGAAAGGUCGCU	4572
GCGACCUUUCCGUGUCUGU	4573	ACAGACACGGAAAGGUCGC	4574
CGACCUUUCCGUGUCUGUG	4575	CACAGACACGGAAAGGUCG	4576
CUUUCCGUGUCUGUGAUCA	4577	UGAUCACAGACACGGAAAG	4578
UUUCCGUGUCUGUGAUCAC	4579	GUGAUCACAGACACGGAAA	4580
UUCCGUGUCUGUGAUCACA	4581	UGUGAUCACAGACACGGAA	4582
AAGGCCUGACAGCUGCCAC	4583	GUGGCAGCUGUCAGGCCUU	4584
GCCAGGAGCUGCUAGCCAA	4585	UUGGCUAGCAGCUCCUGGC	4586
CCAGGAGCUGCUAGCCAAA	4587	UUUGGCUAGCAGCUCCUGG	4588
GAGCUGCUAGCCAAAGUAA	4589	UUACUUUGGCUAGCAGCUC	4590
AGCUGCUAGCCAAAGUAAG	4591	CUUACUUUGGCUAGCAGCU	4592
GCUGCUAGCCAAAGUAAGU	4593	ACUUACUUUGGCUAGCAGC	4594
CUGCUAGCCAAAGUAAGUA	4595	UACUUACUUUGGCUAGCAG	4596
UGCUAGCCAAAGUAAGUAG	4597	CUACUUACUUUGGCUAGCA	4598
GCUAGCCAAAGUAAGUAGG	4599	CCUACUUACUUUGGCUAGC	4600
UAGCCAAAGUAAGUAGGCC	4601	GGCCUACUUACUUUGGCUA	4602
AGCCAAAGUAAGUAGGCCA	4603	UGGCCUACUUACUUUGGCU	4604
GCCAAAGUAAGUAGGCCAA	4605	UUGGCCUACUUACUUUGGC	4606
CCAAAGUAAGUAGGCCAAG	4607	CUUGGCCUACUUACUUUGG	4608
CAAAGUAAGUAGGCCAAGU	4609	ACUUGGCCUACUUACUUUG	4610
AAAGUAAGUAGGCCAAGUU	4611	AACUUGGCCUACUUACUUU	4612
AAGUAAGUAGGCCAAGUUC	4613	GAACUUGGCCUACUUACUU	4614
AGUAAGUAGGCCAAGUUCC	4615	GGAACUUGGCCUACUUACU	4616
GUAAGUAGGCCAAGUUCCU	4617	AGGAACUUGGCCUACUUAC	4618
UAAGUAGGCCAAGUUCCUC	4619	GAGGAACUUGGCCUACUUA	4620
UAGGCCAAGUUCCUCGGUU	4621	AACCGAGGAACUUGGCCUA	4622
AGGCCAAGUUCCUCGGUUC	4623	GAACCGAGGAACUUGGCCU	4624
GGCCAAGUUCCUCGGUUCC	4625	GGAACCGAGGAACUUGGCC	4626
GCCAAGUUCCUCGGUUCCU	4627	AGGAACCGAGGAACUUGGC	4628
CCAAGUUCCUCGGUUCCUA	4629	UAGGAACCGAGGAACUUGG	4630
CAAGUUCCUCGGUUCCUAU	4631	AUAGGAACCGAGGAACUUG	4632
AAGUUCCUCGGUUCCUAUA	4633	UAUAGGAACCGAGGAACUU	4634
AGUUCCUCGGUUCCUAUAG	4635	CUAUAGGAACCGAGGAACU	4636
GUUCCUCGGUUCCUAUAGC	4637	GCUAUAGGAACCGAGGAAC	4638
UUCCUCGGUUCCUAUAGCA	4639	UGCUAUAGGAACCGAGGAA	4640
UCCUCGGUUCCUAUAGCAG	4641	CUGCUAUAGGAACCGAGGA	4642
CAGUGGCAACUUGUGAUGA	4643	UCAUCACAAGUUGCCACUG	4644
AGUGGCAACUUGUGAUGAU	4645	AUCAUCACAAGUUGCCACU	4646
GUGGCAACUUGUGAUGAUG	4647	CAUCAUCACAAGUUGCCAC	4648
GGCAACUUGUGAUGAUGGA	4649	UCCAUCAUCACAAGUUGCC	4650
ACUUGUGAUGAUGGAGCAG	4651	CUGCUCCAUCAUCACAAGU	4652
CUUGUGAUGAUGGAGCAGA	4653	UCUGCUCCAUCAUCACAAG	4654
GUGAUGAUGGAGCAGAGGG	4655	CCCUCUGCUCCAUCAUCAC	4656
UGAUGAUGGAGCAGAGGGC	4657	GCCCUCUGCUCCAUCAUCA	4658
UGGAGCAGAGGGCUGAAGU	4659	ACUUCAGCCCUCUGCUCCA	4660
GGAGCAGAGGGCUGAAGUC	4661	GACUUCAGCCCUCUGCUCC	4662
GAGCAGAGGGCUGAAGUCA	4663	UGACUUCAGCCCUCUGCUC	4664
CUAAAAGCAGCGGAGUGGG	4665	CCCACUCCGCUGCUUUUAG	4666
UAAAAGCAGCGGAGUGGGC	4667	GCCCACUCCGCUGCUUUUA	4668
AAAAGCAGCGGAGUGGGCC	4669	GGCCCACUCCGCUGCUUUU	4670
AAAGCAGCGGAGUGGGCCU	4671	AGGCCCACUCCGCUGCUUU	4672
AAGCAGCGGAGUGGGCCUA	4673	UAGGCCCACUCCGCUGCUU	4674
AGCAGCGGAGUGGGCCUAA	4675	UUAGGCCCACUCCGCUGCU	4676
GCAGCGGAGUGGGCCUAAU	4677	AUUAGGCCCACUCCGCUGC	4678
CAGCGGAGUGGGCCUAAUG	4679	CAUUAGGCCCACUCCGCUG	4680
AGCGGAGUGGGCCUAAUGA	4681	UCAUUAGGCCCACUCCGCU	4682
GCGGAGUGGGCCUAAUGAG	4683	CUCAUUAGGCCCACUCCGC	4684
AGUGGGCCUAAUGAGCUCU	4685	AGAGCUCAUUAGGCCCACU	4686
GUGGGCCUAAUGAGCUCUG	4687	CAGAGCUCAUUAGGCCCAC	4688
UGGGCCUAAUGAGCUCUGG	4689	CCAGAGCUCAUUAGGCCCA	4690
GGGCCUAAUGAGCUCUGGU	4691	ACCAGAGCUCAUUAGGCCC	4692
GGCCUAAUGAGCUCUGGUC	4693	GACCAGAGCUCAUUAGGCC	4694
GCCUAAUGAGCUCUGGUCA	4695	UGACCAGAGCUCAUUAGGC	4696
CCUAAUGAGCUCUGGUCAA	4697	UUGACCAGAGCUCAUUAGG	4698
CUAAUGAGCUCUGGUCAAU	4699	AUUGACCAGAGCUCAUUAG	4700
UAAUGAGCUCUGGUCAAUU	4701	AAUUGACCAGAGCUCAUUA	4702
AAUGAGCUCUGGUCAAUUU	4703	AAAUUGACCAGAGCUCAUU	4704
AUGAGCUCUGGUCAAUUUG	4705	CAAAUUGACCAGAGCUCAU	4706
UGAGCUCUGGUCAAUUUGU	4707	ACAAAUUGACCAGAGCUCA	4708
CUGGUCAAUUUGUUCAUUU	4709	AAAUGAACAAAUUGACCAG	4710
CAAUUUGUUCAUUUUCCAC	4711	GUGGAAAAUGAACAAAUUG	4712
AGUGAGCUUUUCUAUGGGA	4713	UCCCAUAGAAAAGCUCACU	4714
AGCUUUUCUAUGGGAGCAG	4715	CUGCUCCCAUAGAAAAGCU	4716
GAAUUCAGAAGCUAGUAUG	4717	CAUACUAGCUUCUGAAUUC	4718
AUUCAGAAGCUAGUAUGGA	4719	UCCAUACUAGCUUCUGAAU	4720
UUCAGAAGCUAGUAUGGAA	4721	UUCCAUACUAGCUUCUGAA	4722
AAAGGUGAUUUGUGUGACA	4723	UGUCACACAAAUCACCUUU	4724
AUUCUGAUUCUGCCACUUC	4725	GAAGUGGCAGAAUCAGAAU	4726
AUUCUGCCACUUCCUGCCU	4727	AGGCAGGAAGUGGCAGAAU	4728
GCCACUUCCUGCCUGUCAA	4729	UUGACAGGCAGGAAGUGGC	4730
CCACUUCCUGCCUGUCAAA	4731	UUUGACAGGCAGGAAGUGG	4732
AACCUUGGGAAGUUGUUCA	4733	UGAACAACUUCCCAAGGUU	4734
ACCUUGGGAAGUUGUUCAA	4735	UUGAACAACUUCCCAAGGU	4736
CCUUGGGAAGUUGUUCAAC	4737	GUUGAACAACUUCCCAAGG	4738
GGGAAGUUGUUCAACCUAC	4739	GUAGGUUGAACAACUUCCC	4740
GGAAGUUGUUCAACCUACC	4741	GGUAGGUUGAACAACUUCC	4742
GAAGUUGUUCAACCUACCA	4743	UGGUAGGUUGAACAACUUC	4744
AAGUUGUUCAACCUACCAA	4745	UUGGUAGGUUGAACAACUU	4746
AGUUGUUCAACCUACCAAA	4747	UUUGGUAGGUUGAACAACU	4748
GUUGUUCAACCUACCAAAA	4749	UUUUGGUAGGUUGAACAAC	4750
GCAAUAAUAAUACAUCACC	4751	GGUGAUGUAUUAUUAUUGC	4752
AUAAUAAUACAUCACCUCC	4753	GGAGGUGAUGUAUUAUUAU	4754
UAAUACAUCACCUCCUAGG	4755	CCUAGGAGGUGAUGUAUUA	4756
AAUACAUCACCUCCUAGGG	4757	CCCUAGGAGGUGAUGUAUU	4758
AUACAUCACCUCCUAGGGU	4759	ACCCUAGGAGGUGAUGUAU	4760
UACAUCACCUCCUAGGGUU	4761	AACCCUAGGAGGUGAUGUA	4762
ACAUCACCUCCUAGGGUUG	4763	CAACCCUAGGAGGUGAUGU	4764
AAAGGAGUAAGAGGAUAAU	4765	AUUAUCCUCUUACUCCUUU	4766
AAGGAGUAAGAGGAUAAUG	4767	CAUUAUCCUCUUACUCCUU	4768
AGUAAGAGGAUAAUGUAGG	4769	CCUACAUUAUCCUCUUACU	4770
GUAAGAGGAUAAUGUAGGU	4771	ACCUACAUUAUCCUCUUAC	4772
UAAGAGGAUAAUGUAGGUA	4773	UACCUACAUUAUCCUCUUA	4774
AAGAGGAUAAUGUAGGUAA	4775	UUACCUACAUUAUCCUCUU	4776
AGAGGAUAAUGUAGGUAAA	4777	UUUACCUACAUUAUCCUCU	4778
GAGGAUAAUGUAGGUAAAG	4779	CUUUACCUACAUUAUCCUC	4780
GGAUAAUGUAGGUAAAGUC	4781	GACUUUACCUACAUUAUCC	4782
AUAAUGUAGGUAAAGUCCU	4783	AGGACUUUACCUACAUUAU	4784
GUAGGUAAAGUCCUCAUAC	4785	GUAUGAGGACUUUACCUAC	4786
GUAAAGUCCUCAUACCUGG	4787	CCAGGUAUGAGGACUUUAC	4788
UAAAGUCCUCAUACCUGGC	4789	GCCAGGUAUGAGGACUUUA	4790
AAAGUCCUCAUACCUGGCA	4791	UGCCAGGUAUGAGGACUUU	4792
AAGUCCUCAUACCUGGCAC	4793	GUGCCAGGUAUGAGGACUU	4794
AGUCCUCAUACCUGGCACA	4795	UGUGCCAGGUAUGAGGACU	4796
GUCCUCAUACCUGGCACAG	4797	CUGUGCCAGGUAUGAGGAC	4798
UCCUCAUACCUGGCACAGA	4799	UCUGUGCCAGGUAUGAGGA	4800
UCUUGAGGGUGUGGGAAGU	4801	ACUUCCCACACCCUCAAGA	4802
CUUGAGGGUGUGGGAAGUG	4803	CACUUCCCACACCCUCAAG	4804
UUGAGGGUGUGGGAAGUGA	4805	UCACUUCCCACACCCUCAA	4806
UGAGGGUGUGGGAAGUGAG	4807	CUCACUUCCCACACCCUCA	4808
AGGGUGUGGGAAGUGAGGU	4809	ACCUCACUUCCCACACCCU	4810
GGGUGUGGGAAGUGAGGUG	4811	CACCUCACUUCCCACACCC	4812
GGGAAGUGAGGUGCAGCAU	4813	AUGCUGCACCUCACUUCCC	4814
GGAAGUGAGGUGCAGCAUU	4815	AAUGCUGCACCUCACUUCC	4816
GAAGUGAGGUGCAGCAUUG	4817	CAAUGCUGCACCUCACUUC	4818
AAGUGAGGUGCAGCAUUGU	4819	ACAAUGCUGCACCUCACUU	4820
AGUGAGGUGCAGCAUUGUA	4821	UACAAUGCUGCACCUCACU	4822
GUGAGGUGCAGCAUUGUAG	4823	CUACAAUGCUGCACCUCAC	4824
UGAGGUGCAGCAUUGUAGA	4825	UCUACAAUGCUGCACCUCA	4826
GAGGUGCAGCAUUGUAGAU	4827	AUCUACAAUGCUGCACCUC	4828
AGGUGCAGCAUUGUAGAUA	4829	UAUCUACAAUGCUGCACCU	4830
GGUGCAGCAUUGUAGAUAA	4831	UUAUCUACAAUGCUGCACC	4832
GUGCAGCAUUGUAGAUAAG	4833	CUUAUCUACAAUGCUGCAC	4834
UGCAGCAUUGUAGAUAAGA	4835	UCUUAUCUACAAUGCUGCA	4836
GCAUUGUAGAUAAGACAGA	4837	UCUGUCUUAUCUACAAUGC	4838
CAUUGUAGAUAAGACAGAA	4839	UUCUGUCUUAUCUACAAUG	4840
AUUGUAGAUAAGACAGAAG	4841	CUUCUGUCUUAUCUACAAU	4842
AUAAGACAGAAGGGUGGAC	4843	GUCCACCCUUCUGUCUUAU	4844
UAAGACAGAAGGGUGGACU	4845	AGUCCACCCUUCUGUCUUA	4846
AACCUGGCUUGCUUUCCAA	4847	UUGGAAAGCAAGCCAGGUU	4848
CCUGGCUUGCUUUCCAAUU	4849	AAUUGGAAAGCAAGCCAGG	4850
ACCAGAAGUGACUUGGAGG	4851	CCUCCAAGUCACUUCUGGU	4852
CCAGAAGUGACUUGGAGGG	4853	CCCUCCAAGUCACUUCUGG	4854
AGAUGCCAAUGACAUGGUA	4855	UACCAUGUCAUUGGCAUCU	4856
GAUGCCAAUGACAUGGUAG	4857	CUACCAUGUCAUUGGCAUC	4858
AUGCCAAUGACAUGGUAGG	4859	CCUACCAUGUCAUUGGCAU	4860
CAAUGACAUGGUAGGAGCA	4861	UGCUCCUACCAUGUCAUUG	4862
AAUGACAUGGUAGGAGCAA	4863	UUGCUCCUACCAUGUCAUU	4864
AUGACAUGGUAGGAGCAAA	4865	UUUGCUCCUACCAUGUCAU	4866
UGACAUGGUAGGAGCAAAG	4867	CUUUGCUCCUACCAUGUCA	4868
GACAUGGUAGGAGCAAAGA	4869	UCUUUGCUCCUACCAUGUC	4870
AAAAGGUCAGCCUCUAGCU	4871	AGCUAGAGGCUGACCUUUU	4872
AAAGGUCAGCCUCUAGCUA	4873	UAGCUAGAGGCUGACCUUU	4874
AGGUCAGCCUCUAGCUAGG	4875	CCUAGCUAGAGGCUGACCU	4876
GGUCAGCCUCUAGCUAGGA	4877	UCCUAGCUAGAGGCUGACC	4878
GUCAGCCUCUAGCUAGGAU	4879	AUCCUAGCUAGAGGCUGAC	4880
CAGCCUCUAGCUAGGAUCC	4881	GGAUCCUAGCUAGAGGCUG	4882
AGCCUCUAGCUAGGAUCCC	4883	GGGAUCCUAGCUAGAGGCU	4884
AGAGCUGCAACCUUUAGGA	4885	UCCUAAAGGUUGCAGCUCU	4886
GAGCUGCAACCUUUAGGAG	4887	CUCCUAAAGGUUGCAGCUC	4888
AGCUGCAACCUUUAGGAGG	4889	CCUCCUAAAGGUUGCAGCU	4890
UUUAGGAGGUAUCAAAGUG	4891	CACUUUGAUACCUCCUAAA	4892
UUAGGAGGUAUCAAAGUGC	4893	GCACUUUGAUACCUCCUAA	4894
UAGGAGGUAUCAAAGUGCC	4895	GGCACUUUGAUACCUCCUA	4896
GUCAAAGUGGGACAUCGAC	4897	GUCGAUGUCCCACUUUGAC	4898
CAUCGACCAAUGUCUAGAG	4899	CUCUAGACAUUGGUCGAUG	4900
AUCGACCAAUGUCUAGAGC	4901	GCUCUAGACAUUGGUCGAU	4902
ACCAAUGUCUAGAGCCAAC	4903	GUUGGCUCUAGACAUUGGU	4904
CAAUGUCUAGAGCCAACUG	4905	CAGUUGGCUCUAGACAUUG	4906
AAUGUCUAGAGCCAACUGA	4907	UCAGUUGGCUCUAGACAUU	4908
AUGUCUAGAGCCAACUGAU	4909	AUCAGUUGGCUCUAGACAU	4910
UGUCUAGAGCCAACUGAUG	4911	CAUCAGUUGGCUCUAGACA	4912
GUCUAGAGCCAACUGAUGG	4913	CCAUCAGUUGGCUCUAGAC	4914
UCUAGAGCCAACUGAUGGA	4915	UCCAUCAGUUGGCUCUAGA	4916
CUAGAGCCAACUGAUGGAU	4917	AUCCAUCAGUUGGCUCUAG	4918
UAGAGCCAACUGAUGGAUG	4919	CAUCCAUCAGUUGGCUCUA	4920
AGAGCCAACUGAUGGAUGU	4921	ACAUCCAUCAGUUGGCUCU	4922
GAGCCAACUGAUGGAUGUU	4923	AACAUCCAUCAGUUGGCUC	4924
AACUGAUGGAUGUUGGGCA	4925	UGCCCAACAUCCAUCAGUU	4926
UGGAUGUUGGGCAGCUAAA	4927	UUUAGCUGCCCAACAUCCA	4928
GGAUGUUGGGCAGCUAAAG	4929	CUUUAGCUGCCCAACAUCC	4930
GAUGUUGGGCAGCUAAAGA	4931	UCUUUAGCUGCCCAACAUC	4932
UUGGGCAGCUAAAGAGGGA	4933	UCCCUCUUUAGCUGCCCAA	4934
UGGGCAGCUAAAGAGGGAA	4935	UUCCCUCUUUAGCUGCCCA	4936
GGGCAGCUAAAGAGGGAAG	4937	CUUCCCUCUUUAGCUGCCC	4938
GGCAGCUAAAGAGGGAAGG	4939	CCUUCCCUCUUUAGCUGCC	4940
GCAGCUAAAGAGGGAAGGG	4941	CCCUUCCCUCUUUAGCUGC	4942
GGGCAUGGGAUAAGACCUG	4943	CAGGUCUUAUCCCAUGCCC	4944
GGCAUGGGAUAAGACCUGC	4945	GCAGGUCUUAUCCCAUGCC	4946
GCAUGGGAUAAGACCUGCC	4947	GGCAGGUCUUAUCCCAUGC	4948
CAUGGGAUAAGACCUGCCC	4949	GGGCAGGUCUUAUCCCAUG	4950
AUGGGAUAAGACCUGCCCU	4951	AGGGCAGGUCUUAUCCCAU	4952
UGGGAUAAGACCUGCCCUU	4953	AAGGGCAGGUCUUAUCCCA	4954
GGGAUAAGACCUGCCCUUC	4955	GAAGGGCAGGUCUUAUCCC	4956
GGAUAAGACCUGCCCUUCU	4957	AGAAGGGCAGGUCUUAUCC	4958
AGACCUGCCCUUCUUGCUU	4959	AAGCAAGAAGGGCAGGUCU	4960
GACCUGCCCUUCUUGCUUC	4961	GAAGCAAGAAGGGCAGGUC	4962
CCUGCCCUUCUUGCUUCUU	4963	AAGAAGCAAGAAGGGCAGG	4964
CUGCCCUUCUUGCUUCUUG	4965	CAAGAAGCAAGAAGGGCAG	4966
UGCCCUUCUUGCUUCUUGC	4967	GCAAGAAGCAAGAAGGGCA	4968
UCUUGCUUCUUGCCAUUGG	4969	CCAAUGGCAAGAAGCAAGA	4970
CUUGCUUCUUGCCAUUGGG	4971	CCCAAUGGCAAGAAGCAAG	4972
UUGCUUCUUGCCAUUGGGC	4973	GCCCAAUGGCAAGAAGCAA	4974
CCAUUGGGCAGGCAUUGGA	4975	UCCAAUGCCUGCCCAAUGG	4976
CAUUGGGCAGGCAUUGGAG	4977	CUCCAAUGCCUGCCCAAUG	4978
GACCCUACUGCUGAAUGGA	4979	UCCAUUCAGCAGUAGGGUC	4980
UACUGCUGAAUGGAGUGCU	4981	AGCACUCCAUUCAGCAGUA	4982
ACUGCUGAAUGGAGUGCUA	4983	UAGCACUCCAUUCAGCAGU	4984
CUGCUGAAUGGAGUGCUAA	4985	UUAGCACUCCAUUCAGCAG	4986
UGCUGAAUGGAGUGCUAAC	4987	GUUAGCACUCCAUUCAGCA	4988
GCUGAAUGGAGUGCUAACC	4989	GGUUAGCACUCCAUUCAGC	4990
CUGAAUGGAGUGCUAACCC	4991	GGGUUAGCACUCCAUUCAG	4992
UAACCCUGGUGCUAGAGGA	4993	UCCUCUAGCACCAGGGUUA	4994
AACCCUGGUGCUAGAGGAG	4995	CUCCUCUAGCACCAGGGUU	4996
ACCCUGGUGCUAGAGGAGG	4997	CCUCCUCUAGCACCAGGGU	4998
CCCUGGUGCUAGAGGAGGA	4999	UCCUCCUCUAGCACCAGGG	5000
CCUGGUGCUAGAGGAGGAU	5001	AUCCUCCUCUAGCACCAGG	5002
CUGGUGCUAGAGGAGGAUG	5003	CAUCCUCCUCUAGCACCAG	5004
GGUGCUAGAGGAGGAUGGA	5005	UCCAUCCUCCUCUAGCACC	5006
GUGCUAGAGGAGGAUGGAA	5007	UUCCAUCCUCCUCUAGCAC	5008
CUGCAGUGGACAGUGAGGA	5009	UCCUCACUGUCCACUGCAG	5010
UGCAGUGGACAGUGAGGAC	5011	GUCCUCACUGUCCACUGCA	5012
GCAGUGGACAGUGAGGACU	5013	AGUCCUCACUGUCCACUGC	5014
CAGUGGACAGUGAGGACUU	5015	AAGUCCUCACUGUCCACUG	5016
AGUGGACAGUGAGGACUUC	5017	GAAGUCCUCACUGUCCACU	5018
GUGGACAGUGAGGACUUCU	5019	AGAAGUCCUCACUGUCCAC	5020
UGGACAGUGAGGACUUCUU	5021	AAGAAGUCCUCACUGUCCA	5022
GGACAGUGAGGACUUCUUC	5023	GAAGAAGUCCUCACUGUCC	5024
AGUGAGGACUUCUUCCAGC	5025	GCUGGAAGAAGUCCUCACU	5026
GUGAGGACUUCUUCCAGCU	5027	AGCUGGAAGAAGUCCUCAC	5028
UGAGGACUUCUUCCAGCUG	5029	CAGCUGGAAGAAGUCCUCA	5030
GAGGACUUCUUCCAGCUGC	5031	GCAGCUGGAAGAAGUCCUC	5032
GUGCCUGAUGGUGUUGCAG	5033	CUGCAACACCAUCAGGCAC	5034
GAUGGUGUUGCAGUCUGGU	5035	ACCAGACUGCAACACCAUC	5036
UGGUGUUGCAGUCUGGUCA	5037	UGACCAGACUGCAACACCA	5038
GGUGUUGCAGUCUGGUCAG	5039	CUGACCAGACUGCAACACC	5040
GUGUUGCAGUCUGGUCAGA	5041	UCUGACCAGACUGCAACAC	5042
UGCAGUCUGGUCAGAGCUG	5043	CAGCUCUGACCAGACUGCA	5044
GCAGUCUGGUCAGAGCUGG	5045	CCAGCUCUGACCAGACUGC	5046
CAGUCUGGUCAGAGCUGGA	5047	UCCAGCUCUGACCAGACUG	5048
AGUCUGGUCAGAGCUGGAG	5049	CUCCAGCUCUGACCAGACU	5050
GUCUGGUCAGAGCUGGAGC	5051	GCUCCAGCUCUGACCAGAC	5052
UCUGGUCAGAGCUGGAGCC	5053	GGCUCCAGCUCUGACCAGA	5054
UGGUCAGAGCUGGAGCCCU	5055	AGGGCUCCAGCUCUGACCA	5056
GGUCAGAGCUGGAGCCCUA	5057	UAGGGCUCCAGCUCUGACC	5058
GUCAGAGCUGGAGCCCUAC	5059	GUAGGGCUCCAGCUCUGAC	5060
CAAGGGUAAGAGGCCUAUA	5061	UAUAGGCCUCUUACCCUUG	5062
AAGGGUAAGAGGCCUAUAC	5063	GUAUAGGCCUCUUACCCUU	5064
AGGGUAAGAGGCCUAUACU	5065	AGUAUAGGCCUCUUACCCU	5066
GGGUAAGAGGCCUAUACUG	5067	CAGUAUAGGCCUCUUACCC	5068
GGUAAGAGGCCUAUACUGG	5069	CCAGUAUAGGCCUCUUACC	5070
GUAAGAGGCCUAUACUGGG	5071	CCCAGUAUAGGCCUCUUAC	5072
GGGCUGCUUCCAAUGCCUG	5073	CAGGCAUUGGAAGCAGCCC	5074
GGCUGCUUCCAAUGCCUGU	5075	ACAGGCAUUGGAAGCAGCC	5076
GCUGCUUCCAAUGCCUGUC	5077	GACAGGCAUUGGAAGCAGC	5078
CUGCUUCCAAUGCCUGUCC	5079	GGACAGGCAUUGGAAGCAG	5080
UGCUUCCAAUGCCUGUCCU	5081	AGGACAGGCAUUGGAAGCA	5082
GCUUCCAAUGCCUGUCCUU	5083	AAGGACAGGCAUUGGAAGC	5084
CUUCCAAUGCCUGUCCUUU	5085	AAAGGACAGGCAUUGGAAG	5086
UUCCAAUGCCUGUCCUUUA	5087	UAAAGGACAGGCAUUGGAA	5088
UCCAAUGCCUGUCCUUUAG	5089	CUAAAGGACAGGCAUUGGA	5090
CAAUGCCUGUCCUUUAGAG	5091	CUCUAAAGGACAGGCAUUG	5092
AAUGCCUGUCCUUUAGAGC	5093	GCUCUAAAGGACAGGCAUU	5094
AUGCCUGUCCUUUAGAGCU	5095	AGCUCUAAAGGACAGGCAU	5096
CUUCCUCUCUAGCUUAACC	5097	GGUUAAGCUAGAGAGGAAG	5098
UUCCUCUCUAGCUUAACCC	5099	GGGUUAAGCUAGAGAGGAA	5100
UCUCUAGCUUAACCCUGAU	5101	AUCAGGGUUAAGCUAGAGA	5102
UAGCUUAACCCUGAUCCUG	5103	CAGGAUCAGGGUUAAGCUA	5104
GACCAGGUGCAGGAGGAGU	5105	ACUCCUCCUGCACCUGGUC	5106
ACCAGGUGCAGGAGGAGUU	5107	AACUCCUCCUGCACCUGGU	5108
CCAGGUGCAGGAGGAGUUG	5109	CAACUCCUCCUGCACCUGG	5110
CAGGUGCAGGAGGAGUUGU	5111	ACAACUCCUCCUGCACCUG	5112
AGGUGCAGGAGGAGUUGUG	5113	CACAACUCCUCCUGCACCU	5114
UGCAGGAGGAGUUGUGGAA	5115	UUCCACAACUCCUCCUGCA	5116
GCAGGAGGAGUUGUGGAAU	5117	AUUCCACAACUCCUCCUGC	5118
AGGAGGAGUUGUGGAAUUG	5119	CAAUUCCACAACUCCUCCU	5120
GGAGGAGUUGUGGAAUUGU	5121	ACAAUUCCACAACUCCUCC	5122
GAGGAGUUGUGGAAUUGUC	5123	GACAAUUCCACAACUCCUC	5124
AGGAGUUGUGGAAUUGUCA	5125	UGACAAUUCCACAACUCCU	5126
GGAGUUGUGGAAUUGUCAA	5127	UUGACAAUUCCACAACUCC	5128
GAGUUGUGGAAUUGUCAAG	5129	CUUGACAAUUCCACAACUC	5130
AGUUGUGGAAUUGUCAAGG	5131	CCUUGACAAUUCCACAACU	5132
GUUGUGGAAUUGUCAAGGA	5133	UCCUUGACAAUUCCACAAC	5134
UGGAAUUGUCAAGGAUGUC	5135	GACAUCCUUGACAAUUCCA	5136
GGAAUUGUCAAGGAUGUCA	5137	UGACAUCCUUGACAAUUCC	5138
AGUCCAAGCGAGGGAGGGU	5139	ACCCUCCCUCGCUUGGACU	5140
CAAGCGAGGGAGGGUCUGA	5141	UCAGACCCUCCCUCGCUUG	5142
AAGCGAGGGAGGGUCUGAC	5143	GUCAGACCCUCCCUCGCUU	5144
CUGACCCAGUGCUGAUGGA	5145	UCCAUCAGCACUGGGUCAG	5146
AGAUUAGUGGUGGGUGUCU	5147	AGACACCCACCACUAAUCU	5148
AUUAGUGGUGGGUGUCUGG	5149	CCAGACACCCACCACUAAU	5150
UUAGUGGUGGGUGUCUGGU	5151	ACCAGACACCCACCACUAA	5152
UAGUGGUGGGUGUCUGGUA	5153	UACCAGACACCCACCACUA	5154
AGUGGUGGGUGUCUGGUAU	5155	AUACCAGACACCCACCACU	5156
GUGGUGGGUGUCUGGUAUG	5157	CAUACCAGACACCCACCAC	5158
UGGUGGGUGUCUGGUAUGA	5159	UCAUACCAGACACCCACCA	5160
GGUGGGUGUCUGGUAUGAG	5161	CUCAUACCAGACACCCACC	5162
GUGGGUGUCUGGUAUGAGG	5163	CCUCAUACCAGACACCCAC	5164
UGGGUGUCUGGUAUGAGGA	5165	UCCUCAUACCAGACACCCA	5166
GGGUGUCUGGUAUGAGGAU	5167	AUCCUCAUACCAGACACCC	5168
GGUGUCUGGUAUGAGGAUC	5169	GAUCCUCAUACCAGACACC	5170
GUGUCUGGUAUGAGGAUCU	5171	AGAUCCUCAUACCAGACAC	5172
UGUCUGGUAUGAGGAUCUA	5173	UAGAUCCUCAUACCAGACA	5174
CAAGGGUGUCCUACAGAGU	5175	ACUCUGUAGGACACCCUUG	5176
AAGGGUGUCCUACAGAGUG	5177	CACUCUGUAGGACACCCUU	5178
AGGGUGUCCUACAGAGUGG	5179	CCACUCUGUAGGACACCCU	5180
GGGUGUCCUACAGAGUGGA	5181	UCCACUCUGUAGGACACCC	5182
GGUGUCCUACAGAGUGGAG	5183	CUCCACUCUGUAGGACACC	5184
UCCUACAGAGUGGAGUGCU	5185	AGCACUCCACUCUGUAGGA	5186
AGUGGAGUGCUGUCAUAUG	5187	CAUAUGACAGCACUCCACU	5188
GUGGAGUGCUGUCAUAUGG	5189	CCAUAUGACAGCACUCCAC	5190
UGGAGUGCUGUCAUAUGGC	5191	GCCAUAUGACAGCACUCCA	5192
GGAGUGCUGUCAUAUGGCC	5193	GGCCAUAUGACAGCACUCC	5194
GAGUGCUGUCAUAUGGCCU	5195	AGGCCAUAUGACAGCACUC	5196
AGUGCUGUCAUAUGGCCUG	5197	CAGGCCAUAUGACAGCACU	5198
GUGCUGUCAUAUGGCCUGG	5199	CCAGGCCAUAUGACAGCAC	5200
UGCUGUCAUAUGGCCUGGG	5201	CCCAGGCCAUAUGACAGCA	5202
GCUGUCAUAUGGCCUGGGA	5203	UCCCAGGCCAUAUGACAGC	5204
CUGUCAUAUGGCCUGGGAC	5205	GUCCCAGGCCAUAUGACAG	5206
UGUCAUAUGGCCUGGGACG	5207	CGUCCCAGGCCAUAUGACA	5208
GUCAUAUGGCCUGGGACGG	5209	CCGUCCCAGGCCAUAUGAC	5210
AGAGGCCCAAGCACAGCAA	5211	UUGCUGUGCUUGGGCCUCU	5212
GAGGCCCAAGCACAGCAAG	5213	CUUGCUGUGCUUGGGCCUC	5214
AGGCCCAAGCACAGCAAGG	5215	CCUUGCUGUGCUUGGGCCU	5216
GGCCCAAGCACAGCAAGGA	5217	UCCUUGCUGUGCUUGGGCC	5218
CCAAGCACAGCAAGGACAU	5219	AUGUCCUUGCUGUGCUUGG	5220
GCCCGAUUCACCUUUGACG	5221	CGUCAAAGGUGAAUCGGGC	5222
GAUUCACCUUUGACGUGUA	5223	UACACGUCAAAGGUGAAUC	5224
AUUCACCUUUGACGUGUAC	5225	GUACACGUCAAAGGUGAAU	5226
UUGGCAGCCUGAAUGUCAA	5227	UUGACAUUCAGGCUGCCAA	5228
UGGCAGCCUGAAUGUCAAA	5229	UUUGACAUUCAGGCUGCCA	5230
GGCAGCCUGAAUGUCAAAG	5231	CUUUGACAUUCAGGCUGCC	5232
GCAGCCUGAAUGUCAAAGC	5233	GCUUUGACAUUCAGGCUGC	5234
CAGCCUGAAUGUCAAAGCC	5235	GGCUUUGACAUUCAGGCUG	5236
AGCCUGAAUGUCAAAGCCA	5237	UGGCUUUGACAUUCAGGCU	5238
GCCUGAAUGUCAAAGCCAC	5239	GUGGCUUUGACAUUCAGGC	5240
GUCAAAGCCACAUUCUACG	5241	CGUAGAAUGUGGCUUUGAC	5242
UCAAAGCCACAUUCUACGG	5243	CCGUAGAAUGUGGCUUUGA	5244
CAAAGCCACAUUCUACGGG	5245	CCCGUAGAAUGUGGCUUUG	5246
AAAGCCACAUUCUACGGGC	5247	GCCCGUAGAAUGUGGCUUU	5248
GCCACAUUCUACGGGCUCU	5249	AGAGCCCGUAGAAUGUGGC	5250
CCACAUUCUACGGGCUCUA	5251	UAGAGCCCGUAGAAUGUGG	5252
CACAUUCUACGGGCUCUAC	5253	GUAGAGCCCGUAGAAUGUG	5254
UUCUACGGGCUCUACUCUA	5255	UAGAGUAGAGCCCGUAGAA	5256
UCUACGGGCUCUACUCUAU	5257	AUAGAGUAGAGCCCGUAGA	5258
CUACGGGCUCUACUCUAUG	5259	CAUAGAGUAGAGCCCGUAG	5260
CUCUAUGAGUUGUGACUUU	5261	AAAGUCACAACUCAUAGAG	5262
UCUAUGAGUUGUGACUUUC	5263	GAAAGUCACAACUCAUAGA	5264
UGAGUUGUGACUUUCAAGG	5265	CCUUGAAAGUCACAACUCA	5266
GAGUUGUGACUUUCAAGGA	5267	UCCUUGAAAGUCACAACUC	5268
AGUUGUGACUUUCAAGGAC	5269	GUCCUUGAAAGUCACAACU	5270
GUUGUGACUUUCAAGGACU	5271	AGUCCUUGAAAGUCACAAC	5272
GACUUUCAAGGACUUGGCC	5273	GGCCAAGUCCUUGAAAGUC	5274
UUUCAAGGACUUGGCCCAA	5275	UUGGGCCAAGUCCUUGAAA	5276
UUCAAGGACUUGGCCCAAA	5277	UUUGGGCCAAGUCCUUGAA	5278
CCCUACAGUUGGAUAGUCC	5279	GGACUAUCCAACUGUAGGG	5280
CCUACAGUUGGAUAGUCCC	5281	GGGACUAUCCAACUGUAGG	5282
AUUCGUCCUCUUGCACCCA	5283	UGGGUGCAAGAGGACGAAU	5284
UUCGUCCUCUUGCACCCAC	5285	GUGGGUGCAAGAGGACGAA	5286
UCCUCUUGCACCCACCUAC	5287	GUAGGUGGGUGCAAGAGGA	5288
CCUCUUGCACCCACCUACC	5289	GGUAGGUGGGUGCAAGAGG	5290
CUCUUGCACCCACCUACCC	5291	GGGUAGGUGGGUGCAAGAG	5292
CUAGUUAGCUCUUGCUUGU	5293	ACAAGCAAGAGCUAACUAG	5294
UAGUUAGCUCUUGCUUGUG	5295	CACAAGCAAGAGCUAACUA	5296
AGUUAGCUCUUGCUUGUGG	5297	CCACAAGCAAGAGCUAACU	5298
UUAGCUCUUGCUUGUGGAA	5299	UUCCACAAGCAAGAGCUAA	5300
UCCUCAUCUCCCAGCUUGA	5301	UCAAGCUGGGAGAUGAGGA	5302
AUCUCCCAGCUUGAUGGCU	5303	AGCCAUCAAGCUGGGAGAU	5304
UCUCCCAGCUUGAUGGCUU	5305	AAGCCAUCAAGCUGGGAGA	5306
CUCCCAGCUUGAUGGCUUC	5307	GAAGCCAUCAAGCUGGGAG	5308
UCCCAGCUUGAUGGCUUCC	5309	GGAAGCCAUCAAGCUGGGA	5310
CCCAGCUUGAUGGCUUCCU	5311	AGGAAGCCAUCAAGCUGGG	5312
CCAGCUUGAUGGCUUCCUC	5313	GAGGAAGCCAUCAAGCUGG	5314
UGAUGGCUUCCUCCCAAGU	5315	ACUUGGGAGGAAGCCAUCA	5316
GAUGGCUUCCUCCCAAGUU	5317	AACUUGGGAGGAAGCCAUC	5318
GGCUUCCUCCCAAGUUUUC	5319	GAAAACUUGGGAGGAAGCC	5320
CCUCCCAAGUUUUCCAAAU	5321	AUUUGGAAAACUUGGGAGG	5322
CCCAAGUUUUCCAAAUCAU	5323	AUGAUUUGGAAAACUUGGG	5324
CCAAGUUUUCCAAAUCAUC	5325	GAUGAUUUGGAAAACUUGG	5326
CAAGUUUUCCAAAUCAUCU	5327	AGAUGAUUUGGAAAACUUG	5328
AAGUUUUCCAAAUCAUCUG	5329	CAGAUGAUUUGGAAAACUU	5330
GUUUUCCAAAUCAUCUGAU	5331	AUCAGAUGAUUUGGAAAAC	5332
AUCUGAUUUCCUCUUGUCU	5333	AGACAAGAGGAAAUCAGAU	5334
UCUGAUUUCCUCUUGUCUC	5335	GAGACAAGAGGAAAUCAGA	5336
CUGAUUUCCUCUUGUCUCU	5337	AGAGACAAGAGGAAAUCAG	5338
CUCUUGUCUCUGCCAUUCA	5339	UGAAUGGCAGAGACAAGAG	5340
GUUGGACCUCCACACUGCU	5341	AGCAGUGUGGAGGUCCAAC	5342
CCACACUGCUGCAAGGCCU	5343	AGGCCUUGCAGCAGUGUGG	5344
CACACUGCUGCAAGGCCUG	5345	CAGGCCUUGCAGCAGUGUG	5346
ACACUGCUGCAAGGCCUGG	5347	CCAGGCCUUGCAGCAGUGU	5348
UGCAAGGCCUGGGCCAUAU	5349	AUAUGGCCCAGGCCUUGCA	5350
GCAAGGCCUGGGCCAUAUG	5351	CAUAUGGCCCAGGCCUUGC	5352
CAAGGCCUGGGCCAUAUGU	5353	ACAUAUGGCCCAGGCCUUG	5354
AAGGCCUGGGCCAUAUGUU	5355	AACAUAUGGCCCAGGCCUU	5356
AGGCCUGGGCCAUAUGUUG	5357	CAACAUAUGGCCCAGGCCU	5358
GGCCUGGGCCAUAUGUUGC	5359	GCAACAUAUGGCCCAGGCC	5360
GCCUGGGCCAUAUGUUGCU	5361	AGCAACAUAUGGCCCAGGC	5362
CCUGGGCCAUAUGUUGCUG	5363	CAGCAACAUAUGGCCCAGG	5364
GGCCAUAUGUUGCUGGGAA	5365	UUCCCAGCAACAUAUGGCC	5366
CCAUAUGUUGCUGGGAAUU	5367	AAUUCCCAGCAACAUAUGG	5368
GGAAUUUCCUCCACCCUUC	5369	GAAGGGUGGAGGAAAUUCC	5370
GAAUUUCCUCCACCCUUCG	5371	CGAAGGGUGGAGGAAAUUC	5372
AAUUUCCUCCACCCUUCGU	5373	ACGAAGGGUGGAGGAAAUU	5374
AUUUCCUCCACCCUUCGUC	5375	GACGAAGGGUGGAGGAAAU	5376
UUUCCUCCACCCUUCGUCA	5377	UGACGAAGGGUGGAGGAAA	5378
UUCCUCCACCCUUCGUCAU	5379	AUGACGAAGGGUGGAGGAA	5380
UCCUCCACCCUUCGUCAUG	5381	CAUGACGAAGGGUGGAGGA	5382
CCUCCACCCUUCGUCAUGC	5383	GCAUGACGAAGGGUGGAGG	5384
CUCCACCCUUCGUCAUGCA	5385	UGCAUGACGAAGGGUGGAG	5386
CCUUCGUCAUGCAGUGGAG	5387	CUCCACUGCAUGACGAAGG	5388
CUUCGUCAUGCAGUGGAGG	5389	CCUCCACUGCAUGACGAAG	5390
UUCGUCAUGCAGUGGAGGG	5391	CCCUCCACUGCAUGACGAA	5392
CGCCUCCAUUCCUACUAAG	5393	CUUAGUAGGAAUGGAGGCG	5394
GCCUCCAUUCCUACUAAGG	5395	CCUUAGUAGGAAUGGAGGC	5396
CCUCCAUUCCUACUAAGGG	5397	CCCUUAGUAGGAAUGGAGG	5398
CAGAAUCAUUCCAACCGAC	5399	GUCGGUUGGAAUGAUUCUG	5400
AGAAUCAUUCCAACCGACC	5401	GGUCGGUUGGAAUGAUUCU	5402
GAAUCAUUCCAACCGACCC	5403	GGGUCGGUUGGAAUGAUUC	5404
AAUCAUUCCAACCGACCCA	5405	UGGGUCGGUUGGAAUGAUU	5406
AUCAUUCCAACCGACCCAC	5407	GUGGGUCGGUUGGAAUGAU	5408
UCAUUCCAACCGACCCACU	5409	AGUGGGUCGGUUGGAAUGA	5410
UCCAACCGACCCACUGCAA	5411	UUGCAGUGGGUCGGUUGGA	5412
CCAACCGACCCACUGCAAA	5413	UUUGCAGUGGGUCGGUUGG	5414
CAACCGACCCACUGCAAAG	5415	CUUUGCAGUGGGUCGGUUG	5416
AACCGACCCACUGCAAAGA	5417	UCUUUGCAGUGGGUCGGUU	5418
ACCGACCCACUGCAAAGAC	5419	GUCUUUGCAGUGGGUCGGU	5420
CCGACCCACUGCAAAGACU	5421	AGUCUUUGCAGUGGGUCGG	5422
CGACCCACUGCAAAGACUA	5423	UAGUCUUUGCAGUGGGUCG	5424
GACCCACUGCAAAGACUAU	5425	AUAGUCUUUGCAGUGGGUC	5426
ACCCACUGCAAAGACUAUG	5427	CAUAGUCUUUGCAGUGGGU	5428
ACUGCAAAGACUAUGACAG	5429	CUGUCAUAGUCUUUGCAGU	5430
CUGCAAAGACUAUGACAGC	5431	GCUGUCAUAGUCUUUGCAG	5432
UGCAAAGACUAUGACAGCA	5433	UGCUGUCAUAGUCUUUGCA	5434
GCAAAGACUAUGACAGCAU	5435	AUGCUGUCAUAGUCUUUGC	5436
AAAGACUAUGACAGCAUCA	5437	UGAUGCUGUCAUAGUCUUU	5438
AAGACUAUGACAGCAUCAA	5439	UUGAUGCUGUCAUAGUCUU	5440
AGACUAUGACAGCAUCAAA	5441	UUUGAUGCUGUCAUAGUCU	5442
GACUAUGACAGCAUCAAAU	5443	AUUUGAUGCUGUCAUAGUC	5444
CUAUGACAGCAUCAAAUUU	5445	AAAUUUGAUGCUGUCAUAG	5446
UAUGACAGCAUCAAAUUUC	5447	GAAAUUUGAUGCUGUCAUA	5448
GCAUCAAAUUUCAGGACCU	5449	AGGUCCUGAAAUUUGAUGC	5450
AUCAAAUUUCAGGACCUGC	5451	GCAGGUCCUGAAAUUUGAU	5452
UCAAAUUUCAGGACCUGCA	5453	UGCAGGUCCUGAAAUUUGA	5454
UUCAGGACCUGCAGACAGU	5455	ACUGUCUGCAGGUCCUGAA	5456
UCAGGACCUGCAGACAGUA	5457	UACUGUCUGCAGGUCCUGA	5458
CAGGACCUGCAGACAGUAC	5459	GUACUGUCUGCAGGUCCUG	5460
AGGACCUGCAGACAGUACA	5461	UGUACUGUCUGCAGGUCCU	5462
GGACCUGCAGACAGUACAG	5463	CUGUACUGUCUGCAGGUCC	5464
CUGCAGACAGUACAGGCUA	5465	UAGCCUGUACUGUCUGCAG	5466
GACAGUACAGGCUAGAUAA	5467	UUAUCUAGCCUGUACUGUC	5468
ACAGUACAGGCUAGAUAAC	5469	GUUAUCUAGCCUGUACUGU	5470
CAGUACAGGCUAGAUAACC	5471	GGUUAUCUAGCCUGUACUG	5472
AGUACAGGCUAGAUAACCC	5473	GGGUUAUCUAGCCUGUACU	5474
GUACAGGCUAGAUAACCCA	5475	UGGGUUAUCUAGCCUGUAC	5476
UACAGGCUAGAUAACCCAC	5477	GUGGGUUAUCUAGCCUGUA	5478
GCUAGAUAACCCACCCAAU	5479	AUUGGGUGGGUUAUCUAGC	5480
CUAGAUAACCCACCCAAUU	5481	AAUUGGGUGGGUUAUCUAG	5482
AGAUAACCCACCCAAUUUC	5483	GAAAUUGGGUGGGUUAUCU	5484
GAUAACCCACCCAAUUUCC	5485	GGAAAUUGGGUGGGUUAUC	5486
AACCUUUCAGCAUAACGCC	5487	GGCGUUAUGCUGAAAGGUU	5488
ACCUUUCAGCAUAACGCCU	5489	AGGCGUUAUGCUGAAAGGU	5490
CCUUUCAGCAUAACGCCUC	5491	GAGGCGUUAUGCUGAAAGG	5492
CUUUCAGCAUAACGCCUCA	5493	UGAGGCGUUAUGCUGAAAG	5494
UUUCAGCAUAACGCCUCAC	5495	GUGAGGCGUUAUGCUGAAA	5496
UUCAGCAUAACGCCUCACA	5497	UGUGAGGCGUUAUGCUGAA	5498
UCAGCAUAACGCCUCACAU	5499	AUGUGAGGCGUUAUGCUGA	5500
CAGCAUAACGCCUCACAUC	5501	GAUGUGAGGCGUUAUGCUG	5502
AGCAUAACGCCUCACAUCC	5503	GGAUGUGAGGCGUUAUGCU	5504
GCAUAACGCCUCACAUCCC	5505	GGGAUGUGAGGCGUUAUGC	5506
AACGCCUCACAUCCCAAGU	5507	ACUUGGGAUGUGAGGCGUU	5508
ACGCCUCACAUCCCAAGUC	5509	GACUUGGGAUGUGAGGCGU	5510
CGCCUCACAUCCCAAGUCU	5511	AGACUUGGGAUGUGAGGCG	5512
UCACAUCCCAAGUCUAUAC	5513	GUAUAGACUUGGGAUGUGA	5514
CACAUCCCAAGUCUAUACC	5515	GGUAUAGACUUGGGAUGUG	5516
ACAUCCCAAGUCUAUACCC	5517	GGGUAUAGACUUGGGAUGU	5518
CAUCCCAAGUCUAUACCCU	5519	AGGGUAUAGACUUGGGAUG	5520
AAUGCUGUUCUUUCCUAGC	5521	GCUAGGAAAGAACAGCAUU	5522
AUGCUGUUCUUUCCUAGCC	5523	GGCUAGGAAAGAACAGCAU	5524
CUGUUCUUUCCUAGCCACC	5525	GGUGGCUAGGAAAGAACAG	5526
UGUUCUUUCCUAGCCACCU	5527	AGGUGGCUAGGAAAGAACA	5528
GCCAAGAUCAAGAUGUCCC	5529	GGGACAUCUUGAUCUUGGC	5530
UCUUGAUCCCAGCCUGACU	5531	AGUCAGGCUGGGAUCAAGA	5532
CUUGAUCCCAGCCUGACUG	5533	CAGUCAGGCUGGGAUCAAG	5534
UUGAUCCCAGCCUGACUGC	5535	GCAGUCAGGCUGGGAUCAA	5536
UGAUCCCAGCCUGACUGCU	5537	AGCAGUCAGGCUGGGAUCA	5538
CUGACUGCUGCUACAUCUA	5539	UAGAUGUAGCAGCAGUCAG	5540
GACUGCUGCUACAUCUAAU	5541	AUUAGAUGUAGCAGCAGUC	5542
ACUGCUGCUACAUCUAAUC	5543	GAUUAGAUGUAGCAGCAGU	5544
CUGCUGCUACAUCUAAUCC	5545	GGAUUAGAUGUAGCAGCAG	5546
UGCUGCUACAUCUAAUCCC	5547	GGGAUUAGAUGUAGCAGCA	5548
CCUACCAAUGCCUCCUGUC	5549	GACAGGAGGCAUUGGUAGG	5550
CUACCAAUGCCUCCUGUCC	5551	GGACAGGAGGCAUUGGUAG	5552
CCAAUGCCUCCUGUCCCUA	5553	UAGGGACAGGAGGCAUUGG	5554
CAAUGCCUCCUGUCCCUAA	5555	UUAGGGACAGGAGGCAUUG	5556
AAUGCCUCCUGUCCCUAAA	5557	UUUAGGGACAGGAGGCAUU	5558
CCCAGCAUACUGAUGACAG	5559	CUGUCAUCAGUAUGCUGGG	5560
CCAGCAUACUGAUGACAGC	5561	GCUGUCAUCAGUAUGCUGG	5562
CAUACUGAUGACAGCCCUC	5563	GAGGGCUGUCAUCAGUAUG	5564
AUACUGAUGACAGCCCUCU	5565	AGAGGGCUGUCAUCAGUAU	5566
UACUGAUGACAGCCCUCUC	5567	GAGAGGGCUGUCAUCAGUA	5568
ACUGAUGACAGCCCUCUCU	5569	AGAGAGGGCUGUCAUCAGU	5570
CUGAUGACAGCCCUCUCUG	5571	CAGAGAGGGCUGUCAUCAG	5572
UGAUGACAGCCCUCUCUGA	5573	UCAGAGAGGGCUGUCAUCA	5574
GAUGACAGCCCUCUCUGAC	5575	GUCAGAGAGGGCUGUCAUC	5576
AUGACAGCCCUCUCUGACU	5577	AGUCAGAGAGGGCUGUCAU	5578
UGACAGCCCUCUCUGACUU	5579	AAGUCAGAGAGGGCUGUCA	5580
GACAGCCCUCUCUGACUUU	5581	AAAGUCAGAGAGGGCUGUC	5582
ACAGCCCUCUCUGACUUUA	5583	UAAAGUCAGAGAGGGCUGU	5584
CAGCCCUCUCUGACUUUAC	5585	GUAAAGUCAGAGAGGGCUG	5586
AGCCCUCUCUGACUUUACC	5587	GGUAAAGUCAGAGAGGGCU	5588
GCCCUCUCUGACUUUACCU	5589	AGGUAAAGUCAGAGAGGGC	5590
CCCUCUCUGACUUUACCUU	5591	AAGGUAAAGUCAGAGAGGG	5592
CCUCUCUGACUUUACCUUG	5593	CAAGGUAAAGUCAGAGAGG	5594
CUCUCUGACUUUACCUUGA	5595	UCAAGGUAAAGUCAGAGAG	5596
AGAUCUGUCUUCAUACCCU	5597	AGGGUAUGAAGACAGAUCU	5598
GAUCUGUCUUCAUACCCUU	5599	AAGGGUAUGAAGACAGAUC	5600
CUGUCUUCAUACCCUUCCC	5601	GGGAAGGGUAUGAAGACAG	5602

TABLE 9

	SEQ ID		SEQ ID
Sense Sequence	NO:	Antisense Sequence	NO:
CCAGAGCAAGCCGAAGGCA	5603	UGCCUUCGGCUUGCUCUGG	5604
CAGAGCAAGCCGAAGGCAA	5605	UUGCCUUCGGCUUGCUCUG	5606
AGAGCAAGCCGAAGGCAAG	5607	CUUGCCUUCGGCUUGCUCU	5608
GAGCAAGCCGAAGGCAAGC	5609	GCUUGCCUUCGGCUUGCUC	5610
AGCAAGCCGAAGGCAAGCA	5611	UGCUUGCCUUCGGCUUGCU	5612
GCAAGCCGAAGGCAAGCAC	5613	GUGCUUGCCUUCGGCUUGC	5614
CAAGCCGAAGGCAAGCACG	5615	CGUGCUUGCCUUCGGCUUG	5616
AAGCCGAAGGCAAGCACGA	5617	UCGUGCUUGCCUUCGGCUU	5618
AGCCGAAGGCAAGCACGAU	5619	AUCGUGCUUGCCUUCGGCU	5620
GCCGAAGGCAAGCACGAUG	5621	CAUCGUGCUUGCCUUCGGC	5622
AAGGCAAGCACGAUGGCGC	5623	GCGCCAUCGUGCUUGCCUU	5624
AGGCAAGCACGAUGGCGCU	5625	AGCGCCAUCGUGCUUGCCU	5626
AAGCACGAUGGCGCUCACC	5627	GGUGAGCGCCAUCGUGCUU	5628
AGCACGAUGGCGCUCACCA	5629	UGGUGAGCGCCAUCGUGCU	5630
CUGUAGCAGCCGAGCAUCA	5631	UGAUGCUCGGCUGCUACAG	5632
AGCCGAGCAUCAGCCCGAA	5633	UUCGGGCUGAUGCUCGGCU	5634
GUCAGAGUCUCCAGGCUCA	5635	UGAGCCUGGAGACUCUGAC	5636
UCAGAGUCUCCAGGCUCAG	5637	CUGAGCCUGGAGACUCUGA	5638
CAGAGUCUCCAGGCUCAGG	5639	CCUGAGCCUGGAGACUCUG	5640
AGAGUCUCCAGGCUCAGGU	5641	ACCUGAGCCUGGAGACUCU	5642
GAGUCUCCAGGCUCAGGUG	5643	CACCUGAGCCUGGAGACUC	5644
AGUCUCCAGGCUCAGGUGG	5645	CCACCUGAGCCUGGAGACU	5646
GGGUGGCACAGCUGGCAUA	5647	UAUGCCAGCUGUGCCACCC	5648
GUGGCACAGCUGGCAUACG	5649	CGUAUGCCAGCUGUGCCAC	5650
UGGCACAGCUGGCAUACGC	5651	GCGUAUGCCAGCUGUGCCA	5652
CUCCACAGGUGGCGGUAGA	5653	UCUACCGCCACCUGUGGAG	5654
UCCACAGGUGGCGGUAGAC	5655	GUCUACCGCCACCUGUGGA	5656
UGAGCAGCACGCUGGCGUA	5657	UACGCCAGCGUGCUGCUCA	5658
AGCAGCACGCUGGCGUACA	5659	UGUACGCCAGCGUGCUGCU	5660
GCAGCACGCUGGCGUACAU	5661	AUGUACGCCAGCGUGCUGC	5662
CAGCACGCUGGCGUACAUG	5663	CAUGUACGCCAGCGUGCUG	5664
AGCACGCUGGCGUACAUGC	5665	GCAUGUACGCCAGCGUGCU	5666
GCACGCUGGCGUACAUGCU	5667	AGCAUGUACGCCAGCGUGC	5668
CACGCUGGCGUACAUGCUG	5669	CAGCAUGUACGCCAGCGUG	5670
ACGCUGGCGUACAUGCUGA	5671	UCAGCAUGUACGCCAGCGU	5672
CUGGCGUACAUGCUGAGCG	5673	CGCUCAGCAUGUACGCCAG	5674
UGGCGUACAUGCUGAGCGC	5675	GCGCUCAGCAUGUACGCCA	5676
CGCGCACACGUAGUACACC	5677	GGUGUACUACGUGUGCGCG	5678
GCGCACACGUAGUACACCG	5679	CGGUGUACUACGUGUGCGC	5680
CGCACACGUAGUACACCGC	5681	GCGGUGUACUACGUGUGCG	5682
GCACACGUAGUACACCGCC	5683	GGCGGUGUACUACGUGUGC	5684
CACACGUAGUACACCGCCU	5685	AGGCGGUGUACUACGUGUG	5686
ACACGUAGUACACCGCCUU	5687	AAGGCGGUGUACUACGUGU	5688
CACGUAGUACACCGCCUUG	5689	CAAGGCGGUGUACUACGUG	5690
UAGUACACCGCCUUGCAGC	5691	GCUGCAAGGCGGUGUACUA	5692
CCAAGCUCCACACCACGAA	5693	UUCGUGGUGUGGAGCUUGG	5694
CAAGCUCCACACCACGAAG	5695	CUUCGUGGUGUGGAGCUUG	5696
AAGCUCCACACCACGAAGC	5697	GCUUCGUGGUGUGGAGCUU	5698
AGCUCCACACCACGAAGCC	5699	GGCUUCGUGGUGUGGAGCU	5700
CUCCACACCACGAAGCCGU	5701	ACGGCUUCGUGGUGUGGAG	5702
UCCACACCACGAAGCCGUU	5703	AACGGCUUCGUGGUGUGGA	5704
CCACACCACGAAGCCGUUG	5705	CAACGGCUUCGUGGUGUGG	5706
CACACCACGAAGCCGUUGC	5707	GCAACGGCUUCGUGGUGUG	5708
ACACCACGAAGCCGUUGCC	5709	GGCAACGGCUUCGUGGUGU	5710
CACCACGAAGCCGUUGCCA	5711	UGGCAACGGCUUCGUGGUG	5712
ACCACGAAGCCGUUGCCAG	5713	CUGGCAACGGCUUCGUGGU	5714
CCGCGAAGUCUUCCAGCUC	5715	GAGCUGGAAGACUUCGCGG	5716
CGCGAAGUCUUCCAGCUCA	5717	UGAGCUGGAAGACUUCGCG	5718
GCGAAGUCUUCCAGCUCAG	5719	CUGAGCUGGAAGACUUCGC	5720
UUCCAGCUCAGCAGUGUCU	5721	AGACACUGCUGAGCUGGAA	5722
UCCAGCUCAGCAGUGUCUC	5723	GAGACACUGCUGAGCUGGA	5724
CCAGCUCAGCAGUGUCUCG	5725	CGAGACACUGCUGAGCUGG	5726
CAGCUCAGCAGUGUCUCGU	5727	ACGAGACACUGCUGAGCUG	5728
AGCUCAGCAGUGUCUCGUU	5729	AACGAGACACUGCUGAGCU	5730
GCUCAGCAGUGUCUCGUUC	5731	GAACGAGACACUGCUGAGC	5732
CUCAGCAGUGUCUCGUUCC	5733	GGAACGAGACACUGCUGAG	5734
GUAGCAGACCGACAUCCUU	5735	AAGGAUGUCGGUCUGCUAC	5736
UAGCAGACCGACAUCCUUC	5737	GAAGGAUGUCGGUCUGCUA	5738
AGCAGACCGACAUCCUUCU	5739	AGAAGGAUGUCGGUCUGCU	5740
AGACCGACAUCCUUCUGGG	5741	CCCAGAAGGAUGUCGGUCU	5742
GACCGACAUCCUUCUGGGC	5743	GCCCAGAAGGAUGUCGGUC	5744
CCGACAUCCUUCUGGGCCU	5745	AGGCCCAGAAGGAUGUCGG	5746
CGACAUCCUUCUGGGCCUA	5747	UAGGCCCAGAAGGAUGUCG	5748
GACAUCCUUCUGGGCCUAC	5749	GUAGGCCCAGAAGGAUGUC	5750
CUUCUGGGCCUACAGGUGG	5751	CCACCUGUAGGCCCAGAAG	5752
UUCUGGGCCUACAGGUGGG	5753	CCCACCUGUAGGCCCAGAA	5754
UCUGGGCCUACAGGUGGGU	5755	ACCCACCUGUAGGCCCAGA	5756
GGCCUACAGGUGGGUGGAA	5757	UUCCACCCACCUGUAGGCC	5758
CCUACAGGUGGGUGGAAGG	5759	CCUUCCACCCACCUGUAGG	5760
CUACAGGUGGGUGGAAGGC	5761	GCCUUCCACCCACCUGUAG	5762
UACAGGUGGGUGGAAGGCG	5763	CGCCUUCCACCCACCUGUA	5764
ACUUCCCUGCAGCCUGCCU	5765	AGGCAGGCUGCAGGGAAGU	5766
CCUGCAGCCUGCCUCUUUU	5767	AAAAGAGGCAGGCUGCAGG	5768
CUGCAGCCUGCCUCUUUUC	5769	GAAAAGAGGCAGGCUGCAG	5770
GCAGCCUGCCUCUUUUCUG	5771	CAGAAAAGAGGCAGGCUGC	5772
CAGCCUGCCUCUUUUCUGC	5773	GCAGAAAAGAGGCAGGCUG	5774
AGCCUGCCUCUUUUCUGCC	5775	GGCAGAAAAGAGGCAGGCU	5776
GCCUCUUUUCUGCCUGGGA	5777	UCCCAGGCAGAAAAGAGGC	5778
CUUUUCUGCCUGGGAGUCC	5779	GGACUCCCAGGCAGAAAAG	5780
UUUUCUGCCUGGGAGUCCU	5781	AGGACUCCCAGGCAGAAAA	5782
UUCUGCCUGGGAGUCCUGA	5783	UCAGGACUCCCAGGCAGAA	5784
UCUGCCUGGGAGUCCUGAC	5785	GUCAGGACUCCCAGGCAGA	5786
UGCCUGGGAGUCCUGACUU	5787	AAGUCAGGACUCCCAGGCA	5788
GCCUGGGAGUCCUGACUUC	5789	GAAGUCAGGACUCCCAGGC	5790
CUGGGAGUCCUGACUUCCA	5791	UGGAAGUCAGGACUCCCAG	5792
UGGGAGUCCUGACUUCCAC	5793	GUGGAAGUCAGGACUCCCA	5794
GGGAGUCCUGACUUCCACG	5795	CGUGGAAGUCAGGACUCCC	5796
GGAGUCCUGACUUCCACGA	5797	UCGUGGAAGUCAGGACUCC	5798
GAGUCCUGACUUCCACGAG	5799	CUCGUGGAAGUCAGGACUC	5800
AGUCCUGACUUCCACGAGG	5801	CCUCGUGGAAGUCAGGACU	5802
CCUGACUUCCACGAGGACC	5803	GGUCCUCGUGGAAGUCAGG	5804
CUGACUUCCACGAGGACCC	5805	GGGUCCUCGUGGAAGUCAG	5806
UGACUUCCACGAGGACCCA	5807	UGGGUCCUCGUGGAAGUCA	5808
GACUUCCACGAGGACCCAG	5809	CUGGGUCCUCGUGGAAGUC	5810
ACUUCCACGAGGACCCAGA	5811	UCUGGGUCCUCGUGGAAGU	5812
CUUCCACGAGGACCCAGAC	5813	GUCUGGGUCCUCGUGGAAG	5814
UUCCACGAGGACCCAGACC	5815	GGUCUGGGUCCUCGUGGAA	5816
CCCUGCUCCCAGUCAGUUG	5817	CAACUGACUGGGAGCAGGG	5818
CCUGCUCCCAGUCAGUUGA	5819	UCAACUGACUGGGAGCAGG	5820
CUGCUCCCAGUCAGUUGAC	5821	GUCAACUGACUGGGAGCAG	5822
UGCUCCCAGUCAGUUGACC	5823	GGUCAACUGACUGGGAGCA	5824
CCCAGUCAGUUGACCUGCC	5825	GGCAGGUCAACUGACUGGG	5826
CCAGUCAGUUGACCUGCCC	5827	GGGCAGGUCAACUGACUGG	5828
GCCUCCUUCCCAGAGCUCA	5829	UGAGCUCUGGGAAGGAGGC	5830
CCUCCUUCCCAGAGCUCAG	5831	CUGAGCUCUGGGAAGGAGG	5832
CUCCUUCCCAGAGCUCAGU	5833	ACUGAGCUCUGGGAAGGAG	5834
UCCUUCCCAGAGCUCAGUG	5835	CACUGAGCUCUGGGAAGGA	5836
CCUUCCCAGAGCUCAGUGG	5837	CCACUGAGCUCUGGGAAGG	5838
UUCCCAGAGCUCAGUGGUA	5839	UACCACUGAGCUCUGGGAA	5840
UCCCAGAGCUCAGUGGUAA	5841	UUACCACUGAGCUCUGGGA	5842
CAGGCUGUCACUAUCUCUA	5843	UAGAGAUAGUGACAGCCUG	5844
AGGCUGUCACUAUCUCUAC	5845	GUAGAGAUAGUGACAGCCU	5846
UCUCUACCACCACUCCUCU	5847	AGAGGAGUGGUGGUAGAGA	5848
CCACCACUCCUCUAGUCUG	5849	CAGACUAGAGGAGUGGUGG	5850
CACCACUCCUCUAGUCUGG	5851	CCAGACUAGAGGAGUGGUG	5852
ACCACUCCUCUAGUCUGGC	5853	GCCAGACUAGAGGAGUGGU	5854
CCACUCCUCUAGUCUGGCC	5855	GGCCAGACUAGAGGAGUGG	5856
CACUCCUCUAGUCUGGCCC	5857	GGGCCAGACUAGAGGAGUG	5858
AUUCUAGCACAUCUGGGCA	5859	UGCCCAGAUGUGCUAGAAU	5860
UUCUAGCACAUCUGGGCAA	5861	UUGCCCAGAUGUGCUAGAA	5862
UCUAGCACAUCUGGGCAAA	5863	UUUGCCCAGAUGUGCUAGA	5864
CUAGCACAUCUGGGCAAAA	5865	UUUUGCCCAGAUGUGCUAG	5866
GGGUGUAAAGGGACGUGCA	5867	UGCACGUCCCUUUACACCC	5868
GGUGUAAAGGGACGUGCAC	5869	GUGCACGUCCCUUUACACC	5870
GUGUAAAGGGACGUGCACA	5871	UGUGCACGUCCCUUUACAC	5872
UGUAAAGGGACGUGCACAG	5873	CUGUGCACGUCCCUUUACA	5874
GUAAAGGGACGUGCACAGA	5875	UCUGUGCACGUCCCUUUAC	5876
UAAAGGGACGUGCACAGAU	5877	AUCUGUGCACGUCCCUUUA	5878
AAAGGGACGUGCACAGAUC	5879	GAUCUGUGCACGUCCCUUU	5880
AAGGGACGUGCACAGAUCU	5881	AGAUCUGUGCACGUCCCUU	5882
AGGGACGUGCACAGAUCUA	5883	UAGAUCUGUGCACGUCCCU	5884
CGUGCACAGAUCUACUUAC	5885	GUAAGUAGAUCUGUGCACG	5886
GUGCACAGAUCUACUUACC	5887	GGUAAGUAGAUCUGUGCAC	5888
UGCACAGAUCUACUUACCA	5889	UGGUAAGUAGAUCUGUGCA	5890
GCACAGAUCUACUUACCAA	5891	UUGGUAAGUAGAUCUGUGC	5892
CACAGAUCUACUUACCAAG	5893	CUUGGUAAGUAGAUCUGUG	5894
ACAGAUCUACUUACCAAGC	5895	GCUUGGUAAGUAGAUCUGU	5896
CAGAUCUACUUACCAAGCU	5897	AGCUUGGUAAGUAGAUCUG	5898
AGAUCUACUUACCAAGCUG	5899	CAGCUUGGUAAGUAGAUCU	5900
AUCUACUUACCAAGCUGGG	5901	CCCAGCUUGGUAAGUAGAU	5902
UCUACUUACCAAGCUGGGA	5903	UCCCAGCUUGGUAAGUAGA	5904
CUUACCAAGCUGGGAGCAA	5905	UUGCUCCCAGCUUGGUAAG	5906
UUACCAAGCUGGGAGCAAG	5907	CUUGCUCCCAGCUUGGUAA	5908
UACCAAGCUGGGAGCAAGC	5909	GCUUGCUCCCAGCUUGGUA	5910
ACCAAGCUGGGAGCAAGCA	5911	UGCUUGCUCCCAGCUUGGU	5912
GCUGGGAGCAAGCAGGAUU	5913	AAUCCUGCUUGCUCCCAGC	5914
CUGGGAGCAAGCAGGAUUG	5915	CAAUCCUGCUUGCUCCCAG	5916
UGGGAGCAAGCAGGAUUGG	5917	CCAAUCCUGCUUGCUCCCA	5918
GGGAGCAAGCAGGAUUGGG	5919	CCCAAUCCUGCUUGCUCCC	5920
AAAGGUUAAGCAGCAGUAG	5921	CUACUGCUGCUUAACCUUU	5922
AAGGUUAAGCAGCAGUAGG	5923	CCUACUGCUGCUUAACCUU	5924
AGGUUAAGCAGCAGUAGGC	5925	GCCUACUGCUGCUUAACCU	5926
GGUGCCUACUCCUGUCCUG	5927	CAGGACAGGAGUAGGCACC	5928
GUGCCUACUCCUGUCCUGU	5929	ACAGGACAGGAGUAGGCAC	5930
UGCCUACUCCUGUCCUGUG	5931	CACAGGACAGGAGUAGGCA	5932
GCCUACUCCUGUCCUGUGC	5933	GCACAGGACAGGAGUAGGC	5934
CCUACUCCUGUCCUGUGCC	5935	GGCACAGGACAGGAGUAGG	5936
CUACUCCUGUCCUGUGCCU	5937	AGGCACAGGACAGGAGUAG	5938
UACUCCUGUCCUGUGCCUA	5939	UAGGCACAGGACAGGAGUA	5940
ACUCCUGUCCUGUGCCUAU	5941	AUAGGCACAGGACAGGAGU	5942
CUCCUGUCCUGUGCCUAUC	5943	GAUAGGCACAGGACAGGAG	5944
UCCUGUCCUGUGCCUAUCA	5945	UGAUAGGCACAGGACAGGA	5946
GUGCCUAUCACAUUUGCAG	5947	CUGCAAAUGUGAUAGGCAC	5948
CUAUCACAUUUGCAGAGGG	5949	CCCUCUGCAAAUGUGAUAG	5950
UAUCACAUUUGCAGAGGGU	5951	ACCCUCUGCAAAUGUGAUA	5952
AUCACAUUUGCAGAGGGUA	5953	UACCCUCUGCAAAUGUGAU	5954
UCACAUUUGCAGAGGGUAA	5955	UUACCCUCUGCAAAUGUGA	5956
CACAUUUGCAGAGGGUAAG	5957	CUUACCCUCUGCAAAUGUG	5958
ACAUUUGCAGAGGGUAAGA	5959	UCUUACCCUCUGCAAAUGU	5960
CUCACCCUGCUCCUUCCCA	5961	UGGGAAGGAGCAGGGUGAG	5962
CACCCUGCUCCUUCCCAUC	5963	GAUGGGAAGGAGCAGGGUG	5964
CCUGCUCCUUCCCAUCACC	5965	GGUGAUGGGAAGGAGCAGG	5966
UGCUCCUUCCCAUCACCAA	5967	UUGGUGAUGGGAAGGAGCA	5968
CAGUAAGAUUCCCUGGUGG	5969	CCACCAGGGAAUCUUACUG	5970
AGUAAGAUUCCCUGGUGGU	5971	ACCACCAGGGAAUCUUACU	5972
GUAAGAUUCCCUGGUGGUG	5973	CACCACCAGGGAAUCUUAC	5974
UAAGAUUCCCUGGUGGUGG	5975	CCACCACCAGGGAAUCUUA	5976
AAGAUUCCCUGGUGGUGGA	5977	UCCACCACCAGGGAAUCUU	5978
UCCCUGGUGGUGGAAGGAA	5979	UUCCUUCCACCACCAGGGA	5980
UCUGCUGAAUCCUGGUCCU	5981	AGGACCAGGAUUCAGCAGA	5982
CUGCUGAAUCCUGGUCCUG	5983	CAGGACCAGGAUUCAGCAG	5984
UGCUGAAUCCUGGUCCUGC	5985	GCAGGACCAGGAUUCAGCA	5986
UGAAUCCUGGUCCUGCUUC	5987	GAAGCAGGACCAGGAUUCA	5988
GAAUCCUGGUCCUGCUUCU	5989	AGAAGCAGGACCAGGAUUC	5990
AAUCCUGGUCCUGCUUCUG	5991	CAGAAGCAGGACCAGGAUU	5992
AUCCUGGUCCUGCUUCUGU	5993	ACAGAAGCAGGACCAGGAU	5994
UCCUGGUCCUGCUUCUGUU	5995	AACAGAAGCAGGACCAGGA	5996
CCUGGUCCUGCUUCUGUUC	5997	GAACAGAAGCAGGACCAGG	5998
CUGGUCCUGCUUCUGUUCU	5999	AGAACAGAAGCAGGACCAG	6000
UUCUGUUCUCAUCCCUCCC	6001	GGGAGGGAUGAGAACAGAA	6002
CUUCUGCAGUGUGUAUGUU	6003	AACAUACACACUGCAGAAG	6004
UUCUGCAGUGUGUAUGUUG	6005	CAACAUACACACUGCAGAA	6006
UCUGCAGUGUGUAUGUUGC	6007	GCAACAUACACACUGCAGA	6008
CUGCAGUGUGUAUGUUGCC	6009	GGCAACAUACACACUGCAG	6010
UGCAGUGUGUAUGUUGCCU	6011	AGGCAACAUACACACUGCA	6012
GCAGUGUGUAUGUUGCCUG	6013	CAGGCAACAUACACACUGC	6014
CAGUGUGUAUGUUGCCUGG	6015	CCAGGCAACAUACACACUG	6016
AGUGUGUAUGUUGCCUGGU	6017	ACCAGGCAACAUACACACU	6018
GUGUGUAUGUUGCCUGGUC	6019	GACCAGGCAACAUACACAC	6020
UGUGUAUGUUGCCUGGUCU	6021	AGACCAGGCAACAUACACA	6022
GUGUAUGUUGCCUGGUCUC	6023	GAGACCAGGCAACAUACAC	6024
UGUAUGUUGCCUGGUCUCU	6025	AGAGACCAGGCAACAUACA	6026
GUAUGUUGCCUGGUCUCUC	6027	GAGAGACCAGGCAACAUAC	6028
UAUGUUGCCUGGUCUCUCU	6029	AGAGAGACCAGGCAACAUA	6030
AUGUUGCCUGGUCUCUCUG	6031	CAGAGAGACCAGGCAACAU	6032
UGUUGCCUGGUCUCUCUGG	6033	CCAGAGAGACCAGGCAACA	6034
GUUGCCUGGUCUCUCUGGC	6035	GCCAGAGAGACCAGGCAAC	6036
UUGCCUGGUCUCUCUGGCC	6037	GGCCAGAGAGACCAGGCAA	6038
CUGGUCUCUCUGGCCUGCA	6039	UGCAGGCCAGAGAGACCAG	6040
CCUGCAGAGGUGACCCAAA	6041	UUUGGGUCACCUCUGCAGG	6042
CUGCCUUAUCCUUGCCUGU	6043	ACAGGCAAGGAUAAGGCAG	6044
UGCCUUAUCCUUGCCUGUU	6045	AACAGGCAAGGAUAAGGCA	6046
GCCUUAUCCUUGCCUGUUU	6047	AAACAGGCAAGGAUAAGGC	6048
AGUCUCCUGGUCCGGCUGA	6049	UCAGCCGGACCAGGAGACU	6050
GUCAAUGACAGCUUUUCCA	6051	UGGAAAAGCUGUCAUUGAC	6052
UGACAGCUUUUCCAUGUAA	6053	UUACAUGGAAAAGCUGUCA	6054
GACAGCUUUUCCAUGUAAG	6055	CUUACAUGGAAAAGCUGUC	6056
ACAGCUUUUCCAUGUAAGG	6057	CCUUACAUGGAAAAGCUGU	6058
CAGCUUUUCCAUGUAAGGC	6059	GCCUUACAUGGAAAAGCUG	6060
AGCUUUUCCAUGUAAGGCA	6061	UGCCUUACAUGGAAAAGCU	6062
UGUAAGGCAUGGUGCUAGG	6063	CCUAGCACCAUGCCUUACA	6064
GUAAGGCAUGGUGCUAGGU	6065	ACCUAGCACCAUGCCUUAC	6066
UAAGGCAUGGUGCUAGGUU	6067	AACCUAGCACCAUGCCUUA	6068
GCAUGGUGCUAGGUUCCAG	6069	CUGGAACCUAGCACCAUGC	6070
CAUGGUGCUAGGUUCCAGG	6071	CCUGGAACCUAGCACCAUG	6072
AUGGUGCUAGGUUCCAGGA	6073	UCCUGGAACCUAGCACCAU	6074
UGGUGCUAGGUUCCAGGAG	6075	CUCCUGGAACCUAGCACCA	6076
GGUGCUAGGUUCCAGGAGG	6077	CCUCCUGGAACCUAGCACC	6078
GUGCUAGGUUCCAGGAGGA	6079	UCCUCCUGGAACCUAGCAC	6080
UGCAUGGAGGCAUAAUGGU	6081	ACCAUUAUGCCUCCAUGCA	6082
GCAUGGAGGCAUAAUGGUU	6083	AACCAUUAUGCCUCCAUGC	6084
CAUGGAGGCAUAAUGGUUA	6085	UAACCAUUAUGCCUCCAUG	6086
AUGGAGGCAUAAUGGUUAG	6087	CUAACCAUUAUGCCUCCAU	6088
UGGAGGCAUAAUGGUUAGG	6089	CCUAACCAUUAUGCCUCCA	6090
GGAGGCAUAAUGGUUAGGG	6091	CCCUAACCAUUAUGCCUCC	6092
GAGGCAUAAUGGUUAGGGA	6093	UCCCUAACCAUUAUGCCUC	6094
CAUAAUGGUUAGGGAGUCA	6095	UGACUCCCUAACCAUUAUG	6096
AUAAUGGUUAGGGAGUCAU	6097	AUGACUCCCUAACCAUUAU	6098
UAAUGGUUAGGGAGUCAUG	6099	CAUGACUCCCUAACCAUUA	6100
GGUUAGGGAGUCAUGACAC	6101	GUGUCAUGACUCCCUAACC	6102
CAUUACCAGGCUGCACCAG	6103	CUGGUGCAGCCUGGUAAUG	6104
AUUACCAGGCUGCACCAGG	6105	CCUGGUGCAGCCUGGUAAU	6106
UACCAGGCUGCACCAGGAU	6107	AUCCUGGUGCAGCCUGGUA	6108
ACCAGGCUGCACCAGGAUA	6109	UAUCCUGGUGCAGCCUGGU	6110
CCAGGCUGCACCAGGAUAC	6111	GUAUCCUGGUGCAGCCUGG	6112
AAAGGAUGAGUAGGGACAU	6113	AUGUCCCUACUCAUCCUUU	6114
AAGGAUGAGUAGGGACAUA	6115	UAUGUCCCUACUCAUCCUU	6116
AGGAUGAGUAGGGACAUAC	6117	GUAUGUCCCUACUCAUCCU	6118
GUAGGGACAUACUAAGAAG	6119	CUUCUUAGUAUGUCCCUAC	6120
GGACAUACUAAGAAGCAGC	6121	GCUGCUUCUUAGUAUGUCC	6122
AUACUAAGAAGCAGCCCUC	6123	GAGGGCUGCUUCUUAGUAU	6124
UACUAAGAAGCAGCCCUCU	6125	AGAGGGCUGCUUCUUAGUA	6126
ACUAAGAAGCAGCCCUCUC	6127	GAGAGGGCUGCUUCUUAGU	6128
AGAAGCAGCCCUCUCCUCU	6129	AGAGGAGAGGGCUGCUUCU	6130
GAAGCAGCCCUCUCCUCUU	6131	AAGAGGAGAGGGCUGCUUC	6132
CAGCCCUCUCCUCUUGGAA	6133	UUCCAAGAGGAGAGGGCUG	6134
GCCUGGCAGAUGGAUAGAG	6135	CUCUAUCCAUCUGCCAGGC	6136
CCUGGCAGAUGGAUAGAGC	6137	GCUCUAUCCAUCUGCCAGG	6138
CUGGCAGAUGGAUAGAGCU	6139	AGCUCUAUCCAUCUGCCAG	6140
UGGCAGAUGGAUAGAGCUG	6141	CAGCUCUAUCCAUCUGCCA	6142
GGCAGAUGGAUAGAGCUGG	6143	CCAGCUCUAUCCAUCUGCC	6144
GCAGAUGGAUAGAGCUGGG	6145	CCCAGCUCUAUCCAUCUGC	6146
AAAGGCCUCUGCUCAAGUA	6147	UACUUGAGCAGAGGCCUUU	6148
AAGGCCUCUGCUCAAGUAA	6149	UUACUUGAGCAGAGGCCUU	6150
AGGCCUCUGCUCAAGUAAC	6151	GUUACUUGAGCAGAGGCCU	6152
CAGGAGCACUGUCUUAGUU	6153	AACUAAGACAGUGCUCCUG	6154
AGGAGCACUGUCUUAGUUU	6155	AAACUAAGACAGUGCUCCU	6156
GGAGCACUGUCUUAGUUUG	6157	CAAACUAAGACAGUGCUCC	6158
GAGCACUGUCUUAGUUUGG	6159	CCAAACUAAGACAGUGCUC	6160
AGCACUGUCUUAGUUUGGG	6161	CCCAAACUAAGACAGUGCU	6162
GUUCUUCCAAAGCAGAGCU	6163	AGCUCUGCUUUGGAAGAAC	6164
AGCAGAGCUUGAGCUAAGG	6165	CCUUAGCUCAAGCUCUGCU	6166
GCAGAGCUUGAGCUAAGGG	6167	CCCUUAGCUCAAGCUCUGC	6168
CAGAGCUUGAGCUAAGGGC	6169	GCCCUUAGCUCAAGCUCUG	6170
GCUUGAGCUAAGGGCUUGG	6171	CCAAGCCCUUAGCUCAAGC	6172
UUGAGCUAAGGGCUUGGGU	6173	ACCCAAGCCCUUAGCUCAA	6174
UGAGCUAAGGGCUUGGGUA	6175	UACCCAAGCCCUUAGCUCA	6176
GAGCUAAGGGCUUGGGUAC	6177	GUACCCAAGCCCUUAGCUC	6178
AGCUAAGGGCUUGGGUACA	6179	UGUACCCAAGCCCUUAGCU	6180
GCUAAGGGCUUGGGUACAG	6181	CUGUACCCAAGCCCUUAGC	6182
AGGGCUUGGGUACAGGUGA	6183	UCACCUGUACCCAAGCCCU	6184
GGGCUUGGGUACAGGUGAU	6185	AUCACCUGUACCCAAGCCC	6186
GGCUUGGGUACAGGUGAUC	6187	GAUCACCUGUACCCAAGCC	6188
GCUUGGGUACAGGUGAUCC	6189	GGAUCACCUGUACCCAAGC	6190
AGGUGAUCCUGUAUUCUUG	6191	CAAGAAUACAGGAUCACCU	6192
GGUGAUCCUGUAUUCUUGA	6193	UCAAGAAUACAGGAUCACC	6194
GUGAUCCUGUAUUCUUGAG	6195	CUCAAGAAUACAGGAUCAC	6196
UGAUCCUGUAUUCUUGAGC	6197	GCUCAAGAAUACAGGAUCA	6198
UCCUGUAUUCUUGAGCUAA	6199	UUAGCUCAAGAAUACAGGA	6200
CCUGUAUUCUUGAGCUAAG	6201	CUUAGCUCAAGAAUACAGG	6202
UGUAUUCUUGAGCUAAGGG	6203	CCCUUAGCUCAAGAAUACA	6204
GUAUUCUUGAGCUAAGGGC	6205	GCCCUUAGCUCAAGAAUAC	6206
UCUUGAGCUAAGGGCUUGG	6207	CCAAGCCCUUAGCUCAAGA	6208
UUGAGCUAAGGGCUUGGGU	6209	ACCCAAGCCCUUAGCUCAA	6210
UGAGCUAAGGGCUUGGGUA	6211	UACCCAAGCCCUUAGCUCA	6212
GAGCUAAGGGCUUGGGUAC	6213	GUACCCAAGCCCUUAGCUC	6214
AGCUAAGGGCUUGGGUACA	6215	UGUACCCAAGCCCUUAGCU	6216
GCUAAGGGCUUGGGUACAG	6217	CUGUACCCAAGCCCUUAGC	6218
AGGGCUUGGGUACAGGUGA	6219	UCACCUGUACCCAAGCCCU	6220
GGGCUUGGGUACAGGUGAU	6221	AUCACCUGUACCCAAGCCC	6222
GGCUUGGGUACAGGUGAUC	6223	GAUCACCUGUACCCAAGCC	6224
GCUUGGGUACAGGUGAUCC	6225	GGAUCACCUGUACCCAAGC	6226
AGGUGAUCCUGUAUUUGGG	6227	CCCAAAUACAGGAUCACCU	6228
GGUGAUCCUGUAUUUGGGA	6229	UCCCAAAUACAGGAUCACC	6230
AUCCUGUAUUUGGGAGGUU	6231	AACCUCCCAAAUACAGGAU	6232
UCCUGUAUUUGGGAGGUUA	6233	UAACCUCCCAAAUACAGGA	6234
CCUGUAUUUGGGAGGUUAA	6235	UUAACCUCCCAAAUACAGG	6236
CUGUAUUUGGGAGGUUAAC	6237	GUUAACCUCCCAAAUACAG	6238
UGUAUUUGGGAGGUUAACU	6239	AGUUAACCUCCCAAAUACA	6240
GUAUUUGGGAGGUUAACUC	6241	GAGUUAACCUCCCAAAUAC	6242
UAUUUGGGAGGUUAACUCA	6243	UGAGUUAACCUCCCAAAUA	6244
GGAGGUUAACUCAGGAAGU	6245	ACUUCCUGAGUUAACCUCC	6246
GAGGUUAACUCAGGAAGUG	6247	CACUUCCUGAGUUAACCUC	6248
AGGUUAACUCAGGAAGUGA	6249	UCACUUCCUGAGUUAACCU	6250
UCAGGAAGUGAGGGCAUAA	6251	UUAUGCCCUCACUUCCUGA	6252
CAGGAAGUGAGGGCAUAAG	6253	CUUAUGCCCUCACUUCCUG	6254
AGGAAGUGAGGGCAUAAGG	6255	CCUUAUGCCCUCACUUCCU	6256
GGAAGUGAGGGCAUAAGGU	6257	ACCUUAUGCCCUCACUUCC	6258
GAAGUGAGGGCAUAAGGUA	6259	UACCUUAUGCCCUCACUUC	6260
AAGUGAGGGCAUAAGGUAA	6261	UUACCUUAUGCCCUCACUU	6262
AGUGAGGGCAUAAGGUAAA	6263	UUUACCUUAUGCCCUCACU	6264
AAAGCCAUUAAGAGUAUGU	6265	ACAUACUCUUAAUGGCUUU	6266
AAGCCAUUAAGAGUAUGUU	6267	AACAUACUCUUAAUGGCUU	6268
AGCCAUUAAGAGUAUGUUA	6269	UAACAUACUCUUAAUGGCU	6270
UAAGAGUAUGUUAAGUCCC	6271	GGGACUUAACAUACUCUUA	6272
AAGAGUAUGUUAAGUCCCU	6273	AGGGACUUAACAUACUCUU	6274
AGAGUAUGUUAAGUCCCUU	6275	AAGGGACUUAACAUACUCU	6276
GAGUAUGUUAAGUCCCUUC	6277	GAAGGGACUUAACAUACUC	6278
AGUAUGUUAAGUCCCUUCA	6279	UGAAGGGACUUAACAUACU	6280
GUAUGUUAAGUCCCUUCAG	6281	CUGAAGGGACUUAACAUAC	6282
UAUGUUAAGUCCCUUCAGU	6283	ACUGAAGGGACUUAACAUA	6284
AUGUUAAGUCCCUUCAGUA	6285	UACUGAAGGGACUUAACAU	6286
UGUUAAGUCCCUUCAGUAG	6287	CUACUGAAGGGACUUAACA	6288
GUUAAGUCCCUUCAGUAGG	6289	CCUACUGAAGGGACUUAAC	6290
UUAAGUCCCUUCAGUAGGC	6291	GCCUACUGAAGGGACUUAA	6292
UAAGUCCCUUCAGUAGGCC	6293	GGCCUACUGAAGGGACUUA	6294
AAGUCCCUUCAGUAGGCCU	6295	AGGCCUACUGAAGGGACUU	6296
AGUCCCUUCAGUAGGCCUU	6297	AAGGCCUACUGAAGGGACU	6298
GUCCCUUCAGUAGGCCUUG	6299	CAAGGCCUACUGAAGGGAC	6300
UCCCUUCAGUAGGCCUUGG	6301	CCAAGGCCUACUGAAGGGA	6302
CCCUUCAGUAGGCCUUGGG	6303	CCCAAGGCCUACUGAAGGG	6304
CCUUCAGUAGGCCUUGGGA	6305	UCCCAAGGCCUACUGAAGG	6306
CUUCAGUAGGCCUUGGGAA	6307	UUCCCAAGGCCUACUGAAG	6308
AAAAGUAUAGAUUGCCCAA	6309	UUGGGCAAUCUAUACUUUU	6310
AAAGUAUAGAUUGCCCAAG	6311	CUUGGGCAAUCUAUACUUU	6312
AAGUAUAGAUUGCCCAAGA	6313	UCUUGGGCAAUCUAUACUU	6314
AAAGACUGGCAGGGUGAUC	6315	GAUCACCCUGCCAGUCUUU	6316
AAGACUGGCAGGGUGAUCA	6317	UGAUCACCCUGCCAGUCUU	6318
CUGGCAGGGUGAUCAGUCC	6319	GGACUGAUCACCCUGCCAG	6320
GAAUGUACUUAAUGAGUGG	6321	CCACUCAUUAAGUACAUUC	6322
AAUGUACUUAAUGAGUGGG	6323	CCCACUCAUUAAGUACAUU	6324
UGUACUUAAUGAGUGGGCU	6325	AGCCCACUCAUUAAGUACA	6326
GUACUUAAUGAGUGGGCUA	6327	UAGCCCACUCAUUAAGUAC	6328
UACUUAAUGAGUGGGCUAC	6329	GUAGCCCACUCAUUAAGUA	6330
CUUAAUGAGUGGGCUACAG	6331	CUGUAGCCCACUCAUUAAG	6332
UAAUGAGUGGGCUACAGCG	6333	CGCUGUAGCCCACUCAUUA	6334
AAUGAGUGGGCUACAGCGU	6335	ACGCUGUAGCCCACUCAUU	6336
AUGAGUGGGCUACAGCGUA	6337	UACGCUGUAGCCCACUCAU	6338
UGAGUGGGCUACAGCGUAU	6339	AUACGCUGUAGCCCACUCA	6340
GAGUGGGCUACAGCGUAUC	6341	GAUACGCUGUAGCCCACUC	6342
AGUGGGCUACAGCGUAUCC	6343	GGAUACGCUGUAGCCCACU	6344
GUGGGCUACAGCGUAUCCU	6345	AGGAUACGCUGUAGCCCAC	6346
UGGGCUACAGCGUAUCCUC	6347	GAGGAUACGCUGUAGCCCA	6348
AGAGUUGUUCUACCUGGGU	6349	ACCCAGGUAGAACAACUCU	6350
GAGUUGUUCUACCUGGGUA	6351	UACCCAGGUAGAACAACUC	6352
AGUUGUUCUACCUGGGUAU	6353	AUACCCAGGUAGAACAACU	6354
GUUGUUCUACCUGGGUAUA	6355	UAUACCCAGGUAGAACAAC	6356
UUGUUCUACCUGGGUAUAU	6357	AUAUACCCAGGUAGAACAA	6358
UGUUCUACCUGGGUAUAUC	6359	GAUAUACCCAGGUAGAACA	6360
GUUCUACCUGGGUAUAUCC	6361	GGAUAUACCCAGGUAGAAC	6362
UACCUGGGUAUAUCCAAAA	6363	UUUUGGAUAUACCCAGGUA	6364
AGGGUAUGGAGUUUACGAG	6365	CUCGUAAACUCCAUACCCU	6366
GGGUAUGGAGUUUACGAGG	6367	CCUCGUAAACUCCAUACCC	6368
GGUAUGGAGUUUACGAGGG	6369	CCCUCGUAAACUCCAUACC	6370
GUAUGGAGUUUACGAGGGU	6371	ACCCUCGUAAACUCCAUAC	6372
UAUGGAGUUUACGAGGGUU	6373	AACCCUCGUAAACUCCAUA	6374
AUGGAGUUUACGAGGGUUC	6375	GAACCCUCGUAAACUCCAU	6376
UGGAGUUUACGAGGGUUCA	6377	UGAACCCUCGUAAACUCCA	6378
GGAGUUUACGAGGGUUCAA	6379	UUGAACCCUCGUAAACUCC	6380
GAGUUUACGAGGGUUCAAG	6381	CUUGAACCCUCGUAAACUC	6382
AGUUUACGAGGGUUCAAGG	6383	CCUUGAACCCUCGUAAACU	6384
GUUUACGAGGGUUCAAGGU	6385	ACCUUGAACCCUCGUAAAC	6386
UUUACGAGGGUUCAAGGUA	6387	UACCUUGAACCCUCGUAAA	6388
CGAGGGUUCAAGGUAUUUG	6389	CAAAUACCUUGAACCCUCG	6390
GAGGGUUCAAGGUAUUUGG	6391	CCAAAUACCUUGAACCCUC	6392
AGGGUUCAAGGUAUUUGGU	6393	ACCAAAUACCUUGAACCCU	6394
GGGUUCAAGGUAUUUGGUU	6395	AACCAAAUACCUUGAACCC	6396
GGUUCAAGGUAUUUGGUUC	6397	GAACCAAAUACCUUGAACC	6398
GUUCAAGGUAUUUGGUUCA	6399	UGAACCAAAUACCUUGAAC	6400
UUCAAGGUAUUUGGUUCAG	6401	CUGAACCAAAUACCUUGAA	6402
UCAAGGUAUUUGGUUCAGG	6403	CCUGAACCAAAUACCUUGA	6404
CAACUGGCCAGGUCACAGG	6405	CCUGUGACCUGGCCAGUUG	6406
GCCAGGUCACAGGGCAAUC	6407	GAUUGCCCUGUGACCUGGC	6408
CCAGGUCACAGGGCAAUCA	6409	UGAUUGCCCUGUGACCUGG	6410
AGGUCACAGGGCAAUCAAG	6411	CUUGAUUGCCCUGUGACCU	6412
GGUCACAGGGCAAUCAAGU	6413	ACUUGAUUGCCCUGUGACC	6414
GUCACAGGGCAAUCAAGUU	6415	AACUUGAUUGCCCUGUGAC	6416
UCACAGGGCAAUCAAGUUA	6417	UAACUUGAUUGCCCUGUGA	6418
CACAGGGCAAUCAAGUUAC	6419	GUAACUUGAUUGCCCUGUG	6420
ACAGGGCAAUCAAGUUACU	6421	AGUAACUUGAUUGCCCUGU	6422
CAGGGCAAUCAAGUUACUC	6423	GAGUAACUUGAUUGCCCUG	6424
AGGGCAAUCAAGUUACUCU	6425	AGAGUAACUUGAUUGCCCU	6426
CAAUCAAGUUACUCUGUGU	6427	ACACAGAGUAACUUGAUUG	6428
AAUCAAGUUACUCUGUGUU	6429	AACACAGAGUAACUUGAUU	6430
AUCAAGUUACUCUGUGUUU	6431	AAACACAGAGUAACUUGAU	6432
ACUCUGUGUUUCUUUGUCA	6433	UGACAAAGAAACACAGAGU	6434
UCUGUGUUUCUUUGUCAGG	6435	CCUGACAAAGAAACACAGA	6436
UGUUUCUUUGUCAGGACAC	6437	GUGUCCUGACAAAGAAACA	6438
AAAGCAGGGAUUGUGUUCA	6439	UGAACACAAUCCCUGCUUU	6440
AAGCAGGGAUUGUGUUCAU	6441	AUGAACACAAUCCCUGCUU	6442
AGCAGGGAUUGUGUUCAUU	6443	AAUGAACACAAUCCCUGCU	6444
GCAGGGAUUGUGUUCAUUU	6445	AAAUGAACACAAUCCCUGC	6446
CAGGGAUUGUGUUCAUUUG	6447	CAAAUGAACACAAUCCCUG	6448
AGGGAUUGUGUUCAUUUGA	6449	UCAAAUGAACACAAUCCCU	6450
GUGUUCAUUUGAGGGUUUC	6451	GAAACCCUCAAAUGAACAC	6452
UGUUCAUUUGAGGGUUUCA	6453	UGAAACCCUCAAAUGAACA	6454
GUUCAUUUGAGGGUUUCAC	6455	GUGAAACCCUCAAAUGAAC	6456
UUCAUUUGAGGGUUUCACU	6457	AGUGAAACCCUCAAAUGAA	6458
UCAUUUGAGGGUUUCACUG	6459	CAGUGAAACCCUCAAAUGA	6460
CAUUUGAGGGUUUCACUGU	6461	ACAGUGAAACCCUCAAAUG	6462
AGUCUCAGCUUCCAUGCAA	6463	UUGCAUGGAAGCUGAGACU	6464
UCUCAGCUUCCAUGCAACU	6465	AGUUGCAUGGAAGCUGAGA	6466
CUCAGCUUCCAUGCAACUG	6467	CAGUUGCAUGGAAGCUGAG	6468
UCAGCUUCCAUGCAACUGU	6469	ACAGUUGCAUGGAAGCUGA	6470
CAGCUUCCAUGCAACUGUC	6471	GACAGUUGCAUGGAAGCUG	6472
AGCUUCCAUGCAACUGUCC	6473	GGACAGUUGCAUGGAAGCU	6474
GCUUCCAUGCAACUGUCCA	6475	UGGACAGUUGCAUGGAAGC	6476
CUUCCAUGCAACUGUCCAU	6477	AUGGACAGUUGCAUGGAAG	6478
UUCCAUGCAACUGUCCAUC	6479	GAUGGACAGUUGCAUGGAA	6480
CCAUGCAACUGUCCAUCAC	6481	GUGAUGGACAGUUGCAUGG	6482
CAUGCAACUGUCCAUCACG	6483	CGUGAUGGACAGUUGCAUG	6484
AUGCAACUGUCCAUCACGG	6485	CCGUGAUGGACAGUUGCAU	6486
UGCAACUGUCCAUCACGGC	6487	GCCGUGAUGGACAGUUGCA	6488
GCAACUGUCCAUCACGGCU	6489	AGCCGUGAUGGACAGUUGC	6490
CAACUGUCCAUCACGGCUG	6491	CAGCCGUGAUGGACAGUUG	6492
AACUGUCCAUCACGGCUGC	6493	GCAGCCGUGAUGGACAGUU	6494
ACUGUCCAUCACGGCUGCA	6495	UGCAGCCGUGAUGGACAGU	6496
CUGUCCAUCACGGCUGCAA	6497	UUGCAGCCGUGAUGGACAG	6498
UGUCCAUCACGGCUGCAAC	6499	GUUGCAGCCGUGAUGGACA	6500
GUCCAUCACGGCUGCAACU	6501	AGUUGCAGCCGUGAUGGAC	6502
UCCAUCACGGCUGCAACUG	6503	CAGUUGCAGCCGUGAUGGA	6504
CCAUCACGGCUGCAACUGA	6505	UCAGUUGCAGCCGUGAUGG	6506
CAUCACGGCUGCAACUGAA	6507	UUCAGUUGCAGCCGUGAUG	6508
ACAGCGCACCAGAAGCUAA	6509	UUAGCUUCUGGUGCGCUGU	6510
CAGCGCACCAGAAGCUAAA	6511	UUUAGCUUCUGGUGCGCUG	6512
AGCGCACCAGAAGCUAAAG	6513	CUUUAGCUUCUGGUGCGCU	6514
GCGCACCAGAAGCUAAAGU	6515	ACUUUAGCUUCUGGUGCGC	6516
CGCACCAGAAGCUAAAGUC	6517	GACUUUAGCUUCUGGUGCG	6518
GCACCAGAAGCUAAAGUCU	6519	AGACUUUAGCUUCUGGUGC	6520
CACCAGAAGCUAAAGUCUU	6521	AAGACUUUAGCUUCUGGUG	6522
ACCAGAAGCUAAAGUCUUG	6523	CAAGACUUUAGCUUCUGGU	6524
CCAGAAGCUAAAGUCUUGA	6525	UCAAGACUUUAGCUUCUGG	6526
CAGAAGCUAAAGUCUUGAU	6527	AUCAAGACUUUAGCUUCUG	6528
AGAAGCUAAAGUCUUGAUG	6529	CAUCAAGACUUUAGCUUCU	6530
GAAGCUAAAGUCUUGAUGC	6531	GCAUCAAGACUUUAGCUUC	6532
AAGCUAAAGUCUUGAUGCC	6533	GGCAUCAAGACUUUAGCUU	6534
AGCUAAAGUCUUGAUGCCA	6535	UGGCAUCAAGACUUUAGCU	6536
CCCAUUCACAUCUCUGUCA	6537	UGACAGAGAUGUGAAUGGG	6538
UUCACAUCUCUGUCACGUC	6539	GACGUGACAGAGAUGUGAA	6540
UCACAUCUCUGUCACGUCC	6541	GGACGUGACAGAGAUGUGA	6542
CACAUCUCUGUCACGUCCA	6543	UGGACGUGACAGAGAUGUG	6544
UCUCUGUCACGUCCACUAA	6545	UUAGUGGACGUGACAGAGA	6546
CUCUGUCACGUCCACUAAU	6547	AUUAGUGGACGUGACAGAG	6548
UCUGUCACGUCCACUAAUC	6549	GAUUAGUGGACGUGACAGA	6550
CUGUCACGUCCACUAAUCG	6551	CGAUUAGUGGACGUGACAG	6552
UGUCACGUCCACUAAUCGG	6553	CCGAUUAGUGGACGUGACA	6554
GUCACGUCCACUAAUCGGC	6555	GCCGAUUAGUGGACGUGAC	6556
UCACGUCCACUAAUCGGCA	6557	UGCCGAUUAGUGGACGUGA	6558
CACGUCCACUAAUCGGCAA	6559	UUGCCGAUUAGUGGACGUG	6560
ACGUCCACUAAUCGGCAAA	6561	UUUGCCGAUUAGUGGACGU	6562
CGUCCACUAAUCGGCAAAA	6563	UUUUGCCGAUUAGUGGACG	6564
GUCCACUAAUCGGCAAAAG	6565	CUUUUGCCGAUUAGUGGAC	6566
UCCACUAAUCGGCAAAAGG	6567	CCUUUUGCCGAUUAGUGGA	6568
CCACUAAUCGGCAAAAGGA	6569	UCCUUUUGCCGAUUAGUGG	6570
CACUAAUCGGCAAAAGGAG	6571	CUCCUUUUGCCGAUUAGUG	6572
AGAAGAUGACCUAAGUGUG	6573	CACACUUAGGUCAUCUUCU	6574
GAAGAUGACCUAAGUGUGA	6575	UCACACUUAGGUCAUCUUC	6576
AAGAUGACCUAAGUGUGAC	6577	GUCACACUUAGGUCAUCUU	6578
AGAUGACCUAAGUGUGACU	6579	AGUCACACUUAGGUCAUCU	6580
GAUGACCUAAGUGUGACUG	6581	CAGUCACACUUAGGUCAUC	6582
AUGACCUAAGUGUGACUGC	6583	GCAGUCACACUUAGGUCAU	6584
UGACCUAAGUGUGACUGCA	6585	UGCAGUCACACUUAGGUCA	6586
AAAAUGAAGCCAGAGCAGU	6587	ACUGCUCUGGCUUCAUUUU	6588
UCCGACCAAGGAGGAAGGA	6589	UCCUUCCUCCUUGGUCGGA	6590
CCGACCAAGGAGGAAGGAA	6591	UUCCUUCCUCCUUGGUCGG	6592
AGAGCAGGUAAGCAGGAAG	6593	CUUCCUGCUUACCUGCUCU	6594
GAGCAGGUAAGCAGGAAGG	6595	CCUUCCUGCUUACCUGCUC	6596
AGGUAAGCAGGAAGGCCAG	6597	CUGGCCUUCCUGCUUACCU	6598
AGCAGGAAGGCCAGUGUCC	6599	GGACACUGGCCUUCCUGCU	6600
CAGGAAGGCCAGUGUCCCA	6601	UGGGACACUGGCCUUCCUG	6602
UCCCAGACAGGACCCUAAU	6603	AUUAGGGUCCUGUCUGGGA	6604
CCCAGACAGGACCCUAAUG	6605	CAUUAGGGUCCUGUCUGGG	6606
CCAGACAGGACCCUAAUGA	6607	UCAUUAGGGUCCUGUCUGG	6608
CAGACAGGACCCUAAUGAU	6609	AUCAUUAGGGUCCUGUCUG	6610
AGACAGGACCCUAAUGAUC	6611	GAUCAUUAGGGUCCUGUCU	6612
GACAGGACCCUAAUGAUCC	6613	GGAUCAUUAGGGUCCUGUC	6614
GGACCCUAAUGAUCCUGAA	6615	UUCAGGAUCAUUAGGGUCC	6616
CCUAAUGAUCCUGAAUCCA	6617	UGGAUUCAGGAUCAUUAGG	6618
CUAAUGAUCCUGAAUCCAU	6619	AUGGAUUCAGGAUCAUUAG	6620
UGAUCCUGAAUCCAUGUAU	6621	AUACAUGGAUUCAGGAUCA	6622
GAUCCUGAAUCCAUGUAUC	6623	GAUACAUGGAUUCAGGAUC	6624
AUCCUGAAUCCAUGUAUCA	6625	UGAUACAUGGAUUCAGGAU	6626
UCCAUGUAUCAGGAUCCAU	6627	AUGGAUCCUGAUACAUGGA	6628
CCAUGUAUCAGGAUCCAUC	6629	GAUGGAUCCUGAUACAUGG	6630
CAUGUAUCAGGAUCCAUCC	6631	GGAUGGAUCCUGAUACAUG	6632
UCACCUCUCAUUUUCCAAA	6633	UUUGGAAAAUGAGAGGUGA	6634
UCCAAAGCCCUGCCAUGCU	6635	AGCAUGGCAGGGCUUUGGA	6636
CCAAAGCCCUGCCAUGCUG	6637	CAGCAUGGCAGGGCUUUGG	6638
CAUGCUGCCAUCCCACUUC	6639	GAAGUGGGAUGGCAGCAUG	6640
AUGCUGCCAUCCCACUUCC	6641	GGAAGUGGGAUGGCAGCAU	6642
UGCUGCCAUCCCACUUCCC	6643	GGGAAGUGGGAUGGCAGCA	6644
CGGGUUCCCUUUUCCUAAA	6645	UUUAGGAAAAGGGAACCCG	6646
AGCUGCAGCUUAUGGCUUC	6647	GAAGCCAUAAGCUGCAGCU	6648
GCUGCAGCUUAUGGCUUCU	6649	AGAAGCCAUAAGCUGCAGC	6650
CUGCAGCUUAUGGCUUCUC	6651	GAGAAGCCAUAAGCUGCAG	6652
UGCAGCUUAUGGCUUCUCC	6653	GGAGAAGCCAUAAGCUGCA	6654
GCAGCUUAUGGCUUCUCCA	6655	UGGAGAAGCCAUAAGCUGC	6656
CAGCUUAUGGCUUCUCCAG	6657	CUGGAGAAGCCAUAAGCUG	6658
AGCUUAUGGCUUCUCCAGU	6659	ACUGGAGAAGCCAUAAGCU	6660
GCUUAUGGCUUCUCCAGUA	6661	UACUGGAGAAGCCAUAAGC	6662
CUUAUGGCUUCUCCAGUAG	6663	CUACUGGAGAAGCCAUAAG	6664
UUAUGGCUUCUCCAGUAGG	6665	CCUACUGGAGAAGCCAUAA	6666
UAUGGCUUCUCCAGUAGGU	6667	ACCUACUGGAGAAGCCAUA	6668
CACCCAGCCCAGAAGUUCC	6755	GGAACUUCUGGGCUGGGUG	6756
ACCCAGCCCAGAAGUUCCA	6757	UGGAACUUCUGGGCUGGGU	6758
CCAGAAGUUCCAGGGAAGG	6759	CCUUCCCUGGAACUUCUGG	6760
CAGAAGUUCCAGGGAAGGA	6761	UCCUUCCCUGGAACUUCUG	6762
AACUCUCCGGUCCACCAUG	6763	CAUGGUGGACCGGAGAGUU	6764
ACUCUCCGGUCCACCAUGG	6765	CCAUGGUGGACCGGAGAGU	6766
CACCAUGGAGUACCUCUCA	6767	UGAGAGGUACUCCAUGGUG	6768
ACCAUGGAGUACCUCUCAG	6769	CUGAGAGGUACUCCAUGGU	6770
UGGAGUACCUCUCAGCUCU	6771	AGAGCUGAGAGGUACUCCA	6772
GGAGUACCUCUCAGCUCUG	6773	CAGAGCUGAGAGGUACUCC	6774
GAGUACCUCUCAGCUCUGA	6775	UCAGAGCUGAGAGGUACUC	6776
AGUACCUCUCAGCUCUGAA	6777	UUCAGAGCUGAGAGGUACU	6778
CCAGUGACUUACUCAGGUG	6779	CACCUGAGUAAGUCACUGG	6780
CAGUGACUUACUCAGGUGA	6781	UCACCUGAGUAAGUCACUG	6782
AGUGACUUACUCAGGUGAC	6783	GUCACCUGAGUAAGUCACU	6784
GUGACUUACUCAGGUGACU	6785	AGUCACCUGAGUAAGUCAC	6786
UGACUUACUCAGGUGACUG	6787	CAGUCACCUGAGUAAGUCA	6788
GACUUACUCAGGUGACUGC	6789	GCAGUCACCUGAGUAAGUC	6790
ACUUACUCAGGUGACUGCU	6791	AGCAGUCACCUGAGUAAGU	6792
CUUACUCAGGUGACUGCUA	6793	UAGCAGUCACCUGAGUAAG	6794
UUACUCAGGUGACUGCUAA	6795	UUAGCAGUCACCUGAGUAA	6796
UACUCAGGUGACUGCUAAC	6797	GUUAGCAGUCACCUGAGUA	6798
ACUCAGGUGACUGCUAACC	6799	GGUUAGCAGUCACCUGAGU	6800
CUCAGGUGACUGCUAACCC	6801	GGGUUAGCAGUCACCUGAG	6802
GGUGACUGCUAACCCUCCG	6803	CGGAGGGUUAGCAGUCACC	6804
GUGACUGCUAACCCUCCGC	6805	GCGGAGGGUUAGCAGUCAC	6806
UGACUGCUAACCCUCCGCU	6807	AGCGGAGGGUUAGCAGUCA	6808
GACUGCUAACCCUCCGCUC	6809	GAGCGGAGGGUUAGCAGUC	6810
ACUGCUAACCCUCCGCUCU	6811	AGAGCGGAGGGUUAGCAGU	6812
CUGCUAACCCUCCGCUCUA	6813	UAGAGCGGAGGGUUAGCAG	6814
UGCUAACCCUCCGCUCUAC	6815	GUAGAGCGGAGGGUUAGCA	6816
AACCCUCCGCUCUACCCUC	6817	GAGGGUAGAGCGGAGGGUU	6818
ACUCCACAGUGGGCUUGUC	6819	GACAAGCCCACUGUGGAGU	6820
CUCCACAGUGGGCUUGUCA	6821	UGACAAGCCCACUGUGGAG	6822
UCCACAGUGGGCUUGUCAA	6823	UUGACAAGCCCACUGUGGA	6824
CCACAGUGGGCUUGUCAAG	6825	CUUGACAAGCCCACUGUGG	6826
GUCAAGCUCCUGAGCCACC	6827	GGUGGCUCAGGAGCUUGAC	6828
CCAUGGUCUCUCCCUCAUC	6829	GAUGAGGGAGAGACCAUGG	6830
CAUGGUCUCUCCCUCAUCC	6831	GGAUGAGGGAGAGACCAUG	6832
AUGGUCUCUCCCUCAUCCC	6833	GGGAUGAGGGAGAGACCAU	6834
UCUCUCCCUCAUCCCUAAU	6835	AUUAGGGAUGAGGGAGAGA	6836
CUCUCCCUCAUCCCUAAUC	6837	GAUUAGGGAUGAGGGAGAG	6838
UCUCCCUCAUCCCUAAUCG	6839	CGAUUAGGGAUGAGGGAGA	6840
CUCCCUCAUCCCUAAUCGA	6841	UCGAUUAGGGAUGAGGGAG	6842
UCCCUCAUCCCUAAUCGAU	6843	AUCGAUUAGGGAUGAGGGA	6844
CCCUCAUCCCUAAUCGAUA	6845	UAUCGAUUAGGGAUGAGGG	6846
CCUCAUCCCUAAUCGAUAA	6847	UUAUCGAUUAGGGAUGAGG	6848
CUCAUCCCUAAUCGAUAAA	6849	UUUAUCGAUUAGGGAUGAG	6850
AACCUAGAUCUCUCCCUCC	6851	GGAGGGAGAGAUCUAGGUU	6852
ACCUAGAUCUCUCCCUCCC	6853	GGGAGGGAGAGAUCUAGGU	6854
CUAGAUCUCUCCCUCCCUA	6855	UAGGGAGGGAGAGAUCUAG	6856
UAGAUCUCUCCCUCCCUAG	6857	CUAGGGAGGGAGAGAUCUA	6858
AGAUCUCUCCCUCCCUAGC	6859	GCUAGGGAGGGAGAGAUCU	6860
GAUCUCUCCCUCCCUAGCC	6861	GGCUAGGGAGGGAGAGAUC	6862
AUCUCUCCCUCCCUAGCCC	6863	GGGCUAGGGAGGGAGAGAU	6864
UAGCCCUCUAGCCACUCUA	6865	UAGAGUGGCUAGAGGGCUA	6866
AGCCCUCUAGCCACUCUAC	6867	GUAGAGUGGCUAGAGGGCU	6868
CUCUAGCCACUCUACCCUC	6869	GAGGGUAGAGUGGCUAGAG	6870
UCUAGCCACUCUACCCUCA	6871	UGAGGGUAGAGUGGCUAGA	6872
CUAGCCACUCUACCCUCAU	6873	AUGAGGGUAGAGUGGCUAG	6874
UAGCCACUCUACCCUCAUC	6875	GAUGAGGGUAGAGUGGCUA	6876
AGCCACUCUACCCUCAUCA	6877	UGAUGAGGGUAGAGUGGCU	6878
GCCACUCUACCCUCAUCAU	6879	AUGAUGAGGGUAGAGUGGC	6880
CCACUCUACCCUCAUCAUG	6881	CAUGAUGAGGGUAGAGUGG	6882
CACUCUACCCUCAUCAUGC	6883	GCAUGAUGAGGGUAGAGUG	6884
ACUCUACCCUCAUCAUGCC	6885	GGCAUGAUGAGGGUAGAGU	6886
CUCUACCCUCAUCAUGCCC	6887	GGGCAUGAUGAGGGUAGAG	6888
UCUACCCUCAUCAUGCCCU	6889	AGGGCAUGAUGAGGGUAGA	6890
CUACCCUCAUCAUGCCCUU	6891	AAGGGCAUGAUGAGGGUAG	6892
UACCCUCAUCAUGCCCUUU	6893	AAAGGGCAUGAUGAGGGUA	6894
ACCCUCAUCAUGCCCUUUA	6895	UAAAGGGCAUGAUGAGGGU	6896
CCCUCAUCAUGCCCUUUAC	6897	GUAAAGGGCAUGAUGAGGG	6898
CUCAUCAUGCCCUUUACAC	6899	GUGUAAAGGGCAUGAUGAG	6900
UCAUCAUGCCCUUUACACU	6901	AGUGUAAAGGGCAUGAUGA	6902
CCCUUCUUGACUUUUCUUC	6903	GAAGAAAAGUCAAGAAGGG	6904
CUUCUUGACUUUUCUUCUC	6905	GAGAAGAAAAGUCAAGAAG	6906
GACUUUUCUUCUCAACUAC	6907	GUAGUUGAGAAGAAAAGUC	6908
ACUUUUCUUCUCAACUACC	6909	GGUAGUUGAGAAGAAAAGU	6910
CUUUUCUUCUCAACUACCA	6911	UGGUAGUUGAGAAGAAAAG	6912
UUUUCUUCUCAACUACCAG	6913	CUGGUAGUUGAGAAGAAAA	6914
UAUCUAAUAUAAGCUCGGA	6915	UCCGAGCUUAUAUUAGAUA	6916
AUCUAAUAUAAGCUCGGAG	6917	CUCCGAGCUUAUAUUAGAU	6918
UCUAAUAUAAGCUCGGAGU	6919	ACUCCGAGCUUAUAUUAGA	6920
CUAAUAUAAGCUCGGAGUU	6921	AACUCCGAGCUUAUAUUAG	6922
UAAUAUAAGCUCGGAGUUU	6923	AAACUCCGAGCUUAUAUUA	6924
AAUAUAAGCUCGGAGUUUG	6925	CAAACUCCGAGCUUAUAUU	6926
AUAUAAGCUCGGAGUUUGG	6927	CCAAACUCCGAGCUUAUAU	6928
UAUAAGCUCGGAGUUUGGA	6929	UCCAAACUCCGAGCUUAUA	6930
AUAAGCUCGGAGUUUGGAC	6931	GUCCAAACUCCGAGCUUAU	6932
UAAGCUCGGAGUUUGGACG	6933	CGUCCAAACUCCGAGCUUA	6934
AAGCUCGGAGUUUGGACGG	6935	CCGUCCAAACUCCGAGCUU	6936
AGCUCGGAGUUUGGACGGA	6937	UCCGUCCAAACUCCGAGCU	6938
GCUCGGAGUUUGGACGGAG	6939	CUCCGUCCAAACUCCGAGC	6940
CUCGGAGUUUGGACGGAGG	6941	CCUCCGUCCAAACUCCGAG	6942
UCGGAGUUUGGACGGAGGG	6943	CCCUCCGUCCAAACUCCGA	6944
CGGAGUUUGGACGGAGGGU	6945	ACCCUCCGUCCAAACUCCG	6946
UUUGGACGGAGGGUCUGGA	6947	UCCAGACCCUCCGUCCAAA	6948
CCCAGCGACCUUUCCGUGU	6949	ACACGGAAAGGUCGCUGGG	6950
CCAGCGACCUUUCCGUGUC	6951	GACACGGAAAGGUCGCUGG	6952
CAGCGACCUUUCCGUGUCU	6953	AGACACGGAAAGGUCGCUG	6954
AGCGACCUUUCCGUGUCUG	6955	CAGACACGGAAAGGUCGCU	6956
GCGACCUUUCCGUGUCUGU	6957	ACAGACACGGAAAGGUCGC	6958
CGACCUUUCCGUGUCUGUG	6959	CACAGACACGGAAAGGUCG	6960
CUUUCCGUGUCUGUGAUCA	6961	UGAUCACAGACACGGAAAG	6962
UUUCCGUGUCUGUGAUCAC	6963	GUGAUCACAGACACGGAAA	6964
UUCCGUGUCUGUGAUCACA	6965	UGUGAUCACAGACACGGAA	6966
AAGGCCUGACAGCUGCCAC	6967	GUGGCAGCUGUCAGGCCUU	6968
GCCAGGAGCUGCUAGCCAA	6969	UUGGCUAGCAGCUCCUGGC	6970
CCAGGAGCUGCUAGCCAAA	6971	UUUGGCUAGCAGCUCCUGG	6972
GAGCUGCUAGCCAAAGUAA	6973	UUACUUUGGCUAGCAGCUC	6974
AGCUGCUAGCCAAAGUAAG	6975	CUUACUUUGGCUAGCAGCU	6976
GCUGCUAGCCAAAGUAAGU	6977	ACUUACUUUGGCUAGCAGC	6978
CUGCUAGCCAAAGUAAGUA	6979	UACUUACUUUGGCUAGCAG	6980
UGCUAGCCAAAGUAAGUAG	6981	CUACUUACUUUGGCUAGCA	6982
GCUAGCCAAAGUAAGUAGG	6983	CCUACUUACUUUGGCUAGC	6984
UAGCCAAAGUAAGUAGGCC	6985	GGCCUACUUACUUUGGCUA	6986
AGCCAAAGUAAGUAGGCCA	6987	UGGCCUACUUACUUUGGCU	6988
GCCAAAGUAAGUAGGCCAA	6989	UUGGCCUACUUACUUUGGC	6990
CCAAAGUAAGUAGGCCAAG	6991	CUUGGCCUACUUACUUUGG	6992
CAAAGUAAGUAGGCCAAGU	6993	ACUUGGCCUACUUACUUUG	6994
AAAGUAAGUAGGCCAAGUU	6995	AACUUGGCCUACUUACUUU	6996
AAGUAAGUAGGCCAAGUUC	6997	GAACUUGGCCUACUUACUU	6998
AGUAAGUAGGCCAAGUUCC	6999	GGAACUUGGCCUACUUACU	7000
GUAAGUAGGCCAAGUUCCU	7001	AGGAACUUGGCCUACUUAC	7002
UAAGUAGGCCAAGUUCCUC	7003	GAGGAACUUGGCCUACUUA	7004
UAGGCCAAGUUCCUCGGUU	7005	AACCGAGGAACUUGGCCUA	7006
AGGCCAAGUUCCUCGGUUC	7007	GAACCGAGGAACUUGGCCU	7008
GGCCAAGUUCCUCGGUUCC	7009	GGAACCGAGGAACUUGGCC	7010
GCCAAGUUCCUCGGUUCCU	7011	AGGAACCGAGGAACUUGGC	7012
CCAAGUUCCUCGGUUCCUA	7013	UAGGAACCGAGGAACUUGG	7014
CAAGUUCCUCGGUUCCUAU	7015	AUAGGAACCGAGGAACUUG	7016
AAGUUCCUCGGUUCCUAUA	7017	UAUAGGAACCGAGGAACUU	7018
AGUUCCUCGGUUCCUAUAG	7019	CUAUAGGAACCGAGGAACU	7020
GUUCCUCGGUUCCUAUAGC	7021	GCUAUAGGAACCGAGGAAC	7022
UUCCUCGGUUCCUAUAGCA	7023	UGCUAUAGGAACCGAGGAA	7024
UCCUCGGUUCCUAUAGCAG	7025	CUGCUAUAGGAACCGAGGA	7026
CAGUGGCAACUUGUGAUGA	7027	UCAUCACAAGUUGCCACUG	7028
AGUGGCAACUUGUGAUGAU	7029	AUCAUCACAAGUUGCCACU	7030
GUGGCAACUUGUGAUGAUG	7031	CAUCAUCACAAGUUGCCAC	7032
GGCAACUUGUGAUGAUGGA	7033	UCCAUCAUCACAAGUUGCC	7034
ACUUGUGAUGAUGGAGCAG	7035	CUGCUCCAUCAUCACAAGU	7036
CUUGUGAUGAUGGAGCAGA	7037	UCUGCUCCAUCAUCACAAG	7038
GUGAUGAUGGAGCAGAGGG	7039	CCCUCUGCUCCAUCAUCAC	7040
UGAUGAUGGAGCAGAGGGC	7041	GCCCUCUGCUCCAUCAUCA	7042
UGGAGCAGAGGGCUGAAGU	7043	ACUUCAGCCCUCUGCUCCA	7044
GGAGCAGAGGGCUGAAGUC	7045	GACUUCAGCCCUCUGCUCC	7046
GAGCAGAGGGCUGAAGUCA	7047	UGACUUCAGCCCUCUGCUC	7048
CUAAAAGCAGCGGAGUGGG	7049	CCCACUCCGCUGCUUUUAG	7050
UAAAAGCAGCGGAGUGGGC	7051	GCCCACUCCGCUGCUUUUA	7052
AAAAGCAGCGGAGUGGGCC	7053	GGCCCACUCCGCUGCUUUU	7054
AAAGCAGCGGAGUGGGCCU	7055	AGGCCCACUCCGCUGCUUU	7056
AAGCAGCGGAGUGGGCCUA	7057	UAGGCCCACUCCGCUGCUU	7058
AGCAGCGGAGUGGGCCUAA	7059	UUAGGCCCACUCCGCUGCU	7060
GCAGCGGAGUGGGCCUAAU	7061	AUUAGGCCCACUCCGCUGC	7062
CAGCGGAGUGGGCCUAAUG	7063	CAUUAGGCCCACUCCGCUG	7064
AGCGGAGUGGGCCUAAUGA	7065	UCAUUAGGCCCACUCCGCU	7066
GCGGAGUGGGCCUAAUGAG	7067	CUCAUUAGGCCCACUCCGC	7068
AGUGGGCCUAAUGAGCUCU	7069	AGAGCUCAUUAGGCCCACU	7070
GUGGGCCUAAUGAGCUCUG	7071	CAGAGCUCAUUAGGCCCAC	7072
UGGGCCUAAUGAGCUCUGG	7073	CCAGAGCUCAUUAGGCCCA	7074
GGGCCUAAUGAGCUCUGGU	7075	ACCAGAGCUCAUUAGGCCC	7076
GGCCUAAUGAGCUCUGGUC	7077	GACCAGAGCUCAUUAGGCC	7078
GCCUAAUGAGCUCUGGUCA	7079	UGACCAGAGCUCAUUAGGC	7080
CCUAAUGAGCUCUGGUCAA	7081	UUGACCAGAGCUCAUUAGG	7082
CUAAUGAGCUCUGGUCAAU	7083	AUUGACCAGAGCUCAUUAG	7084
UAAUGAGCUCUGGUCAAUU	7085	AAUUGACCAGAGCUCAUUA	7086
AAUGAGCUCUGGUCAAUUU	7087	AAAUUGACCAGAGCUCAUU	7088
AUGAGCUCUGGUCAAUUUG	7089	CAAAUUGACCAGAGCUCAU	7090
UGAGCUCUGGUCAAUUUGU	7091	ACAAAUUGACCAGAGCUCA	7092
CUGGUCAAUUUGUUCAUUU	7093	AAAUGAACAAAUUGACCAG	7094
CAAUUUGUUCAUUUUCCAC	7095	GUGGAAAAUGAACAAAUUG	7096
AGUGAGCUUUUCUAUGGGA	7097	UCCCAUAGAAAAGCUCACU	7098
AGCUUUUCUAUGGGAGCAG	7099	CUGCUCCCAUAGAAAAGCU	7100
GAAUUCAGAAGCUAGUAUG	7101	CAUACUAGCUUCUGAAUUC	7102
AUUCAGAAGCUAGUAUGGA	7103	UCCAUACUAGCUUCUGAAU	7104
UUCAGAAGCUAGUAUGGAA	7105	UUCCAUACUAGCUUCUGAA	7106
AAAGGUGAUUUGUGUGACA	7107	UGUCACACAAAUCACCUUU	7108
AUUCUGAUUCUGCCACUUC	7109	GAAGUGGCAGAAUCAGAAU	7110
AUUCUGCCACUUCCUGCCU	7111	AGGCAGGAAGUGGCAGAAU	7112
GCCACUUCCUGCCUGUCAA	7113	UUGACAGGCAGGAAGUGGC	7114
CCACUUCCUGCCUGUCAAA	7115	UUUGACAGGCAGGAAGUGG	7116
AACCUUGGGAAGUUGUUCA	7117	UGAACAACUUCCCAAGGUU	7118
ACCUUGGGAAGUUGUUCAA	7119	UUGAACAACUUCCCAAGGU	7120
CCUUGGGAAGUUGUUCAAC	7121	GUUGAACAACUUCCCAAGG	7122
GGGAAGUUGUUCAACCUAC	7123	GUAGGUUGAACAACUUCCC	7124
GGAAGUUGUUCAACCUACC	7125	GGUAGGUUGAACAACUUCC	7126
GAAGUUGUUCAACCUACCA	7127	UGGUAGGUUGAACAACUUC	7128
AAGUUGUUCAACCUACCAA	7129	UUGGUAGGUUGAACAACUU	7130
AGUUGUUCAACCUACCAAA	7131	UUUGGUAGGUUGAACAACU	7132
GUUGUUCAACCUACCAAAA	7133	UUUUGGUAGGUUGAACAAC	7134
GCAAUAAUAAUACAUCACC	7135	GGUGAUGUAUUAUUAUUGC	7136
AUAAUAAUACAUCACCUCC	7137	GGAGGUGAUGUAUUAUUAU	7138
UAAUACAUCACCUCCUAGG	7139	CCUAGGAGGUGAUGUAUUA	7140
AAUACAUCACCUCCUAGGG	7141	CCCUAGGAGGUGAUGUAUU	7142
AUACAUCACCUCCUAGGGU	7143	ACCCUAGGAGGUGAUGUAU	7144
UACAUCACCUCCUAGGGUU	7145	AACCCUAGGAGGUGAUGUA	7146
ACAUCACCUCCUAGGGUUG	7147	CAACCCUAGGAGGUGAUGU	7148
AAAGGAGUAAGAGGAUAAU	7149	AUUAUCCUCUUACUCCUUU	7150
AAGGAGUAAGAGGAUAAUG	7151	CAUUAUCCUCUUACUCCUU	7152
AGUAAGAGGAUAAUGUAGG	7153	CCUACAUUAUCCUCUUACU	7154
GUAAGAGGAUAAUGUAGGU	7155	ACCUACAUUAUCCUCUUAC	7156
UAAGAGGAUAAUGUAGGUA	7157	UACCUACAUUAUCCUCUUA	7158
AAGAGGAUAAUGUAGGUAA	7159	UUACCUACAUUAUCCUCUU	7160
AGAGGAUAAUGUAGGUAAA	7161	UUUACCUACAUUAUCCUCU	7162
GAGGAUAAUGUAGGUAAAG	7163	CUUUACCUACAUUAUCCUC	7164
GGAUAAUGUAGGUAAAGUC	7165	GACUUUACCUACAUUAUCC	7166
AUAAUGUAGGUAAAGUCCU	7167	AGGACUUUACCUACAUUAU	7168
GUAGGUAAAGUCCUCAUAC	7169	GUAUGAGGACUUUACCUAC	7170
GUAAAGUCCUCAUACCUGG	7171	CCAGGUAUGAGGACUUUAC	7172
UAAAGUCCUCAUACCUGGC	7173	GCCAGGUAUGAGGACUUUA	7174
AAAGUCCUCAUACCUGGCA	7175	UGCCAGGUAUGAGGACUUU	7176
AAGUCCUCAUACCUGGCAC	7177	GUGCCAGGUAUGAGGACUU	7178
AGUCCUCAUACCUGGCACA	7179	UGUGCCAGGUAUGAGGACU	7180
GUCCUCAUACCUGGCACAG	7181	CUGUGCCAGGUAUGAGGAC	7182
UCCUCAUACCUGGCACAGA	7183	UCUGUGCCAGGUAUGAGGA	7184
UCUUGAGGGUGUGGGAAGU	7185	ACUUCCCACACCCUCAAGA	7186
CUUGAGGGUGUGGGAAGUG	7187	CACUUCCCACACCCUCAAG	7188
UUGAGGGUGUGGGAAGUGA	7189	UCACUUCCCACACCCUCAA	7190
UGAGGGUGUGGGAAGUGAG	7191	CUCACUUCCCACACCCUCA	7192
AGGGUGUGGGAAGUGAGGU	7193	ACCUCACUUCCCACACCCU	7194
GGGUGUGGGAAGUGAGGUG	7195	CACCUCACUUCCCACACCC	7196
GGGAAGUGAGGUGCAGCAU	7197	AUGCUGCACCUCACUUCCC	7198
GGAAGUGAGGUGCAGCAUU	7199	AAUGCUGCACCUCACUUCC	7200
GAAGUGAGGUGCAGCAUUG	7201	CAAUGCUGCACCUCACUUC	7202
AAGUGAGGUGCAGCAUUGU	7203	ACAAUGCUGCACCUCACUU	7204
AGUGAGGUGCAGCAUUGUA	7205	UACAAUGCUGCACCUCACU	7206
GUGAGGUGCAGCAUUGUAG	7207	CUACAAUGCUGCACCUCAC	7208
UGAGGUGCAGCAUUGUAGA	7209	UCUACAAUGCUGCACCUCA	7210
GAGGUGCAGCAUUGUAGAU	7211	AUCUACAAUGCUGCACCUC	7212
AGGUGCAGCAUUGUAGAUA	7213	UAUCUACAAUGCUGCACCU	7214
GGUGCAGCAUUGUAGAUAA	7215	UUAUCUACAAUGCUGCACC	7216
GUGCAGCAUUGUAGAUAAG	7217	CUUAUCUACAAUGCUGCAC	7218
UGCAGCAUUGUAGAUAAGA	7219	UCUUAUCUACAAUGCUGCA	7220
GCAUUGUAGAUAAGACAGA	7221	UCUGUCUUAUCUACAAUGC	7222
CAUUGUAGAUAAGACAGAA	7223	UUCUGUCUUAUCUACAAUG	7224
AUUGUAGAUAAGACAGAAG	7225	CUUCUGUCUUAUCUACAAU	7226
AUAAGACAGAAGGGUGGAC	7227	GUCCACCCUUCUGUCUUAU	7228
UAAGACAGAAGGGUGGACU	7229	AGUCCACCCUUCUGUCUUA	7230
AACCUGGCUUGCUUUCCAA	7231	UUGGAAAGCAAGCCAGGUU	7232
CCUGGCUUGCUUUCCAAUU	7233	AAUUGGAAAGCAAGCCAGG	7234
ACCAGAAGUGACUUGGAGG	7235	CCUCCAAGUCACUUCUGGU	7236
CCAGAAGUGACUUGGAGGG	7237	CCCUCCAAGUCACUUCUGG	7238
AGAUGCCAAUGACAUGGUA	7239	UACCAUGUCAUUGGCAUCU	7240
GAUGCCAAUGACAUGGUAG	7241	CUACCAUGUCAUUGGCAUC	7242
AUGCCAAUGACAUGGUAGG	7243	CCUACCAUGUCAUUGGCAU	7244
CAAUGACAUGGUAGGAGCA	7245	UGCUCCUACCAUGUCAUUG	7246
AAUGACAUGGUAGGAGCAA	7247	UUGCUCCUACCAUGUCAUU	7248
AUGACAUGGUAGGAGCAAA	7249	UUUGCUCCUACCAUGUCAU	7250
UGACAUGGUAGGAGCAAAG	7251	CUUUGCUCCUACCAUGUCA	7252
GACAUGGUAGGAGCAAAGA	7253	UCUUUGCUCCUACCAUGUC	7254
AAAAGGUCAGCCUCUAGCU	7255	AGCUAGAGGCUGACCUUUU	7256
AAAGGUCAGCCUCUAGCUA	7257	UAGCUAGAGGCUGACCUUU	7258
AGGUCAGCCUCUAGCUAGG	7259	CCUAGCUAGAGGCUGACCU	7260
GGUCAGCCUCUAGCUAGGA	7261	UCCUAGCUAGAGGCUGACC	7262
GUCAGCCUCUAGCUAGGAU	7263	AUCCUAGCUAGAGGCUGAC	7264
CAGCCUCUAGCUAGGAUCC	7265	GGAUCCUAGCUAGAGGCUG	7266
AGCCUCUAGCUAGGAUCCC	7267	GGGAUCCUAGCUAGAGGCU	7268
AGAGCUGCAACCUUUAGGA	7269	UCCUAAAGGUUGCAGCUCU	7270
GAGCUGCAACCUUUAGGAG	7271	CUCCUAAAGGUUGCAGCUC	7272
AGCUGCAACCUUUAGGAGG	7273	CCUCCUAAAGGUUGCAGCU	7274
UUUAGGAGGUAUCAAAGUG	7275	CACUUUGAUACCUCCUAAA	7276
UUAGGAGGUAUCAAAGUGC	7277	GCACUUUGAUACCUCCUAA	7278
UAGGAGGUAUCAAAGUGCC	7279	GGCACUUUGAUACCUCCUA	7280
GUCAAAGUGGGACAUCGAC	7281	GUCGAUGUCCCACUUUGAC	7282
CAUCGACCAAUGUCUAGAG	7283	CUCUAGACAUUGGUCGAUG	7284
AUCGACCAAUGUCUAGAGC	7285	GCUCUAGACAUUGGUCGAU	7286
ACCAAUGUCUAGAGCCAAC	7287	GUUGGCUCUAGACAUUGGU	7288
CAAUGUCUAGAGCCAACUG	7289	CAGUUGGCUCUAGACAUUG	7290
AAUGUCUAGAGCCAACUGA	7291	UCAGUUGGCUCUAGACAUU	7292
AUGUCUAGAGCCAACUGAU	7293	AUCAGUUGGCUCUAGACAU	7294
UGUCUAGAGCCAACUGAUG	7295	CAUCAGUUGGCUCUAGACA	7296
GUCUAGAGCCAACUGAUGG	7297	CCAUCAGUUGGCUCUAGAC	7298
UCUAGAGCCAACUGAUGGA	7299	UCCAUCAGUUGGCUCUAGA	7300
CUAGAGCCAACUGAUGGAU	7301	AUCCAUCAGUUGGCUCUAG	7302
UAGAGCCAACUGAUGGAUG	7303	CAUCCAUCAGUUGGCUCUA	7304
AGAGCCAACUGAUGGAUGU	7305	ACAUCCAUCAGUUGGCUCU	7306
GAGCCAACUGAUGGAUGUU	7307	AACAUCCAUCAGUUGGCUC	7308
AACUGAUGGAUGUUGGGCA	7309	UGCCCAACAUCCAUCAGUU	7310
UGGAUGUUGGGCAGCUAAA	7311	UUUAGCUGCCCAACAUCCA	7312
GGAUGUUGGGCAGCUAAAG	7313	CUUUAGCUGCCCAACAUCC	7314
GAUGUUGGGCAGCUAAAGA	7315	UCUUUAGCUGCCCAACAUC	7316
UUGGGCAGCUAAAGAGGGA	7317	UCCCUCUUUAGCUGCCCAA	7318
UGGGCAGCUAAAGAGGGAA	7319	UUCCCUCUUUAGCUGCCCA	7320
GGGCAGCUAAAGAGGGAAG	7321	CUUCCCUCUUUAGCUGCCC	7322
GGCAGCUAAAGAGGGAAGG	7323	CCUUCCCUCUUUAGCUGCC	7324
GCAGCUAAAGAGGGAAGGG	7325	CCCUUCCCUCUUUAGCUGC	7326
GGGCAUGGGAUAAGACCUG	7327	CAGGUCUUAUCCCAUGCCC	7328
GGCAUGGGAUAAGACCUGC	7329	GCAGGUCUUAUCCCAUGCC	7330
GCAUGGGAUAAGACCUGCC	7331	GGCAGGUCUUAUCCCAUGC	7332
CAUGGGAUAAGACCUGCCC	7333	GGGCAGGUCUUAUCCCAUG	7334
AUGGGAUAAGACCUGCCCU	7335	AGGGCAGGUCUUAUCCCAU	7336
UGGGAUAAGACCUGCCCUU	7337	AAGGGCAGGUCUUAUCCCA	7338
GGGAUAAGACCUGCCCUUC	7339	GAAGGGCAGGUCUUAUCCC	7340
GGAUAAGACCUGCCCUUCU	7341	AGAAGGGCAGGUCUUAUCC	7342
AGACCUGCCCUUCUUGCUU	7343	AAGCAAGAAGGGCAGGUCU	7344
GACCUGCCCUUCUUGCUUC	7345	GAAGCAAGAAGGGCAGGUC	7346
CCUGCCCUUCUUGCUUCUU	7347	AAGAAGCAAGAAGGGCAGG	7348
CUGCCCUUCUUGCUUCUUG	7349	CAAGAAGCAAGAAGGGCAG	7350
UGCCCUUCUUGCUUCUUGC	7351	GCAAGAAGCAAGAAGGGCA	7352
UCUUGCUUCUUGCCAUUGG	7353	CCAAUGGCAAGAAGCAAGA	7354
CUUGCUUCUUGCCAUUGGG	7355	CCCAAUGGCAAGAAGCAAG	7356
UUGCUUCUUGCCAUUGGGC	7357	GCCCAAUGGCAAGAAGCAA	7358
CCAUUGGGCAGGCAUUGGA	7359	UCCAAUGCCUGCCCAAUGG	7360
CAUUGGGCAGGCAUUGGAG	7361	CUCCAAUGCCUGCCCAAUG	7362
GACCCUACUGCUGAAUGGA	7363	UCCAUUCAGCAGUAGGGUC	7364
UACUGCUGAAUGGAGUGCU	7365	AGCACUCCAUUCAGCAGUA	7366
ACUGCUGAAUGGAGUGCUA	7367	UAGCACUCCAUUCAGCAGU	7368
CUGCUGAAUGGAGUGCUAA	7369	UUAGCACUCCAUUCAGCAG	7370
UGCUGAAUGGAGUGCUAAC	7371	GUUAGCACUCCAUUCAGCA	7372
GCUGAAUGGAGUGCUAACC	7373	GGUUAGCACUCCAUUCAGC	7374
CUGAAUGGAGUGCUAACCC	7375	GGGUUAGCACUCCAUUCAG	7376
UAACCCUGGUGCUAGAGGA	7377	UCCUCUAGCACCAGGGUUA	7378
AACCCUGGUGCUAGAGGAG	7379	CUCCUCUAGCACCAGGGUU	7380
ACCCUGGUGCUAGAGGAGG	7381	CCUCCUCUAGCACCAGGGU	7382
CCCUGGUGCUAGAGGAGGA	7383	UCCUCCUCUAGCACCAGGG	7384
CCUGGUGCUAGAGGAGGAU	7385	AUCCUCCUCUAGCACCAGG	7386
CUGGUGCUAGAGGAGGAUG	7387	CAUCCUCCUCUAGCACCAG	7388
GGUGCUAGAGGAGGAUGGA	7389	UCCAUCCUCCUCUAGCACC	7390
GUGCUAGAGGAGGAUGGAA	7391	UUCCAUCCUCCUCUAGCAC	7392
CUGCAGUGGACAGUGAGGA	7393	UCCUCACUGUCCACUGCAG	7394
UGCAGUGGACAGUGAGGAC	7395	GUCCUCACUGUCCACUGCA	7396
GCAGUGGACAGUGAGGACU	7397	AGUCCUCACUGUCCACUGC	7398
CAGUGGACAGUGAGGACUU	7399	AAGUCCUCACUGUCCACUG	7400
AGUGGACAGUGAGGACUUC	7401	GAAGUCCUCACUGUCCACU	7402
GUGGACAGUGAGGACUUCU	7403	AGAAGUCCUCACUGUCCAC	7404
UGGACAGUGAGGACUUCUU	7405	AAGAAGUCCUCACUGUCCA	7406
GGACAGUGAGGACUUCUUC	7407	GAAGAAGUCCUCACUGUCC	7408
AGUGAGGACUUCUUCCAGC	7409	GCUGGAAGAAGUCCUCACU	7410
GUGAGGACUUCUUCCAGCU	7411	AGCUGGAAGAAGUCCUCAC	7412
UGAGGACUUCUUCCAGCUG	7413	CAGCUGGAAGAAGUCCUCA	7414
GAGGACUUCUUCCAGCUGC	7415	GCAGCUGGAAGAAGUCCUC	7416
GUGCCUGAUGGUGUUGCAG	7417	CUGCAACACCAUCAGGCAC	7418
GAUGGUGUUGCAGUCUGGU	7419	ACCAGACUGCAACACCAUC	7420
UGGUGUUGCAGUCUGGUCA	7421	UGACCAGACUGCAACACCA	7422
GGUGUUGCAGUCUGGUCAG	7423	CUGACCAGACUGCAACACC	7424
GUGUUGCAGUCUGGUCAGA	7425	UCUGACCAGACUGCAACAC	7426
UGCAGUCUGGUCAGAGCUG	7427	CAGCUCUGACCAGACUGCA	7428
GCAGUCUGGUCAGAGCUGG	7429	CCAGCUCUGACCAGACUGC	7430
CAGUCUGGUCAGAGCUGGA	7431	UCCAGCUCUGACCAGACUG	7432
AGUCUGGUCAGAGCUGGAG	7433	CUCCAGCUCUGACCAGACU	7434
GUCUGGUCAGAGCUGGAGC	7435	GCUCCAGCUCUGACCAGAC	7436
UCUGGUCAGAGCUGGAGCC	7437	GGCUCCAGCUCUGACCAGA	7438
UGGUCAGAGCUGGAGCCCU	7439	AGGGCUCCAGCUCUGACCA	7440
GGUCAGAGCUGGAGCCCUA	7441	UAGGGCUCCAGCUCUGACC	7442
GUCAGAGCUGGAGCCCUAC	7443	GUAGGGCUCCAGCUCUGAC	7444
CAAGGGUAAGAGGCCUAUA	7445	UAUAGGCCUCUUACCCUUG	7446
AAGGGUAAGAGGCCUAUAC	7447	GUAUAGGCCUCUUACCCUU	7448
AGGGUAAGAGGCCUAUACU	7449	AGUAUAGGCCUCUUACCCU	7450
GGGUAAGAGGCCUAUACUG	7451	CAGUAUAGGCCUCUUACCC	7452
GGUAAGAGGCCUAUACUGG	7453	CCAGUAUAGGCCUCUUACC	7454
GUAAGAGGCCUAUACUGGG	7455	CCCAGUAUAGGCCUCUUAC	7456
GGGCUGCUUCCAAUGCCUG	7457	CAGGCAUUGGAAGCAGCCC	7458
GGCUGCUUCCAAUGCCUGU	7459	ACAGGCAUUGGAAGCAGCC	7460
GCUGCUUCCAAUGCCUGUC	7461	GACAGGCAUUGGAAGCAGC	7462
CUGCUUCCAAUGCCUGUCC	7463	GGACAGGCAUUGGAAGCAG	7464
UGCUUCCAAUGCCUGUCCU	7465	AGGACAGGCAUUGGAAGCA	7466
GCUUCCAAUGCCUGUCCUU	7467	AAGGACAGGCAUUGGAAGC	7468
CUUCCAAUGCCUGUCCUUU	7469	AAAGGACAGGCAUUGGAAG	7470
UUCCAAUGCCUGUCCUUUA	7471	UAAAGGACAGGCAUUGGAA	7472
UCCAAUGCCUGUCCUUUAG	7473	CUAAAGGACAGGCAUUGGA	7474
CAAUGCCUGUCCUUUAGAG	7475	CUCUAAAGGACAGGCAUUG	7476
AAUGCCUGUCCUUUAGAGC	7477	GCUCUAAAGGACAGGCAUU	7478
AUGCCUGUCCUUUAGAGCU	7479	AGCUCUAAAGGACAGGCAU	7480
CUUCCUCUCUAGCUUAACC	7481	GGUUAAGCUAGAGAGGAAG	7482
UUCCUCUCUAGCUUAACCC	7483	GGGUUAAGCUAGAGAGGAA	7484
UCUCUAGCUUAACCCUGAU	7485	AUCAGGGUUAAGCUAGAGA	7486
UAGCUUAACCCUGAUCCUG	7487	CAGGAUCAGGGUUAAGCUA	7488
GACCAGGUGCAGGAGGAGU	7489	ACUCCUCCUGCACCUGGUC	7490
ACCAGGUGCAGGAGGAGUU	7491	AACUCCUCCUGCACCUGGU	7492
CCAGGUGCAGGAGGAGUUG	7493	CAACUCCUCCUGCACCUGG	7494
CAGGUGCAGGAGGAGUUGU	7495	ACAACUCCUCCUGCACCUG	7496
AGGUGCAGGAGGAGUUGUG	7497	CACAACUCCUCCUGCACCU	7498
UGCAGGAGGAGUUGUGGAA	7499	UUCCACAACUCCUCCUGCA	7500
GCAGGAGGAGUUGUGGAAU	7501	AUUCCACAACUCCUCCUGC	7502
AGGAGGAGUUGUGGAAUUG	7503	CAAUUCCACAACUCCUCCU	7504
GGAGGAGUUGUGGAAUUGU	7505	ACAAUUCCACAACUCCUCC	7506
GAGGAGUUGUGGAAUUGUC	7507	GACAAUUCCACAACUCCUC	7508
AGGAGUUGUGGAAUUGUCA	7509	UGACAAUUCCACAACUCCU	7510
GGAGUUGUGGAAUUGUCAA	7511	UUGACAAUUCCACAACUCC	7512
GAGUUGUGGAAUUGUCAAG	7513	CUUGACAAUUCCACAACUC	7514
AGUUGUGGAAUUGUCAAGG	7515	CCUUGACAAUUCCACAACU	7516
GUUGUGGAAUUGUCAAGGA	7517	UCCUUGACAAUUCCACAAC	7518
UGGAAUUGUCAAGGAUGUC	7519	GACAUCCUUGACAAUUCCA	7520
GGAAUUGUCAAGGAUGUCA	7521	UGACAUCCUUGACAAUUCC	7522
AGUCCAAGCGAGGGAGGGU	7523	ACCCUCCCUCGCUUGGACU	7524
CAAGCGAGGGAGGGUCUGA	7525	UCAGACCCUCCCUCGCUUG	7526
AAGCGAGGGAGGGUCUGAC	7527	GUCAGACCCUCCCUCGCUU	7528
CUGACCCAGUGCUGAUGGA	7529	UCCAUCAGCACUGGGUCAG	7530
AGAUUAGUGGUGGGUGUCU	7531	AGACACCCACCACUAAUCU	7532
AUUAGUGGUGGGUGUCUGG	7533	CCAGACACCCACCACUAAU	7534
UUAGUGGUGGGUGUCUGGU	7535	ACCAGACACCCACCACUAA	7536
UAGUGGUGGGUGUCUGGUA	7537	UACCAGACACCCACCACUA	7538
AGUGGUGGGUGUCUGGUAU	7539	AUACCAGACACCCACCACU	7540
GUGGUGGGUGUCUGGUAUG	7541	CAUACCAGACACCCACCAC	7542
UGGUGGGUGUCUGGUAUGA	7543	UCAUACCAGACACCCACCA	7544
GGUGGGUGUCUGGUAUGAG	7545	CUCAUACCAGACACCCACC	7546
GUGGGUGUCUGGUAUGAGG	7547	CCUCAUACCAGACACCCAC	7548
UGGGUGUCUGGUAUGAGGA	7549	UCCUCAUACCAGACACCCA	7550
GGGUGUCUGGUAUGAGGAU	7551	AUCCUCAUACCAGACACCC	7552
GGUGUCUGGUAUGAGGAUC	7553	GAUCCUCAUACCAGACACC	7554
GUGUCUGGUAUGAGGAUCU	7555	AGAUCCUCAUACCAGACAC	7556
UGUCUGGUAUGAGGAUCUA	7557	UAGAUCCUCAUACCAGACA	7558
CAAGGGUGUCCUACAGAGU	7559	ACUCUGUAGGACACCCUUG	7560
AAGGGUGUCCUACAGAGUG	7561	CACUCUGUAGGACACCCUU	7562
AGGGUGUCCUACAGAGUGG	7563	CCACUCUGUAGGACACCCU	7564
GGGUGUCCUACAGAGUGGA	7565	UCCACUCUGUAGGACACCC	7566
GGUGUCCUACAGAGUGGAG	7567	CUCCACUCUGUAGGACACC	7568
UCCUACAGAGUGGAGUGCU	7569	AGCACUCCACUCUGUAGGA	7570
AGUGGAGUGCUGUCAUAUG	7571	CAUAUGACAGCACUCCACU	7572
GUGGAGUGCUGUCAUAUGG	7573	CCAUAUGACAGCACUCCAC	7574
UGGAGUGCUGUCAUAUGGC	7575	GCCAUAUGACAGCACUCCA	7576
GGAGUGCUGUCAUAUGGCC	7577	GGCCAUAUGACAGCACUCC	7578
GAGUGCUGUCAUAUGGCCU	7579	AGGCCAUAUGACAGCACUC	7580
AGUGCUGUCAUAUGGCCUG	7581	CAGGCCAUAUGACAGCACU	7582
GUGCUGUCAUAUGGCCUGG	7583	CCAGGCCAUAUGACAGCAC	7584
UGCUGUCAUAUGGCCUGGG	7585	CCCAGGCCAUAUGACAGCA	7586
GCUGUCAUAUGGCCUGGGA	7587	UCCCAGGCCAUAUGACAGC	7588
CUGUCAUAUGGCCUGGGAC	7589	GUCCCAGGCCAUAUGACAG	7590
UGUCAUAUGGCCUGGGACG	7591	CGUCCCAGGCCAUAUGACA	7592
GUCAUAUGGCCUGGGACGG	7593	CCGUCCCAGGCCAUAUGAC	7594
AGAGGCCCAAGCACAGCAA	7595	UUGCUGUGCUUGGGCCUCU	7596
GAGGCCCAAGCACAGCAAG	7597	CUUGCUGUGCUUGGGCCUC	7598
AGGCCCAAGCACAGCAAGG	7599	CCUUGCUGUGCUUGGGCCU	7600
GGCCCAAGCACAGCAAGGA	7601	UCCUUGCUGUGCUUGGGCC	7602
CCAAGCACAGCAAGGACAU	7603	AUGUCCUUGCUGUGCUUGG	7604
GCCCGAUUCACCUUUGACG	7605	CGUCAAAGGUGAAUCGGGC	7606
GAUUCACCUUUGACGUGUA	7607	UACACGUCAAAGGUGAAUC	7608
AUUCACCUUUGACGUGUAC	7609	GUACACGUCAAAGGUGAAU	7610
UUGGCAGCCUGAAUGUCAA	7611	UUGACAUUCAGGCUGCCAA	7612
UGGCAGCCUGAAUGUCAAA	7613	UUUGACAUUCAGGCUGCCA	7614
GGCAGCCUGAAUGUCAAAG	7615	CUUUGACAUUCAGGCUGCC	7616
GCAGCCUGAAUGUCAAAGC	7617	GCUUUGACAUUCAGGCUGC	7618
CAGCCUGAAUGUCAAAGCC	7619	GGCUUUGACAUUCAGGCUG	7620
AGCCUGAAUGUCAAAGCCA	7621	UGGCUUUGACAUUCAGGCU	7622
GCCUGAAUGUCAAAGCCAC	7623	GUGGCUUUGACAUUCAGGC	7624
GUCAAAGCCACAUUCUACG	7625	CGUAGAAUGUGGCUUUGAC	7626
UCAAAGCCACAUUCUACGG	7627	CCGUAGAAUGUGGCUUUGA	7628
CAAAGCCACAUUCUACGGG	7629	CCCGUAGAAUGUGGCUUUG	7630
AAAGCCACAUUCUACGGGC	7631	GCCCGUAGAAUGUGGCUUU	7632
GCCACAUUCUACGGGCUCU	7633	AGAGCCCGUAGAAUGUGGC	7634
CCACAUUCUACGGGCUCUA	7635	UAGAGCCCGUAGAAUGUGG	7636
CACAUUCUACGGGCUCUAC	7637	GUAGAGCCCGUAGAAUGUG	7638
UUCUACGGGCUCUACUCUA	7639	UAGAGUAGAGCCCGUAGAA	7640
UCUACGGGCUCUACUCUAU	7641	AUAGAGUAGAGCCCGUAGA	7642
CUACGGGCUCUACUCUAUG	7643	CAUAGAGUAGAGCCCGUAG	7644
CUCUAUGAGUUGUGACUUU	7645	AAAGUCACAACUCAUAGAG	7646
UCUAUGAGUUGUGACUUUC	7647	GAAAGUCACAACUCAUAGA	7648
UGAGUUGUGACUUUCAAGG	7649	CCUUGAAAGUCACAACUCA	7650
GAGUUGUGACUUUCAAGGA	7651	UCCUUGAAAGUCACAACUC	7652
AGUUGUGACUUUCAAGGAC	7653	GUCCUUGAAAGUCACAACU	7654
GUUGUGACUUUCAAGGACU	7655	AGUCCUUGAAAGUCACAAC	7656
GACUUUCAAGGACUUGGCC	7657	GGCCAAGUCCUUGAAAGUC	7658
UUUCAAGGACUUGGCCCAA	7659	UUGGGCCAAGUCCUUGAAA	7660
UUCAAGGACUUGGCCCAAA	7661	UUUGGGCCAAGUCCUUGAA	7662
CCCUACAGUUGGAUAGUCC	7663	GGACUAUCCAACUGUAGGG	7664
CCUACAGUUGGAUAGUCCC	7665	GGGACUAUCCAACUGUAGG	7666
AUUCGUCCUCUUGCACCCA	7667	UGGGUGCAAGAGGACGAAU	7668
UUCGUCCUCUUGCACCCAC	7669	GUGGGUGCAAGAGGACGAA	7670
UCCUCUUGCACCCACCUAC	7671	GUAGGUGGGUGCAAGAGGA	7672
CCUCUUGCACCCACCUACC	7673	GGUAGGUGGGUGCAAGAGG	7674
CUCUUGCACCCACCUACCC	7675	GGGUAGGUGGGUGCAAGAG	7676
CUAGUUAGCUCUUGCUUGU	7677	ACAAGCAAGAGCUAACUAG	7678
UAGUUAGCUCUUGCUUGUG	7679	CACAAGCAAGAGCUAACUA	7680
AGUUAGCUCUUGCUUGUGG	7681	CCACAAGCAAGAGCUAACU	7682
UUAGCUCUUGCUUGUGGAA	7683	UUCCACAAGCAAGAGCUAA	7684
UCCUCAUCUCCCAGCUUGA	7685	UCAAGCUGGGAGAUGAGGA	7686
AUCUCCCAGCUUGAUGGCU	7687	AGCCAUCAAGCUGGGAGAU	7688
UCUCCCAGCUUGAUGGCUU	7689	AAGCCAUCAAGCUGGGAGA	7690
CUCCCAGCUUGAUGGCUUC	7691	GAAGCCAUCAAGCUGGGAG	7692
UCCCAGCUUGAUGGCUUCC	7693	GGAAGCCAUCAAGCUGGGA	7694
CCCAGCUUGAUGGCUUCCU	7695	AGGAAGCCAUCAAGCUGGG	7696
CCAGCUUGAUGGCUUCCUC	7697	GAGGAAGCCAUCAAGCUGG	7698
UGAUGGCUUCCUCCCAAGU	7699	ACUUGGGAGGAAGCCAUCA	7700
GAUGGCUUCCUCCCAAGUU	7701	AACUUGGGAGGAAGCCAUC	7702
GGCUUCCUCCCAAGUUUUC	7703	GAAAACUUGGGAGGAAGCC	7704
CCUCCCAAGUUUUCCAAAU	7705	AUUUGGAAAACUUGGGAGG	7706
CCCAAGUUUUCCAAAUCAU	7707	AUGAUUUGGAAAACUUGGG	7708
CCAAGUUUUCCAAAUCAUC	7709	GAUGAUUUGGAAAACUUGG	7710
CAAGUUUUCCAAAUCAUCU	7711	AGAUGAUUUGGAAAACUUG	7712
AAGUUUUCCAAAUCAUCUG	7713	CAGAUGAUUUGGAAAACUU	7714
GUUUUCCAAAUCAUCUGAU	7715	AUCAGAUGAUUUGGAAAAC	7716
AUCUGAUUUCCUCUUGUCU	7717	AGACAAGAGGAAAUCAGAU	7718
UCUGAUUUCCUCUUGUCUC	7719	GAGACAAGAGGAAAUCAGA	7720
CUGAUUUCCUCUUGUCUCU	7721	AGAGACAAGAGGAAAUCAG	7722
CUCUUGUCUCUGCCAUUCA	7723	UGAAUGGCAGAGACAAGAG	7724
GUUGGACCUCCACACUGCU	7725	AGCAGUGUGGAGGUCCAAC	7726
CCACACUGCUGCAAGGCCU	7727	AGGCCUUGCAGCAGUGUGG	7728
CACACUGCUGCAAGGCCUG	7729	CAGGCCUUGCAGCAGUGUG	7730
ACACUGCUGCAAGGCCUGG	7731	CCAGGCCUUGCAGCAGUGU	7732
UGCAAGGCCUGGGCCAUAU	7733	AUAUGGCCCAGGCCUUGCA	7734
GCAAGGCCUGGGCCAUAUG	7735	CAUAUGGCCCAGGCCUUGC	7736
CAAGGCCUGGGCCAUAUGU	7737	ACAUAUGGCCCAGGCCUUG	7738
AAGGCCUGGGCCAUAUGUU	7739	AACAUAUGGCCCAGGCCUU	7740
AGGCCUGGGCCAUAUGUUG	7741	CAACAUAUGGCCCAGGCCU	7742
GGCCUGGGCCAUAUGUUGC	7743	GCAACAUAUGGCCCAGGCC	7744
GCCUGGGCCAUAUGUUGCU	7745	AGCAACAUAUGGCCCAGGC	7746
CCUGGGCCAUAUGUUGCUG	7747	CAGCAACAUAUGGCCCAGG	7748
GGCCAUAUGUUGCUGGGAA	7749	UUCCCAGCAACAUAUGGCC	7750
CCAUAUGUUGCUGGGAAUU	7751	AAUUCCCAGCAACAUAUGG	7752
GGAAUUUCCUCCACCCUUC	7753	GAAGGGUGGAGGAAAUUCC	7754
GAAUUUCCUCCACCCUUCG	7755	CGAAGGGUGGAGGAAAUUC	7756
AAUUUCCUCCACCCUUCGU	7757	ACGAAGGGUGGAGGAAAUU	7758
AUUUCCUCCACCCUUCGUC	7759	GACGAAGGGUGGAGGAAAU	7760
UUUCCUCCACCCUUCGUCA	7761	UGACGAAGGGUGGAGGAAA	7762
UUCCUCCACCCUUCGUCAU	7763	AUGACGAAGGGUGGAGGAA	7764
UCCUCCACCCUUCGUCAUG	7765	CAUGACGAAGGGUGGAGGA	7766
CCUCCACCCUUCGUCAUGC	7767	GCAUGACGAAGGGUGGAGG	7768
CUCCACCCUUCGUCAUGCA	7769	UGCAUGACGAAGGGUGGAG	7770
CCUUCGUCAUGCAGUGGAG	7771	CUCCACUGCAUGACGAAGG	7772
CUUCGUCAUGCAGUGGAGG	7773	CCUCCACUGCAUGACGAAG	7774
UUCGUCAUGCAGUGGAGGG	7775	CCCUCCACUGCAUGACGAA	7776
CGCCUCCAUUCCUACUAAG	7777	CUUAGUAGGAAUGGAGGCG	7778
GCCUCCAUUCCUACUAAGG	7779	CCUUAGUAGGAAUGGAGGC	7780
CCUCCAUUCCUACUAAGGG	7781	CCCUUAGUAGGAAUGGAGG	7782
CAGAAUCAUUCCAACCGAC	7783	GUCGGUUGGAAUGAUUCUG	7784
AGAAUCAUUCCAACCGACC	7785	GGUCGGUUGGAAUGAUUCU	7786
GAAUCAUUCCAACCGACCC	7787	GGGUCGGUUGGAAUGAUUC	7788
AAUCAUUCCAACCGACCCA	7789	UGGGUCGGUUGGAAUGAUU	7790
AUCAUUCCAACCGACCCAC	7791	GUGGGUCGGUUGGAAUGAU	7792
UCAUUCCAACCGACCCACU	7793	AGUGGGUCGGUUGGAAUGA	7794
UCCAACCGACCCACUGCAA	7795	UUGCAGUGGGUCGGUUGGA	7796
CCAACCGACCCACUGCAAA	7797	UUUGCAGUGGGUCGGUUGG	7798
CAACCGACCCACUGCAAAG	7799	CUUUGCAGUGGGUCGGUUG	7800
AACCGACCCACUGCAAAGA	7801	UCUUUGCAGUGGGUCGGUU	7802
ACCGACCCACUGCAAAGAC	7803	GUCUUUGCAGUGGGUCGGU	7804
CCGACCCACUGCAAAGACU	7805	AGUCUUUGCAGUGGGUCGG	7806
CGACCCACUGCAAAGACUA	7807	UAGUCUUUGCAGUGGGUCG	7808
GACCCACUGCAAAGACUAU	7809	AUAGUCUUUGCAGUGGGUC	7810
ACCCACUGCAAAGACUAUG	7811	CAUAGUCUUUGCAGUGGGU	7812
ACUGCAAAGACUAUGACAG	7813	CUGUCAUAGUCUUUGCAGU	7814
CUGCAAAGACUAUGACAGC	7815	GCUGUCAUAGUCUUUGCAG	7816
UGCAAAGACUAUGACAGCA	7817	UGCUGUCAUAGUCUUUGCA	7818
GCAAAGACUAUGACAGCAU	7819	AUGCUGUCAUAGUCUUUGC	7820
AAAGACUAUGACAGCAUCA	7821	UGAUGCUGUCAUAGUCUUU	7822
AAGACUAUGACAGCAUCAA	7823	UUGAUGCUGUCAUAGUCUU	7824
AGACUAUGACAGCAUCAAA	7825	UUUGAUGCUGUCAUAGUCU	7826
GACUAUGACAGCAUCAAAU	7827	AUUUGAUGCUGUCAUAGUC	7828
CUAUGACAGCAUCAAAUUU	7829	AAAUUUGAUGCUGUCAUAG	7830
UAUGACAGCAUCAAAUUUC	7831	GAAAUUUGAUGCUGUCAUA	7832
GCAUCAAAUUUCAGGACCU	7833	AGGUCCUGAAAUUUGAUGC	7834
AUCAAAUUUCAGGACCUGC	7835	GCAGGUCCUGAAAUUUGAU	7836
UCAAAUUUCAGGACCUGCA	7837	UGCAGGUCCUGAAAUUUGA	7838
UUCAGGACCUGCAGACAGU	7839	ACUGUCUGCAGGUCCUGAA	7840
UCAGGACCUGCAGACAGUA	7841	UACUGUCUGCAGGUCCUGA	7842
CAGGACCUGCAGACAGUAC	7843	GUACUGUCUGCAGGUCCUG	7844
AGGACCUGCAGACAGUACA	7845	UGUACUGUCUGCAGGUCCU	7846
GGACCUGCAGACAGUACAG	7847	CUGUACUGUCUGCAGGUCC	7848
CUGCAGACAGUACAGGCUA	7849	UAGCCUGUACUGUCUGCAG	7850
GACAGUACAGGCUAGAUAA	7851	UUAUCUAGCCUGUACUGUC	7852
ACAGUACAGGCUAGAUAAC	7853	GUUAUCUAGCCUGUACUGU	7854
CAGUACAGGCUAGAUAACC	7855	GGUUAUCUAGCCUGUACUG	7856
AGUACAGGCUAGAUAACCC	7857	GGGUUAUCUAGCCUGUACU	7858
GUACAGGCUAGAUAACCCA	7859	UGGGUUAUCUAGCCUGUAC	7860
UACAGGCUAGAUAACCCAC	7861	GUGGGUUAUCUAGCCUGUA	7862
GCUAGAUAACCCACCCAAU	7863	AUUGGGUGGGUUAUCUAGC	7864
CUAGAUAACCCACCCAAUU	7865	AAUUGGGUGGGUUAUCUAG	7866
AGAUAACCCACCCAAUUUC	7867	GAAAUUGGGUGGGUUAUCU	7868
GAUAACCCACCCAAUUUCC	7869	GGAAAUUGGGUGGGUUAUC	7870
AACCUUUCAGCAUAACGCC	7871	GGCGUUAUGCUGAAAGGUU	7872
ACCUUUCAGCAUAACGCCU	7873	AGGCGUUAUGCUGAAAGGU	7874
CCUUUCAGCAUAACGCCUC	7875	GAGGCGUUAUGCUGAAAGG	7876
CUUUCAGCAUAACGCCUCA	7877	UGAGGCGUUAUGCUGAAAG	7878
UUUCAGCAUAACGCCUCAC	7879	GUGAGGCGUUAUGCUGAAA	7880
UUCAGCAUAACGCCUCACA	7881	UGUGAGGCGUUAUGCUGAA	7882
UCAGCAUAACGCCUCACAU	7883	AUGUGAGGCGUUAUGCUGA	7884
CAGCAUAACGCCUCACAUC	7885	GAUGUGAGGCGUUAUGCUG	7886
AGCAUAACGCCUCACAUCC	7887	GGAUGUGAGGCGUUAUGCU	7888
GCAUAACGCCUCACAUCCC	7889	GGGAUGUGAGGCGUUAUGC	7890
AACGCCUCACAUCCCAAGU	7891	ACUUGGGAUGUGAGGCGUU	7892
ACGCCUCACAUCCCAAGUC	7893	GACUUGGGAUGUGAGGCGU	7894
CGCCUCACAUCCCAAGUCU	7895	AGACUUGGGAUGUGAGGCG	7896
UCACAUCCCAAGUCUAUAC	7897	GUAUAGACUUGGGAUGUGA	7898
CACAUCCCAAGUCUAUACC	7899	GGUAUAGACUUGGGAUGUG	7900
ACAUCCCAAGUCUAUACCC	7901	GGGUAUAGACUUGGGAUGU	7902
CAUCCCAAGUCUAUACCCU	7903	AGGGUAUAGACUUGGGAUG	7904
AAUGCUGUUCUUUCCUAGC	7905	GCUAGGAAAGAACAGCAUU	7906
AUGCUGUUCUUUCCUAGCC	7907	GGCUAGGAAAGAACAGCAU	7908
CUGUUCUUUCCUAGCCACC	7909	GGUGGCUAGGAAAGAACAG	7910
UGUUCUUUCCUAGCCACCU	7911	AGGUGGCUAGGAAAGAACA	7912
GCCAAGAUCAAGAUGUCCC	7913	GGGACAUCUUGAUCUUGGC	7914
UCUUGAUCCCAGCCUGACU	7915	AGUCAGGCUGGGAUCAAGA	7916
CUUGAUCCCAGCCUGACUG	7917	CAGUCAGGCUGGGAUCAAG	7918
UUGAUCCCAGCCUGACUGC	7919	GCAGUCAGGCUGGGAUCAA	7920
UGAUCCCAGCCUGACUGCU	7921	AGCAGUCAGGCUGGGAUCA	7922
CUGACUGCUGCUACAUCUA	7923	UAGAUGUAGCAGCAGUCAG	7924
GACUGCUGCUACAUCUAAU	7925	AUUAGAUGUAGCAGCAGUC	7926
ACUGCUGCUACAUCUAAUC	7927	GAUUAGAUGUAGCAGCAGU	7928
CUGCUGCUACAUCUAAUCC	7929	GGAUUAGAUGUAGCAGCAG	7930
UGCUGCUACAUCUAAUCCC	7931	GGGAUUAGAUGUAGCAGCA	7932
CCUACCAAUGCCUCCUGUC	7933	GACAGGAGGCAUUGGUAGG	7934
CUACCAAUGCCUCCUGUCC	7935	GGACAGGAGGCAUUGGUAG	7936
CCAAUGCCUCCUGUCCCUA	7937	UAGGGACAGGAGGCAUUGG	7938
CAAUGCCUCCUGUCCCUAA	7939	UUAGGGACAGGAGGCAUUG	7940
AAUGCCUCCUGUCCCUAAA	7941	UUUAGGGACAGGAGGCAUU	7942
CCCAGCAUACUGAUGACAG	7943	CUGUCAUCAGUAUGCUGGG	7944
CCAGCAUACUGAUGACAGC	7945	GCUGUCAUCAGUAUGCUGG	7946
CAUACUGAUGACAGCCCUC	7947	GAGGGCUGUCAUCAGUAUG	7948
AUACUGAUGACAGCCCUCU	7949	AGAGGGCUGUCAUCAGUAU	7950
UACUGAUGACAGCCCUCUC	7951	GAGAGGGCUGUCAUCAGUA	7952
ACUGAUGACAGCCCUCUCU	7953	AGAGAGGGCUGUCAUCAGU	7954
CUGAUGACAGCCCUCUCUG	7955	CAGAGAGGGCUGUCAUCAG	7956
UGAUGACAGCCCUCUCUGA	7957	UCAGAGAGGGCUGUCAUCA	7958
GAUGACAGCCCUCUCUGAC	7959	GUCAGAGAGGGCUGUCAUC	7960
AUGACAGCCCUCUCUGACU	7961	AGUCAGAGAGGGCUGUCAU	7962
UGACAGCCCUCUCUGACUU	7963	AAGUCAGAGAGGGCUGUCA	7964
GACAGCCCUCUCUGACUUU	7965	AAAGUCAGAGAGGGCUGUC	7966
ACAGCCCUCUCUGACUUUA	7967	UAAAGUCAGAGAGGGCUGU	7968
CAGCCCUCUCUGACUUUAC	7969	GUAAAGUCAGAGAGGGCUG	7970
AGCCCUCUCUGACUUUACC	7971	GGUAAAGUCAGAGAGGGCU	7972
GCCCUCUCUGACUUUACCU	7973	AGGUAAAGUCAGAGAGGGC	7974
CCCUCUCUGACUUUACCUU	7975	AAGGUAAAGUCAGAGAGGG	7976
CCUCUCUGACUUUACCUUG	7977	CAAGGUAAAGUCAGAGAGG	7978
CUCUCUGACUUUACCUUGA	7979	UCAAGGUAAAGUCAGAGAG	7980
AGAUCUGUCUUCAUACCCU	7981	AGGGUAUGAAGACAGAUCU	7982
GAUCUGUCUUCAUACCCUU	7983	AAGGGUAUGAAGACAGAUC	7984
CUGUCUUCAUACCCUUCCC	7985	GGGAAGGGUAUGAAGACAG	7986

TABLE 10

	SEQ		SEQ
	ID		ID
Sense Sequence	NO:	Antisense Sequence	NO:
ACACCAGAAGUCACAUUUC	7987	GAAAUGUGACUUCUGGUGU	7988
GAAGUCACAUUUCAUCCUU	7989	AAGGAUGAAAUGUGACUUC	7990
AAGUCACAUUUCAUCCUUU	7991	AAAGGAUGAAAUGUGACUU	7992
AGUCACAUUUCAUCCUUUU	7993	AAAAGGAUGAAAUGUGACU	7994
UUUCAUCCUUUUACAUGGU	7995	ACCAUGUAAAAGGAUGAAA	7996
UUCAUCCUUUUACAUGGUU	7997	AACCAUGUAAAAGGAUGAA	7998
UCAUCCUUUUACAUGGUUC	7999	GAACCAUGUAAAAGGAUGA	8000
CAUCCUUUUACAUGGUUCC	8001	GGAACCAUGUAAAAGGAUG	8002
UGGUUCCCAUCUACCCUCA	8003	UGAGGGUAGAUGGGAACCA	8004
GGUUCCCAUCUACCCUCAC	8005	GUGAGGGUAGAUGGGAACC	8006
GUUCCCAUCUACCCUCACA	8007	UGUGAGGGUAGAUGGGAAC	8008
GGCAAUUCUUCCUCCAGGA	8009	UCCUGGAGGAAGAAUUGCC	8010
GCAAUUCUUCCUCCAGGAC	8011	GUCCUGGAGGAAGAAUUGC	8012
CAAUUCUUCCUCCAGGACC	8013	GGUCCUGGAGGAAGAAUUG	8014
AAUUCUUCCUCCAGGACCC	8015	GGGUCCUGGAGGAAGAAUU	8016
CCCUUGGACUUUGCCCUUC	8017	GAAGGGCAAAGUCCAAGGG	8018
CCUUGGACUUUGCCCUUCU	8019	AGAAGGGCAAAGUCCAAGG	8020
CUUGGACUUUGCCCUUCUU	8021	AAGAAGGGCAAAGUCCAAG	8022
UUGGACUUUGCCCUUCUUA	8023	UAAGAAGGGCAAAGUCCAA	8024
UGGACUUUGCCCUUCUUAC	8025	GUAAGAAGGGCAAAGUCCA	8026
GGACUUUGCCCUUCUUACU	8027	AGUAAGAAGGGCAAAGUCC	8028
UUUGCCCUUCUUACUGGCC	8029	GGCCAGUAAGAAGGGCAAA	8030
UUGCCCUUCUUACUGGCCA	8031	UGGCCAGUAAGAAGGGCAA	8032
UGCCCUUCUUACUGGCCAG	8033	CUGGCCAGUAAGAAGGGCA	8034
UCUUACUGGCCAGGCAGGG	8035	CCCUGCCUGGCCAGUAAGA	8036
GGCCAGAGUCCAGGCUUGA	8037	UCAAGCCUGGACUCUGGCC	8038
GCCAGAGUCCAGGCUUGAC	8039	GUCAAGCCUGGACUCUGGC	8040
GUCCAGGCUUGACUCAUUC	8041	GAAUGAGUCAAGCCUGGAC	8042
AGGCUUGACUCAUUCCCAC	8043	GUGGGAAUGAGUCAAGCCU	8044
GACUCAUUCCCACCUUGUC	8045	GACAAGGUGGGAAUGAGUC	8046
ACUCAUUCCCACCUUGUCC	8047	GGACAAGGUGGGAAUGAGU	8048
UCAUUCCCACCUUGUCCUG	8049	CAGGACAAGGUGGGAAUGA	8050
CACCUUGUCCUGGGCUGAG	8051	CUCAGCCCAGGACAAGGUG	8052
ACCACCCAGCCCAGAAGUU	8053	AACUUCUGGGCUGGGUGGU	8054
CCACCCAGCCCAGAAGUUC	8055	GAACUUCUGGGCUGGGUGG	8056
CACCCAGCCCAGAAGUUCC	8057	GGAACUUCUGGGCUGGGUG	8058
ACCCAGCCCAGAAGUUCCA	8059	UGGAACUUCUGGGCUGGGU	8060
CCAGAAGUUCCAGGGAAGG	8061	CCUUCCCUGGAACUUCUGG	8062
CAGAAGUUCCAGGGAAGGA	8063	UCCUUCCCUGGAACUUCUG	8064
AACUCUCCGGUCCACCAUG	8065	CAUGGUGGACCGGAGAGUU	8066
ACUCUCCGGUCCACCAUGG	8067	CCAUGGUGGACCGGAGAGU	8068
CACCAUGGAGUACCUCUCA	8069	UGAGAGGUACUCCAUGGUG	8070
ACCAUGGAGUACCUCUCAG	8071	CUGAGAGGUACUCCAUGGU	8072
UGGAGUACCUCUCAGCUCU	8073	AGAGCUGAGAGGUACUCCA	8074
GGAGUACCUCUCAGCUCUG	8075	CAGAGCUGAGAGGUACUCC	8076
GAGUACCUCUCAGCUCUGA	8077	UCAGAGCUGAGAGGUACUC	8078
AGUACCUCUCAGCUCUGAA	8079	UUCAGAGCUGAGAGGUACU	8080
CCAGUGACUUACUCAGGUG	8081	CACCUGAGUAAGUCACUGG	8082
CAGUGACUUACUCAGGUGA	8083	UCACCUGAGUAAGUCACUG	8084
AGUGACUUACUCAGGUGAC	8085	GUCACCUGAGUAAGUCACU	8086
GUGACUUACUCAGGUGACU	8087	AGUCACCUGAGUAAGUCAC	8088
UGACUUACUCAGGUGACUG	8089	CAGUCACCUGAGUAAGUCA	8090
GACUUACUCAGGUGACUGC	8091	GCAGUCACCUGAGUAAGUC	8092
ACUUACUCAGGUGACUGCU	8093	AGCAGUCACCUGAGUAAGU	8094
CUUACUCAGGUGACUGCUA	8095	UAGCAGUCACCUGAGUAAG	8096
UUACUCAGGUGACUGCUAA	8097	UUAGCAGUCACCUGAGUAA	8098
UACUCAGGUGACUGCUAAC	8099	GUUAGCAGUCACCUGAGUA	8100
ACUCAGGUGACUGCUAACC	8101	GGUUAGCAGUCACCUGAGU	8102
CUCAGGUGACUGCUAACCC	8103	GGGUUAGCAGUCACCUGAG	8104
GGUGACUGCUAACCCUCCG	8105	CGGAGGGUUAGCAGUCACC	8106
GUGACUGCUAACCCUCCGC	8107	GCGGAGGGUUAGCAGUCAC	8108
UGACUGCUAACCCUCCGCU	8109	AGCGGAGGGUUAGCAGUCA	8110
GACUGCUAACCCUCCGCUC	8111	GAGCGGAGGGUUAGCAGUC	8112
ACUGCUAACCCUCCGCUCU	8113	AGAGCGGAGGGUUAGCAGU	8114
CUGCUAACCCUCCGCUCUA	8115	UAGAGCGGAGGGUUAGCAG	8116
UGCUAACCCUCCGCUCUAC	8117	GUAGAGCGGAGGGUUAGCA	8118
AACCCUCCGCUCUACCCUC	8119	GAGGGUAGAGCGGAGGGUU	8120
ACUCCACAGUGGGCUUGUC	8121	GACAAGCCCACUGUGGAGU	8122
CUCCACAGUGGGCUUGUCA	8123	UGACAAGCCCACUGUGGAG	8124
UCCACAGUGGGCUUGUCAA	8125	UUGACAAGCCCACUGUGGA	8126
CCACAGUGGGCUUGUCAAG	8127	CUUGACAAGCCCACUGUGG	8128
GUCAAGCUCCUGAGCCACC	8129	GGUGGCUCAGGAGCUUGAC	8130
CCAUGGUCUCUCCCUCAUC	8131	GAUGAGGGAGAGACCAUGG	8132
CAUGGUCUCUCCCUCAUCC	8133	GGAUGAGGGAGAGACCAUG	8134
AUGGUCUCUCCCUCAUCCC	8135	GGGAUGAGGGAGAGACCAU	8136
UCUCUCCCUCAUCCCUAAU	8137	AUUAGGGAUGAGGGAGAGA	8138
CUCUCCCUCAUCCCUAAUC	8139	GAUUAGGGAUGAGGGAGAG	8140
UCUCCCUCAUCCCUAAUCG	8141	CGAUUAGGGAUGAGGGAGA	8142
CUCCCUCAUCCCUAAUCGA	8143	UCGAUUAGGGAUGAGGGAG	8144
UCCCUCAUCCCUAAUCGAU	8145	AUCGAUUAGGGAUGAGGGA	8146
CCCUCAUCCCUAAUCGAUA	8147	UAUCGAUUAGGGAUGAGGG	8148
CCUCAUCCCUAAUCGAUAA	8149	UUAUCGAUUAGGGAUGAGG	8150
CUCAUCCCUAAUCGAUAAA	8151	UUUAUCGAUUAGGGAUGAG	8152
AACCUAGAUCUCUCCCUCC	8153	GGAGGGAGAGAUCUAGGUU	8154
ACCUAGAUCUCUCCCUCCC	8155	GGGAGGGAGAGAUCUAGGU	8156
CUAGAUCUCUCCCUCCCUA	8157	UAGGGAGGGAGAGAUCUAG	8158
UAGAUCUCUCCCUCCCUAG	8159	CUAGGGAGGGAGAGAUCUA	8160
AGAUCUCUCCCUCCCUAGC	8161	GCUAGGGAGGGAGAGAUCU	8162
GAUCUCUCCCUCCCUAGCC	8163	GGCUAGGGAGGGAGAGAUC	8164
AUCUCUCCCUCCCUAGCCC	8165	GGGCUAGGGAGGGAGAGAU	8166
UAGCCCUCUAGCCACUCUA	8167	UAGAGUGGCUAGAGGGCUA	8168
AGCCCUCUAGCCACUCUAC	8169	GUAGAGUGGCUAGAGGGCU	8170
CUCUAGCCACUCUACCCUC	8171	GAGGGUAGAGUGGCUAGAG	8172
UCUAGCCACUCUACCCUCA	8173	UGAGGGUAGAGUGGCUAGA	8174
CUAGCCACUCUACCCUCAU	8175	AUGAGGGUAGAGUGGCUAG	8176
UAGCCACUCUACCCUCAUC	8177	GAUGAGGGUAGAGUGGCUA	8178
AGCCACUCUACCCUCAUCA	8179	UGAUGAGGGUAGAGUGGCU	8180
GCCACUCUACCCUCAUCAU	8181	AUGAUGAGGGUAGAGUGGC	8182
CCACUCUACCCUCAUCAUG	8183	CAUGAUGAGGGUAGAGUGG	8184
CACUCUACCCUCAUCAUGC	8185	GCAUGAUGAGGGUAGAGUG	8186
ACUCUACCCUCAUCAUGCC	8187	GGCAUGAUGAGGGUAGAGU	8188
CUCUACCCUCAUCAUGCCC	8189	GGGCAUGAUGAGGGUAGAG	8190
UCUACCCUCAUCAUGCCCU	8191	AGGGCAUGAUGAGGGUAGA	8192
CUACCCUCAUCAUGCCCUU	8193	AAGGGCAUGAUGAGGGUAG	8194
UACCCUCAUCAUGCCCUUU	8195	AAAGGGCAUGAUGAGGGUA	8196
ACCCUCAUCAUGCCCUUUA	8197	UAAAGGGCAUGAUGAGGGU	8198
CCCUCAUCAUGCCCUUUAC	8199	GUAAAGGGCAUGAUGAGGG	8200
CUCAUCAUGCCCUUUACAC	8201	GUGUAAAGGGCAUGAUGAG	8202
UCAUCAUGCCCUUUACACU	8203	AGUGUAAAGGGCAUGAUGA	8204
CCCUUCUUGACUUUUCUUC	8205	GAAGAAAAGUCAAGAAGGG	8206
CUUCUUGACUUUUCUUCUC	8207	GAGAAGAAAAGUCAAGAAG	8208
GACUUUUCUUCUCAACUAC	8209	GUAGUUGAGAAGAAAAGUC	8210
ACUUUUCUUCUCAACUACC	8211	GGUAGUUGAGAAGAAAAGU	8212
CUUUUCUUCUCAACUACCA	8213	UGGUAGUUGAGAAGAAAAG	8214
UUUUCUUCUCAACUACCAG	8215	CUGGUAGUUGAGAAGAAAA	8216
UAUCUAAUAUAAGCUCGGA	8217	UCCGAGCUUAUAUUAGAUA	8218
AUCUAAUAUAAGCUCGGAG	8219	CUCCGAGCUUAUAUUAGAU	8220
UCUAAUAUAAGCUCGGAGU	8221	ACUCCGAGCUUAUAUUAGA	8222
CUAAUAUAAGCUCGGAGUU	8223	AACUCCGAGCUUAUAUUAG	8224
UAAUAUAAGCUCGGAGUUU	8225	AAACUCCGAGCUUAUAUUA	8226
AAUAUAAGCUCGGAGUUUG	8227	CAAACUCCGAGCUUAUAUU	8228
AUAUAAGCUCGGAGUUUGG	8229	CCAAACUCCGAGCUUAUAU	8230
UAUAAGCUCGGAGUUUGGA	8231	UCCAAACUCCGAGCUUAUA	8232
AUAAGCUCGGAGUUUGGAC	8233	GUCCAAACUCCGAGCUUAU	8234
UAAGCUCGGAGUUUGGACG	8235	CGUCCAAACUCCGAGCUUA	8236
AAGCUCGGAGUUUGGACGG	8237	CCGUCCAAACUCCGAGCUU	8238
AGCUCGGAGUUUGGACGGA	8239	UCCGUCCAAACUCCGAGCU	8240
GCUCGGAGUUUGGACGGAG	8241	CUCCGUCCAAACUCCGAGC	8242
CUCGGAGUUUGGACGGAGG	8243	CCUCCGUCCAAACUCCGAG	8244
UCGGAGUUUGGACGGAGGG	8245	CCCUCCGUCCAAACUCCGA	8246
CGGAGUUUGGACGGAGGGU	8247	ACCCUCCGUCCAAACUCCG	8248
UUUGGACGGAGGGUCUGGA	8249	UCCAGACCCUCCGUCCAAA	8250
CCCAGCGACCUUUCCGUGU	8251	ACACGGAAAGGUCGCUGGG	8252
CCAGCGACCUUUCCGUGUC	8253	GACACGGAAAGGUCGCUGG	8254
CAGCGACCUUUCCGUGUCU	8255	AGACACGGAAAGGUCGCUG	8256
AGCGACCUUUCCGUGUCUG	8257	CAGACACGGAAAGGUCGCU	8258
GCGACCUUUCCGUGUCUGU	8259	ACAGACACGGAAAGGUCGC	8260
CGACCUUUCCGUGUCUGUG	8261	CACAGACACGGAAAGGUCG	8262
CUUUCCGUGUCUGUGAUCA	8263	UGAUCACAGACACGGAAAG	8264
UUUCCGUGUCUGUGAUCAC	8265	GUGAUCACAGACACGGAAA	8266
UUCCGUGUCUGUGAUCACA	8267	UGUGAUCACAGACACGGAA	8268
AAGGCCUGACAGCUGCCAC	8269	GUGGCAGCUGUCAGGCCUU	8270
GCCAGGAGCUGCUAGCCAA	8271	UUGGCUAGCAGCUCCUGGC	8272
CCAGGAGCUGCUAGCCAAA	8273	UUUGGCUAGCAGCUCCUGG	8274
GAGCUGCUAGCCAAAGUAA	8275	UUACUUUGGCUAGCAGCUC	8276
AGCUGCUAGCCAAAGUAAG	8277	CUUACUUUGGCUAGCAGCU	8278
GCUGCUAGCCAAAGUAAGU	8279	ACUUACUUUGGCUAGCAGC	8280
CUGCUAGCCAAAGUAAGUA	8281	UACUUACUUUGGCUAGCAG	8282
UGCUAGCCAAAGUAAGUAG	8283	CUACUUACUUUGGCUAGCA	8284
GCUAGCCAAAGUAAGUAGG	8285	CCUACUUACUUUGGCUAGC	8286
UAGCCAAAGUAAGUAGGCC	8287	GGCCUACUUACUUUGGCUA	8288
AGCCAAAGUAAGUAGGCCA	8289	UGGCCUACUUACUUUGGCU	8290
GCCAAAGUAAGUAGGCCAA	8291	UUGGCCUACUUACUUUGGC	8292
CCAAAGUAAGUAGGCCAAG	8293	CUUGGCCUACUUACUUUGG	8294
CAAAGUAAGUAGGCCAAGU	8295	ACUUGGCCUACUUACUUUG	8296
AAAGUAAGUAGGCCAAGUU	8297	AACUUGGCCUACUUACUUU	8298
AAGUAAGUAGGCCAAGUUC	8299	GAACUUGGCCUACUUACUU	8300
AGUAAGUAGGCCAAGUUCC	8301	GGAACUUGGCCUACUUACU	8302
GUAAGUAGGCCAAGUUCCU	8303	AGGAACUUGGCCUACUUAC	8304
UAAGUAGGCCAAGUUCCUC	8305	GAGGAACUUGGCCUACUUA	8306
UAGGCCAAGUUCCUCGGUU	8307	AACCGAGGAACUUGGCCUA	8308
AGGCCAAGUUCCUCGGUUC	8309	GAACCGAGGAACUUGGCCU	8310
GGCCAAGUUCCUCGGUUCC	8311	GGAACCGAGGAACUUGGCC	8312
GCCAAGUUCCUCGGUUCCU	8313	AGGAACCGAGGAACUUGGC	8314
CCAAGUUCCUCGGUUCCUA	8315	UAGGAACCGAGGAACUUGG	8316
CAAGUUCCUCGGUUCCUAU	8317	AUAGGAACCGAGGAACUUG	8318
AAGUUCCUCGGUUCCUAUA	8319	UAUAGGAACCGAGGAACUU	8320
AGUUCCUCGGUUCCUAUAG	8321	CUAUAGGAACCGAGGAACU	8322
GUUCCUCGGUUCCUAUAGC	8323	GCUAUAGGAACCGAGGAAC	8324
UUCCUCGGUUCCUAUAGCA	8325	UGCUAUAGGAACCGAGGAA	8326
UCCUCGGUUCCUAUAGCAG	8327	CUGCUAUAGGAACCGAGGA	8328
CAGUGGCAACUUGUGAUGA	8329	UCAUCACAAGUUGCCACUG	8330
AGUGGCAACUUGUGAUGAU	8331	AUCAUCACAAGUUGCCACU	8332
GUGGCAACUUGUGAUGAUG	8333	CAUCAUCACAAGUUGCCAC	8334
GGCAACUUGUGAUGAUGGA	8335	UCCAUCAUCACAAGUUGCC	8336
ACUUGUGAUGAUGGAGCAG	8337	CUGCUCCAUCAUCACAAGU	8338
CUUGUGAUGAUGGAGCAGA	8339	UCUGCUCCAUCAUCACAAG	8340
GUGAUGAUGGAGCAGAGGG	8341	CCCUCUGCUCCAUCAUCAC	8342
UGAUGAUGGAGCAGAGGGC	8343	GCCCUCUGCUCCAUCAUCA	8344
UGGAGCAGAGGGCUGAAGU	8345	ACUUCAGCCCUCUGCUCCA	8346
GGAGCAGAGGGCUGAAGUC	8347	GACUUCAGCCCUCUGCUCC	8348
GAGCAGAGGGCUGAAGUCA	8349	UGACUUCAGCCCUCUGCUC	8350
CUAAAAGCAGCGGAGUGGG	8351	CCCACUCCGCUGCUUUUAG	8352
UAAAAGCAGCGGAGUGGGC	8353	GCCCACUCCGCUGCUUUUA	8354
AAAAGCAGCGGAGUGGGCC	8355	GGCCCACUCCGCUGCUUUU	8356
AAAGCAGCGGAGUGGGCCU	8357	AGGCCCACUCCGCUGCUUU	8358
AAGCAGCGGAGUGGGCCUA	8359	UAGGCCCACUCCGCUGCUU	8360
AGCAGCGGAGUGGGCCUAA	8361	UUAGGCCCACUCCGCUGCU	8362
GCAGCGGAGUGGGCCUAAU	8363	AUUAGGCCCACUCCGCUGC	8364
CAGCGGAGUGGGCCUAAUG	8365	CAUUAGGCCCACUCCGCUG	8366
AGCGGAGUGGGCCUAAUGA	8367	UCAUUAGGCCCACUCCGCU	8368
GCGGAGUGGGCCUAAUGAG	8369	CUCAUUAGGCCCACUCCGC	8370
AGUGGGCCUAAUGAGCUCU	8371	AGAGCUCAUUAGGCCCACU	8372
GUGGGCCUAAUGAGCUCUG	8373	CAGAGCUCAUUAGGCCCAC	8374
UGGGCCUAAUGAGCUCUGG	8375	CCAGAGCUCAUUAGGCCCA	8376
GGGCCUAAUGAGCUCUGGU	8377	ACCAGAGCUCAUUAGGCCC	8378
GGCCUAAUGAGCUCUGGUC	8379	GACCAGAGCUCAUUAGGCC	8380
GCCUAAUGAGCUCUGGUCA	8381	UGACCAGAGCUCAUUAGGC	8382
CCUAAUGAGCUCUGGUCAA	8383	UUGACCAGAGCUCAUUAGG	8384
CUAAUGAGCUCUGGUCAAU	8385	AUUGACCAGAGCUCAUUAG	8386
UAAUGAGCUCUGGUCAAUU	8387	AAUUGACCAGAGCUCAUUA	8388
AAUGAGCUCUGGUCAAUUU	8389	AAAUUGACCAGAGCUCAUU	8390
AUGAGCUCUGGUCAAUUUG	8391	CAAAUUGACCAGAGCUCAU	8392
UGAGCUCUGGUCAAUUUGU	8393	ACAAAUUGACCAGAGCUCA	8394
CUGGUCAAUUUGUUCAUUU	8395	AAAUGAACAAAUUGACCAG	8396
CAAUUUGUUCAUUUUCCAC	8397	GUGGAAAAUGAACAAAUUG	8398
AGUGAGCUUUUCUAUGGGA	8399	UCCCAUAGAAAAGCUCACU	8400
AGCUUUUCUAUGGGAGCAG	8401	CUGCUCCCAUAGAAAAGCU	8402
GAAUUCAGAAGCUAGUAUG	8403	CAUACUAGCUUCUGAAUUC	8404
AUUCAGAAGCUAGUAUGGA	8405	UCCAUACUAGCUUCUGAAU	8406
UUCAGAAGCUAGUAUGGAA	8407	UUCCAUACUAGCUUCUGAA	8408
AAAGGUGAUUUGUGUGACA	8409	UGUCACACAAAUCACCUUU	8410
AUUCUGAUUCUGCCACUUC	8411	GAAGUGGCAGAAUCAGAAU	8412
AUUCUGCCACUUCCUGCCU	8413	AGGCAGGAAGUGGCAGAAU	8414
GCCACUUCCUGCCUGUCAA	8415	UUGACAGGCAGGAAGUGGC	8416
CCACUUCCUGCCUGUCAAA	8417	UUUGACAGGCAGGAAGUGG	8418
AACCUUGGGAAGUUGUUCA	8419	UGAACAACUUCCCAAGGUU	8420
ACCUUGGGAAGUUGUUCAA	8421	UUGAACAACUUCCCAAGGU	8422
CCUUGGGAAGUUGUUCAAC	8423	GUUGAACAACUUCCCAAGG	8424
GGGAAGUUGUUCAACCUAC	8425	GUAGGUUGAACAACUUCCC	8426
GGAAGUUGUUCAACCUACC	8427	GGUAGGUUGAACAACUUCC	8428
GAAGUUGUUCAACCUACCA	8429	UGGUAGGUUGAACAACUUC	8430
AAGUUGUUCAACCUACCAA	8431	UUGGUAGGUUGAACAACUU	8432
AGUUGUUCAACCUACCAAA	8433	UUUGGUAGGUUGAACAACU	8434
GUUGUUCAACCUACCAAAA	8435	UUUUGGUAGGUUGAACAAC	8436
GCAAUAAUAAUACAUCACC	8437	GGUGAUGUAUUAUUAUUGC	8438
AUAAUAAUACAUCACCUCC	8439	GGAGGUGAUGUAUUAUUAU	8440
UAAUACAUCACCUCCUAGG	8441	CCUAGGAGGUGAUGUAUUA	8442
AAUACAUCACCUCCUAGGG	8443	CCCUAGGAGGUGAUGUAUU	8444
AUACAUCACCUCCUAGGGU	8445	ACCCUAGGAGGUGAUGUAU	8446
UACAUCACCUCCUAGGGUU	8447	AACCCUAGGAGGUGAUGUA	8448
ACAUCACCUCCUAGGGUUG	8449	CAACCCUAGGAGGUGAUGU	8450
AAAGGAGUAAGAGGAUAAU	8451	AUUAUCCUCUUACUCCUUU	8452
AAGGAGUAAGAGGAUAAUG	8453	CAUUAUCCUCUUACUCCUU	8454
AGUAAGAGGAUAAUGUAGG	8455	CCUACAUUAUCCUCUUACU	8456
GUAAGAGGAUAAUGUAGGU	8457	ACCUACAUUAUCCUCUUAC	8458
UAAGAGGAUAAUGUAGGUA	8459	UACCUACAUUAUCCUCUUA	8460
AAGAGGAUAAUGUAGGUAA	8461	UUACCUACAUUAUCCUCUU	8462
AGAGGAUAAUGUAGGUAAA	8463	UUUACCUACAUUAUCCUCU	8464
GAGGAUAAUGUAGGUAAAG	8465	CUUUACCUACAUUAUCCUC	8466
GGAUAAUGUAGGUAAAGUC	8467	GACUUUACCUACAUUAUCC	8468
AUAAUGUAGGUAAAGUCCU	8469	AGGACUUUACCUACAUUAU	8470
GUAGGUAAAGUCCUCAUAC	8471	GUAUGAGGACUUUACCUAC	8472
GUAAAGUCCUCAUACCUGG	8473	CCAGGUAUGAGGACUUUAC	8474
UAAAGUCCUCAUACCUGGC	8475	GCCAGGUAUGAGGACUUUA	8476
AAAGUCCUCAUACCUGGCA	8477	UGCCAGGUAUGAGGACUUU	8478
AAGUCCUCAUACCUGGCAC	8479	GUGCCAGGUAUGAGGACUU	8480
AGUCCUCAUACCUGGCACA	8481	UGUGCCAGGUAUGAGGACU	8482
GUCCUCAUACCUGGCACAG	8483	CUGUGCCAGGUAUGAGGAC	8484
UCCUCAUACCUGGCACAGA	8485	UCUGUGCCAGGUAUGAGGA	8486
UCUUGAGGGUGUGGGAAGU	8487	ACUUCCCACACCCUCAAGA	8488
CUUGAGGGUGUGGGAAGUG	8489	CACUUCCCACACCCUCAAG	8490
UUGAGGGUGUGGGAAGUGA	8491	UCACUUCCCACACCCUCAA	8492
UGAGGGUGUGGGAAGUGAG	8493	CUCACUUCCCACACCCUCA	8494
AGGGUGUGGGAAGUGAGGU	8495	ACCUCACUUCCCACACCCU	8496
GGGUGUGGGAAGUGAGGUG	8497	CACCUCACUUCCCACACCC	8498
GGGAAGUGAGGUGCAGCAU	8499	AUGCUGCACCUCACUUCCC	8500
GGAAGUGAGGUGCAGCAUU	8501	AAUGCUGCACCUCACUUCC	8502
GAAGUGAGGUGCAGCAUUG	8503	CAAUGCUGCACCUCACUUC	8504
AAGUGAGGUGCAGCAUUGU	8505	ACAAUGCUGCACCUCACUU	8506
AGUGAGGUGCAGCAUUGUA	8507	UACAAUGCUGCACCUCACU	8508
GUGAGGUGCAGCAUUGUAG	8509	CUACAAUGCUGCACCUCAC	8510
UGAGGUGCAGCAUUGUAGA	8511	UCUACAAUGCUGCACCUCA	8512
GAGGUGCAGCAUUGUAGAU	8513	AUCUACAAUGCUGCACCUC	8514
AGGUGCAGCAUUGUAGAUA	8515	UAUCUACAAUGCUGCACCU	8516
GGUGCAGCAUUGUAGAUAA	8517	UUAUCUACAAUGCUGCACC	8518
GUGCAGCAUUGUAGAUAAG	8519	CUUAUCUACAAUGCUGCAC	8520
UGCAGCAUUGUAGAUAAGA	8521	UCUUAUCUACAAUGCUGCA	8522
GCAUUGUAGAUAAGACAGA	8523	UCUGUCUUAUCUACAAUGC	8524
CAUUGUAGAUAAGACAGAA	8525	UUCUGUCUUAUCUACAAUG	8526
AUUGUAGAUAAGACAGAAG	8527	CUUCUGUCUUAUCUACAAU	8528
AUAAGACAGAAGGGUGGAC	8529	GUCCACCCUUCUGUCUUAU	8530
UAAGACAGAAGGGUGGACU	8531	AGUCCACCCUUCUGUCUUA	8532
AACCUGGCUUGCUUUCCAA	8533	UUGGAAAGCAAGCCAGGUU	8534
CCUGGCUUGCUUUCCAAUU	8535	AAUUGGAAAGCAAGCCAGG	8536
ACCAGAAGUGACUUGGAGG	8537	CCUCCAAGUCACUUCUGGU	8538
CCAGAAGUGACUUGGAGGG	8539	CCCUCCAAGUCACUUCUGG	8540
AGAUGCCAAUGACAUGGUA	8541	UACCAUGUCAUUGGCAUCU	8542
GAUGCCAAUGACAUGGUAG	8543	CUACCAUGUCAUUGGCAUC	8544
AUGCCAAUGACAUGGUAGG	8545	CCUACCAUGUCAUUGGCAU	8546
CAAUGACAUGGUAGGAGCA	8547	UGCUCCUACCAUGUCAUUG	8548
AAUGACAUGGUAGGAGCAA	8549	UUGCUCCUACCAUGUCAUU	8550
AUGACAUGGUAGGAGCAAA	8551	UUUGCUCCUACCAUGUCAU	8552
UGACAUGGUAGGAGCAAAG	8553	CUUUGCUCCUACCAUGUCA	8554
GACAUGGUAGGAGCAAAGA	8555	UCUUUGCUCCUACCAUGUC	8556
AAAAGGUCAGCCUCUAGCU	8557	AGCUAGAGGCUGACCUUUU	8558
AAAGGUCAGCCUCUAGCUA	8559	UAGCUAGAGGCUGACCUUU	8560
AGGUCAGCCUCUAGCUAGG	8561	CCUAGCUAGAGGCUGACCU	8562
GGUCAGCCUCUAGCUAGGA	8563	UCCUAGCUAGAGGCUGACC	8564
GUCAGCCUCUAGCUAGGAU	8565	AUCCUAGCUAGAGGCUGAC	8566
CAGCCUCUAGCUAGGAUCC	8567	GGAUCCUAGCUAGAGGCUG	8568
AGCCUCUAGCUAGGAUCCC	8569	GGGAUCCUAGCUAGAGGCU	8570
AGAGCUGCAACCUUUAGGA	8571	UCCUAAAGGUUGCAGCUCU	8572
GAGCUGCAACCUUUAGGAG	8573	CUCCUAAAGGUUGCAGCUC	8574
AGCUGCAACCUUUAGGAGG	8575	CCUCCUAAAGGUUGCAGCU	8576
UUUAGGAGGUAUCAAAGUG	8577	CACUUUGAUACCUCCUAAA	8578
UUAGGAGGUAUCAAAGUGC	8579	GCACUUUGAUACCUCCUAA	8580
UAGGAGGUAUCAAAGUGCC	8581	GGCACUUUGAUACCUCCUA	8582
GUCAAAGUGGGACAUCGAC	8583	GUCGAUGUCCCACUUUGAC	8584
CAUCGACCAAUGUCUAGAG	8585	CUCUAGACAUUGGUCGAUG	8586
AUCGACCAAUGUCUAGAGC	8587	GCUCUAGACAUUGGUCGAU	8588
ACCAAUGUCUAGAGCCAAC	8589	GUUGGCUCUAGACAUUGGU	8590
CAAUGUCUAGAGCCAACUG	8591	CAGUUGGCUCUAGACAUUG	8592
AAUGUCUAGAGCCAACUGA	8593	UCAGUUGGCUCUAGACAUU	8594
AUGUCUAGAGCCAACUGAU	8595	AUCAGUUGGCUCUAGACAU	8596
UGUCUAGAGCCAACUGAUG	8597	CAUCAGUUGGCUCUAGACA	8598
GUCUAGAGCCAACUGAUGG	8599	CCAUCAGUUGGCUCUAGAC	8600
UCUAGAGCCAACUGAUGGA	8601	UCCAUCAGUUGGCUCUAGA	8602
CUAGAGCCAACUGAUGGAU	8603	AUCCAUCAGUUGGCUCUAG	8604
UAGAGCCAACUGAUGGAUG	8605	CAUCCAUCAGUUGGCUCUA	8606
AGAGCCAACUGAUGGAUGU	8607	ACAUCCAUCAGUUGGCUCU	8608
GAGCCAACUGAUGGAUGUU	8609	AACAUCCAUCAGUUGGCUC	8610
AACUGAUGGAUGUUGGGCA	8611	UGCCCAACAUCCAUCAGUU	8612
UGGAUGUUGGGCAGCUAAA	8613	UUUAGCUGCCCAACAUCCA	8614
GGAUGUUGGGCAGCUAAAG	8615	CUUUAGCUGCCCAACAUCC	8616
GAUGUUGGGCAGCUAAAGA	8617	UCUUUAGCUGCCCAACAUC	8618
UUGGGCAGCUAAAGAGGGA	8619	UCCCUCUUUAGCUGCCCAA	8620
UGGGCAGCUAAAGAGGGAA	8621	UUCCCUCUUUAGCUGCCCA	8622
GGGCAGCUAAAGAGGGAAG	8623	CUUCCCUCUUUAGCUGCCC	8624
GGCAGCUAAAGAGGGAAGG	8625	CCUUCCCUCUUUAGCUGCC	8626
GCAGCUAAAGAGGGAAGGG	8627	CCCUUCCCUCUUUAGCUGC	8628
GGGCAUGGGAUAAGACCUG	8629	CAGGUCUUAUCCCAUGCCC	8630
GGCAUGGGAUAAGACCUGC	8631	GCAGGUCUUAUCCCAUGCC	8632
GCAUGGGAUAAGACCUGCC	8633	GGCAGGUCUUAUCCCAUGC	8634
CAUGGGAUAAGACCUGCCC	8635	GGGCAGGUCUUAUCCCAUG	8636
AUGGGAUAAGACCUGCCCU	8637	AGGGCAGGUCUUAUCCCAU	8638
UGGGAUAAGACCUGCCCUU	8639	AAGGGCAGGUCUUAUCCCA	8640
GGGAUAAGACCUGCCCUUC	8641	GAAGGGCAGGUCUUAUCCC	8642
GGAUAAGACCUGCCCUUCU	8643	AGAAGGGCAGGUCUUAUCC	8644
AGACCUGCCCUUCUUGCUU	8645	AAGCAAGAAGGGCAGGUCU	8646
GACCUGCCCUUCUUGCUUC	8647	GAAGCAAGAAGGGCAGGUC	8648
CCUGCCCUUCUUGCUUCUU	8649	AAGAAGCAAGAAGGGCAGG	8650
CUGCCCUUCUUGCUUCUUG	8651	CAAGAAGCAAGAAGGGCAG	8652
UGCCCUUCUUGCUUCUUGC	8653	GCAAGAAGCAAGAAGGGCA	8654
UCUUGCUUCUUGCCAUUGG	8655	CCAAUGGCAAGAAGCAAGA	8656
CUUGCUUCUUGCCAUUGGG	8657	CCCAAUGGCAAGAAGCAAG	8658
UUGCUUCUUGCCAUUGGGC	8659	GCCCAAUGGCAAGAAGCAA	8660
CCAUUGGGCAGGCAUUGGA	8661	UCCAAUGCCUGCCCAAUGG	8662
CAUUGGGCAGGCAUUGGAG	8663	CUCCAAUGCCUGCCCAAUG	8664
GACCCUACUGCUGAAUGGA	8665	UCCAUUCAGCAGUAGGGUC	8666
UACUGCUGAAUGGAGUGCU	8667	AGCACUCCAUUCAGCAGUA	8668
ACUGCUGAAUGGAGUGCUA	8669	UAGCACUCCAUUCAGCAGU	8670
CUGCUGAAUGGAGUGCUAA	8671	UUAGCACUCCAUUCAGCAG	8672
UGCUGAAUGGAGUGCUAAC	8673	GUUAGCACUCCAUUCAGCA	8674
GCUGAAUGGAGUGCUAACC	8675	GGUUAGCACUCCAUUCAGC	8676
CUGAAUGGAGUGCUAACCC	8677	GGGUUAGCACUCCAUUCAG	8678
UAACCCUGGUGCUAGAGGA	8679	UCCUCUAGCACCAGGGUUA	8680
AACCCUGGUGCUAGAGGAG	8681	CUCCUCUAGCACCAGGGUU	8682
ACCCUGGUGCUAGAGGAGG	8683	CCUCCUCUAGCACCAGGGU	8684
CCCUGGUGCUAGAGGAGGA	8685	UCCUCCUCUAGCACCAGGG	8686
CCUGGUGCUAGAGGAGGAU	8687	AUCCUCCUCUAGCACCAGG	8688
CUGGUGCUAGAGGAGGAUG	8689	CAUCCUCCUCUAGCACCAG	8690
GGUGCUAGAGGAGGAUGGA	8691	UCCAUCCUCCUCUAGCACC	8692
GUGCUAGAGGAGGAUGGAA	8693	UUCCAUCCUCCUCUAGCAC	8694
CUGCAGUGGACAGUGAGGA	8695	UCCUCACUGUCCACUGCAG	8696
UGCAGUGGACAGUGAGGAC	8697	GUCCUCACUGUCCACUGCA	8698
GCAGUGGACAGUGAGGACU	8699	AGUCCUCACUGUCCACUGC	8700
CAGUGGACAGUGAGGACUU	8701	AAGUCCUCACUGUCCACUG	8702
AGUGGACAGUGAGGACUUC	8703	GAAGUCCUCACUGUCCACU	8704
GUGGACAGUGAGGACUUCU	8705	AGAAGUCCUCACUGUCCAC	8706
UGGACAGUGAGGACUUCUU	8707	AAGAAGUCCUCACUGUCCA	8708
GGACAGUGAGGACUUCUUC	8709	GAAGAAGUCCUCACUGUCC	8710
AGUGAGGACUUCUUCCAGC	8711	GCUGGAAGAAGUCCUCACU	8712
GUGAGGACUUCUUCCAGCU	8713	AGCUGGAAGAAGUCCUCAC	8714
UGAGGACUUCUUCCAGCUG	8715	CAGCUGGAAGAAGUCCUCA	8716
GAGGACUUCUUCCAGCUGC	8717	GCAGCUGGAAGAAGUCCUC	8718
GUGCCUGAUGGUGUUGCAG	8719	CUGCAACACCAUCAGGCAC	8720
GAUGGUGUUGCAGUCUGGU	8721	ACCAGACUGCAACACCAUC	8722
UGGUGUUGCAGUCUGGUCA	8723	UGACCAGACUGCAACACCA	8724
GGUGUUGCAGUCUGGUCAG	8725	CUGACCAGACUGCAACACC	8726
GUGUUGCAGUCUGGUCAGA	8727	UCUGACCAGACUGCAACAC	8728
UGCAGUCUGGUCAGAGCUG	8729	CAGCUCUGACCAGACUGCA	8730
GCAGUCUGGUCAGAGCUGG	8731	CCAGCUCUGACCAGACUGC	8732
CAGUCUGGUCAGAGCUGGA	8733	UCCAGCUCUGACCAGACUG	8734
AGUCUGGUCAGAGCUGGAG	8735	CUCCAGCUCUGACCAGACU	8736
GUCUGGUCAGAGCUGGAGC	8737	GCUCCAGCUCUGACCAGAC	8738
UCUGGUCAGAGCUGGAGCC	8739	GGCUCCAGCUCUGACCAGA	8740
UGGUCAGAGCUGGAGCCCU	8741	AGGGCUCCAGCUCUGACCA	8742
GGUCAGAGCUGGAGCCCUA	8743	UAGGGCUCCAGCUCUGACC	8744
GUCAGAGCUGGAGCCCUAC	8745	GUAGGGCUCCAGCUCUGAC	8746
CAAGGGUAAGAGGCCUAUA	8747	UAUAGGCCUCUUACCCUUG	8748
AAGGGUAAGAGGCCUAUAC	8749	GUAUAGGCCUCUUACCCUU	8750
AGGGUAAGAGGCCUAUACU	8751	AGUAUAGGCCUCUUACCCU	8752
GGGUAAGAGGCCUAUACUG	8753	CAGUAUAGGCCUCUUACCC	8754
GGUAAGAGGCCUAUACUGG	8755	CCAGUAUAGGCCUCUUACC	8756
GUAAGAGGCCUAUACUGGG	8757	CCCAGUAUAGGCCUCUUAC	8758
GGGCUGCUUCCAAUGCCUG	8759	CAGGCAUUGGAAGCAGCCC	8760
GGCUGCUUCCAAUGCCUGU	8761	ACAGGCAUUGGAAGCAGCC	8762
GCUGCUUCCAAUGCCUGUC	8763	GACAGGCAUUGGAAGCAGC	8764
CUGCUUCCAAUGCCUGUCC	8765	GGACAGGCAUUGGAAGCAG	8766
UGCUUCCAAUGCCUGUCCU	8767	AGGACAGGCAUUGGAAGCA	8768
GCUUCCAAUGCCUGUCCUU	8769	AAGGACAGGCAUUGGAAGC	8770
CUUCCAAUGCCUGUCCUUU	8771	AAAGGACAGGCAUUGGAAG	8772
UUCCAAUGCCUGUCCUUUA	8773	UAAAGGACAGGCAUUGGAA	8774
UCCAAUGCCUGUCCUUUAG	8775	CUAAAGGACAGGCAUUGGA	8776
CAAUGCCUGUCCUUUAGAG	8777	CUCUAAAGGACAGGCAUUG	8778
AAUGCCUGUCCUUUAGAGC	8779	GCUCUAAAGGACAGGCAUU	8780
AUGCCUGUCCUUUAGAGCU	8781	AGCUCUAAAGGACAGGCAU	8782
CUUCCUCUCUAGCUUAACC	8783	GGUUAAGCUAGAGAGGAAG	8784
UUCCUCUCUAGCUUAACCC	8785	GGGUUAAGCUAGAGAGGAA	8786
UCUCUAGCUUAACCCUGAU	8787	AUCAGGGUUAAGCUAGAGA	8788
UAGCUUAACCCUGAUCCUG	8789	CAGGAUCAGGGUUAAGCUA	8790
GACCAGGUGCAGGAGGAGU	8791	ACUCCUCCUGCACCUGGUC	8792
ACCAGGUGCAGGAGGAGUU	8793	AACUCCUCCUGCACCUGGU	8794
CCAGGUGCAGGAGGAGUUG	8795	CAACUCCUCCUGCACCUGG	8796
CAGGUGCAGGAGGAGUUGU	8797	ACAACUCCUCCUGCACCUG	8798
AGGUGCAGGAGGAGUUGUG	8799	CACAACUCCUCCUGCACCU	8800
UGCAGGAGGAGUUGUGGAA	8801	UUCCACAACUCCUCCUGCA	8802
GCAGGAGGAGUUGUGGAAU	8803	AUUCCACAACUCCUCCUGC	8804
AGGAGGAGUUGUGGAAUUG	8805	CAAUUCCACAACUCCUCCU	8806
GGAGGAGUUGUGGAAUUGU	8807	ACAAUUCCACAACUCCUCC	8808
GAGGAGUUGUGGAAUUGUC	8809	GACAAUUCCACAACUCCUC	8810
AGGAGUUGUGGAAUUGUCA	8811	UGACAAUUCCACAACUCCU	8812
GGAGUUGUGGAAUUGUCAA	8813	UUGACAAUUCCACAACUCC	8814
GAGUUGUGGAAUUGUCAAG	8815	CUUGACAAUUCCACAACUC	8816
AGUUGUGGAAUUGUCAAGG	8817	CCUUGACAAUUCCACAACU	8818
GUUGUGGAAUUGUCAAGGA	8819	UCCUUGACAAUUCCACAAC	8820
UGGAAUUGUCAAGGAUGUC	8821	GACAUCCUUGACAAUUCCA	8822
GGAAUUGUCAAGGAUGUCA	8823	UGACAUCCUUGACAAUUCC	8824
AGUCCAAGCGAGGGAGGGU	8825	ACCCUCCCUCGCUUGGACU	8826
CAAGCGAGGGAGGGUCUGA	8827	UCAGACCCUCCCUCGCUUG	8828
AAGCGAGGGAGGGUCUGAC	8829	GUCAGACCCUCCCUCGCUU	8830
CUGACCCAGUGCUGAUGGA	8831	UCCAUCAGCACUGGGUCAG	8832
AGAUUAGUGGUGGGUGUCU	8833	AGACACCCACCACUAAUCU	8834
AUUAGUGGUGGGUGUCUGG	8835	CCAGACACCCACCACUAAU	8836
UUAGUGGUGGGUGUCUGGU	8837	ACCAGACACCCACCACUAA	8838
UAGUGGUGGGUGUCUGGUA	8839	UACCAGACACCCACCACUA	8840
AGUGGUGGGUGUCUGGUAU	8841	AUACCAGACACCCACCACU	8842
GUGGUGGGUGUCUGGUAUG	8843	CAUACCAGACACCCACCAC	8844
UGGUGGGUGUCUGGUAUGA	8845	UCAUACCAGACACCCACCA	8846
GGUGGGUGUCUGGUAUGAG	8847	CUCAUACCAGACACCCACC	8848
GUGGGUGUCUGGUAUGAGG	8849	CCUCAUACCAGACACCCAC	8850
UGGGUGUCUGGUAUGAGGA	8851	UCCUCAUACCAGACACCCA	8852
GGGUGUCUGGUAUGAGGAU	8853	AUCCUCAUACCAGACACCC	8854
GGUGUCUGGUAUGAGGAUC	8855	GAUCCUCAUACCAGACACC	8856
GUGUCUGGUAUGAGGAUCU	8857	AGAUCCUCAUACCAGACAC	8858
UGUCUGGUAUGAGGAUCUA	8859	UAGAUCCUCAUACCAGACA	8860
CAAGGGUGUCCUACAGAGU	8861	ACUCUGUAGGACACCCUUG	8862
AAGGGUGUCCUACAGAGUG	8863	CACUCUGUAGGACACCCUU	8864
AGGGUGUCCUACAGAGUGG	8865	CCACUCUGUAGGACACCCU	8866
GGGUGUCCUACAGAGUGGA	8867	UCCACUCUGUAGGACACCC	8868
GGUGUCCUACAGAGUGGAG	8869	CUCCACUCUGUAGGACACC	8870
UCCUACAGAGUGGAGUGCU	8871	AGCACUCCACUCUGUAGGA	8872
AGUGGAGUGCUGUCAUAUG	8873	CAUAUGACAGCACUCCACU	8874
GUGGAGUGCUGUCAUAUGG	8875	CCAUAUGACAGCACUCCAC	8876
UGGAGUGCUGUCAUAUGGC	8877	GCCAUAUGACAGCACUCCA	8878
GGAGUGCUGUCAUAUGGCC	8879	GGCCAUAUGACAGCACUCC	8880
GAGUGCUGUCAUAUGGCCU	8881	AGGCCAUAUGACAGCACUC	8882
AGUGCUGUCAUAUGGCCUG	8883	CAGGCCAUAUGACAGCACU	8884
GUGCUGUCAUAUGGCCUGG	8885	CCAGGCCAUAUGACAGCAC	8886
UGCUGUCAUAUGGCCUGGG	8887	CCCAGGCCAUAUGACAGCA	8888
GCUGUCAUAUGGCCUGGGA	8889	UCCCAGGCCAUAUGACAGC	8890
CUGUCAUAUGGCCUGGGAC	8891	GUCCCAGGCCAUAUGACAG	8892
UGUCAUAUGGCCUGGGACG	8893	CGUCCCAGGCCAUAUGACA	8894
GUCAUAUGGCCUGGGACGG	8895	CCGUCCCAGGCCAUAUGAC	8896
AGAGGCCCAAGCACAGCAA	8897	UUGCUGUGCUUGGGCCUCU	8898
GAGGCCCAAGCACAGCAAG	8899	CUUGCUGUGCUUGGGCCUC	8900
AGGCCCAAGCACAGCAAGG	8901	CCUUGCUGUGCUUGGGCCU	8902
GGCCCAAGCACAGCAAGGA	8903	UCCUUGCUGUGCUUGGGCC	8904
CCAAGCACAGCAAGGACAU	8905	AUGUCCUUGCUGUGCUUGG	8906
GCCCGAUUCACCUUUGACG	8907	CGUCAAAGGUGAAUCGGGC	8908
GAUUCACCUUUGACGUGUA	8909	UACACGUCAAAGGUGAAUC	8910
AUUCACCUUUGACGUGUAC	8911	GUACACGUCAAAGGUGAAU	8912
UUGGCAGCCUGAAUGUCAA	8913	UUGACAUUCAGGCUGCCAA	8914
UGGCAGCCUGAAUGUCAAA	8915	UUUGACAUUCAGGCUGCCA	8916
GGCAGCCUGAAUGUCAAAG	8917	CUUUGACAUUCAGGCUGCC	8918
GCAGCCUGAAUGUCAAAGC	8919	GCUUUGACAUUCAGGCUGC	8920
CAGCCUGAAUGUCAAAGCC	8921	GGCUUUGACAUUCAGGCUG	8922
AGCCUGAAUGUCAAAGCCA	8923	UGGCUUUGACAUUCAGGCU	8924
GCCUGAAUGUCAAAGCCAC	8925	GUGGCUUUGACAUUCAGGC	8926
GUCAAAGCCACAUUCUACG	8927	CGUAGAAUGUGGCUUUGAC	8928
UCAAAGCCACAUUCUACGG	8929	CCGUAGAAUGUGGCUUUGA	8930
CAAAGCCACAUUCUACGGG	8931	CCCGUAGAAUGUGGCUUUG	8932
AAAGCCACAUUCUACGGGC	8933	GCCCGUAGAAUGUGGCUUU	8934
GCCACAUUCUACGGGCUCU	8935	AGAGCCCGUAGAAUGUGGC	8936
CCACAUUCUACGGGCUCUA	8937	UAGAGCCCGUAGAAUGUGG	8938
CACAUUCUACGGGCUCUAC	8939	GUAGAGCCCGUAGAAUGUG	8940
UUCUACGGGCUCUACUCUA	8941	UAGAGUAGAGCCCGUAGAA	8942
UCUACGGGCUCUACUCUAU	8943	AUAGAGUAGAGCCCGUAGA	8944
CUACGGGCUCUACUCUAUG	8945	CAUAGAGUAGAGCCCGUAG	8946
CUCUAUGAGUUGUGACUUU	8947	AAAGUCACAACUCAUAGAG	8948
UCUAUGAGUUGUGACUUUC	8949	GAAAGUCACAACUCAUAGA	8950
UGAGUUGUGACUUUCAAGG	8951	CCUUGAAAGUCACAACUCA	8952
GAGUUGUGACUUUCAAGGA	8953	UCCUUGAAAGUCACAACUC	8954
AGUUGUGACUUUCAAGGAC	8955	GUCCUUGAAAGUCACAACU	8956
GUUGUGACUUUCAAGGACU	8957	AGUCCUUGAAAGUCACAAC	8958
GACUUUCAAGGACUUGGCC	8959	GGCCAAGUCCUUGAAAGUC	8960
UUUCAAGGACUUGGCCCAA	8961	UUGGGCCAAGUCCUUGAAA	8962
UUCAAGGACUUGGCCCAAA	8963	UUUGGGCCAAGUCCUUGAA	8964
CCCUACAGUUGGAUAGUCC	8965	GGACUAUCCAACUGUAGGG	8966
CCUACAGUUGGAUAGUCCC	8967	GGGACUAUCCAACUGUAGG	8968
AUUCGUCCUCUUGCACCCA	8969	UGGGUGCAAGAGGACGAAU	8970
UUCGUCCUCUUGCACCCAC	8971	GUGGGUGCAAGAGGACGAA	8972
UCCUCUUGCACCCACCUAC	8973	GUAGGUGGGUGCAAGAGGA	8974
CCUCUUGCACCCACCUACC	8975	GGUAGGUGGGUGCAAGAGG	8976
CUCUUGCACCCACCUACCC	8977	GGGUAGGUGGGUGCAAGAG	8978
CUAGUUAGCUCUUGCUUGU	8979	ACAAGCAAGAGCUAACUAG	8980
UAGUUAGCUCUUGCUUGUG	8981	CACAAGCAAGAGCUAACUA	8982
AGUUAGCUCUUGCUUGUGG	8983	CCACAAGCAAGAGCUAACU	8984
UUAGCUCUUGCUUGUGGAA	8985	UUCCACAAGCAAGAGCUAA	8986
UCCUCAUCUCCCAGCUUGA	8987	UCAAGCUGGGAGAUGAGGA	8988
AUCUCCCAGCUUGAUGGCU	8989	AGCCAUCAAGCUGGGAGAU	8990
UCUCCCAGCUUGAUGGCUU	8991	AAGCCAUCAAGCUGGGAGA	8992
CUCCCAGCUUGAUGGCUUC	8993	GAAGCCAUCAAGCUGGGAG	8994
UCCCAGCUUGAUGGCUUCC	8995	GGAAGCCAUCAAGCUGGGA	8996
CCCAGCUUGAUGGCUUCCU	8997	AGGAAGCCAUCAAGCUGGG	8998
CCAGCUUGAUGGCUUCCUC	8999	GAGGAAGCCAUCAAGCUGG	9000
UGAUGGCUUCCUCCCAAGU	9001	ACUUGGGAGGAAGCCAUCA	9002
GAUGGCUUCCUCCCAAGUU	9003	AACUUGGGAGGAAGCCAUC	9004
GGCUUCCUCCCAAGUUUUC	9005	GAAAACUUGGGAGGAAGCC	9006
CCUCCCAAGUUUUCCAAAU	9007	AUUUGGAAAACUUGGGAGG	9008
CCCAAGUUUUCCAAAUCAU	9009	AUGAUUUGGAAAACUUGGG	9010
CCAAGUUUUCCAAAUCAUC	9011	GAUGAUUUGGAAAACUUGG	9012
CAAGUUUUCCAAAUCAUCU	9013	AGAUGAUUUGGAAAACUUG	9014
AAGUUUUCCAAAUCAUCUG	9015	CAGAUGAUUUGGAAAACUU	9016
GUUUUCCAAAUCAUCUGAU	9017	AUCAGAUGAUUUGGAAAAC	9018
AUCUGAUUUCCUCUUGUCU	9019	AGACAAGAGGAAAUCAGAU	9020
UCUGAUUUCCUCUUGUCUC	9021	GAGACAAGAGGAAAUCAGA	9022
CUGAUUUCCUCUUGUCUCU	9023	AGAGACAAGAGGAAAUCAG	9024
CUCUUGUCUCUGCCAUUCA	9025	UGAAUGGCAGAGACAAGAG	9026
GUUGGACCUCCACACUGCU	9027	AGCAGUGUGGAGGUCCAAC	9028
CCACACUGCUGCAAGGCCU	9029	AGGCCUUGCAGCAGUGUGG	9030
CACACUGCUGCAAGGCCUG	9031	CAGGCCUUGCAGCAGUGUG	9032
ACACUGCUGCAAGGCCUGG	9033	CCAGGCCUUGCAGCAGUGU	9034
UGCAAGGCCUGGGCCAUAU	9035	AUAUGGCCCAGGCCUUGCA	9036
GCAAGGCCUGGGCCAUAUG	9037	CAUAUGGCCCAGGCCUUGC	9038
CAAGGCCUGGGCCAUAUGU	9039	ACAUAUGGCCCAGGCCUUG	9040
AAGGCCUGGGCCAUAUGUU	9041	AACAUAUGGCCCAGGCCUU	9042
AGGCCUGGGCCAUAUGUUG	9043	CAACAUAUGGCCCAGGCCU	9044
GGCCUGGGCCAUAUGUUGC	9045	GCAACAUAUGGCCCAGGCC	9046
GCCUGGGCCAUAUGUUGCU	9047	AGCAACAUAUGGCCCAGGC	9048
CCUGGGCCAUAUGUUGCUG	9049	CAGCAACAUAUGGCCCAGG	9050
GGCCAUAUGUUGCUGGGAA	9051	UUCCCAGCAACAUAUGGCC	9052
CCAUAUGUUGCUGGGAAUU	9053	AAUUCCCAGCAACAUAUGG	9054
GGAAUUUCCUCCACCCUUC	9055	GAAGGGUGGAGGAAAUUCC	9056
GAAUUUCCUCCACCCUUCG	9057	CGAAGGGUGGAGGAAAUUC	9058
AAUUUCCUCCACCCUUCGU	9059	ACGAAGGGUGGAGGAAAUU	9060
AUUUCCUCCACCCUUCGUC	9061	GACGAAGGGUGGAGGAAAU	9062
UUUCCUCCACCCUUCGUCA	9063	UGACGAAGGGUGGAGGAAA	9064
UUCCUCCACCCUUCGUCAU	9065	AUGACGAAGGGUGGAGGAA	9066
UCCUCCACCCUUCGUCAUG	9067	CAUGACGAAGGGUGGAGGA	9068
CCUCCACCCUUCGUCAUGC	9069	GCAUGACGAAGGGUGGAGG	9070
CUCCACCCUUCGUCAUGCA	9071	UGCAUGACGAAGGGUGGAG	9072
CCUUCGUCAUGCAGUGGAG	9073	CUCCACUGCAUGACGAAGG	9074
CUUCGUCAUGCAGUGGAGG	9075	CCUCCACUGCAUGACGAAG	9076
UUCGUCAUGCAGUGGAGGG	9077	CCCUCCACUGCAUGACGAA	9078
CGCCUCCAUUCCUACUAAG	9079	CUUAGUAGGAAUGGAGGCG	9080
GCCUCCAUUCCUACUAAGG	9081	CCUUAGUAGGAAUGGAGGC	9082
CCUCCAUUCCUACUAAGGG	9083	CCCUUAGUAGGAAUGGAGG	9084
CAGAAUCAUUCCAACCGAC	9085	GUCGGUUGGAAUGAUUCUG	9086
AGAAUCAUUCCAACCGACC	9087	GGUCGGUUGGAAUGAUUCU	9088
GAAUCAUUCCAACCGACCC	9089	GGGUCGGUUGGAAUGAUUC	9090
AAUCAUUCCAACCGACCCA	9091	UGGGUCGGUUGGAAUGAUU	9092
AUCAUUCCAACCGACCCAC	9093	GUGGGUCGGUUGGAAUGAU	9094
UCAUUCCAACCGACCCACU	9095	AGUGGGUCGGUUGGAAUGA	9096
UCCAACCGACCCACUGCAA	9097	UUGCAGUGGGUCGGUUGGA	9098
CCAACCGACCCACUGCAAA	9099	UUUGCAGUGGGUCGGUUGG	9100
CAACCGACCCACUGCAAAG	9101	CUUUGCAGUGGGUCGGUUG	9102
AACCGACCCACUGCAAAGA	9103	UCUUUGCAGUGGGUCGGUU	9104
ACCGACCCACUGCAAAGAC	9105	GUCUUUGCAGUGGGUCGGU	9106
CCGACCCACUGCAAAGACU	9107	AGUCUUUGCAGUGGGUCGG	9108
CGACCCACUGCAAAGACUA	9109	UAGUCUUUGCAGUGGGUCG	9110
GACCCACUGCAAAGACUAU	9111	AUAGUCUUUGCAGUGGGUC	9112
ACCCACUGCAAAGACUAUG	9113	CAUAGUCUUUGCAGUGGGU	9114
ACUGCAAAGACUAUGACAG	9115	CUGUCAUAGUCUUUGCAGU	9116
CUGCAAAGACUAUGACAGC	9117	GCUGUCAUAGUCUUUGCAG	9118
UGCAAAGACUAUGACAGCA	9119	UGCUGUCAUAGUCUUUGCA	9120
GCAAAGACUAUGACAGCAU	9121	AUGCUGUCAUAGUCUUUGC	9122
AAAGACUAUGACAGCAUCA	9123	UGAUGCUGUCAUAGUCUUU	9124
AAGACUAUGACAGCAUCAA	9125	UUGAUGCUGUCAUAGUCUU	9126
AGACUAUGACAGCAUCAAA	9127	UUUGAUGCUGUCAUAGUCU	9128
GACUAUGACAGCAUCAAAU	9129	AUUUGAUGCUGUCAUAGUC	9130
CUAUGACAGCAUCAAAUUU	9131	AAAUUUGAUGCUGUCAUAG	9132
UAUGACAGCAUCAAAUUUC	9133	GAAAUUUGAUGCUGUCAUA	9134
GCAUCAAAUUUCAGGACCU	9135	AGGUCCUGAAAUUUGAUGC	9136
AUCAAAUUUCAGGACCUGC	9137	GCAGGUCCUGAAAUUUGAU	9138
UCAAAUUUCAGGACCUGCA	9139	UGCAGGUCCUGAAAUUUGA	9140
UUCAGGACCUGCAGACAGU	9141	ACUGUCUGCAGGUCCUGAA	9142
UCAGGACCUGCAGACAGUA	9143	UACUGUCUGCAGGUCCUGA	9144
CAGGACCUGCAGACAGUAC	9145	GUACUGUCUGCAGGUCCUG	9146
AGGACCUGCAGACAGUACA	9147	UGUACUGUCUGCAGGUCCU	9148
GGACCUGCAGACAGUACAG	9149	CUGUACUGUCUGCAGGUCC	9150
CUGCAGACAGUACAGGCUA	9151	UAGCCUGUACUGUCUGCAG	9152
GACAGUACAGGCUAGAUAA	9153	UUAUCUAGCCUGUACUGUC	9154
ACAGUACAGGCUAGAUAAC	9155	GUUAUCUAGCCUGUACUGU	9156
CAGUACAGGCUAGAUAACC	9157	GGUUAUCUAGCCUGUACUG	9158
AGUACAGGCUAGAUAACCC	9159	GGGUUAUCUAGCCUGUACU	9160
GUACAGGCUAGAUAACCCA	9161	UGGGUUAUCUAGCCUGUAC	9162
UACAGGCUAGAUAACCCAC	9163	GUGGGUUAUCUAGCCUGUA	9164
GCUAGAUAACCCACCCAAU	9165	AUUGGGUGGGUUAUCUAGC	9166
CUAGAUAACCCACCCAAUU	9167	AAUUGGGUGGGUUAUCUAG	9168
AGAUAACCCACCCAAUUUC	9169	GAAAUUGGGUGGGUUAUCU	9170
GAUAACCCACCCAAUUUCC	9171	GGAAAUUGGGUGGGUUAUC	9172
AACCUUUCAGCAUAACGCC	9173	GGCGUUAUGCUGAAAGGUU	9174
ACCUUUCAGCAUAACGCCU	9175	AGGCGUUAUGCUGAAAGGU	9176
CCUUUCAGCAUAACGCCUC	9177	GAGGCGUUAUGCUGAAAGG	9178
CUUUCAGCAUAACGCCUCA	9179	UGAGGCGUUAUGCUGAAAG	9180
UUUCAGCAUAACGCCUCAC	9181	GUGAGGCGUUAUGCUGAAA	9182
UUCAGCAUAACGCCUCACA	9183	UGUGAGGCGUUAUGCUGAA	9184
UCAGCAUAACGCCUCACAU	9185	AUGUGAGGCGUUAUGCUGA	9186
CAGCAUAACGCCUCACAUC	9187	GAUGUGAGGCGUUAUGCUG	9188
AGCAUAACGCCUCACAUCC	9189	GGAUGUGAGGCGUUAUGCU	9190
GCAUAACGCCUCACAUCCC	9191	GGGAUGUGAGGCGUUAUGC	9192
AACGCCUCACAUCCCAAGU	9193	ACUUGGGAUGUGAGGCGUU	9194
ACGCCUCACAUCCCAAGUC	9195	GACUUGGGAUGUGAGGCGU	9196
CGCCUCACAUCCCAAGUCU	9197	AGACUUGGGAUGUGAGGCG	9198
UCACAUCCCAAGUCUAUAC	9199	GUAUAGACUUGGGAUGUGA	9200
CACAUCCCAAGUCUAUACC	9201	GGUAUAGACUUGGGAUGUG	9202
ACAUCCCAAGUCUAUACCC	9203	GGGUAUAGACUUGGGAUGU	9204
CAUCCCAAGUCUAUACCCU	9205	AGGGUAUAGACUUGGGAUG	9206
AAUGCUGUUCUUUCCUAGC	9207	GCUAGGAAAGAACAGCAUU	9208
AUGCUGUUCUUUCCUAGCC	9209	GGCUAGGAAAGAACAGCAU	9210
CUGUUCUUUCCUAGCCACC	9211	GGUGGCUAGGAAAGAACAG	9212
UGUUCUUUCCUAGCCACCU	9213	AGGUGGCUAGGAAAGAACA	9214
GCCAAGAUCAAGAUGUCCC	9215	GGGACAUCUUGAUCUUGGC	9216
UCUUGAUCCCAGCCUGACU	9217	AGUCAGGCUGGGAUCAAGA	9218
CUUGAUCCCAGCCUGACUG	9219	CAGUCAGGCUGGGAUCAAG	9220
UUGAUCCCAGCCUGACUGC	9221	GCAGUCAGGCUGGGAUCAA	9222
UGAUCCCAGCCUGACUGCU	9223	AGCAGUCAGGCUGGGAUCA	9224
CUGACUGCUGCUACAUCUA	9225	UAGAUGUAGCAGCAGUCAG	9226
GACUGCUGCUACAUCUAAU	9227	AUUAGAUGUAGCAGCAGUC	9228
ACUGCUGCUACAUCUAAUC	9229	GAUUAGAUGUAGCAGCAGU	9230
CUGCUGCUACAUCUAAUCC	9231	GGAUUAGAUGUAGCAGCAG	9232
UGCUGCUACAUCUAAUCCC	9233	GGGAUUAGAUGUAGCAGCA	9234
CCUACCAAUGCCUCCUGUC	9235	GACAGGAGGCAUUGGUAGG	9236
CUACCAAUGCCUCCUGUCC	9237	GGACAGGAGGCAUUGGUAG	9238
CCAAUGCCUCCUGUCCCUA	9239	UAGGGACAGGAGGCAUUGG	9240
CAAUGCCUCCUGUCCCUAA	9241	UUAGGGACAGGAGGCAUUG	9242
AAUGCCUCCUGUCCCUAAA	9243	UUUAGGGACAGGAGGCAUU	9244
CCCAGCAUACUGAUGACAG	9245	CUGUCAUCAGUAUGCUGGG	9246
CCAGCAUACUGAUGACAGC	9247	GCUGUCAUCAGUAUGCUGG	9248
CAUACUGAUGACAGCCCUC	9249	GAGGGCUGUCAUCAGUAUG	9250
AUACUGAUGACAGCCCUCU	9251	AGAGGGCUGUCAUCAGUAU	9252
UACUGAUGACAGCCCUCUC	9253	GAGAGGGCUGUCAUCAGUA	9254
ACUGAUGACAGCCCUCUCU	9255	AGAGAGGGCUGUCAUCAGU	9256
CUGAUGACAGCCCUCUCUG	9257	CAGAGAGGGCUGUCAUCAG	9258
UGAUGACAGCCCUCUCUGA	9259	UCAGAGAGGGCUGUCAUCA	9260
GAUGACAGCCCUCUCUGAC	9261	GUCAGAGAGGGCUGUCAUC	9262
AUGACAGCCCUCUCUGACU	9263	AGUCAGAGAGGGCUGUCAU	9264
UGACAGCCCUCUCUGACUU	9265	AAGUCAGAGAGGGCUGUCA	9266
GACAGCCCUCUCUGACUUU	9267	AAAGUCAGAGAGGGCUGUC	9268
ACAGCCCUCUCUGACUUUA	9269	UAAAGUCAGAGAGGGCUGU	9270
CAGCCCUCUCUGACUUUAC	9271	GUAAAGUCAGAGAGGGCUG	9272
AGCCCUCUCUGACUUUACC	9273	GGUAAAGUCAGAGAGGGCU	9274
GCCCUCUCUGACUUUACCU	9275	AGGUAAAGUCAGAGAGGGC	9276
CCCUCUCUGACUUUACCUU	9277	AAGGUAAAGUCAGAGAGGG	9278
CCUCUCUGACUUUACCUUG	9279	CAAGGUAAAGUCAGAGAGG	9280
CUCUCUGACUUUACCUUGA	9281	UCAAGGUAAAGUCAGAGAG	9282
AGAUCUGUCUUCAUACCCU	9283	AGGGUAUGAAGACAGAUCU	9284
GAUCUGUCUUCAUACCCUU	9285	AAGGGUAUGAAGACAGAUC	9286
CUGUCUUCAUACCCUUCCC	9287	GGGAAGGGUAUGAAGACAG	9288
UAUUUACCACUAAGACUUC	9289	GAAGUCUUAGUGGUAAAUA	9290
AUUUACCACUAAGACUUCU	9291	AGAAGUCUUAGUGGUAAAU	9292
UUUACCACUAAGACUUCUG	9293	CAGAAGUCUUAGUGGUAAA	9294
UUACCACUAAGACUUCUGA	9295	UCAGAAGUCUUAGUGGUAA	9296
UACCACUAAGACUUCUGAC	9297	GUCAGAAGUCUUAGUGGUA	9298
ACCACUAAGACUUCUGACU	9299	AGUCAGAAGUCUUAGUGGU	9300
ACUUCUGACUCCAAUUUAA	9301	UUAAAUUGGAGUCAGAAGU	9302
CUUCUGACUCCAAUUUAAA	9303	UUUAAAUUGGAGUCAGAAG	9304
ACACCCAGUCCCAGAUCCA	9305	UGGAUCUGGGACUGGGUGU	9306
CACCCAGUCCCAGAUCCAA	9307	UUGGAUCUGGGACUGGGUG	9308
ACCCAGUCCCAGAUCCAAA	9309	UUUGGAUCUGGGACUGGGU	9310

TABLE 11

	SEQ		SEQ
	ID		ID
Sense Sequence	NO:	Antisense Sequence	NO:
UUCCAGCUCAGCAGUGUCU	9311	AGACACUGCUGAGCUGGAA	9312
UCCAGCUCAGCAGUGUCUC	9313	GAGACACUGCUGAGCUGGA	9314
CCAGCUCAGCAGUGUCUCG	9315	CGAGACACUGCUGAGCUGG	9316
CAGCUCAGCAGUGUCUCGU	9317	ACGAGACACUGCUGAGCUG	9318
AGCUCAGCAGUGUCUCGUU	9319	AACGAGACACUGCUGAGCU	9320
GCUCAGCAGUGUCUCGUUC	9321	GAACGAGACACUGCUGAGC	9322
CUCAGCAGUGUCUCGUUCC	9323	GGAACGAGACACUGCUGAG	9324
GUAGCAGACCGACAUCCUU	9325	AAGGAUGUCGGUCUGCUAC	9326
UAGCAGACCGACAUCCUUC	9327	GAAGGAUGUCGGUCUGCUA	9328
AGCAGACCGACAUCCUUCU	9329	AGAAGGAUGUCGGUCUGCU	9330
AGACCGACAUCCUUCUGGG	9331	CCCAGAAGGAUGUCGGUCU	9332
GACCGACAUCCUUCUGGGC	9333	GCCCAGAAGGAUGUCGGUC	9334
CCGACAUCCUUCUGGGCCU	9335	AGGCCCAGAAGGAUGUCGG	9336
CGACAUCCUUCUGGGCCUA	9337	UAGGCCCAGAAGGAUGUCG	9338
GACAUCCUUCUGGGCCUAC	9339	GUAGGCCCAGAAGGAUGUC	9340
CUUCUGGGCCUACAGGUGG	9341	CCACCUGUAGGCCCAGAAG	9342
UUCUGGGCCUACAGGUGGG	9343	CCCACCUGUAGGCCCAGAA	9344
UCUGGGCCUACAGGUGGGU	9345	ACCCACCUGUAGGCCCAGA	9346
GGCCUACAGGUGGGUGGAA	9347	UUCCACCCACCUGUAGGCC	9348
CCUACAGGUGGGUGGAAGG	9349	CCUUCCACCCACCUGUAGG	9350
CUACAGGUGGGUGGAAGGC	9351	GCCUUCCACCCACCUGUAG	9352
UACAGGUGGGUGGAAGGCG	9353	CGCCUUCCACCCACCUGUA	9354
ACUUCCCUGCAGCCUGCCU	9355	AGGCAGGCUGCAGGGAAGU	9356
CCUGCAGCCUGCCUCUUUU	9357	AAAAGAGGCAGGCUGCAGG	9358
CUGCAGCCUGCCUCUUUUC	9359	GAAAAGAGGCAGGCUGCAG	9360
GCAGCCUGCCUCUUUUCUG	9361	CAGAAAAGAGGCAGGCUGC	9362
CAGCCUGCCUCUUUUCUGC	9363	GCAGAAAAGAGGCAGGCUG	9364
AGCCUGCCUCUUUUCUGCC	9365	GGCAGAAAAGAGGCAGGCU	9366
GCCUCUUUUCUGCCUGGGA	9367	UCCCAGGCAGAAAAGAGGC	9368
CUUUUCUGCCUGGGAGUCC	9369	GGACUCCCAGGCAGAAAAG	9370
UUUUCUGCCUGGGAGUCCU	9371	AGGACUCCCAGGCAGAAAA	9372
UUCUGCCUGGGAGUCCUGA	9373	UCAGGACUCCCAGGCAGAA	9374
UCUGCCUGGGAGUCCUGAC	9375	GUCAGGACUCCCAGGCAGA	9376
UGCCUGGGAGUCCUGACUU	9377	AAGUCAGGACUCCCAGGCA	9378
GCCUGGGAGUCCUGACUUC	9379	GAAGUCAGGACUCCCAGGC	9380
CUGGGAGUCCUGACUUCCA	9381	UGGAAGUCAGGACUCCCAG	9382
UGGGAGUCCUGACUUCCAC	9383	GUGGAAGUCAGGACUCCCA	9384
GGGAGUCCUGACUUCCACG	9385	CGUGGAAGUCAGGACUCCC	9386
GGAGUCCUGACUUCCACGA	9387	UCGUGGAAGUCAGGACUCC	9388
GAGUCCUGACUUCCACGAG	9389	CUCGUGGAAGUCAGGACUC	9390
AGUCCUGACUUCCACGAGG	9391	CCUCGUGGAAGUCAGGACU	9392
CCUGACUUCCACGAGGACC	9393	GGUCCUCGUGGAAGUCAGG	9394
CUGACUUCCACGAGGACCC	9395	GGGUCCUCGUGGAAGUCAG	9396
UGACUUCCACGAGGACCCA	9397	UGGGUCCUCGUGGAAGUCA	9398
GACUUCCACGAGGACCCAG	9399	CUGGGUCCUCGUGGAAGUC	9400
ACUUCCACGAGGACCCAGA	9401	UCUGGGUCCUCGUGGAAGU	9402
CUUCCACGAGGACCCAGAC	9403	GUCUGGGUCCUCGUGGAAG	9404
UUCCACGAGGACCCAGACC	9405	GGUCUGGGUCCUCGUGGAA	9406
CCCUGCUCCCAGUCAGUUG	9407	CAACUGACUGGGAGCAGGG	9408
CCUGCUCCCAGUCAGUUGA	9409	UCAACUGACUGGGAGCAGG	9410
CUGCUCCCAGUCAGUUGAC	9411	GUCAACUGACUGGGAGCAG	9412
UGCUCCCAGUCAGUUGACC	9413	GGUCAACUGACUGGGAGCA	9414
CCCAGUCAGUUGACCUGCC	9415	GGCAGGUCAACUGACUGGG	9416
CCAGUCAGUUGACCUGCCC	9417	GGGCAGGUCAACUGACUGG	9418
GCCUCCUUCCCAGAGCUCA	9419	UGAGCUCUGGGAAGGAGGC	9420
CCUCCUUCCCAGAGCUCAG	9421	CUGAGCUCUGGGAAGGAGG	9422
CUCCUUCCCAGAGCUCAGU	9423	ACUGAGCUCUGGGAAGGAG	9424
UCCUUCCCAGAGCUCAGUG	9425	CACUGAGCUCUGGGAAGGA	9426
CCUUCCCAGAGCUCAGUGG	9427	CCACUGAGCUCUGGGAAGG	9428
UUCCCAGAGCUCAGUGGUA	9429	UACCACUGAGCUCUGGGAA	9430
UCCCAGAGCUCAGUGGUAA	9431	UUACCACUGAGCUCUGGGA	9432
CAGGCUGUCACUAUCUCUA	9433	UAGAGAUAGUGACAGCCUG	9434
AGGCUGUCACUAUCUCUAC	9435	GUAGAGAUAGUGACAGCCU	9436
UCUCUACCACCACUCCUCU	9437	AGAGGAGUGGUGGUAGAGA	9438
CCACCACUCCUCUAGUCUG	9439	CAGACUAGAGGAGUGGUGG	9440
CACCACUCCUCUAGUCUGG	9441	CCAGACUAGAGGAGUGGUG	9442
ACCACUCCUCUAGUCUGGC	9443	GCCAGACUAGAGGAGUGGU	9444
CCACUCCUCUAGUCUGGCC	9445	GGCCAGACUAGAGGAGUGG	9446
CACUCCUCUAGUCUGGCCC	9447	GGGCCAGACUAGAGGAGUG	9448
AUUCUAGCACAUCUGGGCA	9449	UGCCCAGAUGUGCUAGAAU	9450
UUCUAGCACAUCUGGGCAA	9451	UUGCCCAGAUGUGCUAGAA	9452
UCUAGCACAUCUGGGCAAA	9453	UUUGCCCAGAUGUGCUAGA	9454
CUAGCACAUCUGGGCAAAA	9455	UUUUGCCCAGAUGUGCUAG	9456
GGGUGUAAAGGGACGUGCA	9457	UGCACGUCCCUUUACACCC	9458
GGUGUAAAGGGACGUGCAC	9459	GUGCACGUCCCUUUACACC	9460
GUGUAAAGGGACGUGCACA	9461	UGUGCACGUCCCUUUACAC	9462
UGUAAAGGGACGUGCACAG	9463	CUGUGCACGUCCCUUUACA	9464
GUAAAGGGACGUGCACAGA	9465	UCUGUGCACGUCCCUUUAC	9466
UAAAGGGACGUGCACAGAU	9467	AUCUGUGCACGUCCCUUUA	9468
AAAGGGACGUGCACAGAUC	9469	GAUCUGUGCACGUCCCUUU	9470
AAGGGACGUGCACAGAUCU	9471	AGAUCUGUGCACGUCCCUU	9472
AGGGACGUGCACAGAUCUA	9473	UAGAUCUGUGCACGUCCCU	9474
CGUGCACAGAUCUACUUAC	9475	GUAAGUAGAUCUGUGCACG	9476
GUGCACAGAUCUACUUACC	9477	GGUAAGUAGAUCUGUGCAC	9478
UGCACAGAUCUACUUACCA	9479	UGGUAAGUAGAUCUGUGCA	9480
GCACAGAUCUACUUACCAA	9481	UUGGUAAGUAGAUCUGUGC	9482
CACAGAUCUACUUACCAAG	9483	CUUGGUAAGUAGAUCUGUG	9484
ACAGAUCUACUUACCAAGC	9485	GCUUGGUAAGUAGAUCUGU	9486
CAGAUCUACUUACCAAGCU	9487	AGCUUGGUAAGUAGAUCUG	9488
AGAUCUACUUACCAAGCUG	9489	CAGCUUGGUAAGUAGAUCU	9490
AUCUACUUACCAAGCUGGG	9491	CCCAGCUUGGUAAGUAGAU	9492
UCUACUUACCAAGCUGGGA	9493	UCCCAGCUUGGUAAGUAGA	9494
CUUACCAAGCUGGGAGCAA	9495	UUGCUCCCAGCUUGGUAAG	9496
UUACCAAGCUGGGAGCAAG	9497	CUUGCUCCCAGCUUGGUAA	9498
UACCAAGCUGGGAGCAAGC	9499	GCUUGCUCCCAGCUUGGUA	9500
ACCAAGCUGGGAGCAAGCA	9501	UGCUUGCUCCCAGCUUGGU	9502
GCUGGGAGCAAGCAGGAUU	9503	AAUCCUGCUUGCUCCCAGC	9504
CUGGGAGCAAGCAGGAUUG	9505	CAAUCCUGCUUGCUCCCAG	9506
UGGGAGCAAGCAGGAUUGG	9507	CCAAUCCUGCUUGCUCCCA	9508
GGGAGCAAGCAGGAUUGGG	9509	CCCAAUCCUGCUUGCUCCC	9510
AAAGGUUAAGCAGCAGUAG	9511	CUACUGCUGCUUAACCUUU	9512
AAGGUUAAGCAGCAGUAGG	9513	CCUACUGCUGCUUAACCUU	9514
AGGUUAAGCAGCAGUAGGC	9515	GCCUACUGCUGCUUAACCU	9516
GGUGCCUACUCCUGUCCUG	9517	CAGGACAGGAGUAGGCACC	9518
GUGCCUACUCCUGUCCUGU	9519	ACAGGACAGGAGUAGGCAC	9520
UGCCUACUCCUGUCCUGUG	9521	CACAGGACAGGAGUAGGCA	9522
GCCUACUCCUGUCCUGUGC	9523	GCACAGGACAGGAGUAGGC	9524
CCUACUCCUGUCCUGUGCC	9525	GGCACAGGACAGGAGUAGG	9526
CUACUCCUGUCCUGUGCCU	9527	AGGCACAGGACAGGAGUAG	9528
UACUCCUGUCCUGUGCCUA	9529	UAGGCACAGGACAGGAGUA	9530
ACUCCUGUCCUGUGCCUAU	9531	AUAGGCACAGGACAGGAGU	9532
CUCCUGUCCUGUGCCUAUC	9533	GAUAGGCACAGGACAGGAG	9534
UCCUGUCCUGUGCCUAUCA	9535	UGAUAGGCACAGGACAGGA	9536
GUGCCUAUCACAUUUGCAG	9537	CUGCAAAUGUGAUAGGCAC	9538
CUAUCACAUUUGCAGAGGG	9539	CCCUCUGCAAAUGUGAUAG	9540
UAUCACAUUUGCAGAGGGU	9541	ACCCUCUGCAAAUGUGAUA	9542
AUCACAUUUGCAGAGGGUA	9543	UACCCUCUGCAAAUGUGAU	9544
UCACAUUUGCAGAGGGUAA	9545	UUACCCUCUGCAAAUGUGA	9546
CACAUUUGCAGAGGGUAAG	9547	CUUACCCUCUGCAAAUGUG	9548
ACAUUUGCAGAGGGUAAGA	9549	UCUUACCCUCUGCAAAUGU	9550

TABLE 12

	SEQ		SEQ
	ID		ID
Sense Sequence	NO:	Antisense Sequence	NO:
GACCGCCUGCAGAAGGUUG	9551	CAACCUUCUGCAGGCGGUC	9552
ACCGCCUGCAGAAGGUUGA	9553	UCAACCUUCUGCAGGCGGU	9554
CCGCCUGCAGAAGGUUGAC	9555	GUCAACCUUCUGCAGGCGG	9556
CGCCUGCAGAAGGUUGACU	9557	AGUCAACCUUCUGCAGGCG	9558
GCCUGCAGAAGGUUGACUG	9559	CAGUCAACCUUCUGCAGGC	9560
CAGAAGGUUGACUGCGUGG	9561	CCACGCAGUCAACCUUCUG	9562
AGAAGGUUGACUGCGUGGU	9563	ACCACGCAGUCAACCUUCU	9564
GAAGGUUGACUGCGUGGUA	9565	UACCACGCAGUCAACCUUC	9566
AAGGUUGACUGCGUGGUAG	9567	CUACCACGCAGUCAACCUU	9568
AGGUUGACUGCGUGGUAGG	9569	CCUACCACGCAGUCAACCU	9570
GGUUGACUGCGUGGUAGGG	9571	CCCUACCACGCAGUCAACC	9572
CCAGAGCAAGCCGAAGGCA	9573	UGCCUUCGGCUUGCUCUGG	9574
CAGAGCAAGCCGAAGGCAA	9575	UUGCCUUCGGCUUGCUCUG	9576
AGAGCAAGCCGAAGGCAAG	9577	CUUGCCUUCGGCUUGCUCU	9578
GAGCAAGCCGAAGGCAAGC	9579	GCUUGCCUUCGGCUUGCUC	9580
AGCAAGCCGAAGGCAAGCA	9581	UGCUUGCCUUCGGCUUGCU	9582
GCAAGCCGAAGGCAAGCAC	9583	GUGCUUGCCUUCGGCUUGC	9584
CAAGCCGAAGGCAAGCACG	9585	CGUGCUUGCCUUCGGCUUG	9586
AAGCCGAAGGCAAGCACGA	9587	UCGUGCUUGCCUUCGGCUU	9588
AGCCGAAGGCAAGCACGAU	9589	AUCGUGCUUGCCUUCGGCU	9590
GCCGAAGGCAAGCACGAUG	9591	CAUCGUGCUUGCCUUCGGC	9592
AAGGCAAGCACGAUGGCGC	9593	GCGCCAUCGUGCUUGCCUU	9594
AGGCAAGCACGAUGGCGCU	9595	AGCGCCAUCGUGCUUGCCU	9596
AAGCACGAUGGCGCUCACC	9597	GGUGAGCGCCAUCGUGCUU	9598
AGCACGAUGGCGCUCACCA	9599	UGGUGAGCGCCAUCGUGCU	9600
CUGUAGCAGCCGAGCAUCA	9601	UGAUGCUCGGCUGCUACAG	9602
AGCCGAGCAUCAGCCCGAA	9603	UUCGGGCUGAUGCUCGGCU	9604
GUCAGAGUCUCCAGGCUCA	9605	UGAGCCUGGAGACUCUGAC	9606
UCAGAGUCUCCAGGCUCAG	9607	CUGAGCCUGGAGACUCUGA	9608
CAGAGUCUCCAGGCUCAGG	9609	CCUGAGCCUGGAGACUCUG	9610
AGAGUCUCCAGGCUCAGGU	9611	ACCUGAGCCUGGAGACUCU	9612
GAGUCUCCAGGCUCAGGUG	9613	CACCUGAGCCUGGAGACUC	9614
AGUCUCCAGGCUCAGGUGG	9615	CCACCUGAGCCUGGAGACU	9616
GGGUGGCACAGCUGGCAUA	9617	UAUGCCAGCUGUGCCACCC	9618
GUGGCACAGCUGGCAUACG	9619	CGUAUGCCAGCUGUGCCAC	9620
UGGCACAGCUGGCAUACGC	9621	GCGUAUGCCAGCUGUGCCA	9622
CUCCACAGGUGGCGGUAGA	9623	UCUACCGCCACCUGUGGAG	9624
UCCACAGGUGGCGGUAGAC	9625	GUCUACCGCCACCUGUGGA	9626
UGAGCAGCACGCUGGCGUA	9627	UACGCCAGCGUGCUGCUCA	9628
AGCAGCACGCUGGCGUACA	9629	UGUACGCCAGCGUGCUGCU	9630
GCAGCACGCUGGCGUACAU	9631	AUGUACGCCAGCGUGCUGC	9632
CAGCACGCUGGCGUACAUG	9633	CAUGUACGCCAGCGUGCUG	9634
AGCACGCUGGCGUACAUGC	9635	GCAUGUACGCCAGCGUGCU	9636
GCACGCUGGCGUACAUGCU	9637	AGCAUGUACGCCAGCGUGC	9638
CACGCUGGCGUACAUGCUG	9639	CAGCAUGUACGCCAGCGUG	9640
ACGCUGGCGUACAUGCUGA	9641	UCAGCAUGUACGCCAGCGU	9642
CUGGCGUACAUGCUGAGCG	9643	CGCUCAGCAUGUACGCCAG	9644
UGGCGUACAUGCUGAGCGC	9645	GCGCUCAGCAUGUACGCCA	9646
CGCGCACACGUAGUACACC	9647	GGUGUACUACGUGUGCGCG	9648
GCGCACACGUAGUACACCG	9649	CGGUGUACUACGUGUGCGC	9650
CGCACACGUAGUACACCGC	9651	GCGGUGUACUACGUGUGCG	9652
GCACACGUAGUACACCGCC	9653	GGCGGUGUACUACGUGUGC	9654
CACACGUAGUACACCGCCU	9655	AGGCGGUGUACUACGUGUG	9656
ACACGUAGUACACCGCCUU	9657	AAGGCGGUGUACUACGUGU	9658
CACGUAGUACACCGCCUUG	9659	CAAGGCGGUGUACUACGUG	9660
UAGUACACCGCCUUGCAGC	9661	GCUGCAAGGCGGUGUACUA	9662

TABLE 13

	SEQ		SEQ
	ID		ID
Sense Sequence	NO:	Antisense Sequence	NO:
AGUGGACAGUGAGGACUUC	9663	GAAGUCCUCACUGUCCACU	9664
GUGGACAGUGAGGACUUCU	9665	AGAAGUCCUCACUGUCCAC	9666
UGGACAGUGAGGACUUCUU	9667	AAGAAGUCCUCACUGUCCA	9668
GGACAGUGAGGACUUCUUC	9669	GAAGAAGUCCUCACUGUCC	9670
AGUGAGGACUUCUUCCAGC	9671	GCUGGAAGAAGUCCUCACU	9672
GUGAGGACUUCUUCCAGCU	9673	AGCUGGAAGAAGUCCUCAC	9674
UGAGGACUUCUUCCAGCUG	9675	CAGCUGGAAGAAGUCCUCA	9676
GAGGACUUCUUCCAGCUGC	9677	GCAGCUGGAAGAAGUCCUC	9678
GUGCCUGAUGGUGUUGCAG	9679	CUGCAACACCAUCAGGCAC	9680
GAUGGUGUUGCAGUCUGGU	9681	ACCAGACUGCAACACCAUC	9682
UGGUGUUGCAGUCUGGUCA	9683	UGACCAGACUGCAACACCA	9684
GGUGUUGCAGUCUGGUCAG	9685	CUGACCAGACUGCAACACC	9686
GUGUUGCAGUCUGGUCAGA	9687	UCUGACCAGACUGCAACAC	9688
UGCAGUCUGGUCAGAGCUG	9689	CAGCUCUGACCAGACUGCA	9690
GCAGUCUGGUCAGAGCUGG	9691	CCAGCUCUGACCAGACUGC	9692
CAGUCUGGUCAGAGCUGGA	9693	UCCAGCUCUGACCAGACUG	9694
AGUCUGGUCAGAGCUGGAG	9695	CUCCAGCUCUGACCAGACU	9696
GUCUGGUCAGAGCUGGAGC	9697	GCUCCAGCUCUGACCAGAC	9698
UCUGGUCAGAGCUGGAGCC	9699	GGCUCCAGCUCUGACCAGA	9700
UGGUCAGAGCUGGAGCCCU	9701	AGGGCUCCAGCUCUGACCA	9702
GGUCAGAGCUGGAGCCCUA	9703	UAGGGCUCCAGCUCUGACC	9704
GUCAGAGCUGGAGCCCUAC	9705	GUAGGGCUCCAGCUCUGAC	9706
CAAGGGUAAGAGGCCUAUA	9707	UAUAGGCCUCUUACCCUUG	9708
AAGGGUAAGAGGCCUAUAC	9709	GUAUAGGCCUCUUACCCUU	9710
AGGGUAAGAGGCCUAUACU	9711	AGUAUAGGCCUCUUACCCU	9712
GGGUAAGAGGCCUAUACUG	9713	CAGUAUAGGCCUCUUACCC	9714
GGUAAGAGGCCUAUACUGG	9715	CCAGUAUAGGCCUCUUACC	9716
GUAAGAGGCCUAUACUGGG	9717	CCCAGUAUAGGCCUCUUAC	9718
GGGCUGCUUCCAAUGCCUG	9719	CAGGCAUUGGAAGCAGCCC	9720
GGCUGCUUCCAAUGCCUGU	9721	ACAGGCAUUGGAAGCAGCC	9722
GCUGCUUCCAAUGCCUGUC	9723	GACAGGCAUUGGAAGCAGC	9724
CUGCUUCCAAUGCCUGUCC	9725	GGACAGGCAUUGGAAGCAG	9726
UGCUUCCAAUGCCUGUCCU	9727	AGGACAGGCAUUGGAAGCA	9728
GCUUCCAAUGCCUGUCCUU	9729	AAGGACAGGCAUUGGAAGC	9730
CUUCCAAUGCCUGUCCUUU	9731	AAAGGACAGGCAUUGGAAG	9732
UUCCAAUGCCUGUCCUUUA	9733	UAAAGGACAGGCAUUGGAA	9734
UCCAAUGCCUGUCCUUUAG	9735	CUAAAGGACAGGCAUUGGA	9736
CAAUGCCUGUCCUUUAGAG	9737	CUCUAAAGGACAGGCAUUG	9738
AAUGCCUGUCCUUUAGAGC	9739	GCUCUAAAGGACAGGCAUU	9740
AUGCCUGUCCUUUAGAGCU	9741	AGCUCUAAAGGACAGGCAU	9742
CUUCCUCUCUAGCUUAACC	9743	GGUUAAGCUAGAGAGGAAG	9744
UUCCUCUCUAGCUUAACCC	9745	GGGUUAAGCUAGAGAGGAA	9746
UCUCUAGCUUAACCCUGAU	9747	AUCAGGGUUAAGCUAGAGA	9748
UAGCUUAACCCUGAUCCUG	9749	CAGGAUCAGGGUUAAGCUA	9750
GACCAGGUGCAGGAGGAGU	9751	ACUCCUCCUGCACCUGGUC	9752
ACCAGGUGCAGGAGGAGUU	9753	AACUCCUCCUGCACCUGGU	9754
CCAGGUGCAGGAGGAGUUG	9755	CAACUCCUCCUGCACCUGG	9756
CAGGUGCAGGAGGAGUUGU	9757	ACAACUCCUCCUGCACCUG	9758
AGGUGCAGGAGGAGUUGUG	9759	CACAACUCCUCCUGCACCU	9760
UGCAGGAGGAGUUGUGGAA	9761	UUCCACAACUCCUCCUGCA	9762
GCAGGAGGAGUUGUGGAAU	9763	AUUCCACAACUCCUCCUGC	9764
AGGAGGAGUUGUGGAAUUG	9765	CAAUUCCACAACUCCUCCU	9766
GGAGGAGUUGUGGAAUUGU	9767	ACAAUUCCACAACUCCUCC	9768
GAGGAGUUGUGGAAUUGUC	9769	GACAAUUCCACAACUCCUC	9770
AGGAGUUGUGGAAUUGUCA	9771	UGACAAUUCCACAACUCCU	9772
GGAGUUGUGGAAUUGUCAA	9773	UUGACAAUUCCACAACUCC	9774
GAGUUGUGGAAUUGUCAAG	9775	CUUGACAAUUCCACAACUC	9776
AGUUGUGGAAUUGUCAAGG	9777	CCUUGACAAUUCCACAACU	9778
GUUGUGGAAUUGUCAAGGA	9779	UCCUUGACAAUUCCACAAC	9780
UGGAAUUGUCAAGGAUGUC	9781	GACAUCCUUGACAAUUCCA	9782
GGAAUUGUCAAGGAUGUCA	9783	UGACAUCCUUGACAAUUCC	9784
AGUCCAAGCGAGGGAGGGU	9785	ACCCUCCCUCGCUUGGACU	9786
CAAGCGAGGGAGGGUCUGA	9787	UCAGACCCUCCCUCGCUUG	9788
AAGCGAGGGAGGGUCUGAC	9789	GUCAGACCCUCCCUCGCUU	9790
CUGACCCAGUGCUGAUGGA	9791	UCCAUCAGCACUGGGUCAG	9792
AGAUUAGUGGUGGGUGUCU	9793	AGACACCCACCACUAAUCU	9794
AUUAGUGGUGGGUGUCUGG	9795	CCAGACACCCACCACUAAU	9796
UUAGUGGUGGGUGUCUGGU	9797	ACCAGACACCCACCACUAA	9798
UAGUGGUGGGUGUCUGGUA	9799	UACCAGACACCCACCACUA	9800
AGUGGUGGGUGUCUGGUAU	9801	AUACCAGACACCCACCACU	9802
GUGGUGGGUGUCUGGUAUG	9803	CAUACCAGACACCCACCAC	9804
UGGUGGGUGUCUGGUAUGA	9805	UCAUACCAGACACCCACCA	9806
GGUGGGUGUCUGGUAUGAG	9807	CUCAUACCAGACACCCACC	9808
GUGGGUGUCUGGUAUGAGG	9809	CCUCAUACCAGACACCCAC	9810
UGGGUGUCUGGUAUGAGGA	9811	UCCUCAUACCAGACACCCA	9812
GGGUGUCUGGUAUGAGGAU	9813	AUCCUCAUACCAGACACCC	9814
GGUGUCUGGUAUGAGGAUC	9815	GAUCCUCAUACCAGACACC	9816
GUGUCUGGUAUGAGGAUCU	9817	AGAUCCUCAUACCAGACAC	9818
UGUCUGGUAUGAGGAUCUA	9819	UAGAUCCUCAUACCAGACA	9820
CAAGGGUGUCCUACAGAGU	9821	ACUCUGUAGGACACCCUUG	9822
AAGGGUGUCCUACAGAGUG	9823	CACUCUGUAGGACACCCUU	9824
AGGGUGUCCUACAGAGUGG	9825	CCACUCUGUAGGACACCCU	9826
GGGUGUCCUACAGAGUGGA	9827	UCCACUCUGUAGGACACCC	9828
GGUGUCCUACAGAGUGGAG	9829	CUCCACUCUGUAGGACACC	9830
UCCUACAGAGUGGAGUGCU	9831	AGCACUCCACUCUGUAGGA	9832
AGUGGAGUGCUGUCAUAUG	9833	CAUAUGACAGCACUCCACU	9834
GUGGAGUGCUGUCAUAUGG	9835	CCAUAUGACAGCACUCCAC	9836
UGGAGUGCUGUCAUAUGGC	9837	GCCAUAUGACAGCACUCCA	9838
GGAGUGCUGUCAUAUGGCC	9839	GGCCAUAUGACAGCACUCC	9840
GAGUGCUGUCAUAUGGCCU	9841	AGGCCAUAUGACAGCACUC	9842
AGUGCUGUCAUAUGGCCUG	9843	CAGGCCAUAUGACAGCACU	9844
GUGCUGUCAUAUGGCCUGG	9845	CCAGGCCAUAUGACAGCAC	9846
UGCUGUCAUAUGGCCUGGG	9847	CCCAGGCCAUAUGACAGCA	9848
GCUGUCAUAUGGCCUGGGA	9849	UCCCAGGCCAUAUGACAGC	9850
CUGUCAUAUGGCCUGGGAC	9851	GUCCCAGGCCAUAUGACAG	9852
UGUCAUAUGGCCUGGGACG	9853	CGUCCCAGGCCAUAUGACA	9854
GUCAUAUGGCCUGGGACGG	9855	CCGUCCCAGGCCAUAUGAC	9856
AGAGGCCCAAGCACAGCAA	9857	UUGCUGUGCUUGGGCCUCU	9858
GAGGCCCAAGCACAGCAAG	9859	CUUGCUGUGCUUGGGCCUC	9860
AGGCCCAAGCACAGCAAGG	9861	CCUUGCUGUGCUUGGGCCU	9862
GGCCCAAGCACAGCAAGGA	9863	UCCUUGCUGUGCUUGGGCC	9864
CCAAGCACAGCAAGGACAU	9865	AUGUCCUUGCUGUGCUUGG	9866
GCCCGAUUCACCUUUGACG	9867	CGUCAAAGGUGAAUCGGGC	9868
GAUUCACCUUUGACGUGUA	9869	UACACGUCAAAGGUGAAUC	9870
AUUCACCUUUGACGUGUAC	9871	GUACACGUCAAAGGUGAAU	9872
UUGGCAGCCUGAAUGUCAA	9873	UUGACAUUCAGGCUGCCAA	9874
UGGCAGCCUGAAUGUCAAA	9875	UUUGACAUUCAGGCUGCCA	9876
GGCAGCCUGAAUGUCAAAG	9877	CUUUGACAUUCAGGCUGCC	9878
GCAGCCUGAAUGUCAAAGC	9879	GCUUUGACAUUCAGGCUGC	9880
CAGCCUGAAUGUCAAAGCC	9881	GGCUUUGACAUUCAGGCUG	9882
AGCCUGAAUGUCAAAGCCA	9883	UGGCUUUGACAUUCAGGCU	9884
GCCUGAAUGUCAAAGCCAC	9885	GUGGCUUUGACAUUCAGGC	9886
GUCAAAGCCACAUUCUACG	9887	CGUAGAAUGUGGCUUUGAC	9888
UCAAAGCCACAUUCUACGG	9889	CCGUAGAAUGUGGCUUUGA	9890
CAAAGCCACAUUCUACGGG	9891	CCCGUAGAAUGUGGCUUUG	9892
AAAGCCACAUUCUACGGGC	9893	GCCCGUAGAAUGUGGCUUU	9894
GCCACAUUCUACGGGCUCU	9895	AGAGCCCGUAGAAUGUGGC	9896
CCACAUUCUACGGGCUCUA	9897	UAGAGCCCGUAGAAUGUGG	9898
CACAUUCUACGGGCUCUAC	9899	GUAGAGCCCGUAGAAUGUG	9900
UUCUACGGGCUCUACUCUA	9901	UAGAGUAGAGCCCGUAGAA	9902
UCUACGGGCUCUACUCUAU	9903	AUAGAGUAGAGCCCGUAGA	9904
CUACGGGCUCUACUCUAUG	9905	CAUAGAGUAGAGCCCGUAG	9906
CUCUAUGAGUUGUGACUUU	9907	AAAGUCACAACUCAUAGAG	9908
UCUAUGAGUUGUGACUUUC	9909	GAAAGUCACAACUCAUAGA	9910
UGAGUUGUGACUUUCAAGG	9911	CCUUGAAAGUCACAACUCA	9912
GAGUUGUGACUUUCAAGGA	9913	UCCUUGAAAGUCACAACUC	9914
AGUUGUGACUUUCAAGGAC	9915	GUCCUUGAAAGUCACAACU	9916
GUUGUGACUUUCAAGGACU	9917	AGUCCUUGAAAGUCACAAC	9918
GACUUUCAAGGACUUGGCC	9919	GGCCAAGUCCUUGAAAGUC	9920
UUUCAAGGACUUGGCCCAA	9921	UUGGGCCAAGUCCUUGAAA	9922
UUCAAGGACUUGGCCCAAA	9923	UUUGGGCCAAGUCCUUGAA	9924
CCCUACAGUUGGAUAGUCC	9925	GGACUAUCCAACUGUAGGG	9926
CCUACAGUUGGAUAGUCCC	9927	GGGACUAUCCAACUGUAGG	9928
AUUCGUCCUCUUGCACCCA	9929	UGGGUGCAAGAGGACGAAU	9930
UUCGUCCUCUUGCACCCAC	9931	GUGGGUGCAAGAGGACGAA	9932
UCCUCUUGCACCCACCUAC	9933	GUAGGUGGGUGCAAGAGGA	9934
CCUCUUGCACCCACCUACC	9935	GGUAGGUGGGUGCAAGAGG	9936
CUCUUGCACCCACCUACCC	9937	GGGUAGGUGGGUGCAAGAG	9938
CUAGUUAGCUCUUGCUUGU	9939	ACAAGCAAGAGCUAACUAG	9940
UAGUUAGCUCUUGCUUGUG	9941	CACAAGCAAGAGCUAACUA	9942
AGUUAGCUCUUGCUUGUGG	9943	CCACAAGCAAGAGCUAACU	9944
UUAGCUCUUGCUUGUGGAA	9945	UUCCACAAGCAAGAGCUAA	9946
UCCUCAUCUCCCAGCUUGA	9947	UCAAGCUGGGAGAUGAGGA	9948
AUCUCCCAGCUUGAUGGCU	9949	AGCCAUCAAGCUGGGAGAU	9950
UCUCCCAGCUUGAUGGCUU	9951	AAGCCAUCAAGCUGGGAGA	9952
CUCCCAGCUUGAUGGCUUC	9953	GAAGCCAUCAAGCUGGGAG	9954
UCCCAGCUUGAUGGCUUCC	9955	GGAAGCCAUCAAGCUGGGA	9956
CCCAGCUUGAUGGCUUCCU	9957	AGGAAGCCAUCAAGCUGGG	9958
CCAGCUUGAUGGCUUCCUC	9959	GAGGAAGCCAUCAAGCUGG	9960
UGAUGGCUUCCUCCCAAGU	9961	ACUUGGGAGGAAGCCAUCA	9962
GAUGGCUUCCUCCCAAGUU	9963	AACUUGGGAGGAAGCCAUC	9964
GGCUUCCUCCCAAGUUUUC	9965	GAAAACUUGGGAGGAAGCC	9966
CCUCCCAAGUUUUCCAAAU	9967	AUUUGGAAAACUUGGGAGG	9968
CCCAAGUUUUCCAAAUCAU	9969	AUGAUUUGGAAAACUUGGG	9970
CCAAGUUUUCCAAAUCAUC	9971	GAUGAUUUGGAAAACUUGG	9972
CAAGUUUUCCAAAUCAUCU	9973	AGAUGAUUUGGAAAACUUG	9974
AAGUUUUCCAAAUCAUCUG	9975	CAGAUGAUUUGGAAAACUU	9976
GUUUUCCAAAUCAUCUGAU	9977	AUCAGAUGAUUUGGAAAAC	9978
AUCUGAUUUCCUCUUGUCU	9979	AGACAAGAGGAAAUCAGAU	9980
UCUGAUUUCCUCUUGUCUC	9981	GAGACAAGAGGAAAUCAGA	9982
CUGAUUUCCUCUUGUCUCU	9983	AGAGACAAGAGGAAAUCAG	9984
CUCUUGUCUCUGCCAUUCA	9985	UGAAUGGCAGAGACAAGAG	9986
GUUGGACCUCCACACUGCU	9987	AGCAGUGUGGAGGUCCAAC	9988
CCACACUGCUGCAAGGCCU	9989	AGGCCUUGCAGCAGUGUGG	9990
CACACUGCUGCAAGGCCUG	9991	CAGGCCUUGCAGCAGUGUG	9992
ACACUGCUGCAAGGCCUGG	9993	CCAGGCCUUGCAGCAGUGU	9994
UGCAAGGCCUGGGCCAUAU	9995	AUAUGGCCCAGGCCUUGCA	9996
GCAAGGCCUGGGCCAUAUG	9997	CAUAUGGCCCAGGCCUUGC	9998
CAAGGCCUGGGCCAUAUGU	9999	ACAUAUGGCCCAGGCCUUG	10000
AAGGCCUGGGCCAUAUGUU	10001	AACAUAUGGCCCAGGCCUU	10002
AGGCCUGGGCCAUAUGUUG	10003	CAACAUAUGGCCCAGGCCU	10004
GGCCUGGGCCAUAUGUUGC	10005	GCAACAUAUGGCCCAGGCC	10006
GCCUGGGCCAUAUGUUGCU	10007	AGCAACAUAUGGCCCAGGC	10008
CCUGGGCCAUAUGUUGCUG	10009	CAGCAACAUAUGGCCCAGG	10010
GGCCAUAUGUUGCUGGGAA	10011	UUCCCAGCAACAUAUGGCC	10012
CCAUAUGUUGCUGGGAAUU	10013	AAUUCCCAGCAACAUAUGG	10014
GGAAUUUCCUCCACCCUUC	10015	GAAGGGUGGAGGAAAUUCC	10016
GAAUUUCCUCCACCCUUCG	10017	CGAAGGGUGGAGGAAAUUC	10018
AAUUUCCUCCACCCUUCGU	10019	ACGAAGGGUGGAGGAAAUU	10020
AUUUCCUCCACCCUUCGUC	10021	GACGAAGGGUGGAGGAAAU	10022
UUUCCUCCACCCUUCGUCA	10023	UGACGAAGGGUGGAGGAAA	10024
UUCCUCCACCCUUCGUCAU	10025	AUGACGAAGGGUGGAGGAA	10026
UCCUCCACCCUUCGUCAUG	10027	CAUGACGAAGGGUGGAGGA	10028
CCUCCACCCUUCGUCAUGC	10029	GCAUGACGAAGGGUGGAGG	10030
CUCCACCCUUCGUCAUGCA	10031	UGCAUGACGAAGGGUGGAG	10032
CCUUCGUCAUGCAGUGGAG	10033	CUCCACUGCAUGACGAAGG	10034
CUUCGUCAUGCAGUGGAGG	10035	CCUCCACUGCAUGACGAAG	10036
UUCGUCAUGCAGUGGAGGG	10037	CCCUCCACUGCAUGACGAA	10038
CGCCUCCAUUCCUACUAAG	10039	CUUAGUAGGAAUGGAGGCG	10040
GCCUCCAUUCCUACUAAGG	10041	CCUUAGUAGGAAUGGAGGC	10042
CCUCCAUUCCUACUAAGGG	10043	CCCUUAGUAGGAAUGGAGG	10044

TABLE 14 — Guide RNA Recognition Sequences Near CIDEB Variation(s)

Strand	gRNA Recognition Sequence	SEQ ID NO:
+	AGCTGAGAGGTACTCCATGGTGG	25
+	CAGAGCTGAGAGGTACTCCATGG	26
+	GTCACCTGAGTAAGTCACTGGGG	27
+	AGTCACCTGAGTAAGTCACTGGG	28
+	CAGTCACCTGAGTAAGTCACTGG	29
+	GCTTATATTAGATACTGACCTGG	30
−	GTCAGTATCTAATATAAGCTCGG	31
−	ATATAAGCTCGGAGTTTGGACGG	32
+	CAGACACGGAAAGGTCGCTGGGG	33
+	TTGTGATCACAGACACGGAAAGG	34
−	TCCGTGTCTGTGATCACAAGCGG	35
−	TCCGCTTGTGATCACAGACACGG	36
+	AGCTGTCAGGCCTTTCCGGATGG	37

TABLE 15 — PNPLA3 Guide RNA Recognition Sequences

Strand	gRNA Recognition Sequence	SEQ ID NO:
+	TCGGTCCAAAGACGAAGTCG	75
−	CCTTCCGCACAAGATCTGAG	76
−	TGTCGTACTCCCCATAGAAG	77
−	ATGCATCCAAATATCCTCGA	78
−	ACAACATGCGCGCGTCGCGG	79
−	GGCATTTGCAGAGACCCTGT	80
+	TTAAGCAAGTTCCTCCGACA	81
−	GCGTCCCCAGACGCACCCAG	82
−	CTCAGGATCCATCCCTTCTG	83
+	TCTTACCAGAGTGTCTGATG	84
−	AAGCTCTCGAGAGAAGGTAG	85
−	GCAGAGGCGTAGACTGAGCT	86
+	TAAAAGCGATATGTGGATGG	87
−	CGAACAACATGCGCGCGTCG	88
+	CTGGGAGAGATATGCCTTCG	89
+	AGGTCCTCTCAGATCTTGTG	90
−	CCAACTCACCTTGAGATCCG	91
−	GGAGATGAGCTGGTGGACAT	92
+	TCAGTCTACGCCTCTGCACA	93
−	TCCAGGATGCTCTCATCCCA	94

TABLE 16 — HSD17613 Guide RNA Recognition Sequences

Strand	gRNA Recognition Sequence	SEQ ID NO:
−	AGTGGGTGATGTAACAATCG	95
+	TGAGGTAAGGAATCCCTTCG	96
+	ACCTCTGTGAAAGCCAACAG	97
−	TTCCTAATTACAGCGCGGTG	98
−	ACATTTGAGGTCAACATCCT	99
+	CACTCACCCAAAAATGTCCT	100
−	CAATCGTGGTGAATAATGCT	101
+	CTTCACCAACGACTCCAAGT	102
+	ATACTTACCAATATGGGATG	103
−	CGTCACTGCGCATGCGTATG	104
−	AGCCGATCTTCTCAGCACCA	105
−	ACAGAGCATATTGGTTCTGT	106
−	GAGCTGGGCATGGAATAGGC	107
+	CTGAAGCCACTGTGACGATG	108
−	GCAGCTGAGTGCCGAAAACT	109
−	AGCACTTCTTCCATCGATGA	110
−	CTTCAGTGTGCGGCCACGAA	111
−	AGAGGAGAAAATCTGTGGCT	112
−	TCCTCAGAGGAGAAAATCTG	113
+	GATGTTGACCTCAAATGTCT	114

TABLE 19 — Baseline characteristics of individuals included in exome-wide association analyses Abbreviations: UKB, UK Biobank; GHS, Geisinger Health System; SD, standard deviation; N, number of participants; WHO, World Health Organization; kg/m 2 , kilograms per square meter; mg/dL, milligrams per deciliter; mmHg, millimeters of mercury; IQR, inter-quartile range.

	UKB study	GHS study
Variable	(N = 432,995)	(N = 109,909)
Age, mean (SD) in years	57	(8)	59	(17)
Women, N (%)	234,632	(54)	66,739	(61)
Participant ancestry (%)
European	411,926	(95.1)	109,909	(100)
African	8,544	(2)
East Asian	2,108	(0.5)
South Asian	9,830	(2.3)
Admixed American	587	(0.1)
Body mass index, mean (SD) in kg/m 2	27.4	(4.8)	31.3	(7.3)
Alanine Aminotransferase mean (SD) U/L	23.5	(14.1)	24.8	(11.6)
Aspartate Aminotransferase mean (SD) U/L	26.2	(10.2)	23.7	(6.4)
Body weight, mean (SD) in kg	78	(16)	89	(24)
Body mass index WHO categories, N (%)
Underweight	2,111	(0.5)	813	(0.7)
(<18.5 kg/m 2 )
Healthy weight	140,560	(32.5)	20,097	(18.3)
(18.5 to <25 kg/m 2 )
Overweight	183,668	(42.4)	31,725	(28.9)
(25 to <30 kg/m 2 )
Obesity, non-severe	96,834	(22.4)	41,918	(38.1)
(30 to <40 kg/m 2 )
Severe obesity	8,105	(1.9)	13,377	(12.2)
(40 kg/m 2 )
Blood pressure, mean (SD) in mmHg
Systolic	137	(16)	125	(10)
Diastolic	82	(8)	74	(6)
Low-density lipoprotein cholesterol,	137	(34)	106	(29)
mean (SD) in mg/dL
Triglycerides, median (IQR) in mg/dL	131	(98)	125	(82)

TABLE 20 — Associations with lower transaminase levels for the burden of rare pLOF plus missense variants in the CIDEB gene (gene = CIDEB; genetic exposure = pLOF plus any missense, AAF <1%) Abbreviations: CI, confidence interval; SD, standard deviation; U/L, unit liter; AAF, alternative allele frequency; RR, reference-reference genotype; RA, reference-alternative heterozygous genotype; AA, alternative-alternative homozygous genotype; pLOF, predicted loss of function.

	Beta (95% CI),		AAF,	Genotype counts,
Outcome	per allele	p	fraction of 1	RR\|RA\|AA genotypes
ALT	−0.09 (−0.12, −0.06) SD,	4.8 × 10 −09	0.00333	539,292\|3,609\|3
	−1.24 (−1.66, −0.83) U/L
AST	−0.10 (−0.13, −0.07) SD,	1.0 × 10 −09	0.00333	536,658\|3,589\|3
	−0.95 (−1.26, −0.65) U/L

TABLE 21 — Associations with lower transaminase levels for the burden of rare pLOF variants in the CIDEB gene (gene = CIDEB; genetic exposure = pLOF, AAF <1%) Abbreviations: CI, confidence interval; SD, standard deviation; U/L, unit liter; AAF, alternative allele frequency; RR, reference-reference genotype; RA, reference-alternative heterozygous genotype; AA, alternative-alternative homozygous genotype; pLOF, predicted loss of function.

	Beta (95% CI),		AAF,	Genotype counts,
Outcome	per allele	p	fraction of 1	RR\|RA\|AA genotypes
ALT	−0.12 (−0.18, −0.05) SD,	6.6 × 10 −04	0.0007	542,144\|760\|0
	−1.57 (−2.48, −0.67) U/L
AST	−0.12 (−0.19, −0.06) SD,	2.8 × 10 −04	0.0007	539,495\|755\|0
	−1.25 (−1.91, −0.58) U/L

TABLE 22 — Association between rare pLOF or rare missense variants in CIDEB and liver histopathology phenotypes Abbreviations: OR, odds ratio; SD, standard deviation; CI, confidence interval; Ref, homozygous reference genotype; Het, heterozygous carrier of rare pLOF or missense variant in CIDEB; Hom, homozygous carrier of rare pLOF or missense variant in CIDEB; NASH; nonalcoholic steatohepatitis; NAFLD, nonalcoholic fatty liver disease.

	OR or		CIDEB genotype
	beta SD		counts
Outcome	(95% CI)	P-value	(Ref/Het/Hom)
Steatosis/NASH/	0.34	0.012	Cases: 2778/15/0;
fibrosis vs.	(0.14 to 0.79)		Controls: 795/11/0
normal liver
Simple steatosis vs.	0.37	0.05	Cases: 1206/7/0;
normal liver	(0.14 to 1.00)		Controls: 795/11/0
NASH/fibrosis vs.	0.25	0.007	Cases: 1572/8/0;
normal liver	(0.09 to 0.69)		Controls: 795/11/0
NAFLD	−0.56	0.0007	Participants:
activity score	(−0.88 to −0.24)		3540/25/0

TABLE 27 — Interaction between rare pLOF or missense variants in CIDEB (AAF <1%) and rs72613567 (HSD17B13 splice variant) on ALT levels p-value

	Per allele			for linear
rs72613567-TA	beta		Genotype	interaction
(splice	(95% CI) in		counts,	between CIDEB
LOF variant	SD units of		RR\|RA\|AA	genotype and
in HSD17B13)	ALT levels	p-value	genotypes	rs72613567
T/T	−1.2	2E−04	271776\|1629\|1	0.88
	(−1.9, −0.6)
T/TA	−1.7	3E−06	204162\|1231\|0
	(−2.5, −1.0)
TA/TA	−0.4	6.4E−01	38700\|208\|0
	(−2.2, 1.3)

Claims as granted

22 claims

Classifications

5 codes

IPC · International Patent Classification

Section A — Human necessities

A61P1/16
A61K38/46
A61K31/7088

Section C — Chemistry; metallurgy

C12Q1/6883
C12N15/113

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

2.5 y

916 days filing → grant

Office actions

non-final + final

Responses

no RCE

Examiner

Jane J Zara

art unit 1635 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 48 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Chain of title

⤢ drag to zoom

Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.